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Abstract 
 
Mast cells have an important role in the immune system, but they are centrally involved in the 
pathophysiology of asthma, along with a number of other allergic diseases including rhinitis, 
eczema and irritable bowel disease (Metcalfe et al., 1997; Beaven, 2009). In the allergic 
response they are activated by IgE binding to high affinity receptors and subsequent cross-
linking by antigen. A rise in intracellular Ca2+ is required for mast cells to become activated and 
release mediators into the surrounding areas, which give rise to the symptoms of allergic disease 
(Gilfillan & Tkaczyk, 2006). Elucidating the ion channels responsible for mast cell Ca2+ entry may 
unveil new therapeutic targets for the treatment of asthma and other allergic diseases. 
 
Store-operated Ca2+ entry (SOCE) is a major mechanism for mast cell Ca2+ influx and is known to 
involve highly Ca2+-selective Orai1 channels. TRPC channels are non-selective Ca2+ channels; 
TRPC1, 4 and 5 are thought to be involved in SOCE, whereas TRPC3, 6 and 7 are activated by 
diacylglycerol (DAG). Whilst a limited number of studies carried out in rodent mast cells suggest 
that TRPC channels could be important for Ca2+ entry and mediator release, their functional 
expression and roles in human mast cells have not been characterised. 
 
This study showed that the LAD 2 human mast cell line and primary human lung mast cells 
(HLMCs) express mRNA for TRPC6. TRPC6-like currents were demonstrated for the first time in 
HLMCs, in response to direct activation by the DAG analogue OAG, and downstream of Gq 
protein-coupled P2Y1 receptor stimulation by ADP. This study also revealed for the first time that 
TRPC1 channels are expressed in both LAD 2 cells and HLMCs, and that both TRPC1 and Orai1 
channels are likely to be involved in SOCE. Importantly, this study also indicated that TRPC1 
channels could be involved in Ca2+ entry and mediator release downstream of IgE receptor 
activation. TRPC channels could thus contribute to Ca2+ entry required for mast cell activation in 
allergic disease, and could represent a therapeutic target for the modulation of diseases such as 
asthma. 
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Chapter 1: Introduction 
1.1 Mast cells 
1.1.1 Introduction to mast cells 
 
 
 
 
Mast cells are of haematopoietic origin and have long been recognised for their central role in 
anaphylaxis and allergic disease (Metcalfe et al., 1997). They were first recognised by Paul 
Ehrlich in the 1800s, by the unique staining characteristics of their cytoplasmic granules 
(Metcalfe et al., 1997). Illustrated in figure 1.1 is an electron micrograph of a mast cell, showing 
the many cytoplasmic granules recognised by Ehrlich. He originally named mast cells 
―mastzellen‖ (from the Greek word masto, meaning to feed), after mistakenly believing that they 
consume their surrounding tissue. They are now considered immune cells, with a wide range of 
functions in the innate and adaptive immune responses (Metz & Maurer, 2007). Mast cells exert 
their functions by the secretion of a wide range of mediators, many of which are pre-formed and 
stored in the cytoplasmic granules (Metcalfe et al., 1997). Whilst it is accepted that mast cells 
arise from CD34+/CD117+ pluripotent haematopoietic bone marrow stem cells (Kitamura et al., 
1978), controversy remains regarding their origins; a committed mast cell progenitor has been 
identified in adult mouse bone marrow that only gave rise to mast cells (Chen et al., 2005). 
However, bipotent progenitors have also been described in mouse spleen, which were found to 
be capable of differentiating into mast cells and basophils (Arinobu et al., 2005). Results so far 
obtained in human mast cells favour a multipotent progenitor; CD34+ progenitors gave rise to 
mast cells, basophils, eosinophils and neutrophils when cultured in the presence of SCF 
(Kirshenbaum et al., 1999).  
Figure 1.1. Electron micrograph of a human mast cell 
Note the many cytoplasmic granules, which give rise to unique staining patterns. 
Image (courtesy of Ann Dvorak) reproduced from cover of Laboratory Investigation  87 (10). 
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Immature mast cells circulate in the blood, but require a tissue environment for full maturation 
(Metz & Maurer, 2007). They are preferentially located at sites where the host meets the 
external environment and infection is most likely to occur, for example the mucosa of the 
respiratory and gastrointestinal tract, and the skin (Sellge & Bischoff, 2006). The differentiation 
of progenitor cells into fully mature mast cells is dependent on the activation of c-kit receptors by 
stem cell factor (SCF) and subsequent dimerisation and auto-phosphorylation; KIT-deficient mice 
have considerably reduced mast cell numbers (Grimbaldeston et al., 2005). Inhibition of c-kit 
activity by tyrosine kinase inhibitors in human mast cells induced apoptosis, indicating that the 
continued presence of SCF is also required for long-term mast cell survival (Metcalfe et al., 
1997). In mice, it has been shown that the 47 integrin expressed on mast cell precursors and 
the mucosal address in cell adhesion molecule (MAdCAM)-1 expressed in the intestine are 
important for mast cell precursors homing to the gut (Gurish et al., 2001). In humans, however, 
it remains unidentified at which stage of maturation mast cell progenitors migrate from the blood 
into the tissues, and how this process is regulated (Sellge & Bischoff, 2006).  
 
Tissue maturation of mast cells is dependent on other cells including T-cells and fibroblasts, and 
growth factors such as SCF and nerve growth factor (NGF). The complement of cytokines, 
chemokines and SCF at a particular site also determines the distribution and phenotype of mast 
cells (Metz & Maurer, 2007). This ―mast cell heterogeneity‖ allows them to respond to diverse 
stimuli at different locations.  
 
1.1.2 Classification 
A great deal of evidence for mast cell heterogeneity has come from rodent studies. Traditionally 
they have been classified into two main types based on phenotypical differences observed 
between connective tissue mast cells (CTMC), for example in the peritoneal cavity and skin, and 
mucosal mast cells (MMC) in the intestine (Metcalfe et al., 1997). Phenotypical differences exist 
between the two types of rat mast cell include size, histamine content, and T-cell dependency; 
these differences are summarised in Table 1.1.  
 
Human mast cells also display variations in properties such as size and granule ultrastructure 
(Dvorak, 1989). However, the two main subpopulations of human mast cells are distinguished 
based on their cytoplasmic granule protease content. TC mast cells are thus called because they 
contain tryptase and chymase, whereas T mast cells cells contain tryptase only (Irani et al., 
1989). Human MCT predominate in the gastrointestinal (GI) tract, where they comprise 2-3% of 
the lamina propria, and in the lungs. MCT correspond more closely to rodent MMC, whereas MCTC 
are found in the skin and small intestinal submucosa, and correspond to rodent CTMC (Metcalfe 
et al., 1997).  Table 1.2 summarises the properties of human MCT and MCTC. The heterogeneity 
of both rodent and human mast cells at different sites indicates that the tissue microenvironment 
is an essential factor in determining mast cell phenotype. 
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1.1.3 Model mast cells 
Given the heterogeneity of mast cells between species, and between sites within the same 
organism, it would be ideal to use primary human mast cells for in vitro experiments. Cultured 
primary human lung mast cells have been used in a number of studies to investigate their 
activation mechanisms; such studies provide important insight into how mast cells may 
contribute to the asthmatic phenotype. However, difficulty in obtaining human tissue for mast 
cell isolation and limitations in cell numbers for functional assays mean that it is not always 
possible to use primary human mast cells. Model mast cell lines are thus frequently used.  
The rat basophilic leukaemia (RBL)-1 cell line was originally derived from basophils (Eccleston et 
al., 1973). Whilst this cell line was not able to respond to IgE-mediated stimulation (Siraganian et 
al., 1975), it was used to develop the RBL-2H3 line, which degranulates in response to IgE 
receptor crosslinking (Barsumian et al., 1981), reflecting the behaviour of mast cells and 
basophils. RBL-2H3 cells have a KIT mutation that gives rise to constitutive activation of the 
Table 1.2. Characteristics of T and TC type human mast cells 
Reproduced from (Metcalfe et al., 1997); permission not required for reproduction of figures from this article. 
 
Table 1.1. Phenotypic characteristics of rodent peritoneal cavity mast cells (CTMCs) 
and intestinal mucosa mast cells (MMCs) 
Reproduced from (Metcalfe et al., 1997); permission not required for reproduction of figures from this article. 
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receptor, allowing them to grow independently of SCF (Tsujimura et al., 1995). This feature 
makes the cell line an economical alternative to primary mast cells, as cytokine-dependent 
culture is expensive. RBL-2H3 cells and primary rodent mast cells such as peritoneal mast cells 
have been used extensively to study mast cell function. Studying primary rodent mast cells from 
mice where a gene of interest has been knocked out can provide valuable information on the 
function of certain mast cell proteins. However, there are clear differences between rodent and 
human mast cells including tissue distribution, protease content, cytokine production and 
pharmacological activation (Bischoff, 2007). These species differences highlight the need to 
verify findings obtained in rodents using human mast cells.  
 
LAD 1 and 2, two SCF-dependent human mast cell lines, were generated in the Laboratory of 
Allergic Diseases (LAD), from bone marrow aspirates taken from a patient with mast cell 
sarcoma/leukaemia. Mononuclear cells from five separate bone marrow aspirates were cultured 
in the presence of recombinant human SCF (rhSCF); mast cells persisted in culture and were 
established as cell lines 24 months later (Kirshenbaum et al., 2003). LAD 1 and 2 cells were 
found to double in number approximately every 14 days when cultured with SCF. FACS analysis 
revealed that 98% of cells were positive for tryptase expression and 37% expressed both 
chymase and tryptase, therefore 37% of cells were of the TC type and 63% were of the T type. 
This expression profile most closely resembles that seen in mast cells found in the mucosal layers 
of organs such as the lung (Irani et al., 1986). Antibody analysis of surface markers on LAD cells 
revealed the expression of CD117, the receptor for SCF, and the high affinity IgE receptor FcεRI, 
among others. The cells released β-hexosaminidase and histamine in response to FcεRI 
crosslinking (Kirshenbaum et al., 2003), showing that the high affinity IgE receptor is functionally 
expressed in LAD 1 and 2 cells.  Electron microscopy showed that LAD cells measure 8–15µM in 
diameter and have uneven surfaces; staining with toluidine blue showed round or oval-shaped 
cells with distinct metachromatic staining of the granules (Kirshenbaum et al., 2003). Illustrated 
in figure 1.2 are the staining and surface features of LAD 2 cells.  
 
To verify that the LAD 1 and 2 cell lines were derived from the original patient, DNA isolated 
from the patient‘s bone marrow and that from LAD cells was analysed using six primer pairs, and 
the band patterns were identical. LAD 3–5 cells remain in development (Kirshenbaum et al., 
2003). As LAD 2 cells closely resemble primary human mast cells, require SCF for growth and 
have functional high affinity IgE receptors, they are an extremely useful model for the study of 
human mast cell biology in vitro.   
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An alternative human mast cell line, HMC-1 (Butterfield et al., 1988) , is available, but it has 
some limitations. Firstly, like RBL-2H3 cells, HMC-1 cells have a KIT activating mutation 
(Asp816Val) (Nilsson et al., 1994), which causes CD117 phosphorylation to occur independently 
of SCF, rendering the cells growth factor-independent. This activating mutation is not present in 
LAD 2 cells; they require SCF for proliferation, therefore more closely resemble mature primary 
human mast cells. Additionally, HMC-1 cells do not consistently degranulate in response to IgE 
receptor crosslinking (Butterfield et al., 1988), as surface expression of the high affinity IgE 
receptor is variable (Nilsson et al., 1994). These limitations restrict the usefulness of HMC-1 for 
the study of human mast cells. Very recently a new human mast cell line, LUVA, was developed 
from haematopoietic progenitor cells (Laidlaw et al., 2011). LUVA cells express c-kit and FcεRI, 
and degranulate in response to FcεRI cross-linking. They can be grown in the absence of SCF but 
do not have an activating KIT mutation, suggesting that growth occurs by a c-kit-independent 
mechanism (Laidlaw et al., 2011). The reasons for lack of dependence on SCF are at present 
being investigated in the authors‘ laboratory.  
 
To summarise, a number of models exist for the study of mast cells. Due to the species- and 
site-dependent mast cell heterogeneity that exists, primary human mast cells should ideally be 
used for investigations. In the absence of their availability, LAD 2 cells represent a useful model 
for the in vitro study of human mast cell biology. 
 
Figure 1.2. Images of LAD 2 mast cells 
a: Scanning ion conductance microscopy image of a LAD 2 cell, courtesy of Robert Field, Ionscope Ltd. 
b: Kimura stain of LAD 2 mast cells, showing characteristic metachromatic granule staining 
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1.1.4 The role of mast cells in the immune system 
Whilst mast cells are most well-known for their role in allergic reactions, a number of studies 
have indicated that they are involved in innate and adaptive immune responses. Mast cell-
deficient mice have been used to show that they are crucial for the development of host 
immunity and survival in bacterial infections including septic peritonitis (Echtenacher et al., 
1996). It is now known that mast cells provide protection only after being activated by signals 
from both host and pathogen, such as mannose-binding lectin (bacterial surface protein) and 
host-derived products of the complement cascade (Henz et al., 2001; Metz & Maurer, 2007). 
Following mast cell activation in response to infection, they secrete mediators that recruit other 
inflammatory cells such as neutrophils and macrophages (Metz & Maurer, 2007). Mast cells have 
also been suggested as effector cells in the innate immune response, causing phagocytosis of 
bacteria (Malaviya et al., 1996). They have long been thought to contribute to innate defence 
against parasitic infections; mouse models of nematode infection have been used to show that 
mast cell numbers in the intestinal mucosa are increased during infection, and activation 
stimulates the release of mouse mast cell protease (mMCP)-1m, which contributes to nematode 
expulsion (McDermott et al., 2003). 
 
There is also increasing evidence to suggest that mast cells are important in acquired (adaptive) 
immunity. Studies in mice showed that the recruitment of T cells to draining lymph nodes 
following Escherichia coli infection was enhanced following mast cell activation (McLachlan et al., 
2003). The effect was mimicked by injection of tumour necrosis factor (TNF), suggesting that 
mast cell-derived TNF has a role in T cell recruitment (McLachlan et al., 2003; Metz & Maurer, 
2007).  
 
Mast cells thus have important roles in the initiation and maintenance of host responses to 
pathogens, which are summarised in figure 1.3. However, it must be considered that studies 
addressing the role of mast cells in immunity have mostly been carried out in rodents. Caution 
must be applied when extrapolating results obtained in mice to humans. Human mast cells can 
release a range of immunomodulatory mediators but species differences exist in the production 
of some cytokines and expression of receptors (Bischoff, 2007); these differences could affect 
the role of mast cells in human immunity. 
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1.1.5 The role of mast cells in allergic disease 
Scientific investigations into allergic disease began in 1869, when Charles Blakely performed a 
skin test on himself to show that his hayfever was caused by pollen, which gave rise to an 
urticarial reaction (Beaven, 2009). The term anaphylaxis was introduced in 1902 when Physalia 
tentacle extracts caused anaphylactic shock in dogs that had previously been given an injection 
of the extracts (Beaven, 2009). Subsequent studies showed that histamine could cause the 
symptoms of anaphylactic shock (Riley, 1953), and a correlation was observed between mast cell 
count and histamine levels in urticaria lesions (Riley & West, 1952). Further evidence for the 
involvement of mast cells in anaphylactic reactions was provided by the enhanced presence of 
histamine in dog mastocytomas (Cass et al., 1954). IgE antibodies were identified as the factor 
responsible for sensitivity to allergens in 1967 (Ishizaka & Ishizaka, 1967). The role of mast cells 
in allergic disease is now more fully characterised, and the allergic response is described as a 
type 1 hypersensitivity reaction (Beaven, 2009). Hypersensitivity is an abnormally high immune 
response to a normally harmless molecule such as dust, leading to cell and tissue damage. 
 
Chronic mast cell activation is now known to contribute to the pathophysiology of many allergic 
diseases, including allergic asthma. Asthma is a chronic lung disease that is characterised by 
reversible airway obstruction caused by bronchial hyper-responsiveness, excess mucus 
production and narrowing of the airways (Owen, 2007). Following allergen exposure, an 
asthmatic reaction is initiated by a type 1 hypersensitivity reaction; mast cell mediators are 
present at higher levels from bronchoalveolar lavage fluid (BALF) from patients with asthma 
compared with non-asthmatic controls at this stage (Broide et al., 1991). Mast cell mediators are 
capable of causing mucus secretion, bronchoconstriction and mucosal oedema, all of which 
Figure 1.3. The effects of mast cells on pathogens and other cells of the immune system 
Reproduced with permission from (Metz & Maurer, 2007) 
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contribute to the symptoms of asthma (Bradding et al., 2006). Mast cells are present in increased 
numbers within the airway smooth muscle in asthmatic patients compared with non-asthmatics 
(Brightling et al., 2002), a factor that is thought to contribute to airway hyper-responsiveness 
(Bradding et al., 2006). Localisation of mast cells to the bronchial epithelium and airway mucous 
glands also occurs in asthmatics; in the epithelium they are in close proximity to aeroallergens 
that cause mast cell activation, and they are thought to contribute to mucous gland hyperplasia 
(Bradding et al., 2006). Mast cells are also thought to be involved in the symptoms of chronic 
asthma; mast cell mediators are present at higher levels in BALF from patients with chronic 
asthma compared with non-asthmatics (Broide et al., 1991), and human lung mast cells (HLMCs) 
can release the mediators histamine, leukotriene C4 (LTC4) and interleukin (IL)-8 a week after 
initial exposure to IgE (Cruse et al., 2005). 
 
Current statistics from Asthma UK indicate that asthma currently affects 5.4 million people in the 
UK; it is the most common long-term medical condition, and 1.1 million working days were lost 
due to breathing difficulties in 2008–2009. Several mast cell-stabilising drugs are used in the 
treatment of asthma including disodium cromoglycate, which causes weak (10–20%) inhibition of 
HLMC histamine release in vitro (Church & Hiroi, 1987), and β2-adrenoceptor agonists such as 
salbutamol, which has a more potent effect on mast cell function in vitro but has limited efficacy 
with chronic administration (Church & Hiroi, 1987; Swystun et al., 2000). Omalizumab, a 
recently-licensed treatment for asthma, is a humanised monoclonal antibody that binds 
circulating IgE and prevents it from binding to FcεRI on mast cells in the airway (Thomson et al., 
2011). It has been shown to improve symptoms in patients with allergic asthma and reduce 
airway inflammation (Walker et al., 2006; Rodrigo et al., 2011), highlighting the importance of 
the mast cell as a therapeutic target. The impact of asthma on quality of life, along with the 
economic toll and inadequacy of current therapies in some patients, highlights the need for 
improved asthma treatments. Given the central role of the mast cell in the disease process, 
further research into human lung mast cell activation and inhibition is necessary to reveal 
potential new therapeutic targets for asthma. 
 
In addition to asthma, mast cells play a major part in the manifestation of other allergic disorders 
including allergic rhinitis, peanut allergy and eczema (Owen, 2007), along with gastrointestinal 
disorders such as inflammatory bowel disease and coeliac disease (Barbara et al., 2006; Sellge & 
Bischoff, 2006). Their detrimental effects also extend to autoimmune diseases (Beaven, 2009); 
mast cells have been found to accumulate in the synovial fluid of patients with rheumatoid 
arthritis (Nigrovic & Lee, 2007), and correlations have been found between disease progression 
and mast cell localisation in multiple sclerosis (Beaven, 2009).  Further research into mast cell 
activation mechanisms will thus be of great benefit for the understanding of a wide range of 
conditions in which they are involved, and could lead to the development of new treatments. 
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1.1.6 Mast cell mediators 
The many biological and pathophysioloical roles of mast cells are made possible by the 
heterogeneous group of mediators that they synthesise and release. Mast cell mediators can be 
divided into three categories; preformed granule-associated mediators, lipid-derived mediators 
and cytokines (Metcalfe et al., 1997). 
1.1.6.1 Granule-associated mediators 
Mast cells store a plethora of pro- and anti-inflammatory mediators in their cytoplasmic granules 
that are released upon degranulation. Degranulation is an immediate reaction that occurs 
following mast cell activation, taking place within minutes (Metcalfe et al., 1997). The biogenic 
amine histamine is released upon degranulation; histamine possesses a range of biological 
activities, including vasodilation, bronchoconstriction, increased capillary permeability and airway 
smooth muscle contraction (Lundequist & Pejler, 2011). Mice deficient in histidine decarboxylase 
(HDC), the enzyme catalysing histamine production, have provided further insight, suggesting 
that histamine has a role in allergic airway inflammation (Koarai et al., 2003) and autoimmune 
encephalitis (Musio et al., 2006). It has been known since the 1950s that serotonin is present in 
mast cell granules; it was previously thought to be restricted to rodent mast cells (Lundequist & 
Pejler, 2011) but has recently been shown to be present in human peripheral blood-derived mast 
cells (Kushnir-Sukhov et al., 2007). The major pathophysiological effects of serotonin are 
vasoconstriction and pain (Theoharides et al., 2007). Mast cell granules also contain a number of 
enzymes that are present in lysosomes. β-hexosaminidase is the most well-known, and is 
ubiquitously present in mast cells from all species (Lundequist & Pejler, 2011). It is thought to 
have a role in carbohydrate processing (Theoharides et al., 2007). β-hexosaminidase release is 
frequently used experimentally to quantify the extent of mast cell degranulation. 
 
Proteoglycans are a major constituent of mast cell granules (Lundequist & Pejler, 2011); heparin 
and chondroitin sulphate E are both found in human mast cells (Metcalfe et al., 1979; Metcalfe et 
al., 1997) and stabilise mast cell proteases. Mast cell granule proteoglycans are thought to give 
rise to their staining by Toluidine Blue (Lundequist & Pejler, 2011), as metachromatic staining is 
not visible in mast cells from mice lacking the proteolgycan serglycin (Abrink et al., 2004). Mast 
cell granules are a major site of stored proteases, which account for 25% of total mast cell 
protein (Schwartz et al., 1987). As discussed above, human mast cells are classified based on 
their tryptase and chymase protease content. Chymase gives rise to tissue damage and pain 
when released from the mast cell, whereas tryptase has a role in protease-activated receptor 
(PAR) activation, inflammation and pain (Theoharides et al., 2007). Granule-associated mediators 
thus contribute to the symptoms of asthma and other allergic diseases through their multifaceted 
effects when they are released following mast cell activation.  
1.1.6.2 Lipid-derived mediators 
In addition to the range of granule-associated mediators released by the mast cell, newly-
synthesised mediators are produced upon mast cell activation. It is known that mast cells are 
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capable of differential mediator release without degranulation as they are involved in the 
pathogenesis of inflammatory diseases without causing anaphylactic shock (Theoharides et al., 
2007). The de novo synthesis of lipid-derived mediators derived from arachidonic acid is an 
important event following activation, as they possess potent pro-inflammatory activity (Metcalfe 
et al., 1997). Cyclo-oxygenase metabolites of arachidonic acid include prostaglandins and 
thromboxanes; lipoxygenase products include leukotrienes. LTC4, LTD4 and LTE4 are all produced 
by the lipoxygenase pathway; they induce skin reactions, promote bronchial mucus secretion and 
bronchial constriction, enhance vascular permeability and induce smooth muscle cell constriction 
(Drazen & Austen, 1987; Metcalfe et al., 1997). Prostaglandin (PG) D2 is also generated following 
mast cell activation; it is an inhibitor of platelet aggregation, causes bronchoconstriction and 
pain, and is a neutrophil chemoattractant (Metcalfe et al., 1997; Theoharides et al., 2007). Lipid-
derived mediators thus have a number of pro-inflammatory effects in the lung, which contribute 
to the pathogenesis of asthma. 
1.1.6.3 Cytokines 
Cytokines are protein or glycoprotein molecules with a broad spectrum of biological activities that 
are synthesised and secreted by cells (Metcalfe et al., 1997). Following initial events that occur 
upon mast cell activation, an enhancement of gene expression occurs, followed by the 
production of cytokines (Gilfillan & Tkaczyk, 2006). Since the first demonstration of mast cell 
cytokine production in 1986, when they were shown to produce granulocyte-macrophage colony-
stimulating factor (Chung et al., 1986), mast cells have been shown to generate a vast array of 
cytokines (Metcalfe et al., 1997). The expression of mRNAs for IL-1, IL-3, IL-5, IL-6, interferon 
(IFN)-γ and monocyte chemotactic protein (MCP)-1 were detected in an early study of mouse 
mast cells (Burd et al., 1989); human mast cells are known to express tumour necrosis factor 
(TNF)-α, IL-4, IL-5, IL-6 and IL-8 (Bradding et al., 1992; Ohkawara et al., 1992; Moller et al., 
1993; Metcalfe et al., 1997). These cytokines can have a profound effect on surrounding tissues, 
inducing inflammation, leukocyte migration, cellular hyperplasia and angiogenesis, for example 
(Theoharides et al., 2007). The pro-inflammatory cytokine TNF-α is important in the 
development of the asthmatic phenotype; it induces bronchial hyper-responsiveness and 
neutrophil accumulation in the sputum when inhaled (Bradding et al., 2006). TNF-α protein 
expression is enhanced in BALF in patients with severe asthma compared with non-asthmatics, 
and mRNA expression is elevated in the bronchial mucosa (Howarth et al., 2005; Berry et al., 
2006). In addition to de novo synthesis, it has also been shown that mast cells can store pre-
formed TNF-α in their granules, along with IL-4 and IL-15 (Gordon & Galli, 1990; Lundequist & 
Pejler, 2011).  
 
To summarise, numerous mediators released by mast cell degranulation and synthesised upon 
activation give rise to the various pro- and anti-inflammatory actions of mast cells in various 
tissue types. The types and effects of the various mast cell mediators are summarised in table 
1.3. 
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1.2  Mast cell activation  
IgE-mediated mast cell activation is considered a critical event in the allergic response (Gilfillan & 
Tkaczyk, 2006). This section will describe the series of events leading from mast cell IgE binding 
through to the synthesis and release of the variety of mediators discussed above. The activation 
of mast cells by other stimuli will also be considered. 
Table 1.3. Summary of mast cell mediators and their biological effects 
LTC, leukotriene; SMC, smooth muscle cell; IL, interleukin; IFN, interferon; MCP, monocyte chemotactic 
protein; TNF, tumour necrosis factor. 
Composed from (Metcalfe et al., 1979; Schwartz et al., 1987; Metcalfe et al., 1997; Koarai et al., 2003; Abrink et al., 2004; 
Musio et al., 2006; Theoharides et al., 2007; Lundequist & Pejler, 2011) 
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1.2.1 Activation via the high affinity IgE receptor 
In the allergic response, IgE antibodies to a normally harmless molecule (an allergen, such as 
dust or pollen) are produced by B cells. These antibodies bind to high affinity IgE receptors 
(FcεRI) on the surface of mast cells (Kinet, 1999). Following re-exposure, the allergen cross-links 
IgE bound to FcεRI. This tetrameric receptor consists of the α chain, which binds IgE, along with 
one β and two disulphide-linked γ chains, which together initiate signalling (Gilfillan & Tkaczyk, 
2006). IgE cross-linking by allergen leads to the juxtaposition of two or more FcεRI receptors, 
commencing signalling cascades that ultimately lead to the release of the mediators discussed 
above that are involved in allergic inflammation. It has been shown that early signalling events 
involve interactions of the aggregated receptors with lipid rafts in the membrane (Field et al., 
1999), followed by activation of SRC family kinases and phosphorylation of FcεRI on tyrosine 
residues in immunoreceptor tyrosine-based activation motifs (ITAMs) (Paolini et al., 1991). The 
SRC family kinases Lyn and Syk phosphorylate the adaptor molecule LAT (linker for activation of 
T cells), resulting in its recruitment of cytosolic adaptor molecules such as GRB2 and GADS 
(Gilfillan & Tkaczyk, 2006). The resulting signalling complex allows downstream signalling, 
leading to the release of various mediators. Figure 1.4 details the pathway of FcεRI- mediated 
mast cell activation. 
 
As shown in figure 1.4, activation of the mitogen-activated protein kinase (MAPK) pathway 
generates eicosanoids, including leukotriene C4 and prostaglandin D2. Degranulation occurs 
following increased cytosolic Ca2+ as a result of phospholipase C γ (PLCγ) and protein kinase C 
(PKC) activation. Activated PLCγ catalyses the cleavage of phosphatidylinositol-4,5-biphosphate 
(PtdIns(4,5)P2) to produce inositol-1,4,5-triphosphate (InsP3) and diacylglycerol (DAG), which 
cause calcium release from stores and PKC activation, respectively. It has been shown that the 
PLC inhibitor U73122 inhibits both cytosolic calcium rises and degranulation in human mast cells 
(Gilfillan & Tkaczyk, 2006), demonstrating the importance of  PLCγ in the process. Mast cells 
express two isoforms of PLCγ: PLCγ1 and PLCγ2 (Wilde & Watson, 2001). Whilst it is known that 
in cells of the rat mast cell line RBL-2H3 both isoforms are activated following FcεRI-mediated 
stimulation, it has been difficult to detect PLCγ2 activation in human mast cells (Tkaczyk et al., 
2003), suggesting that PLCγ1 may be the predominant form in humans. 
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In addition to the primary signalling pathway described above, it is believed that a 
―complementary activation pathway‖ exists for FcεRI- mediated mast cell activation (Gilfillan & 
Tkaczyk, 2006). It has been shown that another SRC family kinase, Fyn, is required for 
degranulation (Parravicini et al., 2002; Sanchez-Miranda et al., 2010); this forms part of a 
pathway that does not involve LAT-dependent PLCγ activation, but leads to the activation of 
phosphatidylinositol 3-kinase (PI3K). Described in figure 1.5 is the complementary signalling 
pathway. 
Figure 1.4. The FcεRI-mediated pathway for mast cell activation 
Following FcεRI cross-linking, LAT becomes phosphorylated by Src family kinases LYN and SYK. This 
results in interactions between LAT and cytosolic adaptor molecules such as GRB2 (growth-factor-receptor-
bound protein 2) and GADS (GRB2-related activator protein). The production of eicosanoids occurs 
following activation of the mitogen-activated protein kinase (MAPK) pathway, whereas degranulation takes 
place when PLCγ is activated, leading to Ca2+ mobilisation and protein kinase C (PKC) generation. 
Reproduced with permission from (Gilfillan & Tkaczyk, 2006) 
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PI3K can phosphorylate plasma membrane-associated phosphoinositides via pleckstrin-homology 
domains (Vanhaesebroeck et al., 2001; Gilfillan & Tkaczyk, 2006), thereby providing a docking 
site for the recruitment of signalling molecules to the plasma membrane. Signalling molecules 
involved in mast cell activation that contain pleckstrin homology domains include PLCγ and 
Bruton‘s tyrosine kinase (BTK) (Vanhaesebroeck et al., 2001); these molecules can be recruited 
to the membrane by PI3K. It is thought that this parallel signalling pathway is in place to 
maintain or amplify the calcium signal generated by the PLCγ- mediated signalling pathway, in 
order to optimise mast cell activation (Gilfillan & Tkaczyk, 2006). There are a number of possible 
reasons why multiple signalling cascades exist to mediate FcεRI-dependent mediator release; it 
could ensure that if a mutation occurs in an essential gene encoding a signalling molecule then 
activation still occurs, or may allow flexibility in signalling (Gilfillan & Tkaczyk, 2006).  Another 
possibility is that the complementary pathways could allow the integration of other signalling 
pathways that affect FcεRI -mediated activation. 
 
Figure 1.5. The complementary pathway for mast cell activation (only one receptor 
shown for clarity) 
Following receptor cross-linking, the tyrosine kinase Fyn becomes activated, leading to 
phosphorylation of GAB2 (growth-factor-receptor-bound protein 2), a cytosolic adaptor molecule. 
Consequently, phosphatidylinositol 3-kinase (PI3K) binds to GAB2, which causes PLCγ phosphorylation 
by Bruton‘s tyrosine kinase (BTK). This produces InsP3 via PLCγ-dependent cleavage of PtdIns(4,5)P2, 
which causes increased calcium mobilisation and degranulation. 
Reproduced with permission from (Gilfillan & Tkaczyk, 2006) 
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1.2.2 IgE-independent mast cell activation 
Whilst IgE-mediated mast cell activation is regarded as a key event in the allergic response, mast 
cells express receptors for other physiological ligands, which may induce degranulation, promote 
survival, growth or chemotaxis of mast cells, prime cells for activation by FcεRI cross-linking, or 
provide co-stimulatory signals. 
1.2.2.1 c-kit 
One of the best studied examples is of IgE-independent mast cell activation is via c-kit, the 
receptor for SCF. It has been shown, using studies with knockout mice and cultured human mast 
cells, that SCF-dependent activation of c-kit is necessary for mast cell growth, differentiation and 
survival (Galli et al., 1993; Galli et al., 2005). It has also been found that the presence of SCF is 
necessary for the long term culture of mast cells isolated and purified from the human lung and 
intestine; it is a survival factor, and induces proliferation if present in the growth medium at a 
concentration greater than 10ng/ml (Bischoff et al., 1999; Sanmugalingam et al., 2000; Bischoff, 
2007). 
 
SCF, whilst not inducing degranulation alone, enhances FcεRI-mediated responses (Tkaczyk et 
al., 2004). It has been demonstrated, using human intestinal mast cells, that the release of 
histamine and LTC4 in response to FcεRI cross-linking is enhanced after 6 days of culture with 
SCF compared to controls (Bischoff et al., 1999). For SCF to enhance antigen-mediated 
degranulation, the two signalling pathways must interact; figure 1.6 details the c-kit signalling 
pathway.  
 
As shown in Figure 1.6, SCF signalling via c-kit shares many common responses with the FcεRI 
pathway; PLCγ activation, calcium mobilisation and PI3K activation, for example. SCF, however, 
cannot by itself activate PKC (Hundley et al., 2004); this could explain its inability to induce 
degranulation in the absence of antigen. SCF itself does not induce LAT phosphorylation but does 
phosphorylate NTAL, which is part of the complementary pathway of mast cell activation (see 
figure 1.5). Therefore SCF can enhance the main antigen-mediated activation pathway by 
activating the complementary pathway. 
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1.2.2.2 G protein-coupled receptors 
In addition to c-kit, there is increasing evidence demonstrating the influence of members of the 
G-protein coupled receptor (GPCR) superfamily on mast cells. They have been shown to have a 
wide range of effects, including both enhancement and inhibition of FcεRI-mediated responses, 
and increased chemotaxis (Kuehn & Gilfillan, 2007). C3a, an anaphylotoxin that forms part of the 
complement cascade, can act as a mast cell chemoattractant when bound to its G protein-
coupled C3a receptor (C3aR) (Hartmann et al., 1997). Its effects on antigen-mediated 
degranulation vary depending on the type of mast cell; in RBL-2H3 cells C3a has been shown to 
inhibit mediator release by a C3a receptor-independent mechanism (Erdei et al., 1995), whereas 
in the HMC-1 and LAD 2 human mast cell lines it induces degranulation through the C3a receptor 
(Venkatesha et al., 2005). Sphingosine-1-phosphate (S1P) is a lysophospholipid that binds to a 
family of five GPCRs, two of which (S1P1 and S1P2) have been shown to be expressed by RBL-
2H3 cells (Jolly et al., 2004). They are thought to be important in regulating chemotaxis and 
degranulation; S1P1 induces chemotaxis, whereas S1P2 induces degranulation but inhibits 
Figure 1.6. The mast cell signalling pathway mediated by stem cell factor (SCF) 
binding to KIT  
Upon SCF binding to KIT and subsequent receptor aggregation, tyrosine residues in the cytoplasmic 
tail of KIT autophosphorylate. Cytosolic adaptor molecules such as SHC (SRC homology 2-domain-
containing transforming protein C) and signalling enzymes such as PLCγ and PI3K are then recruited. 
Activation of these signalling enzymes, along with the mitogen-activated protein kinase (MAPK) and 
JAK-STAT (Janus kinase-signal transducer and activator of transcription) pathways, leads to mast cell 
growth, differentiation, survival, chemotaxis and cytokine production. 
Reproduced with permission from (Gilfillan & Tkaczyk, 2006) 
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chemotaxis (Jolly et al., 2004). A higher concentration of S1P is required to bind to S1P2 than 
S1P1. It has therefore been proposed that in allergic reactions, lower concentrations of S1P cause 
mast cells to migrate to their target tissues through binding to S1P, whereas higher S1P 
concentrations activate the S1P2 receptor to cause degranulation and inhibit chemotaxis once at 
the target tissue (Olivera & Rivera, 2005). S1P2-mediated enhancement of FcεRI –mediated 
degranulation has been demonstrated in S1P2-deficient bone marrow mast cells (BMMCs), where 
there was a reduction in antigen-dependent mediator release compared to wild-type cells (Jolly 
et al., 2004). 
 
1.2.2.3 Purinergic signalling 
Adenosine has been reported to produce contrasting responses in mast cell activation; when 
bound to the A3 adenosine GPCR, it enhances FcεRI-dependent mediator release in RBL-2H3 cells 
(Gilfillan et al., 1990) and HLMCs when added after challenge with anti-human IgE (Hughes et 
al., 1984) . However, it has also been shown to inhibit FcεRI- dependent degranulation in HLMCs 
when added before immunological challenge (Hughes et al., 1984). These diverse responses are 
thought to be due to the multiple P1 purinoceptors for adenosine expressed on mast cells (A2A, 
A2B and A3)  producing distinct responses when bound to adenosine (Forsythe & Ennis, 1999). 
 
The nucleotides ATP, ADP and UTP influence cellular behaviour by binding to P2 purinoceptors 
on the cell surface (Abbracchio & Burnstock, 1994). The P2 purinoceptors are divided into two 
subgroups; P2X receptors, which are ligand-gated ion channels, and G-protein coupled P2Y 
receptors (Dubyak & el-Moatassim, 1993). These nucleotides, like adenosine, have been shown 
to produce distinct responses; in rat mast cells ATP has been reported to induce degranulation 
via P2X and P2Y receptors (Jaffar & Pearce, 1990), and enhance FcεRI- mediated histamine 
release (Osipchuk & Cahalan, 1992). Similarly, in HLMCs ATP and UTP have been shown to 
enhance FcεRI- dependent degranulation, probably mediated through P2Y receptors (Schulman 
et al., 1999). The functional expression of ATP-activated P2X1, P2X4 and P2X7 has been 
demonstrated in both LAD 2 cells and HLMCs in our laboratory (Wareham et al., 2009), indicating 
that these receptors could be important in human mast cell signalling.  
 
In contrast to their augmentation of FcεRI-mediated responses, ADP and ATP have been shown 
to block cytokine production in response to a toll-like receptor (TLR)2 agonist in human cord 
blood-derived mast cells (Feng et al., 2004). These findings suggest that, as with adenosine 
receptors, the expression of multiple purinoceptors in mast cells allows ATP, ADP and UTP to 
instigate distinct responses. The observation that cord blood-derived human mast cells express 
P2Y1, P2Y2, P2Y11, P2Y12 and P2Y13 (Feng et al., 2004) supports this idea. 
 
In summary, GPCRs can either provoke mast cell activation, or modify FcεRI-dependent 
degranulation. However, it must be noted that many of the previously described studies have 
been carried out in mouse or rat, as opposed to human, mast cells. From the studies carried out 
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in human mast cells it is apparent that they may behave significantly differently to mouse mast 
cells (Kuehn & Gilfillan, 2007). It is therefore necessary to investigate further the expression of 
GPCRs modulating responses in human mast cells, and to examine to what extent they 
contribute to diseases associated with human mast cells. How GPCR signalling itself is regulated 
in mast cells also remains incompletely understood. The role of regulator of G protein signalling 
(RGS) proteins in human MCs has recently been investigated using the HMC-1 and LAD 2 cell 
lines; it has been shown that the RGS13 protein restricts particular GPCR responses (Bansal et 
al., 2008), thus representing a therapeutic target for allergic inflammatory diseases. 
 
1.2.3 The importance of Ca2+ in mast cell activation 
It is well established that a sustained increase in cytosolic Ca2+ levels is an essential signal for 
degranulation in mast cells (Cochrane & Douglas, 1974; Ozawa et al., 1993; Gilfillan & Tkaczyk, 
2006). Regulated exocytosis, the process by which degranulation occurs, is controlled by soluble 
N-ethyl-maleimide-sensitive factor attachment protein receptor (SNARE) proteins (Puri & Roche, 
2008). Typically vesicular (v) SNAREs interact with SNAREs on the target membrane (t-SNAREs); 
this process is Ca2+-dependent and regulated by Ca2+ sensors (Melicoff et al., 2009). Ca2+ is also 
required for the de novo synthesis of eicosanoids, whose production is dependent on the Ca2+ 
sensitive enzyme PLA2, and in the transcriptional regulation of cytokine production (Melicoff et 
al., 2009). 
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1.3 Ca2+ entry mechanisms 
There are a number of different routes for Ca2+ entry in MCs; one of the most well-studied is via 
store-operated calcium (SOC) channels. Non-store-operated mechanisms include Ca2+ entry via 
the nucleotide-activated P2X and P2Y receptors discussed above, and through store-independent 
TRP channels, which are discussed below in section 1.3.2. Figure 1.7 illustrates the mechanisms 
responsible for Ca2+ fluxes in stimulated mast cells, and the importance of Ca2+ for mast cell 
mediator release. 
1.3.1 Store-operated Ca2+ entry 
Store-operated Ca2+ entry (SOCE), or capacitative Ca2+ entry, is the process by which the 
depletion of Ca2+ stores in the endoplasmic reticulum (ER) by InsP3 binding to its receptor 
activates Ca2+ entry from outside the cell (Parekh & Putney, 2005). The concept of SOCE was 
first proposed in 1986, when it was suggested that Ca2+ influx in non-excitable cells is controlled 
by the amount of Ca2+ in intracellular stores (Putney, 1986). Direct evidence for SOCE was 
provided by a combination of electrophysiological studies and fura-2 Ca2+ measurements in rat 
mast cells (Hoth & Penner, 1992, 1993); the authors showed that depletion of intracellular Ca2+ 
stores gave rise to a current called Ca2+ release-activated Ca2+ current (ICRAC). ICRAC is a highly 
Ca2+-selective, inwardly-rectifying, non-voltage activated current. In the absence of Ca2+, ICRAC 
currents readily permeate Na+ ions, giving rise to current amplification (Parekh & Putney, 2005). 
The biophysical properties of ICRAC currents are illustrated in figure 1.8 Although ICRAC was the 
first store-operated current to be identified and is the best characterised, it is not believed to be 
the only SOCE current (Parekh & Putney, 2005; Cheng et al., 2011; Ma & Beaven, 2011). Early 
studies showed that Ba2+ and Sr2+ ions, which pass through TRPC channels but not ICRAC 
channels (Lis et al., 2007; Ma & Beaven, 2011), can support degranulation in rat peritoneal mast 
cells in the absence of extracellular Ca2+ (Foreman & Mongar, 1972); later studies in RBL cells 
revealed that TRPC5 channels permit Sr2+ entry following store depletion (Ma et al., 2008). 
Various currents with distinct biophysical properties are now thought to be involved in SOCE 
(Parekh & Putney, 2005). 
1.3.1.1 STIM1, Orai1 and ICRAC 
The molecular components of ICRAC remained elusive until recently; a key question was how the 
ER Ca2+ store content is linked to plasma membrane channels. This was resolved with the 
discovery of stromal interaction molecule 1 (STIM1), an ER-resident Ca2+ sensor that regulates 
SOCE, in two independent studies (Liou et al., 2005; Roos et al., 2005). In a siRNA screen to 
identify genes involved in SOCE in Drosophila S2 cells, Roos et al. (2005) showed that knock-
down of Stim inhibited thapsigargin-evoked Ca2+ entry and ICRAC currents activated by passive 
store depletion. The authors showed that knock-down of the human homologue STIM1 similarly 
inhibited ICRAC in Jurkat T cells, and over-expression of STIM1 in HEK-293 cells enhanced SOCE, 
concluding that STIM1 has an essential role in SOCE (Roos et al., 2005).  
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Figure 1.8. Biophysical properties of ICRAC currents 
Current-voltage relationships of ICRAC currents activated by BAPTA-mediated passive store depletion in the 
presence of extracellular Ca2+ (left) or Na+ (right). ICRAC currents are Ca
2+-selective and inwardly-
rectifying, with a  positive reversal potential. In the absence of Ca2+, ICRAC channels are permeable for 
Na+, causing amplification of the current. 
Reproduced with permission from (Feske et al., 2006) 
Figure 1.7. Ca2+ fluxes in stimulated mast cells 
Following FcεRI-evoked signalling, InsP3 binding leads to Ca
2+ release from the ER through the InsP3 
receptors. Ca2+ released close to mitochondria is taken up by the mitochondrial uniporter (U). Ca2+ store 
depletion causes the formation of punctae (not shown) that bring together the Ca2+ sensor STIM1 into 
close contact with Orai and TRPC plasma membrane channels. Ca2+ influx leads to store replenishment 
through uptake by the SERCA pump; equilibrium is maintained by Ca2+ extrusion via Na+/Ca2+ exchangers 
and the ATP-dependent PMCA pump. 
Reproduced with permission from (Ma & Beaven, 2011) 
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In a separate siRNA screen, Liou et al. (2005) identified STIM1 and STIM2 as important proteins 
for SOCE in HeLa cells. Using fluorescently tagged STIM1, the authors showed that following 
store depletion, STIM1 redistributes into punctae at the plasma membrane (Liou et al., 2005). 
Recombinant expression studies revealed that the Ca2+-sensing EF-hand domain and the sterile 
α-motif (SAM) domain (EF-SAM domain) are responsible for initiating STIM1 puncta formation 
upon store depletion (Stathopulos et al., 2006). 
 
The molecular identity of the CRAC channel was revealed in 2006; genome screening and 
mutagenesis studies showed that Orai1, also called CRACM1, is the channel mediating ICRAC 
(Feske et al., 2006; Prakriya et al., 2006; Vig et al., 2006b). Feske et al. (2006) reported that a 
missense mutation in Orai1 is linked to severe combined immunodeficiency (SCID), where it is 
responsible for defective SOCE in T cells. Orai1 channels have four transmembrane regions with 
intracellular N- and C-termini; conserved glutamate residues form the pore and confer Ca2+ 
selectivity (Prakriya et al., 2006). STIM1 and Orai1 were shown to functionally interact by co-
over-expression studies in HEK-293 and Jurkat T cells (Peinelt et al., 2006); whilst over-
expression of either protein alone did not significantly amplify ICRAC, over-expression of STIM1 
and Orai1 greatly potentiated the current. It is now known that a highly conserved SOAR (STIM1 
Orai-activating region) domain in STIM1 activates Orai1 channels (Yuan et al., 2009), and no 
other interactions are required for channel opening (Lee et al., 2010). The importance of STIM1 
and Orai1 in mast cell function was highlighted using mice lacking the proteins; foetal liver-
derived mast cells from STIM1-deficient mice were shown to have reduced IgE-activated Ca2+ 
entry, degranulation and activation of the transcription factors NFκB and NFAT, leading to 
impaired cytokine production (Baba et al., 2008). Mast cells from Orai1-deficient mice were 
shown to exhibit reduced degranulation and cytokine production (Vig et al., 2008). Investigating 
the contribution of STIM1 and Orai1 to SOCE in human mast cells remains to be investigated, but 
it can be hypothesised from studies using rodents that they are essential for human mast cell 
function.  
 
Orai1 channels are highly selective for Ca2+ over other ions, giving rise to the Ca2+ selectivity of 
ICRAC. Previous studies recording ICRAC currents in RBL cells and Jurkat T cells showed that that 
equimolar replacement of Ca2+ ions with Ba2+ in the extracellular recording solution leads to a 
reduction, but not complete inhibition, of the ICRAC current (Hoth, 1995; Zweifach & Lewis, 1995). 
However, these results were obtained in solutions where both Na+ and Ba2+ were present; a 
recent study showed that replacement of Ca2+ with Ba2+ ions when Na+ ions were replaced with 
tetraethyl ammonium (TEA) caused abolition of ICRAC currents mediated by Orai1, 2 and 3 in 
HEK-293 cells (Lis et al., 2007). The authors re-examined Ba2+ permeation of ICRAC in Jurkat T 
cells in the presence and absence of Na+, reporting that currents are inhibited in the absence of 
Na+. It was concluded that ICRAC currents are abolished when Ba
2+ is the sole charge carrier, and 
that Na+ ions carry the current observed in the absence of Ca2+ previously thought to be 
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mediated by Ba2+(Lis et al., 2007). Orai1-mediated ICRAC currents are therefore highly Ca
2+ 
selective, a property that can be used to distinguish them from other store-operated currents. 
 
1.3.1.2  Methods to study ICRAC 
Physiologically, Ca2+ store release is evoked by InsP3 binding to its receptor in the ER. 
Experimental methods for store depletion include dialysis of the cytosol with InsP3 or a high 
concentration of Ca2+ chelators such as EGTA or BAPTA to prevent store refilling. 
Sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) inhibitors such as thapsigargin or 
cyclopiazonic acid (CPA) can also be used to prevent Ca2+ store refilling, causing passive store 
depletion (Parekh & Putney, 2005). Ca2+ imaging is commonly used to monitor SOCE following 
thapsigargin-evoked store depletion; currents are directly monitored using the patch-clamp 
technique, which allows direct application of Ca2+ chelators and InsP3 into the cytosol (Parekh & 
Putney, 2005). 
 
As Orai1 channels have very low conductance (Hogan et al., 2010), they are very difficult to 
detect under standard recording conditions. Ca2+ ions are frequently replaced with Na+ ions 
when recording ICRAC currents to increase the conductance and facilitate identification (Lepple-
Wienhues & Cahalan, 1996; Mercer et al., 2006; Prakriya et al., 2006; Scrimgeour et al., 2009). 
 
Commonly-used non-selective inhibitors of ICRAC include the lanthanides La
3+ and Gd3+ at low 
(~1) µM concentrations (Broad et al., 1999; DeHaven et al., 2009) and 2-
aminoethoxydiphenylborate (2-APB) (Prakriya & Lewis, 2001). A selective small-molecule 
inhibitor of Orai1 channels, synta 66 (GSK1349571A, 3-fluoropyridine-4-carboxylic acid (2‘,5‘-
dimethoxybiphenyl-4-yl)amide), has recently been characterised. Synta compounds were 
developed by Synta pharmaceuticals from Astellas compounds (based on 5-pyrazol-5yl-2-
thiophene-carboxamide), which are moderately potent SOCE inhibitors; the pyrazole ring of 
Astellas compounds was replaced with a phenyl ring in synta compounds (Sweeney et al., 2009). 
Synta 66 was developed through small modifications of synta compounds ; it blocks ICRAC 
currents in RBL cells with reported IC50 values of 3µM (Ng et al., 2008) and 1.4µM (Di Sabatino 
et al., 2009). The selectivity of synta 66 for ICRAC inhibition was confirmed using a panel of 
radioligand binding assays, where its effects on other ion channels, receptors and enzymes were 
compared with known inhibitors of the targets. Little or no significant activity was observed 
against the targets tested, including GABA, muscarinic receptors, P2X receptors, K+ channels, Cl- 
channels and Na+ channels, when synta 66 was used at a concentration causing maximal 
inhibition of ICRAC (10µM) (Di Sabatino et al., 2009). In vascular smooth muscle cells synta 66 has 
been shown to inhibit thapsigargin-evoked ICRAC, whilst TRPC-mediated currents stimulated by 
thapsigargin were unaffected (Li et al., 2011).  The resistance of TRPC1-TRPC5 heteromeric 
channels to synta 66 was confirmed in HEK-293 cells; Ca2+ entry evoked by 100µM Gd3+ in HEK-
TRPC1-TRPC5 cells was unaffected by the compound (Li et al., 2011). Synta 66 can therefore be 
used as a selective ICRAC inhibitor to determine the contribution of Orai1 channels to SOCE.  
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1.3.2 TRP channels 
1.3.2.1 Overview, background and discovery 
Transient receptor potential (TRP) channels are a superfamily of structurally-related channels, 
the majority of which are nonselective cation channels that are permeable to Ca2+. The founding 
member of the superfamily was discovered in Drosophila photoreceptors, where a transient 
rather than a sustained current in response to light (transient receptor potential) was observed in 
flies carrying a trp mutation (Montell et al., 1985; Hardie & Minke, 1992). The mutation gave rise 
to impaired Ca2+ entry, indicating that the TRP protein forms a Ca2+ influx channel in Drosophila 
photoreceptors (Hardie & Minke, 1992). Based on similarity to Drosophila TRP protein sequences, 
28 mammalian TRP channels have since been cloned, which can be divided into six subfamilies 
on the basis of amino acid homology; see figure 1.9. These are TRPC (canonical), TRPV 
(vanilloid), TRPM (melastatin), TRPP (polycystin), TRPA (ankyrin) and TRPML (mucolipin) (Nilius 
et al., 2007). The crystal structures of the TRP channels are not yet available (Flockerzi, 2007), 
but based on their amino acid analogy to other channels and the location of glycosylation sites, 
they are predicted to have six transmembrane domains (S1–S6). The N and C termini are 
thought to be located intracellularly, with the pore-forming loop located between S5 and S6; 
figure 1.10 illustrates the predicted topology of TRP channels. Cytosolic N-termini of TRP 
channels contain a variable number of protein-protein interaction motifs called ankyrin motifs; 
protein-protein interactions is the C termini differ between the various channels and include Ca2+-
calmodulin binding sites, InsP3 interaction sites and PKC interaction sites (Birnbaumer, 2009). All 
TRP channels are permeable to Ca2+ except TRPM4 and TRPM5; these channels are only 
permeable to monovalent cations. Most Ca2+-permeable TRP channels are poorly selective for 
Ca2+, permeating other monovalent and divalent cations; TRPV5 and TRPV6, however, are highly 
selective for Ca2+, with a permeability ratio relative to Na+ of >100 (Nilius et al., 2007). The 
following sections will discuss the different subfamilies of TRP channels, and will consider the role 
of TRPC channels in SOCE. 
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Figure 1.10. Predicted structure and membrane topology of TRP channels. 
Based on sequence homology and glycosylation sites, TRP channels are predicted to have six transmembrane 
segments (S1–S6), with the pore located between S5 and S6. 
Adapted from (Clapham et al., 2001) 
 
Figure 1.9. Phylogenetic tree of the TRP channels 
The TRP superfamily is comprised of canonical (TRPC), vanilloid (TRPV), melastatin (TRPM), polycystin 
(TRPP), ankyrin (TRPA) and mucolipin (TRPML) channels. 
Reproduced with permission from (Nilius et al., 2007) 
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1.3.2.2 TRPV channels 
TRPV1 was the first of the TRP-related channels to be discovered; it was identified in a cDNA 
screening assay to isolate the protein responsible for capsaicin sensitivity in neuronal cells 
(Caterina et al., 1997). TRPV1 is a non-selective Ca2+ channel activated by vanilloids (such as 
capsaicin), heat and pH (Birnbaumer, 2009). There are six TRPV subfamily members; TRPV2, 3 
and 4 were identified by their structural relationship to TRPV1 and are all activated by heat. 
TRPV1–3 can be activated by 2-APB, the commonly-used TRP channel and ICRAC inhibitor (Colton 
& Zhu, 2007), and TRPV4 is sensitive to changes in osmolarity (Plant & Strotmann, 2007). TRPV5 
and TRPV6, the only Ca2+-selective channels in the TRP superfamily, are regulated by Ca2+ and 
hormones such as vitamin D3 (Mensenkamp et al., 2007; Wissenbach & Niemeyer, 2007). 
 
TRPV channels are involved in the pathophysiology of some diseases; TRPV1 has been implicated 
in pain associated with conditions including inflammatory bowel disease, ulcerative colitis, 
osteoarthritis and pancreatitis (Yiangou et al., 2001; Fernihough et al., 2005; Nilius et al., 2007). 
TRPV2 expression is up-regulated in muscle tissue from patients with Duchenne muscular 
dystrophy (Iwata et al., 2003), and is thought to be involved in increased Ca2+ influx associated 
with the condition (Nilius et al., 2007). The expression of TRPV6 is increased in prostate cancer 
tissue and is a putative target of oestrogen-based therapies for the disease (Zhuang et al., 
2002). Due to their Ca2+ selectivity, TRPV5 and TRPV6 are thought to play a role in Ca2+ 
homeostasis; Ca2+-related disorders such as vitamin D-deficiency rickets type 1 and 
postmenopausal osteoporosis are also hypothesised to involve these channels (van Abel et al., 
2005). 
 
TRPV2 mRNA has been detected in HLMCs by microarray analysis; more recent Western blot 
analyses of bone marrow-derived mast cells, RBL-2H3 cells and LAD 2 cells revealed protein 
expression for TRPV1, TRPV2 and TRPV6 (Turner et al., 2007). Their role in mast cell function 
has not yet been determined, but TRPV channels are hypothesised to mediate Ca2+ entry in 
response to diverse stimuli including changes in the physical environment (Turner et al., 2007). 
 
1.3.2.3 TRPM channels 
The first TRPM channel to be identified was melastatin (now called TRPM1), a protein that is 
down-regulated in melanoma cells (Duncan et al., 1998). There are 8 TRPM channels; a feature 
of this subfamily is that three members have enzyme domains in the C terminus, conferring 
special properties. TRPM2 has an ADP-ribose phosphatase-related NUDIX domain that confers 
responsiveness to ADP-ribose (Eisfeld & Luckhoff, 2007); TRPM6 and TRPM7 contain a C-
terminal atypical α-kinase domain, which permits protein-protein interactions in the assembly of 
signalling complexes (Birnbaumer, 2009). TRPM channels have variable permeability to divalent 
ions, ranging from Ca2+ impermeable (TRPM4 and TRPM5) (Vennekens & Nilius, 2007) to highly 
Ca2+ and Mg2+ permeable (TRPM6 and TRPM7) (Penner & Fleig, 2007). TRPM2 is activated by 
ADP ribose, H2O2 and heat (Eisfeld & Luckhoff, 2007); TRPM4 and TRPM5 are also heat-sensitive 
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channels (Birnbaumer, 2009). In contrast, TRPM8 is a cold-activated channel that is sensitive to 
cooling agents such as menthol (Voets et al., 2007). TRPM6 and TRPM7 are regulated by 
intracellular Mg2+; a study carried out in our laboratory showed that TRPM7 channels are 
expressed in human mast cells and are essential for their survival (Wykes et al., 2007). TRPM 
channels have been implicated in a range of disorders, including malignant melanoma (TRPM1), 
taste dysfunction (TRPM5) and immune hyper-responsiveness (TRPM4). 
 
1.3.2.4 TRPA channels 
There is currently one mammalian TRPA family member, TRPA1, which is expressed in dorsal 
root ganglion (DRG) and trigeminal ganglion (TG) neurons (Garcia-Anoveros & Nagata, 2007). 
TRPA1 has a distinctive long N-terminal region, with 18 predicted ankyrin repeats. It is activated 
by pungent compounds, including isothiocyanates, which are found in mustard, wasabi and 
horseradish. Other activators include cinnamaldehyde, found in cinnamon, and allicin, produced 
from freshly crushed garlic (Garcia-Anoveros & Nagata, 2007). TRPA1 is thus considered a sensor 
of environmental irritants. 
 
1.3.2.5 TRPP channels 
Mutations in PKD1 and PKD2, the genes encoding TRPP1 and TRPP2, are associated with 
autosomal-dominant polycystic kidney disease (Witzgall, 2007). TRPP1 and TRPP2 are thought to 
interact, with TRPP1 recruiting TRPP2 to the plasma membrane (Nilius et al., 2007). There is 
limited knowledge about the activation mechanisms of TRPP channels; TRPP2 is activated by 
mechanical stress and Ca2+, and TRPP3 is thought to form a complex with PKD2L3 to form a sour 
taste receptor (Nilius et al., 2007). 
 
1.3.2.6 TRPML channels 
The TRPML subfamily consists of three mammalian members, TRPML1–3. TRPML1 is thought to 
be involved in the nuclear localisation of endosomes as it contains a nuclear localisation 
sequence. Mutations in the gene encoding TRPML1 (MCONL1) cause mucolipidosis type IV, a 
neurodegenerative lysosomal storage disorder (Nilius et al., 2007). Relatively little is known 
about TRPML2 and TRPML3. 
 
The TRP superfamily therefore represents a heterogeneous group of cation-permeable ion 
channels that are sensitive to a range of environmental stimuli and involved in the 
pathophysiology of various diseases. Channels from the TRPC subfamily, the focus of this thesis, 
are the most closely related to Drosophila TRP channels, and have a variety of physiological 
roles. The rest of this chapter will focus on TRPC channels, discussing their properties, functions 
and involvement in SOCE. 
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1.3.2.7 TRPC channels 
The seven TRPC channels share a TRP box structure near the C-terminus, containing the 
conserved amino acid sequence EWKFAR (Nilius et al., 2007). Like other TRP channels, the 
putative pore region of TRPC channels is located between S5 and S6; evidence for the 
importance of this conserved pore region was obtained from site-directed mutagenesis studies 
(Hofmann et al., 2002). The exact location of the pore helix and selectivity filter, however, has 
not yet been elucidated for TRPC channels (Dietrich et al., 2005b). TRPC channels are believed 
to function as tetrameric channel assemblies (Nilius et al., 2007). 
 
The TRPC channels are all non-selective, Ca2+-permeable cation channels that are activated 
downstream of PLC. On the basis of structural homology and functional similarities they can be 
divided into two subgroups: TRPC1/4/5 and TRPC3/6/7. TRPC2 is a pseudogene in humans so 
will not be discussed further (Yildirim & Birnbaumer, 2007). TRPC3/6/7 channels are activated by 
DAG, whereas TRPC1/4/5 channels are insensitive to DAG and thought to be sensitive to store 
depletion (Clapham et al., 2001). The following sections will discuss the properties of homomeric 
TRPC channels, along with their potential roles, activation mechanisms and 
heteromultimerisation potential. 
 
1.3.2.8 The DAG-regulated TRPC channels: TRPC3, 6 and 7 
TRPC3, 6 and 7 channels are a structurally- and functionally-related subfamily, sharing 70–80% 
amino acid homology and sensitivity to DAG (Hofmann et al., 1999; Okada et al., 1999). 
1.3.2.8.1 TRPC3 
Human (h) TRPC3 was the second member of the TRPC subfamily to be cloned using HEK-293 
cell cDNA and a TRP channel-specific probe, R34716 (Zhu et al., 1996). Human and mouse 
TRPC3 cDNA share 96.41% sequence homology, and both contain an additional exon to give rise 
to an alternative splice variant with an extended N-terminus (Yildirim et al., 2005). As with other 
TRPC channels, there is limited information available on the pore region and selectivity filter of 
TRPC3; based on analogy to voltage-gated K+ channels (Kv) and site-directed mutagenesis 
experiments with the related TRPC1 channel (Liu et al., 2003), the pore is believed to be 
between S5 and S6 (Eder et al., 2007). In support of this theory, expression of dominant-
negative TRPC6 (with mutations in the putative pore region) in HEK-293 cells expressing TRPC3 
suppressed TRPC3 channel activity (Hofmann et al., 2002). The current-voltage (I/V) relationship 
of TRPC channel currents can be used to identify the channels present; when expressed in HEK-
293 cells, TRPC3 forms a non-selective cation channel, showing both inward (negative voltages) 
and outward (positive voltages) current. The current is described as outwardly-rectifying, as the 
current at positive voltages is greater than that at negative voltages. A reversal potential (the 
voltage at which there is no net current flow) of 0mV is indicative of a non-selective ion channel. 
Shown in figure 1.11 is the current-voltage relationship of homomeric TRPC3 channels, along 
with the closely-related TRPC6 and 7 channels. 
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TRPC3 channels show considerable basal activity, which is thought to be linked to the 
glycosylation status of the channel (Dietrich et al., 2003). Activity is enhanced in response to 
stimulation of PLC-linked receptors with ligands including carbachol, histamine and ADP (Eder et 
al., 2007). In addition to direct activation by DAG produced by PLC, illustrated by application of 
the membrane-permeable analogue 1-Oleoyl-2-acetyl-sn-glycerol (OAG) to Chinese hamster 
ovary (CHO)-K1 cells expressing hTRPC3 (Hofmann et al., 1999), regulation by store depletion 
downstream of PLC activation has also been suggested (Zhu et al., 1996). Evidence for activation 
by store depletion remains limited, however, and will be discussed in section 1.3.2.11. 
 
TRPC3 has been proposed to form a macromolecular signalling complex through interactions with 
other components of the Gq-coupled PLC signalling pathway including Gq proteins, PLCβ, InsP3 
receptors and caveolin-1, a marker of lipid raft domains in the plasma membrane (Lockwich et 
al., 2001). Disruption of the actin cytoskeleton has been shown to reduce TRPC3 surface 
expression and attenuate TRPC3-mediated Sr2+ entry, suggesting that the cytoskeleton is 
responsible for TRPC3 surface expression (Lockwich et al., 2001). Putative structural motifs in 
TRPC3 that mediate interactions with other signalling molecules and structural proteins include 
ankyrin repeats that interact with PLC and caveolin, a combined interaction domain in the C-
terminus called CaM-InsP3 receptor binding site (CIRB) and a PKC interaction domain (Eder et al., 
2007). It remains to be determined whether the targeting of TRPC3 to precise membrane 
microdomains is essential for gating by DAG, or whether interactions of the channel with caveolin 
are only involved in membrane trafficking (Eder et al., 2007). 
 
PKC has been implicated in the down-regulation of TRPC3 channels; it has been shown that DAG 
activation of TRPC3 channels expressed in the DT40 chicken B-cell line is prevented when cells 
were pre-treated with phorbol 12-myristate 13-acetate (PMA) to activate PKC (Venkatachalam et 
al., 2003). Channel de-activation was retarded in the presence of a PKC inhibitor, suggesting that 
DAG induces biomodal regulation of TRPC3 channels, causing rapid activation followed by a 
slower, PKC-mediated deactivation phase (Venkatachalam et al., 2003; Eder et al., 2007).   
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TRPC3 is predominantly expressed in the specific regions of the brain (cerebellum, cortex and 
hippocampus), in the heart, and is present at high levels in embryonic tissues. It is therefore 
thought to have a role in development of neuronal and cardiac tissue (Eder et al., 2007). TRPC3 
knock-out mice showed defects in walking behaviour, indicating a critical role of TRPC3 in motor 
co-ordination (Hartmann et al., 2008). Transgenic mice where TRPC3 is over-expressed 
specifically in the heart showed cardiomyopathy, which was inhibited by disruption of the 
calcineurin gene, and cardiac myocytes isolated from these mice displayed enhanced angiotensin 
II-evoked Ca2+ entry (Nakayama et al., 2006). The role of TRPC3 channels in immune cells has 
not been extensively investigated, but has been suggested to be involved in T cell Ca2+ entry 
downstream of T cell receptor stimulation and PLCγ activation (Philipp et al., 2003).The authors 
showed that the TRPC3 gene was defective in human T cell mutants with impaired Ca2+ entry; 
expression of wild-type TRPC3 in these mutants rescued Ca2+ currents. The role of TRPC3 
channels in mast cell Ca2+ entry has not been investigated. 
 
1.3.2.8.2 TRPC6 
TRPC6 cDNA was first cloned from mouse brain in 1997, where it was shown to mediate La3+- 
and SKF-96365- sensitive calcium entry in response to GPCR stimulation when expressed in COS 
cells (Boulay et al., 1997). Human TRPC6 (hTRPC6) was isolated in 1999; expression in CHO-K1 
cells resulted in calcium entry and outwardly-rectifying currents downstream of H1 histamine 
receptor activation, as well as direct activation by OAG and SAG, another DAG analogue 
(Hofmann et al., 1999). hTRPC6 protein consists of 931 amino acids and is 93% homologous to 
mouse TRPC6  (mTRPC6) (Hofmann et al., 1999). Three splice variants of hTRPC6 have been 
reported in airway smooth muscle cells; in addition to the full length hTRPC6 cloned by Hofmann 
Figure 1.11. Current-voltage (I/V) relationships of TRPC3, 6 and 7 channels 
Channels were expressed in HEK293 cells and activated downstream of receptor stimulation. TRPC3 and 
TRPC7 have high basal activity compared with TRPC6 (see grey traces). Note that voltage is displayed to -
100mV in the negative direction and only +60mV in the positive direction; all channels are outwardly-
rectifying with a reversal potential close to 0mV. 
Reproduced with permission from (Dietrich et al., 2005b) 
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et al, Δ316-431 has a deletion in transmembrane region S1 and Δ377-431 has a shorter deletion 
in the same region (Corteling et al., 2004).  
 
Like TRPC3, TRPC6 is a Ca2+-permeable non-selective cation channel; the I/V relationship of 
TRPC6 expressed in HEK-293 cells displays inward and outward current with outward rectification 
and a reversal potential close to 0mV (see figure 1.11). In HEK cells over-expressing TRPC6 
channels (HEK-TRPC6 cells) it has been suggested that Ca2+ only forms a small percentage of 
whole-cell currents in the presence of Na+; this was shown to be dependent on the membrane 
potential, with large increases in intracellular Ca2+ occurring at negative membrane potentials 
(between -50 and -80mV), and a greater contribution from Na+ ions when the potential was 
uncontrolled (Estacion et al., 2006). These results suggest that the contribution of TRPC6 
channels to Ca2+ entry is cell-type specific and dependent upon the membrane potential, which is 
determined by the complement of ion channels present (Estacion et al., 2006; Dietrich & 
Gudermann, 2007).  
 
Unlike TRPC3 and the closely related TRPC7, TRPC6 channels are not constitutively active. It is 
thought that post-translational protein modifications are responsible for the lack of basal activity; 
TRPC6 is glycosylated at two extracellular sites (loops 1 and 2), whereas TRPC3 is glycosylated 
on the first extracellular loop only (Dietrich et al., 2003). When TRPC6 glycosylation mutants 
were expressed in HEK-293 cells, greater basal activity was observed, providing further evidence 
for the involvement of glycosylation status in basal activity (Dietrich et al., 2003). The direct 
activation of hTRPC6 channels by DAG has been demonstrated by the application of OAG, SAG, 
DOG and the DAG lipase inhibitor RHC80267 to CHO-K1 cells expressing TRPC6 (Hofmann et al., 
1999). Activation is known to be independent of PKC, as current onset was shown to be 
unaffected by a PKC inhibitory peptide in HEK-TRPC6 cells (Shi et al., 2004). Physiologically, 
TRPC6 currents are activated by DAG produced downstream of PLC-linked receptors; carbachol 
and histamine have been used to activate the channels in heterologous expression systems 
(Boulay et al., 1997; Hofmann et al., 1999; Inoue et al., 2001; Venkatachalam et al., 2003; 
Cayouette et al., 2004; Estacion et al., 2004; Shi et al., 2004; Estacion et al., 2006; Bousquet et 
al., 2010). It has been suggested that a regulated exocytosis pathway is involved in the 
activation of TRPC6; co-immunoprecipitation studies showed that the surface expression of 
TRPC6 (indicated by degree of co-immunoprecipitation with caveolin-1) was enhanced following 
Gq-coupled receptor stimulation in HEK-TRPC6 cells (Cayouette et al., 2004). In native cells, Gq-
coupled receptor activation by platelet-activating factor has been shown to activate TRPC6-like 
currents in primary human lung macrophages (Finney-Hayward et al., 2010), arginine-vasopresin 
(AVP) activated the channel in A7r5 smooth muscle cells (Jung et al., 2002), and ADP activation 
of P2Y1 GqPCRs has been reported to stimulate TRPC6-like currents in primary mouse 
megakaryocytes (Carter et al., 2006). 
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TRPC6 channels undergo complex regulation by Ca2+, along with protein serine and tyrosine 
phosphorylation (Dietrich & Gudermann, 2007). Both activation and inactivation of carbachol- 
and OAG- induced TRPC6 currents in HEK-TRPC6 cells were accelerated in the presence of 
extracellular Ca2+ compared with its absence (Shi et al., 2004). Pre-treatment of these cells with 
a calmodulin (CaM) antagonist attenuated TRPC6 activation by carbachol or OAG; current density 
was also reduced by CaM kinase II inhibition and when ATP was not present in the patch pipette. 
These results suggest that phosphorlyation by CaM kinase II is required for TRPC6 activation (Shi 
et al., 2004). PKC contributes to TRPC6 inactivation by the phosphorylation of a key serine 
residue on the channel; PMA inhibited carbachol- and OAG- evoked hTRPC6 currents in HEK-293 
cells (Estacion et al., 2004), and a PKC inhibitory peptide increased the time-course of 
inactivation (Shi et al., 2004). Recent mutagenesis studies of mTRPC6 revealed that serine 488 is 
the target for PKC phosphorylation, which mediates TRPC6 inactivation (Bousquet et al., 2010).  
Whilst PKC-mediated phosphorylation causes TRPC6 inactivation, Fyn, a Src family protein 
tyrosine kinase, has been shown to increase TRPC6 channel activity (Dietrich & Gudermann, 
2007). Immunoprecipitation experiments in COS-7 cells expressing TRPC6 showed that epidermal 
growth factor (EGF) receptor stimulation gives rise to tyrosine phosphorylation of TRPC6, and 
that Fyn and TRPC6 physically interact (Hisatsune et al., 2004). The addition of Fyn kinase to 
OAG-stimulated cells also enhanced TRPC6 currents (Hisatsune et al., 2004). A recent study 
showed that FcεRI- but not thapsigargin-evoked Ca2+ entry was impaired in Fyn-deficient mouse 
bone marrow-derived mast cells (see figure 1.12). This Ca2+ entry was sensitive to Gd3+, a 
commonly-used inhibitor of TRPC channels. Immunoprecipitation experiments confirmed that Fyn 
kinase and TRPC6 interact in mast cells; the authors concluded that TRPC6 channels are likely to 
contribute to receptor-operated Ca2+ entry downstream of FcεRI, and that Fyn kinase contributes 
to their activation (Sanchez-Miranda et al., 2010). 
 
There is growing evidence to suggest that TRPC6 has an important role in a number of 
physiological processes (Dietrich & Gudermann, 2007). TRPC6 is abundantly expressed in smooth 
muscle cells (SMCs), and has been shown using biophysical characterisation and gene 
suppression to be the α1-adrenoceptor-activated cation channel in vascular SMCs (Inoue et al., 
2001). TRPC6 is also thought to be responsible for vasopressin-evoked Ca2+ currents in an aortic 
SMC line, A7r5 (Jung et al., 2002). Whilst these results suggest that TRPC6 channels could be 
important for cardiovascular function, TRPC6-deficient mice have increased artery contractility 
(Dietrich et al., 2005c). These conflicting results are likely to be due to compensatory up-
regulation of constitutively active TRPC3 channels in the absence of TRPC6, giving rise to 
increased SMC contractility (Dietrich et al., 2005a). Gain-of-function mutations in TRPC6 are 
associated with the kidney disease focal segmental glomerulosclerosis (FSGS), which is 
characterised by proteinuria and progressive loss of kidney function (Reiser et al., 2005; Winn et 
al., 2006). It is thought that the mutations are associated with disrupted podocyte function, 
where TRPC6 is normally organised into a signalling complex with nephrin and podocin (Dietrich 
& Gudermann, 2007). 
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There are also emerging roles for TRPC6 channels in immune cells; in addition to their possible 
role in FcεRI-dependent Ca2+ entry in mast cells (discussed above), immunohistochemistry 
experiments revealed TRPC6 expression in human lung neutrophils (Li et al., 2005). TRPC6 
mRNA has also been detected in macrophages isolated from the alveolar space and lung tissues 
of patients with chronic obstructive pulmonary disease (COPD) and smokers (Li et al., 2005), and 
recent electrophysiological studies confirmed the functional expression of TRPC6 channels in 
human lung macrophages (Finney-Hayward et al., 2010). Of the TRPC channels, TRPC6 in 
particular is highly expressed in the lung compared with other organs (Li et al., 2005). Together 
these data suggest that TRPC6 channels could contribute to lung inflammation in COPD. TRPC6 
has also been implicated in the migration of immune cells; bone marrow-derived neutrophil 
granulocytes isolated from TRPC6-deficient mice showed impaired migration and Ca2+ entry in 
response to Gq-coupled chemokine receptors (Damann et al., 2009), suggesting the importance 
of TRPC6 for neutrophil chemotaxis. 
 
1.3.2.8.3 TRPC7 
TRPC7 was the last TRPC channel to be discovered; it was cloned from mouse brain using a 
TRPC2 cDNA probe to identify homologous sequences (Okada et al., 1999). Sequence 
comparison with TRPC1–6 cDNA revealed a novel TRPC homologue, which was designated 
mTRPC7 (Okada et al., 1999). hTRPC7 was isolated from human brain in 2002 as part of a 
screening programme to identify novel ion channels (Riccio et al., 2002); it shares 98% sequence 
Figure 1.12. Ca2+ entry evoked by FcεRI, but not thapsigargin, is impaired in mast 
cells from Fyn-deficient mice. 
A: Thapsigargin (thap)-evoked Ca2+ entry was of similar amplitude in bone marrow-derived mast cells 
from wild-type (black trace) and Fyn-deficient (grey trace) mice. 
B: DNP-HSA was used to cross-link IgE anti-NP bound to FcεRI; Ca2+ entry was significantly reduced 
in mast cells from Fyn-deficient mice (grey trace) compared with wild-type mice (black trace). Ca2+ 
entry was sensitive to Gd3+ (100µM), a commonly-used inhibitor of TRPC channels. 
Reproduced with permission from (Sanchez-Miranda et al., 2010) 
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homology with mTRPC7 (Numaga et al., 2007). Two splice variants of mTRPC7 have been 
reported, both with exon deletions (Okada et al., 1999). 
 
TRPC7 is a non-selective Ca2+-permeable cation channel like its relatives TRPC3 and TRPC6; the 
I/V relationship for homomeric TRPC7 is almost linear with some flattening around the reversal 
potential (see figure 1.11). Ion substitution experiments suggested that TRPC7 has permeability 
ratio of Cs:Na:Ca2+:Ba2+ of 1:1.1:5.9:5.0 (Okada et al., 1999). Like TRPC3, TRPC7 has high 
constitutive activity (see grey trace in figure 1.11), and activity is enhanced by DAG 
independently of PKC (Okada et al., 1999). Physiologically it is thought to be activated by DAG 
produced downstream of PLC-coupled receptor stimulation; GPCR stimulation by carbachol 
(Riccio et al., 2002; Shi et al., 2004) and ATP (Okada et al., 1999) has been shown to activate 
the channel in heterologous expression systems.  
 
In contrast to the complex regulation of TRPC6 channels by Ca2+, mTRPC7 is only inhibited by 
elevated concentrations of Ca2+; increasing extracellular Ca2+ to 1mM reduced the current 
density of carbachol-activated currents in HEK-TRPC7 cells, and vigorous buffering of intracellular 
Ca2+ accelerated activation by carbachol (Shi et al., 2004). Negative regulation of TRPC7 
channels by Ca2+ was inhibited by the CaM antagonist calmidazolium, indicating that Ca2+-CaM 
negatively regulates the channel (Shi et al., 2004). Like TRPC3 and TRPC6 channels, TRPC7 is 
negatively regulated by PKC; pre-treatment with PMA inhibited OAG-induced Mn2+influx in HEK-
mTRPC6 cells (Okada et al., 1999), and TRPC7 current inactivation was delayed by a PKC 
inhibitory peptide (Shi et al., 2004). Shown in figure 1.13 are experimental results obtained by 
Shi et al. (2004) illustrating the negative regulation of carbachol-activated TRPC6 and TRPC7 
channels expressed in HEK-293 cells. 
 
Relatively few physiological roles have been identified for TRPC7, compared with TRPC3 and 
TRPC6 (Dietrich et al., 2005b). It is expressed in the heart, lung and eye at high levels, with 
lower expression in the brain, spleen and testis (Okada et al., 1999). Due to its constitutive 
activity and expression patterns, it has been suggested that TRPC7 is involved in background 
currents such as pacemaking activity of sinoatrial node cells, and in the regulation of resting 
membrane potential in SMCs (Dietrich & Gudermann, 2007). 
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1.3.2.8.4 Pharmacology of the DAG-regulated TRPC channels 
As discussed above, the membrane-permeable DAG analogue OAG is frequently used to study 
the direct activation of TRPC3/6/7 channels, and they can be activated by the stimulation of Gq-
coupled receptors with ligands including carbachol, histamine and ADP. 
 
There are no selective pharmacological inhibitors of TRPC3/6/7 channels, but non-selective 
inhibitors including lanthanides, 2-APB, flufenamate and SKF-96365 have been used extensively 
to characterise the channels. 2-APB has been shown to inhibit metacholine-induced Ca2+ entry in 
HEK-TRPC3 cells in a concentration-dependent manner, with maximal (but not complete) 
Figure 1.13. PKC mediates inactivation of TRPC6 and TRPC7 channels 
A: Carbachol-evoked currents in HEK-TRPC6 cells in the presence (grey) or absence (black, ―0.1 EGTA‖) of a 
PKC inhibitory peptide. 
B: Bar graph comparing the effects of PKC inhibitors on the time-course of inactivation of TRPC6. Time-
course was significantly increased following pre-incubation with calphostin C (calC) or when PKC inhibitory 
peptide was applied intracellularly (PKC-IP), compared with control (0.1 EGTA internal solution).  
C: Bar graph comparing TRPC6 (left) and TRPC7 (right) current density at two different concentrations of 
intracellular Ca2+ (80nM, white, and 2µM, grey). Elevated concentrations of intracellular Ca2+ significantly 
caused a reduction in current density. The presence of the PKC activator PDBu significantly reduced both 
TRPC6 and TRPC7 current density, and it was increased by PKC inhibitory peptide. Together these results 
show that PKC, and intracellular Ca2+, negatively regulate TRPC6 and TRPC7 channels. 
Reproduced with permission from (Shi et al., 2004) 
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inhibition occurring at 30µM. This concentration of 2-APB also caused partial inhibition (~50%) of 
OAG- and receptor- activated Ba2+ entry in HEK cells expressing TRPC6 or TRPC7 channels 
(Lievremont et al., 2005). It is not known why 2-APB only induces partial block of TRPC3/6/7 
channels whilst completely inhibiting SOCE at the same concentrations; inhibition is thought to 
occur by different mechanisms for the two channel types (Lievremont et al., 2005). The partial 
block suggests that 2-APB inhibits TRPC3/6/7 channels allosterically and not simply by pore 
occlusion.  
 
SKF-96365 was initially characterised as an inhibitor of receptor-operated Ca2+ entry, attenuating 
ADP-evoked Ca2+ entry in platelets  with an IC50 of 8.5µM (Merritt et al., 1990). SKF-96365 has 
been shown to inhibit heterologously expressed TRPC6 channels with an IC50 of 4.2µM (Inoue et 
al., 2001), and receptor- activated TRPC6 currents in rabbit portal vein smooth muscle with an 
IC50 of 5.1µM (Inoue et al., 2001). More recently, 10µM SKF-96365 has been reported to abolish 
OAG-induced TRPC6 currents in human epithelial breast cancer cells (Guilbert et al., 2008), and 
100µM SKF-96365 inhibited receptor-operated TRPC6 currents in human lung macrophages 
(Finney-Hayward et al., 2010). An IC50 of 8µM was reported for the inhibition of TRPC3 channels 
expressed in CHO cells (Halaszovich et al., 2000). The mechanism by which SKF-96365 inhibits 
TRPC channels is largely unknown, but it is known not to compete with Ca2+ (Merritt et al., 
1990). 
 
Lanthanides (La3+and Gd3+) are commonly used to inhibit TRPC channels. Gd3+ has been shown 
to block heterologously expressed TRPC3 and TRPC6 channels with IC50 values of 2.5µM and 
2.3µM, respectively (Inoue et al., 2001; Dietrich et al., 2005b), and 100µM Gd3+ has been 
reported to completely inhibit receptor-operated Sr2+ entry in A7r5 smooth muscle cells (Broad et 
al., 1999). The sensitivity of TRPC3 channels to blockade by lanthanides has been extensively 
analysed in different systems and found to be highly variable. 250µM La3+ was required to inhibit 
Ca2+ entry through TRPC3 channels in COS-M6 cells by 40% (Zhu et al., 1996), but 150µM 
caused complete inhibition of TRPC3 channels expressed in HEK cells (Zhu et al., 1998). 200µM 
Gd3+ has been reported to abolish TRPC3 currents in HEK cells (Zhu et al., 1998), but in Chinese 
Hamster Ovary (CHO) cells, Gd3+ inhibited TRPC3 currents with an IC50 of 0.1µM; complete 
inhibition was achieved by 10µM (Halaszovich et al., 2000). It has been suggested based on 
inside-out patch-clamp experiments that lanthanides act on TRPC channels from the intracellular 
side of the membrane, and that the concentration required to block the channel is dependent 
upon cell type-specific lanthanide uptake rates (Halaszovich et al., 2000). These observations 
highlight the importance of establishing an appropriate concentration of Gd3+ for TRPC channel 
inhibition in a particular cell type. Experiments in DT40 chicken lymphocytes showed that the 
addition of Gd3+ causes rapid inhibition of fully-developed hTRPC3-mediated Ca2+ entry, 
suggesting that the lanthanide directly blocks the channel (Trebak et al., 2002). 
 
The non-steroidal anti-inflammatory agent flufenamic acid (FFA) is a non-selective cation channel 
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blocker (Tu et al., 2009a) with complex effects on the TRPC subfamily. Whilst FFA inhibits 
TRPC3- and TRPC7-mediated currents when the channels are expressed in HEK-293 cells and 
activated by carbachol (Inoue et al., 2001), it has been shown to potentiate mTRPC6 channel 
activity at 100-500µM in these cells (Inoue et al., 2001). Potentiation of agonist-activated 
currents by FFA, along with current properties, has been used as a diagnostic tool for TRPC6 
currents in a number of systems, including A7r5 smooth muscle cells (Jung et al., 2002), primary 
megakaryocytes (Carter et al., 2006) and cortical neurons (Tu et al., 2009b). It has recently been 
shown in human podocytes that 200µM FFA stimulates 2-APB and SKF-96365- sensitive Ca2+ 
entry, which is abolished by dominant negative TRPC6 expression; the authors concluded that 
FFA is a tool to selectively activate TRPC6 channels and study them in native cells (Foster et al., 
2009). 
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1.3.2.9 DAG-independent TRPC channels: TRPC1, 4 and 5 
TRPC1, 4 and 5 form a structurally-related subfamily of channels. Like TRPC3/6/7 channels they 
are activated downstream of PLC, but their activation is independent of DAG and less well-
defined than that for the TRPC3/6/7 subgroup. There is growing evidence to suggest that 
channels from the TRPC1/4/5 subgroup are activated by store depletion; this will be discussed in 
section 1.3.2.11. Described in this section are the properties of TRPC1, 4 and 5 channels, along 
with the genes and discovery. 
 
1.3.2.9.1 TRPC1 
TRPC1 was the first member of the mammalian TRP family to be discovered; it was identified in 
a screen of the Genbank database for homologues of Drosophila TRP channels and cloned from 
foetal human brain cDNA (Zhu et al., 1995). The TRPC1 protein was later expressed in CHO-K1 
cells and gave rise to non-selective currents activated by store depletion (Zitt et al., 1996). There 
are two splice variants of hTRPC1, TRPC1 and TRPC1A (Zitt et al., 1996); whilst four splice 
variants exist in mouse, two of these are highly truncated and thought to be non-functional 
(Sakura & Ashcroft, 1997; Rychkov & Barritt, 2007). In the TRPC1 N-terminal region, three 
ankyrin repeats have been identified, along with a binding site for caveolin-1. Calmodulin and 
InsP3 receptor binding sites at the C-terminal region have also been found (Rychkov & Barritt, 
2007). A number of studies employing immunofluorescence techniques have investigated the 
intracellular localisation of TRPC1. The channels have been shown, in heterologous expression 
systems and in native cells, to be present at both the plasma membrane, where they co-localise 
with cholesterol-rich lipid rafts (Lockwich et al., 2001), and at intracellular sites including the ER 
and Golgi membranes. (Wang et al., 1999; Xu & Beech, 2001; Uehara, 2005).  
 
Of the TRPC channels, the structure and pore region have been most extensively investigated for 
TRPC1. The membrane topology has been investigated using truncation mutants of TRPC1 
channels expressed in HEK-293 cells. Whilst TRPC1 contains 8 hydrophobic regions (HRs) that 
could potentially span the membrane, only 6 form membrane-spanning subunits. HR 3 is thought 
to sit outside the membrane on the cytosolic side, whereas HR7 is suggested to reside in the 
membrane but not span it (Dohke et al., 2004). Figure 1.14 indicates the predicted membrane 
topology of TRPC1. Neutralisation of negatively charged residues in the TM5-TM6 region of 
TRPC1 gave rise to reduced Ca2+ currents when the mutants were expressed in HEK-293 cells 
(Liu et al., 2003). Taken together with the more extensive studies into voltage-gated K+ and Ca2+ 
channels, which are used as models for the structure and topology of TRP channels (Rychkov & 
Barritt, 2007), the results obtained by Liu et al. (2003) suggest that negatively charged residues 
located close to the TM5-TM6 pore regulate ion flow thorough TRPC1 channels. 
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In the initial characterisation of TRPC1, it was found to produce a linear, non-selective cation 
channel with a reversal potential close to 0mV and an estimated single channel conductance of 
16 picosiemens when expressed in CHO-K1 cells (Zitt et al., 1996). Currents with similar 
properties were recorded in Sf9 insect cells transfected with TRPC1 (Sinkins et al., 1998). The 
activation of TRPC1 by Ca2+ store depletion is discussed below in section 1.3.2.11. In addition to 
this mode of activation, TRPC1 channels have been suggested as components of a store 
depletion-independent channel activated by mechanical stretch, called mechanosensitive cation 
channel (MscCa), in Xenopus laevis oocytes (Maroto et al., 2005).  
 
TRPC1-mediated Ca2+ entry has been suggested to have an important physiological role in 
replenishing depleted intracellular Ca2+ stores (Rychkov & Barritt, 2007). As they are also 
permeable to Na+, TRPC1 channels have also been proposed to have a role in Na+ entry in 
excitable cells, leading to membrane depolarisation and the activation of transporters and 
exchangers (Eder et al., 2005). In  contrast to some TRPC channels, TRPC1 is widely expressed 
in many animal tissues, including brain, heart, lung, smooth muscle, salivary gland and liver (Wu 
et al., 2010); this extensive expression suggests that the channel may serve a range of functions 
in different cell types. TRPC1-deficient mice have been reported to show increased weight 
(Dietrich et al., 2007) and impaired salivary gland secretion (Liu et al., 2007) due to defects in 
SOCE. In line with this observation, TRPC1-deficient human salivary gland (HSG) cells exhibit 
impaired Ca2+ entry (Cheng et al., 2011), providing further evidence for the involvement of 
TRPC1 channels in salivary gland function. Ca2+ entry through TRPC1 is also thought to have a 
role in the regulation of nerve growth cone movement downstream of netrin-1 receptor 
activation and store depletion (Wang & Poo, 2005). 
 
The function of TRPC1 channels in immune cells has not been extensively characterised, but 
TRPC1 mRNA has been detected in human skin mast cells (Bradding et al., 2003), B 
lymphoblasts (Roedding et al., 2006) and the human T-cell line HPB-ALL (Rao & Kaminski, 2006). 
A recent study in mouse bone marrow-derived mast cells showed that siRNA knock-down of 
TRPC1 channels caused defects in Ca2+ influx and degranulation downstream of FcεRI cross-
Figure 1.14. Predicted membrane topology of TRPC1 channels 
Whilst TRPC1 is predicted to have 8 hydrophobic segments, only 6 are thought to span the membrane.  
Figure reproduced from (Dohke et al., 2004); copyright permission not required from the Journal of Biological Chemistry. 
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linking (Suzuki et al., 2010). Given its expression in the lung, it is reasonable to hypothesise that 
TRPC1 channels could also be expressed in HLMCs and have a role in the essential Ca2+ entry 
required for mediator release. 
 
1.3.2.9.2 TRPC4 
TRPC4 cDNA was initially cloned from bovine adrenal gland as a store-operated, Ca2+ and Ba2+-
permeable cation channel (Philipp et al., 1996); the human homologue was cloned from a kidney 
cDNA library (McKay et al., 2000). Like the other TRPC channels, TRPC4 contains N-terminal 
ankyrin repeats, the TRP box and a CaM binding site (Cavalie, 2007). Uniquely to TRPC4 and 
TRPC5, however, it contains a PDZ-binding site (Tang et al., 2001). PDZ domains are protein-
protein interaction sites involved in the organisation of signalling complexes. The PDZ binding 
domain is known to be important for the assembly of TRPC4 channels in signalling complexes at 
the plasma membrane; TRPC4 mutants lacking the PDZ binding domain have reduced surface 
expression (Mery et al., 2002). 
 
Homomeric TRPC4 and TRPC5 channels have a unique s-shaped current-voltage relationship 
(shown in figure 1.15), which is often described as ―doubly-rectifying‖, and a reversal potential 
close to 0mV. The factors contributing to the unique I/V relationship have been studied in more 
depth for TRPC5 (section 1.3.2.9.3) than TRPC4 so will be discussed below. In most studies 
investigating homomeric TRPC4 channels they have been activated downstream of GPCRs using 
carbachol as a ligand (Philipp et al., 1996; Schaefer et al., 2000; Plant & Schaefer, 2003). Like 
the related TRPC1 and TRPC5 channels, they are thought to be activated by store depletion; this 
is discussed below in section 1.3.2.11.  
 
TRPC4-deficient mice exhibit reduced Ca2+ entry in aortic endothelial cells and acetylcholine-
induced vasorelaxation of aortic rings, suggesting that TRPC4 channels have a role in vascular 
function (Freichel et al., 2001). Ca2+ entry in lung vascular endothelial cells in response to 
thrombin stimulation was also reduced in these mice. TRPC4-deficient mice have also been used 
to reveal a role for the channel in the brain; 5-hydroxytryptamine (5-HT)-coupled Ca2+ entry 
leading to GABA release in thalamic relay neurons was shown to be defective (Munsch et al., 
2003). Studies in chromaffin and PC12 cells have shown that TRPC4-mediated Ca2+ entry can 
trigger a secretory response (Obukhov & Nowycky, 2002); TRPC4 has also been suggested to 
have a role in the depolarisation of neurons and smooth muscle cells (Cavalie, 2007). TRPC4 is 
thus likely to have a number of physiological roles in excitable cells; there are no reports of its 
expression or functional roles in cells of the immune system. 
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1.3.2.9.3 TRPC5 
TRPC5 was initially cloned from mouse brain (Okada et al., 1998); human TRPC5 (hTRPC5) was 
cloned as part of a screen of the X chromosome for genes involved in non-syndromic mental 
retardation (Sossey-Alaoui et al., 1999). Like the other TRP channels, TRPC5 is believed to have 
six membrane-spanning regions with intracellular N- and C-termini. Similarly to TRPC4, 
homomeric TRPC5 channels in heterologous expression systems have a characteristic s-shaped, 
doubly-rectifying I/V relationship, which is shown in figure 1.15. The unique I/V relationship of 
TRPC5 is thought to be due in part to its voltage-dependence; whilst the channel is not voltage-
gated, it can be modulated by voltage once switched on by another mechanism (Beech, 2007). 
Hyperpolarisation has been suggested to enhance opening of the channel, giving rise to the 
inwardly-rectifying component (Beech, 2007). TRPC5 has an estimated single channel 
conductance of 41 picosiemens (Jung et al., 2003) and is permeable to Ca2+, Ba2+, Mn2+ and 
Sr2+, as well as monovalent cations including Na+ (Okada et al., 1999; Schaefer et al., 2000; 
Venkatachalam et al., 2003; Beech, 2007). As described for TRPC1, amino acids between TM5 
and TM6 are likely to form the selectivity filter for TRPC5; mutation of the leucine-phenylalanine-
tryptophan sequence to alanine-alanine-alanine gives rise to a dominant negative TRPC5 mutant 
with damaged ion flux (Strubing et al., 2003). 
 
Figure 1.15. TRPC4 and TRPC5 currents activated by carbachol 
Carbachol was applied to HEK293 cells expressing mTRPC4 (A,C) or mTRPC5 (B,D). A and B show the time-
course of current activation; I/V relationships are shown in C and D. Note the characteristic s-shaped I/V 
relationship of these channels. 
Reproduced with permission from (Plant & Schaefer, 2003) 
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TRPC5 is known to be activated by a multiplicity of signals. In addition to activation by store 
depletion, which is described in section 1.3.2.11, store-independent receptor activation is known 
to take place. Carbachol-evoked Ca2+ entry in HEK-293 cells expressing TRPC5 (HEK-TRPC5 cells) 
was reduced, but not inhibited by thapsigargin pre-treatment (Zeng et al., 2004), indicating that 
the channel is involved in both store-dependent and –independent Ca2+ entry downstream of 
receptor activation. Receptor activation of TRPC5 has been described following carbachol 
application to CHO-K1 cells expressing mTRPC5 (Schaefer et al., 2000), prostaglandin E2 
stimulation of Xenopus laevis oocytes (Tabata et al., 2002), and B cell receptor cross-linking in 
DT40 B cells (Venkatachalam et al., 2003). DAG is not involved in the activation of TRPC5 
channels following receptor stimulation; application of OAG or elevation of DAG concentration by 
a DAG lipase inhibitor inhibited the activation of TRPC5. This inhibition was relieved in the 
presence of a PKC inhibitor, indicating that the inhibitory action of DAG on TRPC5 occurs via PKC 
(Venkatachalam et al., 2003). This is in contrast to the stimulatory action of DAG on TRPC3/6/7 
channels, which is PKC-independent (Hofmann et al., 1999). 
 
Another mechanism of action for TRPC5 channels is external ionic activation. Whilst lanthanides 
such as Gd3+ potentiate mTRPC5 and inhibit TRPC1, 3, 6 and 7, hTRPC5 is activated by Gd3+ in 
the absence of any other stimuli (Zeng et al., 2004). This striking feature of hTRPC5 was 
demonstrated using HEK-TRPC5 cells; it was shown that 100µM Gd3+ gave rise to Ca2+ entry and 
whole-cell currents that were not inhibited by GDP-β-S, indicating the lack of involvement of G 
proteins (Zeng et al., 2004). The stimulatory effect of lanthanides on TRPC5 channels was 
investigated in more detail in HEK-mTRPC5 cells, where it was shown that at concentrations 
greater than 1µM, Gd3+ and La3+ potentiated TRPC5 currents in a concentration-dependent 
manner. Inhibition of the currents occurred at millimolar concentrations of lanthanide. Shown in 
figure 1.16 are the effects of lanthanides on TRPC5 channels, compared with TRPC6 channels. 
Neutralisation of negatively charged amino acids (glutamic acid 543, 595 and 598) situated 
extracellularly and close to the putative pore-forming loop of TRPC5 gave rise to a loss of La3+ 
potentiation (Jung et al., 2003), indicating that these residues are responsible for the stimulatory 
effects of lanthanides. Identical amino acids are present at corresponding sties in TRPC4, which 
is also potentiated by lanthanides, but not in TRPC3/6/7 (Jung et al., 2003). Activation by 
lanthanides thus provides a way to selectively study TRPC4 and TRPC5 channels whilst inhibiting 
the other TRPCs. 
 
5–10mM extracellular Ca2+ has also been reported to stimulate hTRPC5 channels expressed in 
HEK-293 cells. The steep concentration-response curve and rapid desensitisation resembled the 
response to Gd3+ (Zeng et al., 2004), and the authors suggested that both ions act at a common 
extracellular site to mediate external ionic activation of TRPC5 channels.  
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Sphingosine-1-phosphate has been identified as an activator of TRPC5 channels in a screen of 
potential lipid regulators using HEK-TRPC5 cells (Xu et al., 2006b). It was reported to give rise to 
Ca2+ entry in TRPC5-expressing, but not non-expressing, cells in a concentration-dependent 
manner. S1P was also shown to activate TRPC1-TRPC5 heteromeric assemblies expressed in HEK 
cells, but not TRPC1 channels alone (Xu et al., 2006b). When applied to human saphenous vein 
SMCs, S1P gave rise to Ca2+ entry that had two phases, both of which were sensitive to the 
inhibitory TRPC5 antibody T5E3. The mechanisms of action of S1P on TRPC5 channels were 
further investigated in HEK-TRPC5 cells; treatment with pertussis toxin or the PLC inhibitor 
U73122 inhibited S1P-evoked Ca2+ entry, indicating the respective involvement of Gi/o-coupled 
receptors and PLC. A recent study suggested that group 6 phospholipase A2 (PLA2) enzymes, 
which release the fatty acids lysophosphatidylcholine (LPC) and arachidonic acid (AA) from 
glycerol, are involved in the activation of TRPC5 by extracellular S1P (Al-Shawaf et al., 2011). An 
intracellular mechanism of action of S1P has also been suggested; it was reported to elicit single-
Figure 1.16. The effects of lanthanides of mTRPC5 and mTRPC6 channels expressed in 
HEK293 cells 
A: Dual effects of lanthanides on histamine-activated TRPC5 currents; graph shows whole-cell currents 
recorded at -60mV. µM concentrations of Gd3+ caused potentiation. 5mM La3+ (inset) inhibited TRPC5 
currents. B: Inhibition of receptor-operated TRPC6 currents by increasing concentrations of La3+. C: 
Concentration-dependent effects of lanthanides on TRPC5 channels. D: Concentration-dependent 
effects of lanthanides on TRPC6 channels. 
Reproduced from (Jung et al., 2003); copyright permission not required from the Journal of Biological Chemistry. 
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channel events in inside-out patch clamp experiments of HEK-TRPC5 cells (Xu et al., 2006b). As 
S1P can be transported across the membrane or accumulate intracellularly following activation of 
S1P receptors (Saba & Hla, 2004), it was concluded that TRPC5 can be activated by S1P by two 
different mechanisms; TRPC5 can act as an ionotropic receptor for intracellular S1P, or become 
activated downstream of PLC production following S1P receptor stimulation (Xu et al., 2006b). 
S1P is a complex signalling molecule, regulating many physiological processes through binding its 
receptors (S1P1-5) and by intracellular mechanisms (Strub et al., 2010). In mast cells S1P1 is 
important for chemotaxis and S1P2 contributes to degranulation (Jolly et al., 2004). This 
highlights the potential importance of TRPC5 in mediating inflammatory cell activation. 
Interestingly, S1P has been found at increased levels in the airways of asthmatic patients 
compared with non-asthmatics (Ammit et al., 2001); S1P in the lung may therefore represent an 
important mechanism for mast cell activation in asthma. 
 
Reduced thioredoxin has also been shown to activate TRPC5 channels expressed in HEK-293 
cells, along with TRPC5-like currents in fibroblast-like synovial cells taken from patients with 
rheumatoid arthritis (Xu et al., 2008). TRPC5 is thus activated by a range of different agonists, 
indicating that it is a versatile sensor with the potential to mediate Ca2+ entry in response to 
different stimuli. 
 
Despite extensive research into the activation and properties of heterologously expressed TRPC5 
channels, its physiological roles have not been thoroughly characterised. TRPC5-deficient mice 
have no obvious defects, although they have been reported to show less anxiety-like behaviour 
(Riccio et al., 2009). TRPC5 has been implicated in the regulation of neuronal growth cone 
extension; expression of dominant negative TRPC5 in hippocampal neurones led to enhanced 
growth cone extension (Greka et al., 2003). A TRPC5-like current activated by muscarinic 
receptor stimulation has been reported in stomach SMCs, suggesting that the channel could be 
involved in acetylcholine-induced SMC depolarisation (Lee et al., 2003b). S1P-evoked SMC 
motility was inhibited by an inhibitory TRPC5 antibody, the non-selective TRPC5 inhibitor 2-APB 
and dominant negative TRPC5, suggesting that S1P sensing by TRPC5 causes SMC motility. The 
physiological role of TRPC5 channels has not been extensively characterised in the immune 
system, but one study (discussed below in section 1.3.2.11) showed that TRPC5 could contribute 
to FcεRI-evoked degranulation in RBL-2H3 cells (Ma et al., 2008).  
 
1.3.2.9.4 Pharmacology of TRPC1/4/5 channels 
As with TRPC3/6/7 channels, there are no selective inhibitors of TRPC1, 4 and 5. The lanthanide 
Gd3+, whilst activating TRPC4 and 5 in the micromolar range, has been used extensively to inhibit 
TRPC1 channels (Rychkov & Barritt, 2007); 10µM Gd3+ inhibits TRPC1 channels expressed in 
CHO-K1 cells (Zitt et al., 1996). Lanthanides at millimolar concentrations can be used to inhibit 
TRPC4 and TRPC5 channels; 5mM La3+ and Gd3+ were shown to inhibit histamine-activated 
TRPC5 channels expressed in HEK-293 cells (Jung et al., 2003). 100µM 2-APB has been shown to 
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inhibit TRPC1 channels expressed in HEK-293 cells (Zagranichnaya et al., 2005). TRPC5 is 
inhibited by 2-APB with an IC50 of 20µM in HEK-TRPC5 cells (Xu et al., 2005a). Outside-out patch 
clamp recordings revealed that 2-APB inhibits TRPC5 channels from the extracellular side of the 
membrane, and mild voltage-dependence of inhibition occurred, indicating that 2-APB may 
interfere with channel gating (Xu et al., 2005a). The non-selective TRPC channel blocker SKF-
96365 has been shown to inhibit receptor-activated TRPC5 and store-operated TRPC1 expressed 
in HEK-293 cells (Okada et al., 1998; Zagranichnaya et al., 2005). FFA has been shown to inhibit 
TRPC5-like currents in mouse SMCs at a concentration of 100µM (Lee et al., 2003b). The lack of 
selective pharmacological inhibitors of TRPC channels means that they are very difficult to study 
in native cells.  However, when used in combination with electrophysiological studies to analyse 
the properties of currents stimulated with known activators of the channels, pharmacological 
inhibitors can provide useful information on the channels present. Inhibition of a TRPC-like 
current by 10µM Gd3+, for example, would indicate that TRPC4 and TRPC5 channels are not 
involved. 
 
1.3.2.10 Heteromultimerisation potential of TRPC channels 
A number of experimental approaches were employed by Hofmann et al. (2002) to determine 
the heteromultimerisation potential of TRPC channels. Cellular co-trafficking experiments 
revealed that wild-type TRPC3 and TRPC6 could traffick a targeting-deficient TRPC6 mutant to 
the cell membrane, and that TRPC4 could target a defective TRPC1. A dominant-negative TRPC6 
mutant was shown to suppress TRPC3 and TRPC6 currents, but not those mediated by TRPC4 or 
TRPC5. Fluorescence resonance energy transfer (FRET) experiments showed that TRPC channels 
can can assemble into homo- or hetero-tetramers within the confines of the TRPC1/4/5 and 
TRPC3/6/7 subfamilies; immunoprecipitation experiments of c-myc tagged TRPC subunits 
confirmed these observations (Hofmann et al., 2002). Co-immunoprecipitation studies in rat 
brain synaptosomes were in accordance with these results, showing that interactions can occur 
within, but not between, TRPC channel subgroups. More recently, novel interactions between 
TRPC1 plus TRPC4 or TRPC5 with TRPC6 have been reported in the rat embryonic brain but not 
in adult brain (Strubing et al., 2003). This suggests that novel TRPC channel complexes between 
the two subgroups may play a role in neuronal development. Novel interactions between the 
subgroups have also been suggested based on co-immunopreciptation studies of TRPC subunits 
expressed in HEK-293 cells; TRPC3 was precipitated with TRPC1 in the presence of STIM1, and 
TRPC6 with TRPC4 (Yuan et al., 2007).  
 
In some cases, the I/V relationship can be analysed to assess whether a homomeric or 
heteromeric TRPC current is present in native cell types. For example, whilst homomeric TRPC5 
channels have a characteristic s-shaped I/V relationship, TRPC5-TRPC1 heteromeric assemblies 
expressed in HEK-293 cells give rise to a more outwardly-rectifying relationship, without 
inflection near 0mV (Xu et al., 2006b). 
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To summarise, a large body of experimental evidence supports the heteromeric assembly of 
TRPC channels within subgroups. There is, however, emerging evidence to suggest that novel 
assemblies across subgroups may occur, which could extend the functional diversity of TRPC 
channels. 
 
1.3.2.11 TRPC channels and store-operated Ca2+ entry 
TRPC channels were originally proposed to be the molecular determinants of ICRAC when they 
were identified as PLC-activated channels in Drosophila photoreceptors (Hardie & Minke, 1992). 
Electrophysiological evidence later revealed that TRPC channels do not possess the same 
biophysical properties as ICRAC and have larger conductance than Orai1 channels (Parekh & 
Putney, 2005; Ma & Beaven, 2011); TRPC channels also lack the Ca2+ selectivity of ICRAC, 
conducting other divalent ions such as Ba2+ and Sr2+ (Ma et al., 2008). As SOCE channels are 
thought to encompass a family of channels with distinct properties (Parekh & Putney, 2005), it 
has been proposed that TRPC channels form another type of SOCE channel, distinct from ICRAC 
and sometimes referred to as ISOC (Parekh & Putney, 2005; Cheng et al., 2011). 
 
A number of reports have suggested that TRPC channels, especially from the TRPC1/4/5 
subgroup, are regulated by STIM1; in the first studies it was shown that STIM1 co-
immunoprecipitates with TRPC1, 4 and 5 but not with TRPC3, 6 and 7 in HEK-293 cells (Huang et 
al., 2006). The same study revealed that STIM1 gates TRPC1 via the STIM1 cytoplasmic ERM 
domain; this was extended to other TRPC channels to show that TRPC1, 3, 4, 5 and 6 are gated 
by STIM1 (Yuan et al., 2007). This study showed that STIM1 regulates TRPC1, 4 and 5 by direct 
interaction, and indirectly regulates TRPC3 and 6 by mediating their interaction with TRPC1 and 
4, respectively. The authors proposed that SOCE channels are those that are regulated by STIM1 
and require store depletion-dependent STIM1 clustering; all TRPCs except TRPC7 function as 
SOCE channels by this definition (Yuan et al., 2007). In contrast, one study reported that TRPC 
channel activity is not affected by STIM1 knock-down, and co-expression of STIM1 does not 
enhance the activity of TRPC channels transiently expressed in HEK-293 cells (DeHaven et al., 
2009). However, there is a large body of evidence from a number of different laboratories 
supporting the regulation of TRPC channels by STIM1. In addition to the data discussed above, 
TRPC1 and STIM1 were shown to co-immunoprecipitate in mouse pancreatic acinar cells; store 
depletion with thapsigargin enhanced their interaction (Hong et al., 2011). Similar results were 
obtained using co-immunoprecipitation in mouse pulmonary artery smooth muscle cells and 
human saphenous vein smooth muscle cells (Li et al., 2008; Ng et al., 2009), indicating the 
association of STIM1 and TRPC1 in native cells. Mutagenesis studies revealed that the gating of 
TRPC1, but not Orai1, involves electrostatic interactions between two negatively charged 
aspartate residues in the TRP box region of TRPC1 (residues 639 and 640) and two positively 
charged lysine residues (684 and 685) in the STIM1 ERM domain (Zeng et al., 2008). Mutation of 
these positively charged residues to negatively charged glutamic acid residues (684EE685) 
produces a STIM1 mutant that lacks the ability to gate TRPC1; expression of STIM1684EE685 in 
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human salivary gland (HSG) cells suppressed thapsigargin-evoked SOCE (Cheng et al., 2011). As 
the TRP box is conserved across the TRPC channels, it has been suggested that electrostatic 
interactions also mediate contacts between STIM1 and other TRPC channels (Lee et al., 2010).  
 
As suggested by Yuan et al. (2007), regulation by STIM1 can be used to define TRPC channels as 
SOCE channels. A number of other approaches have also been taken to demonstrate the 
involvement of TRPC channels, especially TRPC1, in SOCE in a number of different cell types. 
TRPC1 was first implicated as a SOCE channel based on heterologous expression studies in 
Chinese hamster ovary (CHO) cells; TRPC1 expression enhanced Ca2+ entry following store 
depletion and gave rise to InsP3- and thapsigargin-induced non-selective currents in whole-cell 
patch clamp studies (Zitt et al., 1996). The role of native TRPC1 channels in SOCE has been 
extensively investigated in salivary gland cells, where RNA knock-down of TRPC1 has been 
shown to attenuate SOCE in mouse and human (Liu et al., 2007; Ong et al., 2007). Over-
expression of TRPC1 increased SOCE, and the expression of TRPC1 with a mutated putative pore 
region (TRPC1 Δ567-793) reduced thapsigargin- and carbachol-evoked SOCE in human salivary 
gland (HSG) cells (Liu et al., 2003; Ong et al., 2007). Suppression of TRPC1 currents by shRNA 
or the expression of a STIM1 mutant lacking TRPC1 gating was reported to reveal store-operated 
ICRAC currents, which are masked by the larger TRPC1 currents in HSG cells when both channels 
are activated following store depletion (Cheng et al., 2011). Together, these data indicate that 
TRPC1 is a functional component of SOCE in salivary gland cells. Genetic knock-down of TRPC1 
has been shown to attenuate thapsigargin-evoked SOCE in B lymphocytes (Mori et al., 2002);  
inhibition of the channel with an inhibitory TRPC1 antibody (T1E3) reduced SOCE in human 
arterial smooth muscle cells (Xu & Beech, 2001). In the human liver HL-7702 cell line, over-
expression of STIM1 and TRPC1 gave rise to a 2.5-fold increase in thapsigargin-induced SOCE 
(Zhang et al., 2010b). In HEK-293 cells, over-expression of TRPC1 has been reported to increase 
SOCE and thapsigargin-induced non-selective cation currents (Cheng et al., 2008), and enhance 
Ba2+ entry following thapsigargin application (Wu et al., 2000). 
 
A number of reports have suggested that Orai1 is functionally required for store-operated TRPC1 
channels. In human platelets, TRPC1 and Orai1 were reported to co-immunoprecipitate; this 
interaction was prevented by an antibody to the Orai1 C-terminus that inhibits STIM1-Orai1 
interaction (Jardin et al., 2008). The authors concluded that Orai1 is required for the interaction 
of STIM1 and TRPC1, and that STIM1 interacts with TRPC1 and Orai1 channels in a complex 
following store depletion. The concept of a STIM1-Orai1-TRPC1 ternary complex was supported 
by immunocytochemistry data showing that TRPC1 and Orai1 channels strongly co-localise in the 
plasma membrane in HSG cells; co-localisation of STIM1 and TRPC1 as well as STIM1 and Orai1 
was enhanced by thapsigargin pre-treatment (Ong et al., 2007). TRPC1 and Orai1 were also 
shown to interact by co-immunoprecipitation in HSG cells; interaction was found to increase 
following store depletion (Ong et al., 2007). The authors suggested that a STIM1-Orai1-TRPC1 
ternary complex is involved in SOCE, and that all three proteins are essential for SOCE. It has 
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been reported that a complex of STIM-1, Orai1 and TRPC1 can be co-immunoprecipitated from 
HEK cells expressing the three proteins, and treating HEK cells with TRPC1 siRNA has been 
shown to reduce STIM1-Orai1 interaction (Ong et al., 2007; Kim et al., 2009b). Additionally, 
Orai1 siRNA was reported to reduce STIM1-TRPC1 interaction, suggesting that the interaction of 
TRPC1 and Orai1 with STIM1 is enhanced by the presence of both channels (Kim et al., 2009b). 
The expression of Orai1 in TRPC1-expressing HEK cells has also been shown to enhance SOCE 
(Liao et al., 2009). Whilst all these experiments suggest that store-operated TRPC1 channels are 
functionally dependent on Orai1 channels, co-immunoprecipitation and siRNA studies do not 
provide evidence for the direct interaction of TRPC1 and Orai1 channels.  
 
It has recently been proposed that the surface expression of TRPC1 is affected by Orai1-
mediated SOCE, but that the channels do not form a heteromeric assembly (Cheng et al., 2011). 
The authors showed that Orai1-mediated ICRAC currents, detected by the characteristic inwardly-
rectifying I/V relationship, are present when TRPC1 is knocked-down by shRNA in HSG cells. 
Similar results were obtained when a STIM1 mutant lacking TRPC1 gating was expressed; it was 
concluded that SOCE in HSG cells is composed of a large TRPC1 current and a separate smaller 
ICRAC current mediated by Orai1. Plasma membrane insertion of TRPC1, which is enhanced by 
thapsigargin treatment, was shown to be partially dependent on Orai1; expression of the 
dominant negative Orai1 mutant E106Q reduced the surface expression of TRPC1 following store 
depletion (Cheng et al., 2011).  TRPC1 trafficking was not affected by the expression of a STIM1 
mutant defective in TRPC1 gating, but channel activation was suppressed under these 
conditions. Novel experiments revealed that TRPC1 and Orai1 co-immunoprecipitate following 
store depletion, but this was inhibited in the presence of STIM1 siRNA. The authors concluded 
that STIM1 is required for the activity of TRPC1 following store depletion, but Orai1-mediated 
SOCE is required for its surface expression. A model was proposed where TRPC1 is present in 
recycling vesicles; following store depletion STIM1 interacts with TRPC1 to retain the vesicles at 
the cell surface, and recruits Orai1 to the same plasma membrane microdomains. Ca2+ entry via 
Orai1 was proposed to cause plasma membrane insertion of TRPC1 channels and subsequent 
gating of TRPC1 by STIM1. This model of TRPC1 and Orai1 functional dependence is illustrated 
in figure 1.17; it accounts for previous observations that TRPC1 and Orai1 co-localise (Ong et al., 
2007; Jardin et al., 2008), that this interaction is enhanced by store depletion (Ong et al., 2007), 
and that TRPC1-STIM1 interactions are inhibited by Orai1 siRNA (Kim et al., 2009a). It therefore 
represents a likely scenario for the dependence of TRPC1 channels on Orai1-mediated SOCE in 
other cell types. 
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Figure 1.17. Model for TRPC1 activation by store depletion 
STIM1 is located in the ER membrane, and Orai1 in the plasma membrane. TRPC1 is hypothesized 
to be localised in vesicles. Following store depletion, STIM1 aggregates and translocates to the 
plasma membrane, activating Orai1 channels. Orai1-mediated Ca2+ entry enhances TRPC1 
insertion into the plasma membrane where it is gated by STIM1 to cause further SOCE. 
Adapted from (Cheng et al., 2011) 
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The plasma membrane localisation of TRPC1 and Orai1 channels is controlled by cholesterol- and 
sphingomyelin- rich regions called lipid rafts (Lingwood & Simons, 2010). Caveolin 1 has been 
shown to regulate the localisation of TRPC1 (Brazer et al., 2003), and STIM1-Orai1 association 
has recently been shown to be controlled by the ordering of lipids. The association of the two 
proteins is enhanced by ordered PtdIns(4,5)P2 and reduced by disordered PtdIns(4,5)P2; the 
balance is determined by different isoforms of PIP5 kinase (Calloway et al., 2011). PIP5 kinase-β 
enhances the ordering of PtdIns(4,5)P2 and the association of STIM1 and Orai1, whereas PIP5 
kinase-γ negatively regulates these processes (Calloway et al., 2011). Proteins are also crucially 
involved in determining plasma membrane structure and lipid order, and interactions between 
proteins and lipids bring about complexity in membrane structure (Lingwood & Simons, 2010). 
Interestingly, it has been shown in HEK-293 cells that TRPC1 associates into plasma membrane 
lipid rafts only when STIM1 is co-expressed; total internal reflection fluorescence (TIRF) 
microscopy experiments revealed that TRPC1-caveolin co-localisation was observed in 76% of 
cells when STIM1 was present, but only 11% when STIM1 was not present. Disruption of lipid 
rafts using the cholesterol-sequestering agent methyl-β-cyclodextrin (MβCD) in this study 
reduced thapsigargin-induced TRPC1 currents by 80%, suggesting that lipid raft assembly is 
essential for the store-operated behaviour of TRPC1 (Alicia et al., 2008). Another study showed 
that TRPC1 and STIM1 co-localisation in lipid rafts was inhibited by MβCD in HEK-293 and HSG 
cells; this inhibition was reversed by replenishing membrane cholesterol (Pani et al., 2008). 
Thapsigargin-evoked Ca2+ entry in HSG cells was also impaired following cholesterol disruption 
with either MβCD or filipin (Pani et al., 2008). Together these important studies highlight the 
significance of plasma membrane microdomains in the store-operated behaviour of TRPC1 
channels. In the model shown above, the close proximity of Orai1 and TRPC channels in lipid raft 
microdomains is important to mediate STIM1-dependent TRPC1 gating. 
 
Whilst a large body of evidence indicates that TRPC1 is activated by store depletion and is 
dependent on Orai1 channel activity, some studies suggest that TRPC1 is not activated by store 
depletion. DeHaven et al. (2009) showed that no carbachol-induced SOCE occurred in HEK cells 
transfected with TRPC1 in the presence of 5µM Gd3+. The inclusion of 5µM Gd3+ in this study was 
intended to inhibit endogenous Orai1 channels and reveal the contribution of TRPC channels to 
SOCE (DeHaven et al., 2009). It is possible that TRPC1-mediated SOCE did not occur in the 
presence of 5µM Gd3+ due to the dependence of store-operated TRPC1 channels on Orai1-
mediated Ca2+ entry, as depicted above in figure 1.17. Whilst 5µM Gd3+ does not inhibit TRPC 
channels per se (Broad et al., 1999; DeHaven et al., 2009), it does inhibit Orai1-mediated SOCE, 
which could compromise the ability of TRPC1 channels to insert into the plasma membrane in 
lipid raft microdomains and become activated by STIM1. It has also been suggested that the 
store-dependent or –independent nature of TRPC1 is determined by STIM1 (Yuan et al., 2007; 
Alicia et al., 2008). It has been shown in HEK-293 cells that STIM1 levels are crucial to the store-
operated behaviour of TRPC1; when TRPC1 was expressed without STIM1 in HEK-293 cells, it 
was not activated by thapsigargin. The size of thapsigargin-induced TRPC1 currents became 
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larger with increasing levels of STIM1 expression, showing that STIM1 association with TRPC1 
converts it from a receptor-operated to a store-operated channel (Alicia et al., 2008). It has also 
been shown that TRPC6, whilst not typically activated by store depletion, can interact with 
TRPC4 in a STIM1-dependent manner to produce a store-operated heteromultimeric channel 
(Yuan et al., 2007). This study supports the theory that TRPC channels can be activated by 
STIM1 to confer store-operated behaviour, or act as STIM1-independent non-store operated 
channels. It is possible that STIM1 expression levels were lower in the study by DeHaven et al. 
(2009) compared with other studies showing that TRPC1 channels are SOCE channels in HEK-
293 cells, giving rise to store-independent behaviour in that study. It is also known that TRPC1 
channel assemblies at the plasma membrane following store depletion are the result of complex 
interactions involving lipid rafts, STIM1, Orai1-mediated Ca2+ entry, vesicle fusion and possibly 
interaction with other TRPC channels (Yuan et al., 2007; Alicia et al., 2008; Lee et al., 2010; 
Lingwood & Simons, 2010; Calloway et al., 2011; Cheng et al., 2011); differences in these 
factors between experimental systems could account for the apparent non-store-operated 
behaviour of TRPC1 channels in the study by DeHaven et al. (2009). 
 
Discrepancies have also been reported regarding the store-operated behaviour of TRPC1 in 
platelets. Whilst studies using an inhibitory antibody suggested that TRPC1 mediates SOCE in 
human platelets (Rosado et al., 2002), normal SOCE was observed in platelets derived from 
TRPC1-deficient mice (Varga-Szabo et al., 2008). The authors suggested that the antibody used 
in the study by Rosado et al. (2002) was non-specific and that TRPC1 is not a store-operated 
channel in platelets. Species-dependent differences and the platelet isolation methods used have 
been suggested as possible reasons for the conflicting results (Salido et al., 2009); it is also 
possible that species- or cell- dependent variations in other factors such as STIM1 and Orai1, as 
discussed above, gave rise to conflicting results. Variation in the expression level of channels in 
different studies has also been suggested to account for confounding results (Vazquez et al., 
2003; Salido et al., 2009). It has been shown in DT40 chicken B-lymphocytes that when 
expressed at low levels, TRPC3 can be activated by thapsigargin-evoked store depletion, but 
when expressed at higher levels it could only be activated by PLC-coupled muscarinic receptors 
(Vazquez et al., 2003). The authors concluded that at low expression levels, TRPC3 channels 
could stoichiometrically associate with other proteins to confer store-operated behaviour; for 
example, association with TRPC1 allows interaction with STIM1 (Yuan et al., 2007). At elevated 
expression levels, however, it is likely that TRPC3 channels were present at much higher levels 
than the native proteins in DT40 cells, so could not associate with the interacting partners 
required to confer store-operated behaviour (Vazquez et al., 2003). It is possible that varying 
levels of channel expression, giving rise to altered interactions with other proteins, could account 
for discrepancies in results using heterologous expression systems to determine the store-
operated behaviour of TRPC channels. To summarise, although some studies suggest that TRPC1 
is not activated by store depletion, a number of factors could account for inconsistent results, 
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and a large body of evidence indicates that TRPC1 is a STIM1-regulated, Orai1-dependent, store-
operated Ca2+ channel. 
 
In addition to TRPC1, the related TRPC4 and TRPC5 channels have also been proposed as store-
operated channels. As discussed above, STIM1 has been shown to interact with both channels 
(Yuan et al., 2007), and the conserved TRP box structure suggests that TRPC4 and 5, like 
TRPC1, may be gated by electrostatic interactions between negatively charged aspartate 
residues in the channel and positively charged lysine residues in STIM1 (Zeng et al., 2008). 
Endothelial cells from TRPC4-deficient mice display reduced InsP3-induced currents compared 
with those from wild-type mice (Freichel et al., 2001). Expression of TRPC4 in CHO and RBL-2H3 
cells gave rise to thapsigargin- and InsP3- evoked currents that could be recorded in the 
presence of extracellular Ca2+ or Ba2+ (Warnat et al., 1999). Thapsigargin-evoked Ba2+ and Ca2+ 
entry was enhanced in HEK-293 cells expressing human TRPC5 compared with cells not 
expressing the channel, and TRPC5 expression gave rise to CPA-induced currents (Zeng et al., 
2004). In arteriolar smooth muscle cells, application of the T5E3 TRPC5-blocking antibody 
inhibited CPA-induced currents with the biophysical properties corresponding to TRPC1-TRPC5 
heteromeric channels (Xu et al., 2006a); these data suggest that TRPC1-TRPC5 heteromers are 
also SOCE channels. However, there are some conflicting data concerning TRPC4 and TRPC5 as 
SOCE channels; Schaefer et al. (2000) failed to observe store-operated currents activated by 
InsP3 in HEK-293 cells expressing mouse TRPC4 or TRPC5. Receptor-mediated mTRPC5 
activation was shown to be unaffected by InsP3 receptor inhibition in HEK-293 cells (Plant & 
Schaefer, 2003); these results apparently contradict those described previously suggesting that 
TRPC4 and 5 are SOCE channels. As discussed previously in the context of TRPC1, it is possible 
that the availability of STIM1 in different systems, or the expression level of heterologously 
expressed channels, could account for contrasting results. Experiments questioning the role of 
TRPC4 and TRPC5 in SOCE were all carried out using mouse channels expressed in HEK cells; it 
is possible that species-dependent variations in the channels, or interacting partners, could also 
be responsible for discrepancies. 
 
In the only study investigating the store-operated behaviour of TRPC channels in mast cells, Ma 
et al. (2008) showed that Sr2+ and Ca2+ entry occur following FcεRI cross-linking or store 
depletion with thapsigargin in Ca2+ free solution, indicating that the non-selective TRPC channels 
are involved. Divalent entry following store depletion with thapsigargin was substantially 
impaired when TRPC5 channels were knocked-down using shRNA in RBL-2H3 cells. These results 
are illustrated in figure 1.18. STIM1 and Orai1 knock-down also suppressed thapsigargin-evoked 
Sr2+ and Ca2+ entry, and over-expression of TRPC5 and STIM1 enhanced divalent ion entry (Ma 
et al., 2008). Based on the knowledge that Orai1 channels are highly Ca2+-selective and do not 
conduct other divalent ions such as Sr2+ (Hoth & Penner, 1992; Lis et al., 2007), the authors 
proposed that TRPC5 channels are activated by STIM1 following store depletion and that TRPC5, 
STIM1 and Orai1 are functionally dependent (Ma et al., 2008).  
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These results are in accordance with the model proposed for the STIM1- and Orai1-dependent 
activation of TRPC1 in figure 1.17; SOCE through Orai1 channels could promote the association 
of TRPC5 channels into lipid raft domains where they are gated by STIM1 to give rise to TRPC5-
mediated SOCE. Similar studies to those carried out for TRPC1 are required to elucidate whether 
TRPC4 and TRPC5 channels co-localise with STIM1, and whether store depletion enhances their 
interaction. Whilst further investigation is required, this study investigating TRPC5 channels in 
RBL-2H3 cells suggests that store-operated TRPC channels are activated by STIM1 in mast cells 
and are functionally dependent on Orai1, as described for HSG cells in figure 1.17.  
 
TRPC3, 6 and 7 are considered as DAG-regulated channels activated downstream of receptor 
stimulation, but the possibility that these channels are also activated by store depletion cannot 
be excluded. As described above, TRPC3 and TRPC6 have been shown to interact indirectly with 
STIM1 via interactions with TRPC1 and TRPC4, respectively (Yuan et al., 2007), suggesting that 
they could function as store-operated channels under some conditions. When TRPC3 was 
originally cloned it was reported to form thapsigargin-activated Ca2+ channels when expressed in 
HEK-293 cells (Zhu et al., 1996). However, when constitutive TRPC3-mediated Ca2+ entry was 
subtracted from that induced by thapsigargin and carbachol, it was concluded that TRPC3 is 
sensitive to receptor activation but not store depletion (Zhu et al., 1998). Association with other 
channels could account for the apparent store-operated behaviour of TRPC3 in some studies; 
Figure 1.18. TRPC5-mediated SOCE in RBL-2H3 cells 
a: Sr2+ and Ca2+ entry were assessed following FcεRI cross-linking in RBL-2H3 cells. The trace reflects Ca2+ 
release from stores (1st peak), entry of Sr2+ (2nd peak, TRPC-mediated) and entry of Ca2+ (3rd peak, TRPC 
and Orai-mediated). Reproduced with permission from (Ma & Beaven, 2011) 
b: Divalent ion entry following store depletion with thapsigargin in RBL-2H3 cells transfected with TRPC5 
shRNA (green trace) and in control cells (red trace). The entry of both divalent ions was impaired in the 
absence of TRPC5, suggesting that this channel mediates SOCE in RBL-2H3 cells. 
Reproduced with permission from (Ma et al., 2008). Copyright 2008. The American Association of Immunologists, Inc. 
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whilst it was previously thought to interact only with TRPC6 and TRPC7, it has recently been 
proposed that TRPC3 interacts with TRPC1, based on studies in HEK-293 (Yuan et al., 2007) and 
HSG cells (Liu et al., 2005). It was reported that thapsigargin and OAG evoke currents with 
similar properties in HSG cells, and that the two agonists do not have an additive effect. TRPC1 
and TRPC3 co-immunoprecipitated in these cells, and were shown by yeast two-hybrid analysis 
to interact via their N-terminal regions; knock-down of TRPC1 or TRPC3 gave rise to a reduction 
in OAG- and thapsigargin- evoked currents (Liu et al., 2005).  The authors concluded that TRPC3 
can form a store-operated channel when interacting with TRPC1 that can also be activated by 
agonist stimulation; such novel channel assemblies may increase the diversity of store-operated 
Ca2+ channels in different cell types. As discussed above, TRPC3 has been shown to form store-
operated channels when expressed at low levels and store-independent DAG-activated channels 
when expressed at higher levels; it is likely that interaction with other channels such as TRPC1 at 
low expression levels could give rise to store-operated TRPC3 channels in some cell types 
(Vazquez et al., 2003). Store-operated behaviour of TRPC3 channels independently of other 
channels has not been demonstrated in any cell type, and they are generally considered to be 
receptor-operated channels activated by DAG (Trebak et al., 2003). 
 
TRPC6 is not thought to be activated by store depletion; when the channel was first cloned it 
was demonstrated that thapsigargin-evoked Ca2+ entry was not increased by the expression of 
TRPC6 in HEK-293 cells (Boulay et al., 1997). Electrophysiological characterisation of hTRPC6 
expressed in CHO-K1 cells revealed that the channel is not activated by InsP3, or store depletion 
by thapsigargin (Hofmann et al., 1999). It has, however, recently been shown that TRPC6 
channel density at the plasma membrane is increased by store depletion as well as receptor 
activation (Cayouette et al., 2004); the authors speculate that an increase in cytosolic Ca2+ 
caused by store depletion may cause TRPC6 translocation. The localisation of TRPC6 channels at 
discrete plasma membrane microdomains along with TRPC4 and STIM1 proteins and interaction 
with the same accessory proteins could account for their co-immunoprecipitation reported in 
HEK-293 cells (Yuan et al., 2007). 
 
Whilst TRPC7 was not reported to interact with STIM1 in the study by Yuan et al. (2007) in HEK-
293 cells, Lievremont et al. (2004) reported enhanced Ba2+ entry following thapsigargin 
stimulation of HEK-293 cells when TRPC7 was expressed. However, the same group later 
reported that knock-down of STIM1 and Orai1 did not affect TRPC7-mediated Ba2+ entry, and 
currents were not observed following InsP3-mediated store depletion in HEK cells expressing 
TRPC7 (DeHaven et al., 2009). The authors concluded that TRPC7 is not a store-operated 
channel, and that previously observed activation by thapsigargin could be as a result of SERCA 
inhibition per se and not due to store depletion. To summarise, there is a lack of conclusive 
evidence implicating TRPC3, 6 and 7 channels in SOCE, whereas a number of studies suggest 
that TRPC1, 4 and 5 are STIM1-regulated SOCE channels. 
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1.3.2.12 Methods to study store-operated TRPC channels 
Difficulties arise in studying contribution of TRPC channels to store-operated Ca2+ entry due to 
the lack of selective pharmacological inhibitors. Methods used to activate store-activated TRPC 
channels, such as thapsigargin-mediated inhibition of the SERCA pump, also activate Orai1 
channels; it is important to distinguish between the two channels in order to establish their 
relative contributions to SOCE. This is possible by examination of the I/V relationships of the two 
channels; as discussed above, ICRAC has an inwardly-rectifying I/V relationship with a positive 
reversal potential, whereas TRPC channels have outwardly-rectifying relationships with a reversal 
potential close to 0mV (compare figures 1.8, 1.11 and 1.15). The selective ICRAC inhibitor synta 
66 can also be used in conjunction with activators of SOCE, in order to determine the 
contribution of TRPC channels. Another important property that can be used to distinguish the 
two channels is Ca2+ permeability; whilst Orai1 is highly selective for Ca2+, many studies have 
demonstrated that TRPC channels can readily permeate Ba2+ ions, including but not limited to 
(Trebak et al., 2002; Ma et al., 2008; DeHaven et al., 2009; Tu et al., 2009b; Bousquet et al.). 
ICRAC currents mediated by Orai1, 2, and 3 channels are abolished when Ba
2+ is the sole charge 
carrier (Lis et al., 2007); glutamate residues in the transmembrane regions of Orai channels are 
thought to be responsible for their Ca2+ selectivity (Vig et al., 2006a).As many Ca2+ indicator 
dyes can bind to both Ca2+ and Ba2+, it is possible to employ Ca2+ imaging techniques to 
determine the Ba2+ permeability of SOCE channels to assess the involvement of TRPC channels. 
 
1.4 TRPC channels in mast cells 
Given the crucial importance of Ca2+ in mast cell activation and inflammatory mediator release, 
characterisation of the ion channels responsible for Ca2+ entry is important as they provide 
potential therapeutic targets for mast cell modulation in allergic diseases such as asthma. Studies 
carried out in RBL cells (Ma et al., 2008; Sanchez-Miranda et al., 2010) indicate that TRPC 
channels could be important for Ca2+ entry mediating mast cell degranulation, and results from 
an affymetrix mRNA screen indicate that TRPC1 channels may be functionally expressed in 
primary human mast cells (Bradding et al., 2003). This study aimed to characterise the functional 
expression of TRPC channels in human mast cells using the LAD 2 cell line and primary HLMCs, 
to investigate their role in SOCE in these cells, and to assess whether they have a role in human 
mast cell mediator release. 
 
The experimental tools that can be used to study TRPC channels that have been discussed in this 
chapter are summarised in table 1.4. 
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Table 1.4. Summary of pharmacological methods to study TRPC channels 
Experimental use of these tools is discussed in the text above. 
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Chapter 2: Materials and methods 
2.1 HEK 293 cell lines over-expressing TRPC channels 
2.1.1  HEK-TRPC5 cells  
Generation of the cell line 
The tetracycline-inducible HEK-TRPC5 cell line used in this study was a generous gift from 
Professor David Beech. To generate the cell line, human TRPC5 cDNA was cloned from two 
plasmids containing overlapping TRPC5 fragments. Primers were used to amplify the C-terminal 
region of TRPC5 from plasmid 2B11 and the N-terminal region from plasmid 6A1; further 
amplification reactions were used to generate full-length TRPC5 cDNA. HEK-293 cells stably 
expressing Tet repressor (T-Rex 293 cell line) were transfected with hTRPC5/pcDNA4 using 
lipofectamine 2000 reagent (Zeng et al., 2004). 
 
HEK-TRPC5 cell culture 
HEK-TRPC5 cells were grown in 25cm2 Nunclon™Δ surface tissue culture flasks and incubated at 
37oC in a 5% CO2 humidified atmosphere. Cells were cultured in  Dulbecco‘s modified Eagle‘s 
medium (DMEM)-F12 media supplemented with 10% foetal calf serum (FCS); those stably 
expressing TRPC5 were selected for using 400µg/ml zeocin and 5µg/ml blasticidin (―TRPC5 
selective media‖). Blasticidin powder was dissolved in H2O as 10mg/ml stock, filter sterilised and 
stored at -20oC. Zeocin was purchased as a 100mg/ml stock solution. Cells were split twice per 
week; cell dissociation solution (CDS) was used to harvest the cells, which were then centrifuged 
at 1000rpm for 4 minutes. Following resuspension, HEK-TRPC5 cells were split 1 in 5 or 1 in 8, 
depending on density. Cells were plated onto coverslips and incubated with 1µg/ml tetracycline 
in TRPC5 selective media for 24 hours when required to induce TRPC5 expression. Tetracycline 
powder was dissolved in H2O as a 1mg/ml stock, filter sterilised and stored at -20
oC. 
 
To freeze HEK-TRPC5 cells, 2 million cells in 1ml FCS + 10% DMSO in a cryovial were placed in a 
―Mr Frosty‖ cryo 1oC freezing container and kept at -80oC overnight. Vials of cells were then 
transferred to liquid nitrogen for long-term storage. To thaw cells, vials were placed in a 37oC 
water bath upon removal from liquid nitrogen. The FCS + 10% DMSO cell suspension was 
transferred to 5ml of DMEM-F12 and washed twice by centrifugation at 1000rpm for 4 minutes 
followed by resuspension in DMEM-F12. After the final wash, cells were resuspended in 5ml HEK-
TRPC5 selective media for culture. 
 
 
 
 Chapter 2: Materials and methods 
57 
 
2.1.2 HEK-TRPC6 cells 
Generation of the cell line  
The stable HEK-TRPC6 cell line was a generous gift from Professor Guylain Boulay. TRPC6 was 
cloned from mouse brain RNA using a PCR reaction, and specific primers were used to amplify 
mouse TRPC6 (mTRPC6). To create the stable cell line, HEK-293 cells were transfected with 
mTRPC6-pcDNA3 using a calcium phosphate-based protocol. Transfected cells were grown in the 
presence of G418 to select for resistance, which is conferred by pcDNA3. G418-resistant cells 
were expanded to produce the HEK-TRPC6 cell line (Boulay et al., 1997). 
 
HEK-TRPC6 Cell culture 
HEK-TRPC6 cells were grown in DMEM containing 10% FCS and 400µg/ml G418 to select for 
TRPC6 expression (―TRPC6 selective media‖) and were incubated at 37oC in a 5% CO2 humidified 
atmosphere. G418 powder was dissolved as a 50mg/ml stock in H2O and stored at 4
oC. Cells 
were split twice per week, using CDS to harvest them followed by centrifugation at 1000rpm for 
4 minutes. Following resuspension, they were split 1 in 5 or 1 in 8, depending on density. Cells 
were plated onto coverslips in HEK-TRPC6 selective media when required for experiments. 
 
HEK-TRPC6 cells were frozen and thawed as described above for HEK-TRPC5 cells. However, 
immediately following thawing, the cells do not stick properly to standard tissue culture flasks (L. 
Wilson, unpublished observation); for this reason they were grown on poly-D-lysine-coated 
25cm2 tissue culture flasks for one week after thawing. At all other times they were cultured in 
25cm2 Nunclon™Δ surface tissue culture flasks.  
 
2.2 The LAD 2 human mast cell line 
2.2.1 Derivation of the cell line 
As described in chapter 1.1.3, LAD 2 cells were generated in the Laboratory of Allergic Diseases 
(LAD), from bone marrow aspirates taken from a patient with mast cell sarcoma/leukaemia. 
These cells express CD117 and are dependent on SCF for growth.  
 
2.2.2 LAD 2 cell culture 
The LAD 2 cell line used in this study was a kind gift from Dr Dean Metcalfe, Laboratory of 
Allergic Diseases, National Institutes of Health, USA. Cells were cultured in serum-free StemPro-
34 media supplemented with StemPro-34 nutrient supplement and 2mM L-glutamine (―complete 
LAD 2 media‖). 100ng/ml rhSCF was added to the media weekly upon use from frozen aliquots 
of a 100µg/ml solution in PBS + 0.1% bovine serum albumin (BSA). Cells were maintained at a 
density of 200 000 to 500 000 cells per ml of media in 25cm2 Nunclon™Δ surface tissue culture 
flasks; they were counted weekly and fed or diluted as appropriate. Cells were incubated at 37oC 
in a 5% CO2 humidified atmosphere. 
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To obtain frozen stocks of LAD 2 cells, 10 million cells were suspended in 1.5ml non-FCS, non-
DMSO containing PZerve cryopreservative supplemented with 200ng/ml rhSCF as described 
previously (Kirshenbaum et al., 2003). Vials of cells were placed in a ―Mr Frosty‖ cryo 1oC 
freezing container and incubated for 30 minutes at 25oC, 1 hour at -20oC and 1 hour at -70oC. 
Vials were then placed in liquid nitrogen for long-term storage. For thawing, cells were slowly 
equilibrated to room temperature and added to 1.5ml complete LAD 2 media supplemented with 
100ng/ml rhSCF. Cells were agitated at room temperature in 12.5cm2 flasks for 6 hours, followed 
by incubation at 37oC in 5% CO2 for 24 hours. Cells were then transferred to a 25cm
2 tissue 
culture flask and 3ml of complete LAD 2 media with 100ng/ml SCF was added. 
 
 
2.3 Isolation, purification and long-term culture of primary human 
lung mast cells (HLMCs) 
Mast cells were isolated from human lung tissue obtained from surgical resections in 
collaboration with Dr Peter Peachell, Department of Infection and Immunity, University of 
Sheffield. All patients donating tissue gave informed written consent, and the study was 
approved by the Local Research Ethics Committee. 
2.3.1 HLMC Isolation 
HLMCs were obtained from macroscopically normal lung tissue taken from patients undergoing 
resection for lung cancer as described previously (Sanmugalingam et al., 2000). All steps were 
carried out aseptically. Large bronchi were removed if necessary and lung tissue was cut into 
strips 0.5cm wide using scissors. Using tweezers and scissors, strips of tissue were cut into small 
squares and put into a funnel lined with 100µm gauze. Tissue was washed with DMEM + 2% FCS 
before being transferred to a straight-sided jar and chopped to a fine pulp using two pairs of 
scissors. Tissue pulp was washed twice in a funnel lined with 100µm gauze using DMEM + 2% 
FCS before being placed in a sterile screw top pot for overnight storage. 4ml of DMEM + 10% 
FCS + 1% antibiotic/antimycotic solution (A/A; contains 10 units/ml penicillin, 10 units/ml 
streptomycin and 25µg/ml amphotericin B) + 1% MEM non-essential amino acids (NEAA) per 1g 
of tissue was added to the tissue pulp, and the tissue was stored at 4oC overnight. Overnight 
storage in antibiotics was done to help prevent the growth of infectious micro-organisms.  
 
The following day, lung tissue was digested using 37.5mg hyaluronidase and 50mg collagenase 
type 1A per 10g tissue for 90 minutes at 37oC with stirring. To liberate cells from connective 
tissue the pulp was forced through a 50ml syringe 30 times and was filtered through a 100µm 
gauze with DMEM + 2% FCS three times. Dispersed cells were then washed twice in DMEM + 
2% FCS by centrifuging at 1200rpm for 8 minutes. After the final wash, cells were resuspended 
in 10ml DMEM + 2% FCS and were counted on a haemocytometer using Kimura stain in a 1:10 
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mast cell:stain ratio. Mast cells appear cerise in colour when stained with Kimura, so can be 
identified in a mixed cell population.  
2.3.2 HLMC purification 
Mast cells were purified using immunomagnetic affinity selection as described previously 
(Okayama et al., 1994). Anti-mouse IgG1 Dynabeads® coated with mouse anti-c-kit antibody 
(mAb YB5.B8, see section 2.3.4 ―Coating of magnetic beads with anti-CD117 antibody‖) were 
used to positively select CD117-expressing HLMCs. Figure 2.1 illustrates the HLMC purification 
procedure. 
 
Cells were centrifuged at 1200rpm for 8 minutes at 4oC, resuspended in 4ml HBSS/FCS-protein 
and incubated at 4oC for 30 minutes under continuous rotation. This blocking stage prevents 
nonspecific binding during purification. After incubation, cells were added to 10ml of cold HBSS + 
2% FCS, passed through a 100µm cell strainer, and centrifuged at 1200rpm for 8 minutes at 4oC. 
The appropriate volume of anti-CD117-coated Dynabeads® was washed (see section 2.3.4 for 
details); the Dynabead:mast cell ratio is 5:1 so the appropriate volume could be calculated from 
the cell count performed earlier. Following centrifugation, the cells were resuspended in 1ml 
HBSS/protein containing the appropriate amount of beads and incubated in a cryotube at 4oC for 
90 minutes under continuous rotation. 
 
After the incubation, cells were transferred to a larger 15ml tube and resuspended in 10ml HBSS 
+ 2% FCS. The tube was placed in a Dynal® MPC™-1 magnetic field for 3 minutes and the 
supernatant was removed. This was repeated two further times; after the final wash, cells were 
resuspended in 1ml DMEM + 10% FCS + A/A + NEAA and a final count was performed. 
 Chapter 2: Materials and methods 
60 
 
 
 
 
 
Figure 2.1. Schematic diagram representing mast cell purification using Dynabeads®. 
Dynabeads® conjugated to sheep anti-mouse IgG are coated with mouse anti-human CD117. The mixed 
cell population is incubated with coated Dynabeads®, which stick to CD117 on the surface of mast cells 
(MC, blue). Only mast cells attached to Dynabeads® remain attached to the magnet, isolating them from 
other cells. 
Adapted with permission from K. Wareham PhD thesis, 2010.  
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2.3.3 HLMC culture 
HLMCs were maintained at a density of 200 000 to 500 000 cells per ml in DMEM + 10% FCS + 
A/A + NEAA supplemented with 100ng/ml SCF, 50ng/ml IL-6 and 10ng/ml IL-10. Cytokines were 
added to the media when required from frozen stocks of 100µg/ml SCF, 50µg/ml IL-6 and 
10µg/ml IL-10 in sterile PBS + 0.1% BSA. Cells were counted weekly and fed or diluted as 
appropriate. HLMCs were maintained at 37oC in a 5% CO2 humidified atmosphere, in 12.5cm
2 BD 
FalconTM cell culture flasks or 12-well cell culture plates as appropriate. 
 
2.3.4 Coating of beads with anti-CD117 antibody 
Magnetic Dynabeads® conjugated to sheep anti-mouse IgG were coated with mouse anti-human 
CD117 antibody by the following procedure. 
1. To wash the beads, 100µl beads were added to 15ml HBSS + 2% FCS in a 15ml tube. 
The tube was placed in an MPC-1 magnetic field for 3 minutes and the supernatant was 
removed, followed by resuspension in 15ml HBSS + 2% FCS. 
2. Beads were washed three times; after the final wash beads were resuspended in 400µl 
HBSS/protein solution.  
3. Anti-human CD117 antibody was added to the bead suspension at an antibody:bead 
ratio of 1:12.5 The mix was incubated at 4oC for 2 hours under continuous rotation. 
4. The beads were washed (as in step 1) three times; after the final wash they were 
resuspended in 100µl HBSS/protein with 1% NaN3 and stored at 4
oC. 
5. Immediately before use, anti-CD117-coated beads were washed to remove toxic NaN3. 
The appropriate amount of beads was added to 15ml HBSS + 2% FCS and washed as in 
step 1. After the final wash, beads were resuspended in 1ml HBSS/protein to use for 
purification. 
 
2.3.5 Buffers for HLMC preparation  
The following recipes were used to prepare the solutions required for HLMC isolation. 
1. DMEM + 10% FCS + A/A + NEAA: DMEM with HEPES and glutamax with 10% FCS, 1% 
A/A solution and 1% NEAA. 
2. HBSS/protein: HBSS + 2% FCS + 10% horse serum + 1% BSA, stored at -20oC 
3. Collagenase type 1A: Powder dissolved as 75mg/ml stock in phosphate buffered saline 
(PBS), stored at -20oC. 
4. Hyaluronidase: Powder dissolved as 37.5mg/ml stock in PBS, stored at -20oC. 
5. Kimura stain: 11ml of 0.05% toluidine blue solution, 0.8ml of 0.03% light green, 0.5ml 
saponin saturated in 50% ethanol, 5ml phosphate buffer at pH 6.4. 
6. Phosphate buffer: 0.067M Na2HPO4 (0.59g in 50ml H2O) and 0.067M KH2PO4 (0.449g in 
50ml H2O); titrate pH of KH2PO4 to 6.4 with Na2HPO4. 
7. 0.05% toluidine blue: 0.05g toluidine blue dissolved in 50ml 1.8% NaCl. Add 22ml 
ethanol and make up to 100ml with H2O.  
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2.3.6 Isolation of impure HLMCs for secretion assays 
As sufficient numbers of pure HLMCs were not able to be obtained using the method above for 
mediator release assays, impure preparations of cells isolated in the laboratory of Dr P. Peachell 
were used for such studies. The cells were isolated from macroscopically normal lung tissue, as 
described previously (Havard et al., 2011). Lung tissue was chopped vigorously using scissors 
and the chopped tissue washed over a 100µm pore size nylon mesh using PBS. Tissue was 
digested in 35mg collagenase per 10g of tissue at 37oC under constant agitation. Following 
digestion, tissue was disrupted using a syringe and washed over nylon gauze using PBS + 10% 
FCS. The filtrates were centrifuged at 480g, 10 min, 25oC, and pellets were resuspended in PBS 
+ 10% FCS. This wash was repeated three times, and mast cells were counted; typically 3–13% 
of all cells were mast cells. Mediator release assays were performed the day after cell isolation 
following overnight incubation in RPMI 1640 buffer with 10 units/ml penicillin, 10mg/ml 
streptomycin and 50mg/ml gentamicin. HLMC isolation was not carried out aseptically and cells 
could not be maintained long-term in culture. 
 
2.4 Coverslip preparation 
For electrophysiology and Ca2+ imaging experiments cells were plated onto 1.5mm thick glass 
coverslips (VWR). Coverslips were washed in 95% ethanol + 5% acetic acid for 6 hours, rinsed 
with water and autoclaved. HEK-TRPC5 and HEK-TRPC6 cells were plated directly onto sterile 
washed coverslips at a 1 in 5 or 1 in 8 dilution from a confluent 25cm2 tissue culture flask. After 
30 minutes at 37oC, cells were flooded with selective media. 
 
Non-adherent LAD 2 cells and HLMCs were plated onto coverslips coated with 0.1% poly-L-lysine 
hydrobromide. Poly-L-lysine was dissolved in sterile H2O; 70µl was applied to 13mm coverslips, 
and 150µl was applied to 16mm coverslips. Following a 30 minute incubation at 37oC, coverslips 
were rinsed with sterile H2O and dried under sterile conditions. Cells were placed on the coverslip 
and incubated for 30 minutes at 37oC to allow attachment, before flooding with culture medium. 
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2.5 Ca2+ Imaging 
Fluorescent Ca2+ imaging was used in this study to quantify changes in intracellular Ca2+. 
Fluorescence, defined as the emission of light by a molecule that has absorbed light, is caused 
when an electron returns to its ground state by emitting a photon of light after being excited to a 
higher energy level. Figure 2.2 illustrates the energy changes in fluorescence. The emitted 
photon has energy equivalent to the difference between the lowest excited state and the ground 
state so has less energy than the absorbed photon. This difference, called the Stokes shift, 
allows fluorescence to be visualised because emitted light has a longer wavelength than 
absorbed light. 
 
2.5.1 Calcium indicator dyes 
Ca2+ indicators have altered fluorescent properties when they bind Ca2+ (Paredes et al., 2008) so 
can be used to monitor changes in intracellular Ca2+ levels. They are derivatives of Ca2+ chelators 
such as EGTA and BAPTA (Tsien, 1980), and many dyes are now available for the detection of 
intracellular Ca2+ over a range of concentrations and in different organelles (Paredes et al., 
2008). They can broadly be classed into single wavelength and ratiometric dyes; single 
wavelength dyes such as fluo-4 are usually bright and used for Ca2+ detection when more than 
one indicator is present. Ratiometric indicators such as fura-2 are advantageous as they reduce 
the problems of photobleaching, uneven dye loading and leakage commonly associated with 
fluorescent indicators (Paredes et al., 2008). 
 
Fura-2 was used in this study as it is a ratiometric dye, and it was appropriate to use with the 
available detection methods. Fura-2 is a dual excitation, UV light-excitable Ca2+ indicator. The 
peak absorbance is 380nm when Ca2+ is not bound, shifting to 340nm when Ca2+ is bound. This 
shift can be observed by measuring emission at 510nm (see figure 2.3). 
 
In addition to Ca2+, fura-2 can be used as an indicator of other divalent ions including Ba2+ and 
Sr2+. The dissociation constant (Kd) of fura-2 is 236nM for Ca2+, 780nM for Ba2+ and 2.62µM for 
Sr2+. The acetoxymethyl (AM) ester form of fura-2 was used in this study to facilitate loading of 
the cells. AM esters are engineered onto Ca2+ dyes as they are sufficiently hydrophobic to cross 
the cell membrane; once inside the cell, esterases cleave the AM group and the dye remains 
inside the cell (Paredes et al., 2008). 
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Figure 2.3. Fluorescence excitation spectra of fura-2 
A higher concentration of bound Ca2+ gives rise to a higher absorbance at 340nm and a lower 
absorbance at 380nm. Emission is monitored at 510nm. 
Image reproduced from http://www.invitrogen.com/site/us/en/home/References/Molecular-Probes-The-
Handbook.html with permission from Life Technologies Ltd. 
 
 
Figure 2.2. Energy level changes in fluorescence 
When energy, such as light energy, is absorbed, an electron (green, e-) moves to a higher energy state. A 
small amount of energy is lost as heat or through molecular collisions and the electron drops to a lower 
excited state. To re-enter the ground state the electron emits a photon of light (seen as fluorescence) in 
order to lose its energy. 
Adapted from The Molecular Probes® Handbook—A Guide to Fluorescent Probes and Labeling Technologies edited by 
Iain Johnson and Michelle Spence 
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2.5.2 Calcium imaging experiments 
2.5.2.1 Loading of cells with Fura-2-AM 
Cells were plated onto 16mm coverslips as described in section 2.4. Cells were loaded with 1µM 
fura-2 AM at 37oC for 30 minutes. HEK-293 cells and HLMCs were loaded in DMEM + 10% FCS + 
0.1% BSA; LAD 2 cells were loaded in StemPro-34 media + 0.1% BSA. Antibiotics were not 
present in the media when cells were loaded. Cells were then washed for 15 minutes in the 
appropriate media at 37oC, followed by a 15 minute wash in standard imaging solution. Cells 
were protected from light at all stages. 
2.5.2.2 Calcium imaging apparatus 
Coverslips were placed in a superfusion chamber and mounted on an inverted microscope 
(Axiovert S100 TV, Zeiss) equipped with a 40X oil immersion objective (NA 1.3, Zeiss). Cells were 
alternately illuminated at 340 and 380nm with a 20ms exposure time using a monochromator 
(Polychrome IV, TILL Photonice LPS-150). The shutter was closed between exposures to reduce 
the exposure of fura-2-loaded cells to UV light. Emitted light was passed through a 510nm band 
pass filter and collected by a 512B CCD camera (Roper Scientific, Photometrics UK). Images were 
acquired at a rate of 1 frame every 2 seconds using Metamorph® Meta imaging software. The 
intensifier gain was set at 3500 and the linear gain at 1x for all experiments. 
 
The recording chamber was continually superfused with standard imaging solution at a rate of 
approximately 1.5ml/minute. Syringes on a perfusion rack were used to apply solutions to cells, 
as illustrated in figure 2.4. Bungs with plastic tubing in the centre were placed in all containers of 
solution to ensure a constant flow rate. The outflow tube was connected to a peristaltic pump 
(Watson Marlow SciQ 323) to transfer solution into a waste bottle. The time taken for solutions 
to reach the bath was measured at 40 seconds; solutions were fully equilibrated after another 30 
seconds. Bars showing the application of solutions in figures have been corrected for this delay.  
 
Experiments were carried out at room temperature unless otherwise stated. When heating was 
required, tubes containing solutions were passed through a heating block before application to 
cells, and a thermometer was placed in the perfusion chamber to check the required temperature 
was reached. Cotton wool was wrapped around the tube to retain heat. A maximum temperature 
of 35oC was able to be reached using this method. 
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2.5.2.3 Recording solutions 
Unless indicated otherwise, standard imaging solution was perfused onto cells prior to the 
addition of other solutions. Standard imaging solution contained (in mM): 147 NaCl, 10 HEPES, 
16 glucose, 2 KCl, 2 CaCl2, 1 MgCl2 and 0.1% BSA. Ca
2+-free solution contained (in mM): 147 
NaCl, 10 HEPES, 16 glucose, 2 KCl, 3MgCl2 and 0.1% BSA. Ba
2+-containing solution contained (in 
mM): 147 NaCl, 10 HEPES, 16 glucose, 2 KCl, 2 BaCl2, 1 MgCl2 and 0.1% BSA. The solution was 
titrated to pH7.3 using NaOH, and the osmolarity was approximately 307mOsm/litre. 
2.5.2.4 HLMC staining 
When Ca2+ imaging experiments were carried out on primary HLMCs, cells were incubated with a 
phycoerythrin (PE)-tagged anti-CD117 IgG1 antibody for 10 minutes to assess the purity of the 
cells following experimental protocols. Antibody-labelled cells were excited at 488nm and an 
image was taken after the light was passed through a 520nm emission filter; HLMCs were 
stained as shown in figure 2.5. Incubation for 10 minutes with an IgG1 isotype control antibody 
did not give rise to fluorescence when cells were excited at 488nm. HLMCs on coverslips were 
found to be >98% pure by this method.  
 
Figure 2.4. Schematic diagram of the Ca2+ imaging perfusion system 
Standard imaging solution in a 1 litre bottle continually superfused cells on a coverslip in the recording 
chamber. Syringes on a perfusion rack were used to apply additional solutions to cells; the outflow tube 
was connected to a peristaltic pump. 
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2.5.2.5 Ca2+ imaging data analysis 
Metamorph® Meta imaging software was used to analyse all Ca2+ imaging experiments. A region 
of interest (ROI) was placed over each cell in the field of view on the 340nm and 380nm images 
and raw fluorescence values were exported to a Microsoft Excel spreadsheet, along with 
background fluorescence values for each wavelength. Using the spreadsheet, background 
fluorescence corresponding to the same frame was subtracted from the fluorescence value for 
each cell, for both the 340nm and 380nm signals. The background-subtracted 340nm 
fluorescence values were then divided by the background-subtracted 380nm fluorescence values 
to give ―F340/380‖. To work out the amplitude of Ca
2+ entry following the application of a particular 
agonist, the mean F340/380 of the 5 frames prior to agonist application was calculated. This value 
was subtracted from the maximum F340/380 in the presence of agonist to give change in F340/380, or 
ΔF340/380. When calculating the percentage of cells responding to a particular agonist, 
―responders‖ were classed as cells where the fluorescence ratio in the presence of agonist rose 
by more than 10 standard deviations above the baseline fluorescence. 
 
Data were then copied into OriginPro 8.5 for graphing and further analyses. When concentration 
response curves were constructed, data were fitted using the Hill equation: y= 
Vmax*x^n/(k^n+x^n). Ca2+ imaging figures are displayed in this thesis as 5 representative 
individual cells, indicated by different coloured traces, and the mean ± standard error of the 
mean (SEM) of all cells, unless otherwise stated. Concentration-response curves are plotted as 
concentration of solution against mean ΔF340/380. GraphPad Prism 5 was used for all statistical 
analyses. Student‘s T test or one-way ANOVA was used as appropriate; log transformations of 
percentage data were carried out before statistical analysis. 
Figure 2.5. HLMCs loaded with fura-2 and stained with anti-CD117 
a: Image of fura 2- loaded HLMCs excited at 340nm. 
b (i): Image of same coverslip of HLMCs as in part (a) incubated with PE-tagged anti-CD117 for 10 
minutes and excited at 488 nm. (ii): HLMCs were incubated with PE-tagged mouse IgG1 isotype control 
and excited at 488nm. 
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2.6 Electrophysiology 
2.6.1 Development of the patch clamp technique 
The patch clamp technique was first used by Neher and Sakmann to record currents through 
acetylcholine-activated channels in frog skeletal muscle (Neher & Sakmann, 1976). The 
technique was developed from early voltage clamp studies of the squid giant axon (Hodgkin et 
al., 1952); this method measures the flow of ions across a cell membrane as electric current, 
whilst the voltage of the membrane is controlled with a feedback amplifier. The patch clamp 
method was subsequently refined to enable high current resolution, and the giga seal was 
discovered; it was found that a fire-polished clean pipette could form a seal of more than 10GΩ 
with a clean cell membrane when suction was applied (Hamill et al., 1981).The principle of patch 
clamping is that a patch of membrane is electrically isolated from the external solution and 
current flowing in the patch is recorded. A fire-polished glass pipette filled with an electrolyte 
solution is pushed against the cell surface and suction is applied to form a seal. A high-resistance 
seal is required to electrically isolate the patch of membrane and to reduce the current noise of 
the recording. When a gigaseal is achieved, a number of different patch clamp recording 
configurations can be used (figure 2.6). These configurations allow the recording of membrane 
currents when the cell is voltage-clamped by the amplifier. The composition of intracellular and 
extracellular solutions can be varied in order to investigate the physiological role of ion channels 
in electrically excitable and non-excitable cells. 
 
2.6.2 Recording configurations 
Illustrated in figure 2.6 are the different patch clamp recording configurations that can be 
achieved after the formation of a giga-seal. The cell-attached configuration is used for single-
channel recordings. The inside-out patch clamp configuration is obtained by pulling the 
membrane patch from the cell into the bath solution; the inside of the cell is in contact with the 
extracellular solution. When further suction is applied to a cell attached patch, the whole-cell 
recording configuration is achieved. The inside of the cell is in contact with the pipette solution 
and can be voltage-clamped or current-clamped. In the whole-cell recording configuration the 
contents of the cell equilibrate with the pipette solution over time (Fenwick et al., 1982); the 
intracellular solution can therefore be controlled to record currents through different ion 
channels. From the whole-cell mode, the pipette can be pulled away from the cell, allowing the 
membrane to reseal and giving rise to the outside-out patch configuration. The intracellular face 
of the membrane is in contact with the extracellular solution in this configuration. 
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In the whole-cell recording configuration, the cell contents are in equilibrium with the pipette 
solution; depending on the pipette tip width and the length of the recording, intracellular 
signalling molecules can dialyse into the pipette. This can be problematic if important cellular 
components are lost, such as second messengers. To avoid such problems, the perforated patch 
configuration can be used; instead of rupturing the membrane to gain access to the inside of the 
cell, small pores are created by the inclusion of gramicidin (Rhee et al., 1994) or amphotericin 
(Rae et al., 1991) in the patch pipette. This technique maintains a more complete intracellular 
environment than the whole-cell configuration, but is difficult to implement because pore-forming 
agents can interfere with seal formation. 
 
2.6.3 Patch clamp experiments 
LAD 2 cells and HLMCs were plated onto 13mm coverslips coated with 0.1% poly-L-lysine for 
patch clamp experiments. HEK-TRPC5 and HEK-TRPC6 cells were plated onto non-coated 
coverslips. The whole-cell recording configuration was used for patch-clamp experiments in this 
study. 
 
Figure 2.6. Patch clamp recording configurations 
Modified from Ogden, D. 1994. Microelectrode Techniques: The Plymouth Workshop handbook. 
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2.6.4 Patch clamp apparatus 
Patch clamp experiments were carried out using an EPC-10 amplifier (HEKA, Lambrecht, 
Germany). The patch clamp amplifier is a current-to-voltage converter with a high gain, allowing 
small currents to be recorded using a silver chloride-coated wire electrode inside the patch 
pipette (see figure 2.7). The voltage measured by this electrode is compared with that measured 
by a reference electrode in contact with the extracellular solution. The amplifier can be used to 
control the voltage inside the patch pipette (voltage clamp); this can be kept constant, or 
changed in a step-wise or ramp-wise fashion. Alternatively, the amplifier can be used to current 
clamp the cell and record changes in voltage. 
 
2.6.5 Pipette preparation 
Patch pipettes were produced from filamented boroscillate glass (World Precision Instruments 
Inc.) using a DMZ universal puller, and fire-polished using a heated wire mounted on the stage 
of a compound microscope (Narishige). Polished pipettes had a resistance of 2–5MΩ when filled 
with internal solution. 
 
2.6.6 Superfusion system 
The superfusion system on the patch clamp rig was similar to that for the Ca2+ imaging rig 
shown in figure 2.4. Coverslips with cells attached were placed in a superfusion bath above an 
inverted microscope (Axiovert 100, Zeiss) and viewed at a magnification of 10x or 40x to allow 
visualisation of single cells. The bath was continuously superfused with standard external 
solution at a rate of approximately 2ml/minute, and the outflow tube was connected to a 
peristaltic pump, as described above for Ca2+ imaging experiments. A ―bubble trap‖ was created, 
consisting of a syringe with a bung and needle, through which the outflow solution passed to 
reduce perfusion-related noise. 
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2.6.7 Fast-flow system 
A fast-flow system was used to apply solutions rapidly and accurately to a cell of interest. 
Syringes containing solutions were connected to silicone tubing, which was inserted into four fine 
glass capillary tubes in the superfusion chamber (see figure 2.8). The flow through each tube 
was controlled by a rapid solution chamber system (RSC 160, BioLogic Science Instruments); a 
valve system controlled solution flow through each tube. In all experiments, one tube (tube 4) 
contained standard external solution and was aligned with the cell of interest; agonists and 
antagonists were placed in the other tubes. The capillary tubes were carefully aligned on a 
barrel, which rotated to allow focal application of the different solutions to the cell of interest. 
Every time the system was set up, the capillary tubes were carefully aligned by eye to ensure 
correct positioning and focal drug application upon rotation of the barrel. The correct alignment 
was tested experimentally by focal application of 5mM ATP to LAD 2 cells; it has previously been 
shown in our laboratory that 5mM ATP gives rise to P2X7 currents with rapid onset and current 
amplitude in the nA range (Wareham et al., 2009). This was done to ensure that a P2X7 current 
with similar amplitude and kinetics was produced from each tube, confirming the correct 
alignment of the tubes. Figure 2.9 shows P2X7-mediated currents in a representative LAD 2 cell. 
 
Figure 2.7. Schematic diagram of the patch clamp amplifier. 
Simplified diagram of a voltage clamp amplifier. The cell membrane acts as a capacitor (Cm, storing charge) 
and a resistor (Rm, impeding the movement of ions). The access resistance (or series resistance, Rs) is 
created mainly by the opening of the patch pipette. The operational amplifier is a current-to-voltage converter 
with a feedback resistor (Rf), which gives the amplifier high gain, allowing small currents to be recorded. The 
amplifier measures the voltage inside the patch pipette relative to that recorded by the reference electrode. 
Amplifier correctional circuits for the cancellation of pipette and cell capacitance are not shown. 
Modified from Ogden, D. 1994. Microelectrode Techniques: The Plymouth Workshop handbook. 
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Figure 2.9. P2X7 currents in LAD 2 cells 
Superimposed current-time trace showing P2X7 currents in a single LAD 2 cell in response to 5mM ATP 
applied for 5 seconds at 30 second intervals. Each coloured trace represents a different fast flow tube; tube 4 
contained standard external solution and did not generate a current when applied to the cell. The currents 
generated from each tube were similar in size and kinetics, indicating good alignment of the tubes. 
 
Figure 2.8. Schematic representation of the fast flow system 
Syringes containing solutions were connected to glass capillary tubes attached to a rotating barrel to 
rapidly apply solutions to cells of interest. 
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2.6.8 Recording solutions 
Standard extracellular recording solution contained (in mM): 147 NaCl, 10 HEPES, 16 glucose, 2 
KCl, 2 CaCl2, 1 MgCl2. The solution was titrated to pH7.3 using NaOH, and the osmolarity was 
approximately 307mOsm/litre. Agonists and antagonists to be applied to cells were made up in 
standard extracellular solution. An internal solution recipe previously used for the recording of 
TRPC3, 5, 6 and 7 channels expressed in HEK-293 cells (Yuan et al., 2007) was used for all 
voltage-clamp experiments in this study, unless otherwise stated, containing (in mM): 140 CsCl, 
2 MgCl2, 5 EGTA, 10 HEPES, 1.5 CaCl2, 1 Na-ATP. The estimated cytoplasmic free Ca
2+ 
concentration was 70nM. CsOH was used to titrate the pH to 7.3, and the osmolarity was 
approximately 300mOsm/litre. For current-clamp experiments a KCl-based internal solution was 
used, containing (in mM): K+ glutamate 125, NaCl 8mM, EGTA 10, HEPES 10, CaCl2 3.6, MgCl2 6. 
KOH was used to titrate the pH to 7.3, and the osmolarity was approximately 307mOsm/litre. 
 
2.6.9 Experimental protocols 
2.6.9.1 Whole-cell recordings 
The whole-cell recording configuration was used for the majority of electrophysiology 
experiments in this study (unless otherwise stated), and experiments were carried out at room 
temperature. Pipettes were filled with internal solution following filtering of the solution through 
a nylon mesh with 0.2µm pore diameter; tips were filled via glass filament action. The filled 
pipette was secured into the electrode holder, and positive pressure was applied to avoid 
blocking of the pipette tip prior to forming a seal. A seal test was performed to calculate pipette 
resistance; a +5mV pulse of 5ms duration was applied, and the current was displayed in the 
oscilloscope window of the amplifier software. Figure 2.10 depicts changes in the oscilloscope 
window as the pipette enters the bath, through to whole-cell recording. The pipette tip was 
aligned above the cell of interest, using a coarse manipulator (Newport 360 90, Newport Spectra-
Physics Ltd), under 10x magnification. The objective was switched to 40x magnification, positive 
pressure removed, and a micromanipulator (Burleigh PZ-301, EXFO) was used to gently lower 
the pipette tip onto the cell membrane. A deflection in the current trace displayed in the 
oscilloscope window and an increase in pipette resistance were indicative of cell contact. Gentle 
continuous suction was applied to form a gigaseal (>1GΩ), and pipette capacitance was 
cancelled using the amplifier correction circuitry. Short applications of suction were then used to 
rupture the patch of membrane in the pipette whilst maintaining a gigaseal; entry into whole-cell 
configuration was indicated by an increase in amplitude and a widening of the transients due to 
contributions from the cell membrane capacitance and access resistance. These transients were 
cancelled using the amplifier correction circuitry, and cells were voltage-clamped at -60mV for 
recordings (all recordings were carried out in voltage-clamp mode unless otherwise stated). 
Recordings were started 1 minute after the whole-cell configuration was achieved, to allow time 
for solution equilibration.  
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1 second ramps ranging from -100mV to +100mV were applied to cells every 2 seconds for the 
examination of agonist-induced currents. Resting currents were recorded by applying ramps to 
cells in the absence of the agonist; these recordings were subtracted from those in the presence 
of agonist to produce an agonist-activated I/V relationship, which can be used to assess which 
channels are active. In order to verify that the intended membrane potential was achieved within 
the time over which the ramp was applied, 1 second voltage steps ranging from -100mV to 
+100mV in 20mV increments were applied to LAD 2 cells in the whole-cell recording 
configuration. The I/V relationship constructed from the application of voltage steps was then 
compared with the I/V relationship resulting from ramp application; as shown in figure 2.11 the 
traces overlay, indicating that the required membrane potential was achieved when ramps were 
applied. 
2.6.9.2 Perforated patch recordings 
For perforated patch clamp recordings, standard internal solution was used, with 350µg/ml 
gramicidin added. The solution was not filtered prior to pipette filling. Experiments were carried 
out as described above for whole-cell recordings until a gigaseal was obtained (cell-attached 
mode). The pipette capacitance was cancelled using the amplifier correction circuitry and time 
was allowed for gramicidin to form pores in the membrane. Pore formation was monitored by 
observing a decrease in access resistance and an increase in amplitude of the capacitance 
transients when the test pulse was applied. When equilibrium between gramicidin in the pipette 
and the membrane was reached, the transients stopped changing and the access resistance 
remained constant; this process took around 30–45 minutes. The membrane capacitance and 
access resistance transients were cancelled using the correction circuitry, and recordings 
commenced. 
2.6.9.3 Current-clamp recordings 
Current-clamp recordings were carried out using the perforated patch configuration to determine 
the resting membrane potential of LAD 2 cells, and to investigate whether depolarisation occurs 
following FcεRI cross-linking. Following gramicidin pore formation and the achievement of 
equilibrium (described above in section 2.6.9.2), the amplifier was switched into current-clamp 
mode; current was set to 0 and the voltage was measured. In these experiments, cells were 
incubated overnight with 300ng/ml IgE and stimulated with 3µg/ml anti-IgE, which was focally 
applied. All cells had a negative resting membrane potential, ranging from -0.12mV to -20.21mV. 
The average resting potential was measured at -12.66mV ± 5.51 (n=6); 66% of cells showed 
depolarisation upon anti-IgE application, when ―depolarisation‖ was classed as a voltage change 
of >10mV. Results are shown in figure 2.12. For all further voltage clamp experiments, cells were 
held at -60mV as described previously for TRPC channel recordings (Xu et al., 2005a). 
 Chapter 2: Materials and methods 
75 
 
 
 
 
 
 
 
 
Figure 2.11. Current-voltage relationships recorded in LAD 2 cells 
a: 1 second voltage steps were applied to LAD 2 cells in 20mV increments. Traces are shown for steps at -
100mV, -60mV, -20mV, 20mV, 60mV, 80mV and 100mV. 
b: I/V relationships resulting from application of steps and ramps in LAD 2 cells. Black trace shows resulting 
current when a 1 second ramp from -100mV to +100mV was applied. Red and blue traces show I/V 
relationships taken from the start and end voltage steps shown in (a), respectively (shown as * and ** on 
traces in (a) ). 
Figure 2.10. Schematic diagram showing the stages involved in reaching whole-cell 
configuration. 
a: Patch pipette in bath, seal test applied (5mV, 5ms). b: Deflection in the current trace as the pipette 
touches the cell membrane. c: Gigaseal formation after gentle continuous suction. d: Pipette capacitance 
cancelled using amplifier correction circuitry. e: Membrane ruptured by short application of suction to 
establish whole-cell patch clamp recording configuration. Cell capacitance then cancelled using amplifier 
correction circuitry. 
Reproduced with permission from Yuan, Y. and Atchison, W. D. 2003. Electrophysiological Studies of Neurotoxicants on 
Central Synaptic Transmission in Acutely Isolated Brain Slices. Current Protocols in Toxicology. 17:11.11.1–11.11.38 
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2.6.10  Capacitance and series resistance 
Capacitance is the ability to store charge. There are many sources of stray capacitance in patch 
clamp recordings; these must be charged when the voltage is changed in a patch clamp 
experiment, so ideally should be kept to a minimum. A major source of capacitance is the 
pipette; capacitance arises across the pipette wall, and is called fast capacitance (Cf). This can 
be seen in the oscilloscope display as sharp transients at the beginning and end of the seal test 
when a gigaseal is formed (see figure 2.10c), due to charging and discharging of the pipette wall 
as the voltage is changed. To reduce pipette capacitance, pipettes were coated with Sylgard®, an 
inert, hydrophobic resin that thickens the pipette wall and prevents the bath solution creeping up 
the pipette. Maintaining a low bath volume also reduces the length of pipette in contact with the 
solution, reducing the area of capacitance coupling. 
 
Figure 2.12. Voltage changes in LAD 2 cells stimulated with anti-IgE 
Perforated patch current clamp recordings of LAD 2 cells incubated overnight with 300ng/ml IgE and 
stimulated with 3µg/ml anti-IgE as indicated by the horizontal bars. a: example voltage trace of a cell that 
depolarised in response to anti-IgE application; this occurred in 66% of cells (4/6). A cell was classed as 
showing deplolarisation when the voltage changed by >10mV when anti-IgE was applied. b:example voltage 
trace of a cell that did not depolarise in response to anti-IgE, as occurred in 34% of cells (2/6). c: line series 
graph showing voltage recorded at the start of the recording  (―start‖) and peak voltage during anti-IgE 
application for each cell (―+anti-IgE‖).  
 
Time (s) Time (s) 
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Series resistance, or access resistance (Rs), acts as a barrier to current flow in the patch clamp 
circuit. This is mainly created by resistance in the pipette tip; a high series resistance can be 
indicative of a blocked tip. The cell capacitance and series resistance affect how quickly and 
accurately the membrane potential reflects the command potential; current injected to change 
the holding potential of the cell must first charge the capacitors and overcome series resistance. 
This can be a problem if rapid changes in membrane potential are required, as the potential of 
the membrane may not reach the desired value in time. The amplifier can be used to 
compensate for capacitance and series resistance if necessary by adding a voltage signal to the 
command potential. Cs and Rs values were cancelled in this study but not compensated for; 
figure 2.11 shows that the desired potential was reached in time when ramps were applied.  
2.6.11  Data analysis 
All recordings were examined using Patchmaster software; relevant ramps were exported as .asc 
files and opened in OriginPro 8.5 for graphing and further analysis. Current-time series were 
imported into OriginPro 8.5 as .dat files. All current values were divided by the cell capacitance 
value and displayed as pA/pF, so that currents were normalised to cell size. When concentration 
response curves were constructed, data were fitted using the Hill equation: y= 
Vmax*x^n/(k^n+x^n). 
 
When analysing agonist-induced I/V relationships, the resting I/V was subtracted from that in the 
presence of agonist. To compare currents in the presence of agonist and solvent or antagonist, 
the peak current in the presence of solution of interest (measured at +100 and -100mV) was 
subtracted from the resting current (measured at +100 and -100mV) to give change in current, 
or ΔpA/pF. Current-time graphs for one representative cell are typically shown in this thesis; I/V 
curves are typically shown as mean ± SEM. Statistical analyses were carried out using GraphPad 
Prism 5. 
 
When investigating transient and sustained currents, a current was classed as ―sustained‖ if 
more than 50% of current remained 2 minutes after cessation of drug application. 
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2.7 Polymerase chain reaction (PCR) 
2.7.1 RNA extraction and cDNA production 
Total RNA was extracted from approximately 3 million LAD 2 cells using a Qiagen® RNeasy kit, 
according to manufacturers‘ instructions. For HLMCs, due to limited cell numbers, a Qiagen® RNA 
micro kit was used to extract total RNA from 10 000 cells that were 97–100% pure, as 
determined by staining with Kimura stain and counting using a haemocytometer. RNA was 
converted to cDNA using an iScriptTM cDNA synthesis kit in a reaction volume of 20µl. As a 
negative control for each reaction, reverse transcriptase was replaced with an equivalent volume 
of H2O (-RT sample). The reverse transcription reaction was carried out using a Mycycler thermo 
cycler (Bio Rad), and the protocol was as follows; 25oC for 5 min, 42oC for 30 min, 85oC for 5 
min, 4oC for 5 min,  85oC for 5 min, hold at room temperature. cDNA was stored at -20oC for use 
in PCR reactions. PCR reactions were carried out using beta actin primers (positive control) with 
each cDNA sample to verify its integrity before primers for TRPC channels were tested. 
2.7.2 Primers 
To assess the expression of TRPC channel mRNA in LAD 2 cells and HLMCs, previously published 
primers were used. The primers were designed based on human gene sequences; products were 
verified by DNA sequencing (Wang et al., 2003). Primer sequences are shown in table 2.1. 
Primers were dissolved as a stock concentration of 2pmol/µl for use in PCR reactions. 
2.7.3 PCR reaction 
For the PCR reaction, a mastermix was made containing the following ingredients (volumes given 
per sample): 
 2.5µl 10x PCR buffer 
 2.5µl dNTPs 
 4µl MgCl2 
 9.5µl H2O 
 0.5µl Taq DNA polymerase 
To each reaction, 19µl mastermix was added, along with 1µl cDNA (or –RT sample from cDNA 
reaction) and 2.5µl of each primer. For positive controls, total human brain cDNA was used. 
 
PCR reactions were performed using a Mycycler thermo cycler (Bio Rad); the following cycles 
were used: 
 Stage 1: 94oC 5 min 
 Stage 2 (50 cycles): 
94oC 1 min 
58oC for TRPC1, 3, 4 and 6; 55oC for TRPC5; 53oC for TRPC7; 1 min 
72oC 1min 
 Stage 3: 72oC 7 min 
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2.7.4 Gel electrophoresis 
PCR products were run on 1% agarose gel containing 0.005% ethidium bromide, made up in 
TRIS-acetate-EDTA (TAE) buffer. Loading dye (New England Biolabs) was added to the samples 
and they were run at 100V alongside a wide range DNA molecular weight marker (New England 
Biolabs), using a consort E844 power supply. TAE buffer contained (in mM): 40 Tris base, 1.14 
acetic acid and 1 EDTA. Following electrophoresis, gels were visualised using a BioDoc-it imaging 
system (UVP BioImaging Systems). 
 
 
2.8 Mediator release assays 
The release of granule-associated mediators including histamine and β-hexosaminidase from 
both LAD 2 cells and HLMCs can be measured experimentally. 
2.8.1  β-hexosaminidase release assays  
2.8.1.1 LAD 2 cells 
β-hexosaminidase release is commonly assayed as a marker of rat mast cell degranulation, and 
LAD 2 cells have been shown to release it following FcεRI cross-linking (Kirshenbaum et al., 
2003). β-hexosaminidase is an enzyme whose substrate, p-nitrophenyl-N-acetyl-β-D-
glucosaminidase, is converted to the chromogenic product p-nitrophenol. The reaction can be 
measured by light absorbance at 405nm, indicating how much β-hexosaminidase is released. 
 
The method for measuring β-hexosaminidase release from LAD 2 cells was adapted from that 
used to assess release from adherent RBL-2H3 cells (Ramkumar et al., 1993). To assess β-
hexosaminidase from LAD 2 cells following FcεRI cross-linking, cells were incubated overnight 
Table 2.1. PCR primer information 
Primer sequences were taken from (Wang et al., 2003) 
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with 300ng/ml human IgE at 37oC and 5% CO2. The following day, they were centrifuged at 
1000rpm for 4 minutes, resuspended in standard imaging solution and placed in a V-bottomed 
96-well plate at a concentration of 50 000 cells per well. If required, antagonists were added and 
the plate was incubated for 5 minutes at 37oC, 5% CO2. Agonists (3µg/ml anti-IgE for FcεRI 
cross-linking experiments) were diluted in standard imaging solution and added to each well. The 
plate was incubated for 30 minutes at 37oC, 5% CO2, followed by centrifugation at 1500rpm for 
10 minutes. 40µl supernatant from each well was added to 40µl p-nitrophenyl-N-acetyl-β-D-
glucosaminidase (at a concentration of 2mM diluted in 0.2M citrate buffer) in another 96 well 
plate. The substrate plate was incubated for 2.5 hours at 37oC, 5% CO2, and the reaction was 
stopped by adding 90µl 1M Tris HCl, pH 9.0. The plate absorbance at 405nm was measured 
using an Expert Plus microplate reader (Biochrom Ltd) with Digiread software. Spontaneous 
release was determined by the addition of imaging solution only to cells; total release was 
determined by lysis of cells with 0.1% Triton-X-100. Background absorbance readings were 
determined from wells containing imaging solution and p-nitrophenyl-N-acetyl-β-D-
glucosaminidase only. Experiments were carried out in duplicate on a single plate. 
 
2.8.1.2  β-hexosaminidase release assays: HLMCs 
β-hexosaminidase release was not able to be carried out on HLMCs using the method described 
above for LAD 2 cells, because sufficient numbers of pure cells were not able to be obtained in 
our laboratory due to the limited availability of lung tissue. HLMC release assays were carried out 
in collaboration with Dr Peter Peachell, using impure suspensions of HLMCs isolated using the 
method described in section 2.3.6. Release assays were carried out one day after cell isolation. 
The number of HLMCs in a suspension was counted using Kimura stain. Cells were centrifuged at 
1000rpm for 4 minutes, resuspended in standard imaging solution, and 50 000 HLMCs per 
condition were placed into 15ml centrifuge tubes. If required, antagonists were added and the 
tubes were incubated for 5 minutes at 37oC, 5% CO2. Agonists (3µg/ml anti-IgE for FcεRI cross-
linking experiments) were diluted in standard imaging solution and added to each tube; tubes 
were incubated for 30 minutes at 37oC, 5% CO2. Tubes were then centrifuged at 1000 rpm for 4 
minutes, and 40µl supernatant was assayed for β-hexosaminidase release as described above for 
LAD 2 cells. The remainder of the supernatant was stored at -20oC and assayed for histamine 
content. 
 
2.8.1.3  Data analysis: β-hexosaminidase assays 
Absorbance readings were imported into Microsoft Excel. Average background values were 
subtracted from all values, and average spontaneous release values were then subtracted from 
all other readings. Release was calculated as a percentage of total release, determined by Triton-
X-100 lysis. Percentage release values were imported into OriginPro 8.5 for graphing, and 
statistical analyses were carried out using Graphpad Prism 5. Results are displayed as mean ± 
SEM; N numbers refer to the number of wells. Experiments were typically carried out in duplicate 
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on one plate and repeated three times for LAD 2 cells. For HLMCs, the number of donors used is 
indicated in the figure legend. 
 
2.8.2  Histamine release assays 
2.8.2.1 Protocol: histamine release assays in HLMCs 
Impure HLMCs were stimulated and centrifuged as described above for β-hexosaminidase release 
(section 2.8.1); supernatant was stored at -20oC and histamine release was measured in the 
laboratory of Dr P. Peachell, using a fluorimetric method described previously (Siraganian, 1974). 
An automated sampler dispensed reference histamine solutions of known concentration, water, 
and the samples into the system. Histamine was extracted into butanol, followed by a wash with 
NaOH, and back-extraction of histamine into HCl in the presence of heptane. The aqueous phase 
was mixed with o-phthaldialdehyde (OPT) in the presence of NaOH. OPT is commonly used to 
quantify protein concentrations as it reacts with amino groups to form a fluorescent moiety. The 
reaction was stopped by the addition of HCl; the resulting fluorescence was detected with a 
fluorometer and recorded using a chart recorder. A pump with calibrated tubes allowed precise 
volumes of the different reagents to be delivered into the system. Histamine release was 
measured as a percentage of total release for each donor, determined by lysis with 0.5% 
perchloric acid. 
 
2.8.2.2  Data analysis: histamine assays 
Peaks on the chart recorder were measured with a pencil and ruler, and the values put into 
Microsoft Excel. Average spontaneous release values were subtracted from all readings, and 
release was calculated as a percentage of total release, determined by lysis with perchloric acid. 
Percentage release values were imported into OriginPro 8.5 for graphing, and statistical analyses 
were carried out using Graphpad Prism 5. Results are displayed as mean ± SEM; N numbers 
refer to the number of sample. Experiments were typically carried out in duplicate on each 
donor; the number of donors for each experiment is stated in the figure legend. 
 
2.8.3  Release assay solutions 
Cells were suspended in standard imaging solution for the assessment of mediator release, to 
allow comparisons to be made between results. p-nitrophenyl-N-acetyl-β-D-glucosaminidase was 
used at 2mM, diluted in citrate buffer; 2.34g citric acid and 2.588g sodium citrate in 100ml H2O, 
pH adjusted to 4.5 with HCl. 1M Tris HCl was dissolved in H2O and the pH adjusted to 9.0 using 
NaOH. 
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2.9 Mast cell motility assays 
Motility assays were carried out using a method previously published for HLMCs (Brightling et al., 
2005) using transwells with 8µM fibronectin-coated inserts in 24 well plates (BD Biosciences). 50 
000 LAD 2 cells were placed onto each insert and 500µl agonist was added to wells below the 
inserts. Following a three hour incubation at 37oC and 5% CO2, wells were photographed and the 
number of cells in a defined central region were counted.  
 
2.10  Reagents 
2.10.1  Cell culture reagents 
DMEM, DMEM-F12, FCS, zeocin, blasticidin, cell dissociation solution, G418, tetracycline, 
StempPro-34, nutrient supplement, L-glutamine, HBSS, antibiotic/antimycotic solution, MEM non-
essential amino acids and Dynabeads® were obtained from Invitrogen Life Technologies (Paisley, 
UK). Stem cell factor, IL-6 and IL-10 were obtained from R&D Systems (Abingdon, UK). DMSO, 
collagenase type 1A, hyaluronidase and poly-L-lysine hydrobromide were obtained from Sigma 
Aldrich (Poole, UK); mouse anti-human CD117 was obtained from BD PharmingenTM, BD 
Biosciences (Oxford, UK). 
 
2.10.2  Antibodies and PCR reagents 
PE-tagged anti-CD117 was obtained from Miltenyi Biotech (Surrey, UK). PCR mastermix 
ingredients and DNA ladders were from New England Biolabs (Hitchin, UK). Custom-made 
primers were from Invitrogen Life Technologies (Paisley, UK). 
 
2.10.3  All other reagents 
Compounds were dissolved in sterile H2O and stored at -20
oC unless otherwise stated. Anti-IgE, 
ATP, SKF-96365, GdCl3, ADP, carbachol, UTP, PMA (dissolved in DMSO), ionomycin (dissolved in 
DMSO), flufenamic acid (dissolved in 95% ethanol) and p-nitrophenyl-N-acetyl-β-D-
glucosaminidase (dissolved in DMSO) were from Sigma Aldrich (Poole, UK). Fibronectin was from 
BD Biosciences (Oxford, UK). Synta 66 (dissolved in DMSO) was a generous gift from GSK 
Stevenage. OAG, S1P and thapsigargin (all in DMSO) and MRS2179 were from Tocris Bioscience 
(Bristol, UK). Ro-31-8425 (dissolved in DMSO) and human IgE myeloma (dissolved in NaCl) were 
from Merck Bioscience (Middlesex, UK). NP-BSA (dissolved in PBS) was from Biosearch 
Technologies, Inc. (Novato, USA), and human IgE anti-NP (stored at 4oC) was from ABD Serotec 
(Kidlington, UK). 
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Chapter 3: Human mast cell activation 
Initial studies into human mast cell activation aimed to investigate whether FcεRI-mediated 
allergic activation and stimulation by GPCRs could be quantified in human mast cells using Ca2+ 
imaging and secretion assays. The entry of Ba2+ ions following intracellular Ca2+ store depletion 
was assessed in order to obtain preliminary data on which ion channels may be responsible for 
store-operated Ca2+ entry in human mast cells. Finally, mRNA expression for the six human TRPC 
channels was characterised using RT-PCR. 
3.1 Assessment of different IgE/anti-IgE combinations to activate 
LAD 2 cells 
Activation of mast cells by anti-IgE cross-linking of IgE bound to FcεRI (Cochrane & Douglas, 
1974)  is the best-studied mechanism of mast cell activation, and represents physiological 
activation by allergens (Metz & Maurer, 2007). Thus, it was firstly important to verify that LAD 2 
cells do indeed secrete in response to FcεRI cross-linking as reported (Kirshenbaum et al., 2003), 
and secondly to establish a combination of IgE/anti-IgE that reliably activates the cells. LAD 2 
cells were incubated overnight with various concentrations of human IgE (0.1–3µg/ml) and 
stimulated with various concentrations of anti-human IgE (0.3–100µg/ml); β-hexosaminidase 
release was measured as described in chapter 2.8. As shown in figure 3.1a (i), anti-IgE gave rise 
to concentration-dependent secretion of β-hexosaminidase. Concentrations above 100µg/ml were 
not tested as this involved a 1 in 5 dilution from the stock solution and likely would have led to 
non-specific solvent effects; moreover, higher concentrations would have required un-economical 
amounts of anti-IgE. Increasing the concentration of IgE alone did not appear to have an effect 
on secretion, suggesting that FcεRI receptors are fully occupied at the lowest concentration of 
IgE tested. 300ng/ml human IgE was used for all future experiments.  
 
Calbiochem anti-human IgE was then compared with Sigma anti-human IgE (used by (Shim et 
al., 2003)); see figure 3.1a (ii). As shown, both types of anti-IgE effectively stimulated 
concentration-dependent β-hexosaminidase release from LAD 2 cells; with Sigma anti-IgE the 
curve reached a plateau at concentrations above 10µg/ml, whereas the Calbiochem anti-IgE did 
not appear to cause maximal release even at 100µg/ml. For this reason, and because 
Calbiochem anti-IgE contains 0.1% sodium azide not present in the Sigma product, Sigma anti-
human IgE was used for future experiments. The sub-maximal concentration of 3µg/ml was 
selected for use in future studies.   
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When the LAD 2 cell line was originally characterised, it was shown that the cells released β-
hexosaminidase in response to NP-BSA cross-linking of anti-NP IgE bound to FcεRI, with a 
maximal release of around 40% (Kirshenbaum et al., 2003). This method of stimulation was 
carried out in our laboratory; LAD 2 cells were incubated overnight with 300ng/ml anti-NP IgE 
and stimulated with various concentrations of NP-BSA before assaying for β-hexosaminidase 
release. As shown in figure 3.1b (i), NP-BSA elicited concentration-dependent secretion from LAD 
2 cells, with maximal release of around 20%. Compared in figure 3.1b (ii) is maximal β-
hexosaminidase release elicited by Calbiochem or Sigma anti-IgE, and NP-BSA. The maximal 
Figure 3.1. IgE-mediated β-hexosaminidase secretion in LAD 2 cells 
a (i): Cells were sensitised overnight with different concentrations of human IgE (indicated by coloured 
lines; see legend) and stimulated with Calbiochem anti-human IgE at the concentrations shown (N=4 for 
300ng/ml IgE, N=2 for all other concentrations). In (ii), cells were incubated overnight with 300ng/ml IgE 
and stimulated with various concentrations of Calbiochem (black) and Sigma (blue) anti-IgE (N=4). Β-
hexosaminidase release was measured, and is expressed as ―% total‖; total release was determined by lysis 
with 0.5% Triton X-100. 
b (i): Cells were sensitised overnight with 300ng/ml human IgE anti-NP and stimulated with varying 
concentrations of NP-BSA, as shown. The bar chart in (ii) compares the maximal release in response to 
Sigma (clear bar) and Calbiochem (blue bar) anti-human IgE, and NP-BSA (green bar, N=4). *: means were 
significantly different, p<0.05, one-way ANOVA with Tukey post-test.  
Experiments in part (a) were carried out by Kathryn Wareham 
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release stimulated by NP-BSA in LAD 2 cells was approximately half of that measured in response 
to anti-IgE and the 40% maximal release reported previously for NP-BSA stimulation 
(Kirshenbaum et al., 2003). For this reason, the IgE anti-NP/NP-BSA combination was not used 
further.  
 
3.2 Cytosolic Ca2+ fluxes upon receptor activation 
Cytosolic Ca2+ entry is an essential prerequisite for mast cell mediator secretion following FcεRI 
cross-linking (Cochrane & Douglas, 1974); typically this consists of Ca2+ release from intracellular 
stores, followed by entry from outside the cell across the plasma membrane (Vig & Kinet, 2009). 
In order to assess the contribution of different ion channels to this Ca2+ entry, it was investigated 
whether human mast cell activation led to quantifiable increases in cytosolic Ca2+. LAD 2 cells 
were loaded with fura-2-AM, and fluorescent imaging was used as detailed in chapter 2.5 to 
investigate the Ca2+ signalling that occurs downstream of FcεRI cross-linking. Shown in Figure 
3.2a (i) is Ca2+ entry in LAD 2 cells incubated overnight with 300ng/ml IgE and stimulated with 
3µg/ml anti-IgE in the presence of extracellular Ca2+; 96% of cells responded to anti-IgE 
application, where ―responders‖ were classed as cells where the fluorescence ratio in the 
presence of anti-IgE rose by more than 10 standard deviations above the baseline fluorescence. 
In part (ii) no Ca2+ was present in the recording solution, and 81% of cells responded to anti-IgE 
application. Similar observations were made in three separate experiments. Figure 3.2a (iii) 
shows the mean Ca2+ entry in LAD 2 cells in the presence and absence of extracellular Ca2+; 
when Ca2+ was present, LAD 2 cells showed a sustained Ca2+ entry phase in response to FcεRI 
cross-linking. In the absence of extracellular Ca2+, a transient release of Ca2+ from intracellular 
stores can be seen. 
 
This experiment was repeated on primary HLMCs; as shown in figure 3.2b, following anti-IgE 
application a rapid, transient Ca2+ release could be seen in 88% of cells in the absence of 
extracellular Ca2+, when the same criteria to classify responding cells were used as described for 
LAD 2 cells. In one donor tested (donor 411), 100% of cells (n=4) responded to anti-IgE 
application in the absence of extracellular Ca2+; 82% of cells responded in donor 410 (n=11). 
When extracellular Ca2+ was present, prolonged Ca2+ entry in HLMCs occurred in 100% of cells 
tested, corresponding to influx through plasma membrane ion channels. As similar results were 
obtained from two separate donors, the average traces in 3.2b (iii) were calculated using data 
from both donors The change in fluorescence corresponding to the size of Ca2+ release from 
stores was significantly larger in HLMCs than in LAD 2 cells (0.44±0.1 and 0.11±0.02, 
respectively; p<0.0001, unpaired Student‘s T-test). The reasons for this will be discussed in 
section 3.5. 
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Whilst IgE-mediated signalling is an important mechanism for mast cell activation, ligands for 
other receptors are likely to be present in vivo at sites of mast cell activation. ATP is present at 
high concentrations at sites of inflammation and is degraded to produce ADP, AMP and 
adenosine (Bulanova & Bulfone-Paus, 2010). ADP has been shown to stimulate histamine release 
from mouse mast cells (Saito et al., 1991) so could be an important stimulator of human mast 
cells. Of the ADP receptors P2Y1, P2Y12 and P2Y13, the Gq-coupled P2Y1 has been reported to be 
expressed in HLMCs (Schulman et al., 1999); whilst FcεRI is coupled to PLCγ (Park et al., 1991), 
P2Y1 activation leads to PLCβ stimulation (Gilfillan & Tkaczyk, 2006). In order to explore the 
potential for differential coupling between receptors and Ca2+ signalling pathways, Ca2+ 
responses through P2Y1 receptors were then investigated. Because these receptors are coupled 
to PLCβ, it can be hypothesised that their stimulation could lead to store-released Ca2+ and the 
downstream activation of plasma membrane Ca2+ channels such as TRPC channels. 
Figure 3.2. IgE-induced Ca2+ signals in LAD 2 cells and HLMCs 
Fura 2-loaded cells sensitised overnight with 300ng/ml IgE were stimulated with 1/300 anti-IgE, which was 
bath applied as indicated by the horizontal bars. 
a: IgE-mediated Ca2+ entry in LAD 2 cells, shown by F340/380, in the presence (i) or absence (ii) of 2mM 
extracellular Ca2+. Traces in (i) and (ii) show individual representative cells. Part (iii) shows mean ± SEM in 
the presence (black trace; n=75 cells, N=3 individual experiments, 96% of cells responded) or absence 
(blue trace; n=32, N=3, 81% of cells responded) of extracellular Ca2+. 
b: Experiments were carried out in HLMCs as in (a); n=30, N=4, 100% of cells responded in the presence 
of extracellular Ca2+. n=15, N=3, 88% of cells responded in the absence of extracellular Ca2+. Results are 
representative of 2 separate donors.  
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As shown in figure 3.3a, HLMCs show sustained Ca2+ entry in response to ADP stimulation of P2Y 
receptors when extracellular Ca2+ is present, corresponding to intracellular store depletion 
followed by prolonged influx across the cell membrane. Figure 3.3b shows Ca2+ fluxes in the 
absence of extracellular Ca2+; as with IgE-mediated stimulation, HLMCs show a transient release 
of Ca2+ from intracellular stores following activation with ADP. 100% of cells responded to ADP 
application in the presence and absence of extracellular Ca2+, when using the same criteria to 
classify ―responders‖ as described above for IgE-mediated responses in LAD 2 cells and HLMCs. 
It is evident that there was some variability between cells in the time course of ADP responses; 
as shown in figure 3.3a (i), some cells displayed a rise in Ca2+ before others. Figure 3.3a (ii) 
shows mean data taken from HLMCs from four separate donors; each donor was then analysed 
individually to determine whether the variability was donor-dependent. Shown in figure 3.4 are 
ADP responses in the four different donors, represented by different coloured lines. 
 
 
 
Figure 3.3. ADP-induced Ca2+ signals in HLMCs 
Fura-2-loaded cells were stimulated with 100µM ADP in the presence (a) and absence (b) of 
2mM extracellular Ca2+. (i) shows individual representative cell traces. (ii) shows mean ± SEM; 
n=53 cells, N=8 experiments, representative of 4 donors in part (a). N=9, N=3, representative 
of 2 donors in part (b).  100% of cells responded to ADP application in both parts.  
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As shown above, whilst 100% of HLMCs tested responded to ADP, there was donor-dependent 
variability in the size and time course of the responses. Cells from donors 370 and 410 (blue and 
green traces, respectively) showed a similar time-course of response, with an initial rise in 
intracellular Ca2+ followed by a small drop and a plateau phase. HLMCs from donor 360 displayed 
a larger initial Ca2+ entry peak, followed by a gradual decrease; cells from donor 411 showed an 
initial peak in Ca2+, with a rapid decline followed by a plateau. These data demonstrate that 
there is donor-dependent variability in HLMC responses to ADP; this could be due to the 
complement of ADP receptors present, or the expression of different plasma membrane ion 
channels activated downstream of PLCβ. These possibilities will be explored in section 3.5.   
 
When comparing IgE- and ADP-dependent Ca2+ entry in HLMCs (compare figure 3.3a with figure 
3.2b), it is evident that the change in fluorescence was greater following IgE-mediated 
stimulation. Figure 3.5 illustrates this difference; as shown, both Ca2+ release from stores and 
Ca2+ influx across the membrane were significantly higher with IgE-mediated stimulation 
compared to ADP activation of P2Y receptors. This difference could be due to differential 
coupling to downstream signalling pathways and will be discussed in section 3.5. 
 
To summarise, whilst there were differences in the Ca2+ signalling occurring downstream of 
FcεRI- and P2Y receptor-mediated HLMC activation, both mechanisms of stimulation led to store-
dependent Ca2+ release and Ca2+ entry in HLMCs. The data obtained show that Ca2+ imaging can 
be used as a tool to investigate the ion channels activated downstream of receptor signalling in 
human mast cells; this was used later in the study to identify whether TRPC channels may be 
coupled to FcεRI- and P2Y- mediated signalling.  
Figure 3.4. Comparison of ADP responses in HLMCs from different donors. 
Data shown in figure 3.3a (ADP responses in the presence of extracellular Ca2+) were separated into 
different donors, and average F340/380 was calculated. Data from different donors (indicated by numbers 
in legend) are shown by different coloured lines; traces show mean ± SEM. n numbers are as follows: 11 
for 360, 10 for 370, 15 for 410, 12 for 411. 
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3.3 Ba2+and Ca2+ ion entry following store depletion in human mast 
cells 
Having established that fura-2 imaging can be used to visualise Ca2+ release from intracellular 
stores and influx across the plasma membrane, it was possible to use a protocol of store 
depletion in the absence of extracellular Ca2+ followed by divalent ion addition, to assess the 
selectivity of plasma membrane channels contributing to Ca2+ influx. It is known that the Ca2+ 
release-activated Ca2+ current ICRAC (Hoth & Penner, 1993) activated downstream of store 
depletion is mediated by  Ca2+- selective Orai1 channels (Feske et al., 2006; Prakriya et al., 
2006; Vig et al., 2006b); there is also strong evidence to suggest that TRPC channels, which are 
permeable to Ba2+ as well as other cations (Ma et al., 2008), are activated downstream of store 
depletion. Ba2+ can be used as an experimental tool to evaluate whether channels other than 
Orai1, such as TRPC channels, may be activated downstream of Ca2+ store depletion in human 
mast cells. The entry of Ba2+ and Ca2+, which can both bind to fura-2 (Schilling et al., 1989), was 
assessed following depletion of intracellular stores by three different methods; firstly, 
thapsigargin was used to passively deplete intracellular stores by inhibiting Ca2+ re-uptake via the 
SERCA pump (Lytton et al., 1991). Secondly, anti-IgE was used to cross-link FcεRI following 
overnight incubation with IgE, and finally ADP was applied to stimulate P2Y receptors, leading to 
downstream store depletion. Results obtained in LAD 2 cells are shown in figure 3.6; when the 
stores were depleted by thapsigargin, anti-IgE or ADP, a small transient rise in fluorescence 
could be seen, corresponding to Ca2+ store release. This was followed by further increases in 
fluorescence when Ba2+ or Ca2+ ions were added back to the external solution, showing entry of 
these divalent ions from the extracellular solution. When thapsigargin was used to deplete 
stores, 94% of cells showed an increase in fluorescence corresponding to Ba2+ entry; 100% 
responded to Ca2+ ion re-addition. Following FcεRI cross-linking, Ba2+ entry occurred in 95% of 
Figure 3.5. Comparison of IgE- and ADP- mediated Ca2+ signalling in HLMCs 
Bar graph comparing IgE (white)- and ADP (blue)- stimulated Ca2+ entry (ΔF340/380 in the presence of 
extracellular Ca2+) and release from stores (ΔF340/380 in the absence of extracellular Ca
2+). Means 
were significantly different, p<0.0001 (***) or p<0.001 (**), unpaired student‘s T-test. 
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cells and Ca2+ entry in 83% of cells. Interestingly, cells not responding to Ba2+ ion addition 
following FcεRI cross-linking did respond to Ca2+ application; this suggests that different cells 
may express a distinct complement of channels. Following P2Y stimulation with ADP, Ba2+ entry 
occurred in 86% of cells and Ca2+ entry in 96% of cells. Ca2+ entry occurred in 85% of the cells 
that did not show Ba2+ entry following P2Y receptor stimulation, again suggesting that the 
expression of TRPC and Orai channels activated downstream of store depletion may vary from 
cell to cell. 
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Figure 3.6. Ba2+ and Ca2+ ions enter LAD 2 cells following store depletion 
Fura-2-loaded LAD 2 cells were superfused with Ca2+-free external solution and stimulated with (a) 
2µM thapsigargin (TG), (b) 3µg/ml anti-IgE, following overnight incubation with 300ng/ml IgE, or 
(c) 100µM ADP, to stimulate P2Y purinoceptors. Solutions containing 2mM Ba2+ or Ca2+ were bath-
applied as indicated by the horizontal bars. In all parts, (i) shows example individual cell traces and 
(ii) shows mean ± SEM. n numbers are as follows; (a): n=36 cells, N=4 experiments. (b): n=40, 
N=4. (c): n=57 N=4. 
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Ba2+and Ca2+entry following intracellular store depletion was also assessed in primary HLMCs, to 
give an indication of which channels may be involved in SOCE in these cells. Results are shown in 
figure 3.7; as with LAD 2 cells, a transient Ca2+ entry could be seen in the absence of 
extracellular Ca2+ when the stores were depleted by thapsigargin, or by downstream signalling of 
FcεRI and P2Y receptors. Ba2+ and Ca2+ entry could then be observed when the ions were added 
to the extracellular solution. The percentage of cells where Ba2+ and Ca2+ entry occurred 
following store depletion was assessed in the donors tested; results are summarised in table 3.2. 
As with previous data, cells were classed as ―responders‖ when the fluorescence ratio increased 
by more than 10 standard deviations above the baseline fluorescence when Ba2+ and Ca2+ ions 
were added to the solution following store depletion. In both LAD 2 cells and HLMCs, it should be 
noted that the time course for internal store release differed in both cell types depending on the 
agent used to deplete the stores; this is expected given their different modes of action, and will 
be discussed in section 3.5.  
 
In both cell types, the amplitude of the Ba2+ component is similar under all conditions and 
smaller than Ca2+ entry; it is known that fura-2 has a lower affinity for Ba2+ than Ca2+ (Kd values 
of 780 and 236 , respectively) (Schilling et al., 1989), meaning that fura-2 is approximately 3.3 
fold more sensitive for Ca2+. The change in fluorescence corresponding to Ba2+ and Ca2+ entry 
was assessed and the results are shown in table 3.1. In LAD 2 cells, the size of Ca2+ entry was 
around 3.5 times larger than Ba2+ entry following all three methods of stimulation; given the Kd 
values, this indicates that the size of Ba2+ entry was similar to Ca2+ entry following store 
depletion in LAD 2 cells.  In HLMCs, however, the size of Ba2+ entry was similar following store 
depletion by the different mechanisms, but the size of Ca2+ entry varied. Ca2+ entry was less 
than 3.3 times greater than Ba2+ entry in all conditions, indicating that Ba2+ entry could have 
been greater than Ca2+ entry in HLMCs. It is likely that divalent ion influx through the Ba2+-
permeable channels represents a small component of the influx through all Ca2+-permeable 
channels; Ba2+ entry would be expected to occur through TRPC channels activated downstream 
of store depletion only, whereas Ca2+ influx could occur through TRPC channels and Ca2+-
selective Orai channels. Ba2+ entry may appear greater than Ca2+ entry in HLMCs because Ca2+ is 
a negative regulator of both TRPC (Singh et al., 2002; Shi et al., 2004) and Orai (DeHaven et al., 
2007) channels; Ba2+ is a poor substrate for Ca2+ regulatory sites (Uvelius et al., 1974; Ohya et 
al., 1988) so cannot cause channel inhibition. This, along with the contributions of the different 
channels, is discussed in more detail in section 3.5. 
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Figure 3.7. Ba2+ and Ca2+ ions enter HLMCs following store depletion 
Fura 2-loaded HLMCs were superfused with Ca2+-free external solution and stimulated with (a) 2µM 
thapsigargin (TG), (b) 1/300 anti-IgE, following overnight incubation with 300ng/ml IgE, or (c) 100µM 
ADP, to stimulate P2Y purinoceptors. Solutions containing 2mM Ba2+ or Ca2+ were bath-applied as 
indicated by the horizontal bars. In all parts, (i) shows example individual cell traces and part (ii) shows 
mean ± SEM. n numbers are as follows; (a): n=33 cells, N=4 experiments from 2 donors. (b): n=30, N=4, 
N=2 donors (c): n=9 N=3, N=2 donors. 
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Following the demonstration that Ba2+ ions can enter both LAD 2 cells and primary HLMCs after 
store depletion, it was investigated whether divalent ions other than Ca2+could also support 
human mast cells functionally. It has previously been shown that Ba2+ and Sr2+, as well as other 
divalent ions, can support degranulation in RBL-2H3 cells (Hide & Beaven, 1991; Ma et al., 
2008), and has been suggested that TRPC channels are the carriers of these divalent ions (Ma et 
al., 2008). The ability of different divalent ions to support degranulation has not been 
investigated in human mast cells; therefore, β-hexosaminidase release from LAD 2 cells 
stimulated via FcεRI was measured in the presence of Ca2+, Ba2+ and Sr2+ ions in the 
extracellular solution. The results (figure 3.8) show that these divalent ions can support 
degranulation in LAD 2 cells stimulated via FcεRI; β-hexosaminidase release elicited by 300ng/ml 
NP-BSA was not significantly different in the presence of the different divalent ions. NP-BSA was 
used to cross-link human IgE anti-NP in this experiment as it was carried out before the 
comparison of IgE/anti-IgE combinations shown in figure 3.1.  
Table 3.2. Ba2+ and Ca2+ entry in HLMCs following store depletion 
The percentage of cells displaying Ba2+ or Ca2+ entry was assessed in HLMCs following store 
depletion with thapsigargin (―TG‖), anti-IgE (―IgE‖) and ADP. D1: donor 1 (410). D2: donor 2 
(411) 
 
Table 3.1. Comparison of Ba2+ and Ca2+ entry following store depletion in LAD 2 
cells and HLMCs 
Baseline fluorescence was subtracted from peak fluorescence in the presence of Ba2+ or Ca2+, to 
give ―ΔF340/380‖ corresponding to the entry of each divalent ion. ΔF340/380 corresponding to Ca
2+ 
entry was then divided by that for Ba2+ entry to calculate―Ca2+/Ba2+‖ .  There was no significant 
difference in the mean divalent ion entry elicited by the different mechanisms of store depletion 
in both cell types (one-way ANOVA with Tukey post-test). 
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The observation that divalent ions other than Ca2+ can enter human mast cells following store 
depletion and support degranulation suggest that non-selective cation channels, such as TRPC 
channels, may contribute to Ca2+ entry brought about by these stimuli in vivo. It was therefore 
necessary to assess which TRPC family members are present in human mast cells. 
 
3.4 mRNA expression for TRPC channels in human mast cells 
RT-PCR was used to characterise mRNA expression of the six human TRPC channels in LAD 2 
cells and HLMCs using the primers and methods detailed in chapter 2.7. As shown in figure 3.9a, 
it was found that LAD 2 cells express mRNA transcripts for TRPC1, 3, 5, 6 and 7, but not TRPC4. 
Total human brain cDNA was used as a positive control for the TRPC4 primers. Expression of 
some of the different TRPC channels in HLMCs varied between donors. An example band pattern 
for TRPC mRNA expression in one donor tested is shown in figure 3.9b; the results taken from 
three HLMC donors (A387, A410 and A411) are shown in table 3.3. TRPC1 and TRPC6 mRNA 
transcripts were found to be present in HLMCs from all donors tested; TRPC5 and 7 transcripts 
were present in one donor only (A387 and A410, respectively). mRNA transcripts for TRPC3 and 
4 were not present in any donor tested. These results confirm that TRPC channels are expressed 
in human mast cells, suggesting that they could have a role in mediating the divalent ion entry 
reported earlier in this chapter. 
 
Figure 3.8. Ba2+ and Sr2+ ions can support degranulation in LAD 2 cells 
LAD 2 cells incubated overnight with 300ng/ml human IgE anti-NP were stimulated with 300ng/ml 
NP-BSA. β-hexosaminidase release was measured and expressed as % total, which was determined 
by lysis with 0.5% Triton X-100. There was no significant difference in the mean β-hexosaminidase 
release supported by the different divalent ions (one-way ANOVA, N=4). 
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TRPC channel  mRNA expression (number of donors)  
TRPC1  3/3  
TRPC3  0/3  
TRPC4  0/3  
TRPC5  1/3  
TRPC6  3/3  
TRPC7  1/3  
 
 
Table 3.3. Summary of TRPC mRNA expression in HLMCs  
RT-PCR was carried out on samples taken from three HLMC donors (A387, A410 and A411); the table 
shows how many donors mRNA for each TRPC channel was expressed in.  
 
Figure 3.9. TRPC channel mRNA expression in human mast cells  
RT-PCR was carried out on total RNA isolated from LAD 2 cells and HLMCs. 
a: LAD 2 cells expressed mRNA for TRPC1,3, 5, 6 and 7, with band sizes corresponding to their expected 
size as detailed in chapter  2. ―+RT‖ and ―-RT‖ indicate the presence and absence of reverse transcriptase 
in the reaction to produce cDNA. The positive control for TRPC4 primers was total human brain cDNA.  
b: Example band pattern for TRPC channel mRNA expression in one donor of HLMCs tested, expressing 
TRPC1, 5 and 6 mRNA. 
The housekeeping gene β-actin was used as a positive control to test the integrity of all cDNA samples 
before PCR was carried out for the TRPC channels.  
 
 Chapter 3: Human mast cell activation 
97 
 
3.5 Discussion 
In the allergic response, for example in the airways of asthma sufferers, mast cells are activated 
by anti-IgE cross-linking of IgE bound to FcεRI (Segal et al., 1977). At the time that this work 
was done, LAD 2 cells were the only human mast cell line reported to degranulate in response to 
FcεRI cross-linking (Kirshenbaum et al., 2003) and were therefore a potentially good model to 
study IgE-mediated human mast cell activation. This preliminary part of the study aimed firstly to 
verify that LAD 2 cells secreted β-hexosaminidase in response to IgE receptor cross-linking, and 
to establish a combination of IgE/anti-IgE that reliably activates the cells. Following overnight 
incubation with IgE, the cells were found to secrete β-hexosaminidase in a concentration-
dependent manner in response to Calbiochem anti-IgE (figure 3.1a). These data are in 
accordance with results obtained by Kirshenbaum et al. (2003) showing that LAD 2 cells released 
β-hexosaminidase in response to NP-BSA cross-linking of anti-NP IgE bound to FcεRI in a 
concentration-dependent manner, with maximal release of approximately 40%. Following FcεRI 
cross-linking, a complex series of intracellular signalling events leads to downstream mediator 
release. These signalling cascades are discussed in detail in chapter 1.2, but importantly for the 
release of pre-formed mediators by degranulation, the FcεRI-proximal signalling complex 
activates PLCγ; degranulation follows the cleavage of PtdInsP2 by PLCγ to generate InsP3 and 
DAG, which cause Ca2+ release from stores and PKC activation, respectively. In addition, P13K, 
which is activated downstream of Fyn phosphorylation, is also thought to be required for optimal 
degranulation (Gilfillan & Tkaczyk, 2006). As β-hexosaminidase is a marker for mast cell 
degranulation (Schwartz et al., 1979), the results obtained in this study confirm that IgE-
mediated activation of LAD 2 cells stimulates this complex signalling cascade, leading to 
degranulation.  
 
Whilst LAD 2 cells degranulated in response to anti-IgE application in a concentration-dependent 
manner, the concentration of IgE that was used to incubate the cells overnight had little effect 
on the subsequent amount of β-hexosaminidase secretion. The α subunit of FcεRI is responsible 
for binding IgE with high affinity, and it is believed that IgE/FcεRI interaction occurs with 1:1 
stoichiometry (Kinet, 1999). This, along with the previous observation that mouse serum 
containing low titres of IgE antibodies is able to sensitise rat mast cells (Prouvost-Danon et al., 
1975), suggests that low concentrations of IgE are able to sufficiently sensitise FcεRI. 
Additionally, it has been shown that only a fraction of FcεRI must be cross-linked to allow optimal 
degranulation in RBL-2H3 cells (Ortega et al., 1988). Therefore, it is likely that in this study, 
sufficient numbers of FcεRI receptors were occupied with IgE at all concentrations tested. 
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It has previously been shown using RBL-2H3 cells that FcεRI stability on the mast cell surface is 
dependent on the binding of IgE. In the absence of IgE, receptors are divided between daughter 
cells during mitosis, and are replenished in the G1 stage of the cell cycle (Furuichi et al., 1985); 
figure 3.10 illustrates this process. When cells are not dividing, however, FcεRI receptors are 
rapidly lost from the cell surface. In the presence of IgE this loss does not occur (Furuichi et al., 
1985); this is thought to be due to the protection of FcεRI degradation by bound IgE (Kinet, 
1999). Whilst it has not been investigated whether this IgE-mediated increase of FcεRI surface 
expression is concentration-dependent, it is reasonable to conclude that all concentrations of IgE 
tested in this study were sufficient to bind FcεRI on the surface of LAD 2 cells, protecting the 
receptors from degradation and allowing cross-linking when the cells were stimulated with anti-
IgE. 
 
Anti-human IgE from Calbiochem was then compared with Sigma anti-human IgE, which has 
previously been used to stimulate histamine release from basophils at a concentration of 2µM 
(Shim et al., 2003), in order to select the most appropriate to use in future experiments. When 
looking at the concentration-response curves (figure 3.1a (ii)), it appears that the Calbiochem 
anti-IgE curve is shifted to the right when compared with the Sigma version; this could be 
because the latter has a higher affinity for IgE, therefore lower concentrations were required to 
achieve β-hexosaminidase release compared to the Calbiochem version. The bell-shaped 
concentration response curve seen in response to Sigma anti-IgE is consistent with results 
obtained previously using the LAD 2 cell line (Kirshenbaum et al., 2003) and mouse mast cells 
(Gimborn et al., 2005). The phosphatase SHIP has been implicated in the reduction of IgE-
dependent secretion at supra-optimal concentrations of anti-IgE; BMMCs from SHIP-deficient 
mice have been reported to be more susceptible to antigen-induced degranulation than those 
from WT mice (Huber et al., 1998), and basophils from hyper-allergic patients contain lower 
Figure 3.10. FcεRI variation in the cell cycle 
Receptors are equally divided between daughter cells in mitosis (M), resulting in a 50% decrease in the 
number of receptors per cell. Receptors are then replenished in G1 phase, the gap that occurs before 
DNA synthesis (S phase). Levels then remain constant through gap 2 (G2), until they are halved again 
at M phase (Furuichi et al., 1985). 
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levels of SHIP than those from healthy individuals (Vonakis et al., 2001). It has been suggested 
that SHIP is weakly activated at optimal mast cell stimulation levels, whereas at supra-optimal 
concentrations of anti-IgE it is more strongly activated, thus is able to negatively regulate 
degranulation. In support of this theory, SHIP1 has been reported to be more strongly 
phosphorylated following supra-optimal activation, compared to optimal stimulation (Gimborn et 
al., 2005). In this study, it is possible that when 10µg/ml Sigma anti-IgE was used to cause 
maximal degranulation, SHIP was weakly activated; when the concentration of anti-IgE was 
increased to 100µg/ml, however, this could have resulted in SHIP becoming more strongly 
activated and the concomitant small reduction in degranulation. If the concentration of anti-IgE 
was increased above 100µg/ml in this study, degranulation would be expected to decrease 
further due to SHIP and other negative regulators such as the actin cytoskeleton (Gimborn et al., 
2005) becoming more strongly activated; although beyond the remit of this study, this would be 
an interesting avenue for further investigation. 
 
Another difference between the two types of anti-IgE tested was that Calbiochem anti-IgE 
contained ≤0.1% sodium azide. Although this is a very low concentration, sodium azide is known 
to cause cell death (Sato et al., 2008), therefore might be expected to have toxic effects when 
applied to cells. For this reason, and because the concentration-response curve did not reach a 
plateau with Calbiochem anti-IgE, Sigma anti-human IgE was chosen as the ligand. 
 
In the initial characterisation of the LAD 2 cell line, NP-BSA was used to crosslink human IgE 
anti-NP bound to FcεRI and stimulate β-hexosaminidase release, with a maximal release of 
approximately 40% (Kirshenbaum et al., 2003). However, the maximal release measured in this 
study in response to NP-BSA was around 20%, compared with 40% reported previously 
(Kirshenbaum et al., 2003). Release observed in this study could be lower than that obtained by 
Kirshenbaum et al. (2003) due to phenotypic variation. It has previously been reported that LAD 
2 cells have an unstable phenotype in culture compared to terminally differentiated primary mast 
cells (Laidlaw et al., 2011); for example, c-kit expression is down-regulated in response to IL-4 in 
LAD 2 cells, whereas its expression is stable in mature skin mast cells (Thienemann et al., 2004). 
In addition, FcεRI expression is known to vary in a cell-cycle dependent manner, as discussed 
above and shown in figure 3.10. It has been shown that RBL-2H3 cells tightly regulate ICRAC 
currents as they progress through the cell cycle; currents are up-regulated in S phase during 
chromatin duplication, and strongly suppressed during mitosis (Tani et al., 2007). It is possible 
that similar cell cycle-dependent variations in ICRAC and other currents could occur in LAD 2 cells. 
It is therefore possible that cell cycle- or passage number-dependent down-regulation of FcεRI, 
ion channels or other components of the signalling cascade could have occurred in the LAD 2 
cells used in this study compared with those used by Kirshenbaum et al. (2003); this would 
account for the reduced β-hexosaminidase secretion. 
It is also evident that spontaneous release, which was subtracted from all values, was higher in 
this study; this was measured at an average of 14% in this study (n=6), whereas Kirshenbaum 
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et al. (2003) report very low spontaneous release (2-3%). Technical differences in the assay 
conditions could account for the higher spontaneous release observed in our laboratory. For 
example, although in both laboratories a HEPES-buffered NaCl- based assay buffer was used, 
there were differences in composition. Whilst the buffer used in our laboratory contained 2mM 
CaCl2 and 1mM MgCl2, that used by Kirshenbaum et al. (2003) had 1.8mM CaCl2 and 1.3mM 
MgSO4 (Woolhiser et al., 2001). Therefore, minor experimental differences or passage number-
dependent phenotypic changes may have been responsible for the higher spontaneous release in 
our laboratory; subtracting higher values would thus result in reduced secretion levels in 
response to NP-BSA. 
  
When comparing the results obtained in this study (summarised in figure 3.1b (ii)), it is apparent 
that the maximal release in response to anti-IgE was approximately double that elicited by NP-
BSA. These assays were carried out using the same protocol and similar passage numbers of LAD 
2 cells, therefore differences cannot be explained by differences in procedure or phenotypic 
changes. The difference in secretion seen between the two ligands is likely to be due to their 
mechanisms of action. Whilst the anti-IgE used in this study is an IgG antibody produced in goat 
to specifically react with the heavy chain of IgE antibodies, NP-BSA is a synthetic hapten-protein 
conjugate. The use of hapten-protein conjugates to study immunology was pioneered in the 
early 20th century by Karl Landsteiner, who showed that small molecules can elicit an immune 
response in rabbits when attached to larger proteins (Landsteiner & Simms, 1923). Hapten-
protein conjugates have different cross-linking potentials depending on a number of factors, 
including valency between hapten and carrier protein, avidity of bonds, number of hapten 
molecules attached per carrier and size of carrier protein (Oda et al., 2004). In addition, hapten-
protein conjugates are a mixture of molecules with different numbers of haptens per carrier, 
resulting in a heterogeneous mix (Oda et al., 2009). The NP-BSA used in this study had an 
average of 16 NP molecules per BSA (NP16-BSA); a previous study reported that NP19-BSA has an 
avidity of 1.4 x 108 for interaction with antibody when interactions were measured using surface 
plasmon resonance with an immobilised antibody, and analysed using a Scatchard plot (Oda et 
al., 2009). Whilst caution should be applied due to the heterogeneity of NP-BSA molecules in 
suspension, it is likely that the NP-BSA used in this study had a similar avidity value to that 
reported by Oda et al. (2009). Whilst data is not available regarding the avidity of the Anti-IgE 
used in our laboratory, a higher value could account for its increased propensity to induce 
degranulation. The heterogeneous nature of NP-BSA could also account for the differences in 
results obtained in this study and those reported by Kirshenbaum et al. (2003) where NP-BSA 
was the stimulus for LAD 2 degranulation.  
 
Having established an appropriate combination of IgE/anti-IgE to activate human mast cells, 
Ca2+ imaging was then used to demonstrate that quantifiable changes in intracellular Ca2+ could 
be measured following FcεRI cross-linking. Whilst the signalling events that occur immediately 
after receptor cross-linking are common for all types of mediators, those further downstream 
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diverge to regulate the release of different mediators (Gilfillan & Tkaczyk, 2006). The signalling 
pathways are detailed in chapter 1.2; importantly for Ca2+ entry, cross-linked FcεRI receptors 
aggregate into lipid raft microdomains in the plasma membrane (Field et al., 1999), where the 
formation of macromolecular signalling complexes occurs, which trigger downstream release of 
different mediators. Importantly for granule-associated mediators, PLCγ is activated (Zhang et 
al., 2000), which catalyses the production of DAG and InsP3 from PtdIns(4,5)P2 (Gilfillan & 
Tkaczyk, 2006); InsP3 binds its receptor in the endoplasmic reticulum and causes transient Ca
2+ 
release from intracellular stores. This could be seen in fura-2-loaded LAD 2 cells and HLMCs in 
this study; IgE receptor cross-linking led to a small rise in fura-2 fluorescence in the absence of 
extracellular Ca2+, corresponding to release from intracellular stores (figure 3.2a (ii) and b (ii)).  
 
Ca2+ release from stores is sensed by STIM1 (Stathopulos et al., 2006); the activation of plasma 
membrane Ca2+ channels then follows, leading to a sustained increase in cytosolic Ca2+ (Hoth & 
Penner, 1992), which is essential for mast cell degranulation (Cochrane & Douglas, 1974). Ca2+ 
entry could be seen in fura-2-loaded LAD 2 cells and HLMCs in this study; FcεRI cross-linking in 
the presence of extracellular Ca2+ led to a sustained increase in fluorescence, indicative of Ca2+ 
entry from outside the cell. It has recently been shown that Orai1 mediates ICRAC, the first 
identified and most well-characterised store-operated Ca2+ current (Feske et al., 2006; Prakriya 
et al., 2006; Vig et al., 2006b); studies using knock-out mice have shown that Orai1 is essential 
for FcεRI-induced mast cell degranulation, cytokine production and lipid mediator release (Vig et 
al., 2008). Other work, detailed in chapter 1.3.2, suggests that plasma membrane TRPC channels 
are activated downstream of intracellular store depletion. Therefore, store-operated Ca2+ entry in 
human mast cells following FcεRI cross-linking may be occurring through a combination of Orai1 
channels and store-operated TRPC channels; this hypothesis is explored later in this chapter, and 
in chapter 5. 
 
In addition to the store-operated Ca2+ channels activated following the Lyn-LAT-PLCγ cascade, 
evidence exists for the requirement of an initial Ca2+ influx that is not controlled by store 
depletion for full mast cell activation (Lee & Oliver, 1995). BMMCs from Fyn-deficient mice are 
unable to fully degranulate, an effect that is restored by the Ca2+ ionophore A23187 (Parravicini 
et al., 2002; Sanchez-Miranda et al., 2010); these cells also exhibit defective Ca2+ entry in 
response to FcεRI cross-linking but not thapsigargin (Sanchez-Miranda et al., 2010), suggesting 
that SOCE is unaffected by Fyn knockout, but receptor-operated Ca2+ entry is reduced. As the 
Fyn- controlled channels were sensitive to 2-APB, and TRPC3/6/7 channels were shown to 
associate with Fyn in WT BMMCs, the authors concluded that non store-operated TRPC channels 
from the TRPC3/6/7 subfamily are activated downstream of FcεRI cross-linking via Fyn kinase, to 
provide Ca2+ influx necessary for optimal degranulation. The Fyn-dependent complementary 
activation pathway has not yet been evaluated in human mast cells; it would be insightful to 
investigate whether Fyn knock-out has similar effects as those observed in mouse BMMCs. It is 
also possible that the DAG-operated TRPC channels could be activated downstream of the LYN-
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LAT-PLCγ signalling cascade described above following FcεRI cross-linking, as DAG is produced 
by PLCγ. The contribution of TRPC3/6/7 channels to Ca2+ entry and mediator release 
downstream of FcεRI cross-linking was assessed later in this study and is discussed in chapter 6. 
 
It is evident that both Ca2+ store release and entry are bigger in HLMCs than in LAD 2 cells; as 
discussed previously, this could be due to lower levels of FcεRI present in LAD 2 cells due to cell 
cycle-dependent regulation. It has been reported that tryptase and chymase expression in mast 
cells is dependent on the level of differentiation; terminally differentiated skin mast cells 
contained higher levels of these enzymes than the less mature LAD 2 cells (Guhl et al., 2010). It 
is possible that LAD 2 cells contain lower levels of FcεRI than those present in terminally 
differentiated HLMCs, which could account for activation of downstream signalling molecules to a 
lesser degree, and reduced Ca2+ release and entry as a result. It has been reported that B cells 
exhibit maturation stage-dependent differences in Ca2+ signalling downstream of B cell antigen 
receptor activation at various stages of the signalling cascade, including Lyn phosphorylation, 
PLCγ levels and phosphorylation of adaptor proteins (Benschop et al., 2001). Reduced levels of 
the signalling molecules activated downstream of FcεRI in LAD 2 cells compared to HLMCs would 
account for the decreased Ca2+ entry seen in figure 3.2. It is also possible that different ion 
channels account for the Ca2+ entry in the two different cell types; different combinations of the 
six human TRPC channels and the three isoforms of Orai would lead to channels with altered 
conductance. Orai1-mediated currents have an estimated single channel conductance of around 
30 femtosiemens (Hogan et al., 2010) compared with 16 picosiemens for TRPC1 (Rychkov & 
Barritt, 2007) and 28-37 picosiemens for TRPC6 (Dietrich & Gudermann, 2007); therefore TRPC 
channels activated downstream of FcεRI would be expected to effect greater Ca2+ entry than 
Orai channels. RT-PCR results (figure 3.9) in this study showed that TRPC channel expression 
varies between LAD 2 cells and HLMCs; for example, mRNA for TRPC3 was expressed in LAD 2 
cells but was not present in HLMCs. It is therefore possible that a different complement of 
channels mediates FcεRI-induced Ca2+ entry in the two different cell types, resulting in different 
levels of Ca2+ entry.  
 
In summary, the results obtained using fura-2 imaging showed that Ca2+ entry can be measured 
in human mast cells following FcεRI cross-linking. It is likely that a variety of ion channels, 
possibly including TRPC channels, are activated downstream of IgE-mediated stimulation. In 
order to explore the potential for differential coupling between receptors and Ca2+ signalling in 
HLMCs, Ca2+ responses downstream of PLCβ-coupled GqPCRs were then investigated using ADP 
stimulation of P2Y1 receptors. ADP application stimulated Ca
2+ entry; this is in agreement with 
previous results showing that P2Y1 receptors are expressed in HLMCs (Schulman et al., 1999). In 
contrast to FcεRI signalling, stimulation of GPCRs promotes the exchange of GDP bound to Gα 
subunits of trimeric G proteins (Gαβγ) for GTP, which results in the activation of Gα and Gβγ 
subunits. These activated G protein components then activate downstream signalling in mast 
cells (Bansal et al., 2008). Whilst GPCR signalling in mast cells is not as well characterised as that 
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occurring downstream of FcεRI, it is known that P2Y1 receptors are coupled to PLCβ and the 
generation of InsP3 (Gilfillan & Tkaczyk, 2006). InsP3 production leads to Ca
2+ release from 
stores and subsequent entry from outside the cell (Communi et al., 2000); in this study Ca2+ 
release from stores could be seen when ADP was applied in the absence of extracellular Ca2+ 
(figure 3.3b), and influx through plasma membrane ion channels occurred when extracellular 
Ca2+ was present (figure 3.3a). These data are in accordance with a previous study showing that 
ADP stimulates Ca2+ influx in cord blood-derived human mast cells (Feng et al., 2004).  Whether 
the combination of ion channels regulating Ca2+ influx following GPCR activation and FcεRI 
remains to be determined. 
 
When looking at the size and time-course of ADP-induced Ca2+ entry in HLMCs, it is evident that 
there was donor-dependent variability. HLMCs from donors 370 and 410 showed a similar time-
course of response, with an initial rise in intracellular Ca2+ followed by a plateau; the plateau is 
likely to represent Ca2+ entry across the plasma membrane downstream of P2Y1 and PLCβ 
activation. The time-course of Ca2+ entry in donors 370 and 410 was similar to that reported by 
Feng et al. (2004) in human cord blood-derived mast cells, where P2Y1 receptors were shown to 
be responsible. In donors 360 and 411, a larger initial Ca2+ peak could be seen; this could be due 
to P2X1 receptor activation. P2X1 receptors are Ca
2+-permeable ligand-gated ion channels with 
characteristic fast opening and rapid declining of the current in the presence of agonist in a 
process called desensitisation (North & Surprenant, 2000). ADP has been suggested to activate 
P2X1 receptors, which are functionally expressed in HLMCs (Wareham et al., 2009), with an EC50 
of 30µM (Evans et al., 1995; North & Surprenant, 2000); a concentration of 100µM ADP might 
therefore be expected to activate these receptors. A more recent study reported that P2X1 
receptors in megakaryocytes are activated by commercially obtained ADP at a concentration of 
10µM, but not by purified ADP at concentrations up to 100µM (Mahaut-Smith et al., 2000). The 
authors suggest that contamination by ATP is responsible for the activation of P2X1 receptors by 
commercial samples of ADP. As the ADP used in this study is certified to be ≥95% pure, it is 
possible that contaminating ATP, which activates P2X1 receptors with an EC50 of around 1µM 
(North & Surprenant, 2000),was present at a sufficient concentration to activate these receptors 
in this study. It is possible that donor-dependent expression of P2X1 receptors was responsible 
for the more rapid Ca2+ entry seen in donors 360 and 411 compared with those from donors 370 
and 410. 
 
Differential expression of P2Y receptors could also account for the donor-dependent variability in 
ADP-induced Ca2+ entry shown in figure 3.4. ADP is able to activate P2Y1,P2Y12 and P2Y13 (von 
Kugelgen, 2006); whilst P2Y1 couples to Gq proteins and PLCβ, P2Y12 and P2Y13 are coupled to Gi 
proteins (Communi et al., 2001; Nicholas, 2001), causing downstream inhibition of cyclic 
adenosine monophosphate (cAMP) production. Therefore, donor-dependent expression of the 
different ADP-sensitive P2Y receptors could elicit distinct downstream responses, giving rise to 
the differences observed in Ca2+ signalling.  
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As discussed above in relation to FcεRI-induced Ca2+ signalling, the complement of ion channels 
activated downstream of P2Y receptor stimulation may also vary between donors. It is known 
that the levels of InsP3 fall quickly following elevation downstream of P2Y receptors, because P2Y 
receptors rapidly desensitise (Chang et al., 2007). Ca2+ influx through InsP3-regulated channels, 
including Orai1 (Feske et al., 2006; Prakriya et al., 2006; Vig et al., 2006b) and possibly store-
operated TRPC channels (Ong et al., 2007; Liao et al., 2008; Ma et al., 2008), is likely to be 
transient because incoming Ca2+ is taken up into ER stores and not released again in the absence 
of InsP3 (Chang et al., 2007). Ca
2+ entry through ion channels that are not dependent on InsP3, 
for example the DAG-activated TRPC3/6/7 channels, could be more sustained; differential ion 
channel expression between donors could therefore account for the differences in the size and 
time course of Ca2+ entry seen downstream of ADP stimulation. Previous studies carried out in 
RBL-2H3 cells have suggested that Orai1-mediated ICRAC activated downstream of receptor 
stimulation is an all-or-nothing event in single cells; increasing agonist concentration was 
reported to increase the number of responding cells and not the size of Ca2+ entry, giving rise to 
a graded response in the population of cells (Chang et al., 2007). It is possible that ICRAC 
activation downstream of P2Y receptor stimulation in this study occurred in a greater number of 
HLMCs from some donors compared with others, causing the differences in amplitude and time 
course of the Ca2+ signals shown in figure 3.4. Whilst outside the aims of this project, 
investigation of the all-or-nothing nature of ICRAC currents in human mast cells would provide 
insightful information on the channels activated downstream of P2Y receptor activation. 
 
It is evident that both Ca2+ store release and entry are larger in HLMCs following FcεRI cross-
linking than following ADP stimulation (see figure 3.5). This is likely to be due to differential 
downstream coupling of the two classes of receptor. Following GqPCR activation, soluble PLCβ 
enzymes are attracted to PtdIns(4,5)P2 in the membrane by their phosphoinositide binding 
domain and by activated Gα-GTP (Falkenburger et al., 2010); PLCγ is regulated by key tyrosine 
residues in LAT, which is activated following FcεRI cross-linking (Saito et al., 1991). Additional 
Src homology domains in PLCγ that are not present in PLCβ mediate its interaction with 
phosphorylated tyrosine residues (Wilde & Watson, 2001). Different phosphoinositides are 
maintained in distinct membrane compartments by the subcellular distribution of kinases and 
phosphatases; for example, PtdIns(4,5)P2 is maintained by high PIP 5-kinase activity, which 
preserves its phosphorylated state (Mao & Yin, 2007). Two isoforms of PIP 5-kinase have been 
shown to synthesise distinct pools of PtdIns(4,5)P2 in the membrane, which have separate roles 
in SOCE and InsP3 generation (Vasudevan et al., 2009). The pools of PtdIns(4,5)P2 are thought 
to be spatially segregated by membrane heterogeneity and the degree of lipid order (Calloway et 
al., 2011). It is possible that these distinct pools of PtdIns(4,5)P2 react with PLCβ and PLCγ, thus 
targeting them to different regions of the membrane where they can regulate specific Ca2+ 
channels. Ca2+ channels are located at discrete regions of the plasma membrane within 
specialised lipid raft microdomains; for example TRPC1 interacts directly with caveolin 1, which 
regulates its plasma membrane localisation (Brazer et al., 2003). Many other Ca2+ channels, 
 Chapter 3: Human mast cell activation 
105 
 
including the other TRPC channels, Orai1 channels and voltage-gated Ca2+ channels (Pani & 
Singh, 2009), have been shown to localise in distinct plasma membrane regions. It has recently 
been shown that PtdIns(4,5)P2 in ordered lipid membrane regions promotes STIM1-Orai1 
association, whereas PtdIns(4,5)P2 in disordered lipid regions inhibits this association (Calloway 
et al., 2011). It is therefore likely that PLCβ and PLCγ are targeted to specific regions of the 
membrane, where they act on discrete pools of PtdIns(4,5)P2 to activate distinct channels, giving 
rise to the differences in Ca2+ signalling seen following FcεRI- or ADP- mediated activation.   
 
Distinct downstream regulatory mechanisms could also account for the larger Ca2+ release and 
entry seen in FcεRI-stimulated HLMCs compared with ADP-mediated activation. Regulator of G 
protein signalling (RGS) proteins are expressed in mast cells and impair G protein signalling by 
accelerating GTPase activity and the deactivation of G proteins; RGS13 has been shown to be 
particularly important in restricting GPCR-mediated Ca2+ entry in HMC-1 cells (Bansal et al., 
2008). FcεRI-mediated mast cell activation is known to be negatively regulated by NTAL (Zhu et 
al., 2004) and LYN (Gilfillan & Tkaczyk, 2006). These distinct regulatory mechanisms could 
account for the reduction in Ca2+ store release and entry seen in response to P2Y activation 
compared with that observed downstream of FcεRI. 
 
In summary, fura-2 Ca2+ imaging can be used to measure ADP- and FcεRI-mediated Ca2+ release 
and entry in human mast cells. Due to the distinct downstream coupling of the two receptors as 
a result of spatial regulation in the plasma membrane, it is likely that different ion channels are 
activated as a result of P2Y and FcεRI stimulation. 
 
In order to gain further insight into which ion channels may be involved in store-operated Ca2+ 
entry in human mast cells, a protocol of Ca2+ store depletion in the absence of extracellular Ca2+, 
followed by divalent ion re-addition, was employed. Following passive store depletion by 
thapsigargin (Lytton et al., 1991), FcεRI cross-linking and ADP stimulation of P2Y receptors in 
this study, Ba2+ and Ca2+ ions entered LAD 2 cells and HLMCs (figures 3.6 and 3.7). It is 
apparent that the time course for internal store release differed depending on the agent used to 
deplete the stores in both LAD 2 cells and HLMCs. This is expected given the different 
mechanisms of action of the agents used. In both cell types, thapsigargin application resulted in 
a small, slow Ca2+ release from stores; this agent works by inhibiting Ca2+ re-uptake into stores 
through the SERCA pump (Lytton et al., 1991). Stores are therefore prevented from re-filling as 
opposed to being actively depleted; as a result the time-course for depletion is slow, as seen in 
figures 3.6a and 3.7a. Anti-IgE, on the other hand, resulted in a more transient, quick release 
from stores; this is consistent with the activation of PLCγ (Park et al., 1991), production of InsP3, 
and depletion of stores by InsP3 receptor binding (Gilfillan & Tkaczyk, 2006). ADP-induced Ca
2+ 
store release was quicker in onset than that induced by thapsigargin; this is likely to be due to 
the activation of PLCβ (Gilfillan & Tkaczyk, 2006) and the resulting production of InsP3 causing 
store release. The size of Ca2+ release downstream of P2Y receptor stimulation was smaller than 
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that caused by FcεRI cross-linking; this is likely to be due to the differential coupling of the two 
types of receptor and resulting differences in downstream signalling, as discussed above. InsP3 
generation depends on the availability of PtdIns(4,5)P2, which is generated primarily by the 
phosphorylation of phosphatidylinositol-4-phosphate (PI4P) by the lipid kinase 
phosphatidylinositol 4-phosphate 5-kinase (PIP5 kinase) (Wang et al., 2008). PtdIns(4,5)P2 levels 
are therefore regulated by a number of factors; different levels of this enzyme at particular 
regions of the membrane targeted by PLCβ and PLCγ could result in differential production of 
InsP3 depending on the isoform of PLC that is active, causing store depletion to a greater degree 
with FcεRI-mediated PLCγ stimulation than P2Y-mediated PLCβ activation, for example.  
 
It is also possible that human mast cells contain greater levels of PLCγ than PLCβ, which could 
result in the production of more InsP3 and causing greater levels of store depletion. It has 
previously been reported that different isoforms of PLCγ and PLCβ in bovine parathyroid gland 
are expressed at varying levels (Dare et al., 1998); human mast cells express two isoforms of 
PLCγ, with PLCγ1 believed to be the main active form (Wilde & Watson, 2001; Tkaczyk et al., 
2003). The expression of PLCβ isoforms in mast cells has not been investigated, but it can be 
hypothesised that differential expression of PLCβ and PLCγ isoforms with different catalytic 
abilities for the generation of InsP3 would lead to differing levels of store depletion dependent on 
the isoforms present. An assessment of the levels of different PLC enzymes in HLMCs using 
quantitative PCR, for example, would be an interesting avenue of investigation to gain insight 
into the mechanisms of store depletion occurring following GPCR and receptor tyrosine kinase 
activation. 
 
Despite the differences seen in the time-course of initial Ca2+ store release, there was no 
significant difference in the size of divalent ion entry in both cell types when different methods of 
activation were used, suggesting that store depletion was the primary factor controlling channel 
activation. The results obtained in this study are in agreement with a previous study showing 
that Sr2+ions were able to enter RBL-2H3 cells following store depletion (Ma et al., 2008). The 
authors reported that shRNA-mediated knockdown of TRPC5 impaired Sr2+ entry following store 
depletion with thapsigargin, concluding that TRPC5 is likely to be a component of store-operated 
Ca2+ channels in RBL-2H3 cells. The results obtained in this study suggest that channels other 
than Ca2+-selective Orai1 channels may be involved in SOCE, such as the non-selective TRPC 
channels. Results from previous studies recording ICRAC currents in RBL cells and Jurkat T cells 
challenge the view that Orai channels cannot permeate Ba2+ ions, showing that equimolar 
replacement of Ca2+ ions with Ba2+ in the extracellular recording solution leads to a reduction, 
but not complete inhibition, of the ICRAC current (Hoth, 1995; Zweifach & Lewis, 1995). However, 
these results were obtained in solutions where both Na+ and Ba2+ were present; a recent study 
showed that replacement of Ca2+ with Ba2+ ions when Na+ ions were replaced with TEA caused 
abolition of ICRAC currents mediated by Orai1, 2 and 3 in HEK-293 cells (Lis et al., 2007). The 
authors re-examined Ba2+ permeation of ICRAC in Jurkat T cells in the presence and absence of 
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Na+, reporting that currents are inhibited in the absence of Na+. It was concluded that ICRAC 
currents are abolished when Ba2+ is the sole charge carrier, and that Na+ ions carry the current 
observed in the absence of Ca2+ previously thought to be mediated by Ba2+(Lis et al., 2007). 
Many studies have demonstrated that TRPC channels can readily permeate Ba2+ ions, including 
but not limited to (Trebak et al., 2002; Ma et al., 2008; DeHaven et al., 2009; Tu et al., 2009b; 
Bousquet et al.). Therefore, the Ba2+ entry seen in this study is unlikely to be through Orai 
channels, suggesting a role for the nonselective TRPC channels in SOCE.  
 
It is also unlikely that TRP channels other than those from the TRPC family contribute to Ba2+ 
entry in this study, although TRPV (Bradding et al., 2003) and TRPM (Bradding et al., 2003; 
Wykes et al., 2007) channel mRNA transcripts are expressed in HLMCs. Most other TRP channels 
would not be activated downstream of Ca2+ store depletion; for example, TRPV channels are 
activated by heat and capsaicin (Pingle et al., 2007) and TRPA channels are sensitive to irritants 
and pungent compounds (Garcia-Anoveros & Nagata, 2007). TRPV6 can be constitutively active, 
but is highly Ca2+ selective and does not permeate Ba2+ or Sr2+ so would be unable to mediate 
Ba2+ entry downstream of Ca2+ store depletion (Wissenbach & Niemeyer, 2007). There have 
been reports suggesting that TRPM3 is activated by store depletion, for example a small increase 
in Ca2+ entry through human TRPM3 channels following store depletion has been described 
under some conditions (Lee et al., 2003a). However, it has been shown that the expression of 
TRPM3 in HEK-293 cells did not enhance Mn2+ entry in response to thapsigargin or GPCR 
stimulation (Grimm et al., 2003), and store depletion does not affect D-erythro-sphingosine-
mediated activation of TRPM3 (Grimm et al., 2005). Therefore, TRPM3 has not convincingly been 
shown to be activated by store depletion (Oberwinkler & Phillipp, 2007). Finally, TRPM5 is 
activated downstream of GPCR stimulation and PLCβ-mediated InsP3 generation, but it is only 
permeable to the monovalent cations Na+, K+ and Cs+ and does not permeate divalent ions 
(Liman, 2007). The contribution of TRP channels from subfamilies other than TRPC channels to 
Ba2+ entry downstream of intracellular store depletion can therefore be excluded. 
 
As PLCβ and PLCγ are respectively activated downstream of FcεRI and GqPCRs, it is important to 
consider the contribution of PLC to divalent ion entry following store depletion by the different 
mechanisms. In contrast to the other stimuli used, it has previously been shown in RBL-2H3 cells 
that thapsigargin stimulates PLC only minimally (Cissel et al., 1998). Caution should be applied 
due to these results being obtained in rat; there are distinct functional differences between rat 
and human mast cells including receptor expression and mediator release (Bischoff, 2007). 
However, whilst they have not been investigated in human mast cells, the basic principles of 
thapsigargin and receptor signalling are likely to be similar to those in RBL-2H3 cells. Therefore, 
because divalent ion entry was observed downstream of thapsigargin stimulation, which does not 
activate PLC, it could be suggested that store depletion per se was able to activate the Ba2+-
permeable channels in this study, as opposed to channels only becoming active as a result of 
PLC signalling. Repeating these experiments in the presence of a PLC inhibitor would 
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demonstrate the relative contributions of store depletion and PLC-mediated signalling to Ba2+-
permeable channel activation following the different mechanisms of activation. 
 
It is important to consider that different channels could be activated following the different 
methods of store depletion; for example, passive store depletion by thapsigargin may trigger 
activation of the TRPC1/4/5 subgroup, whereas PLC activation downstream of P2Y receptor 
signalling might be expected to activate TRPC3/6/7 channels through DAG production. As 
discussed previously, the coupling of PLCβ and PLCγ to distinct regions in the plasma membrane 
could mean that ADP and FcεRI-mediated store depletion leads to the activation of different 
channels. However, the size of Ba2+ entry in both LAD 2 cells and HLMCs was not significantly 
different when different methods of store depletion were used, suggesting the involvement of 
the same channels. It must be noted that Ba2+ has a lower affinity for fura-2 than Ca2+(Kd values 
of 780 and 236nM, respectively) (Schilling et al., 1989); therefore if the size of Ba2+ and Ca2+ 
entry was the same, it would be expected that the change in fura-2 fluorescence occurring due 
to Ba2+ entry would be approximately 3.3. fold smaller than that corresponding to Ca2+ entry. 
The ratio of Ca2+ to Ba2+ entry was calculated and is shown in table 3.1. In LAD 2 cells, the 
change in fura-2 fluorescence indicating Ca2+ entry was around 3.5 fold higher than that for Ba2+ 
entry; given the Kd values, this suggests that the size of Ba
2+ and Ca2+ entry was similar 
following all mechanisms of activation. This was unexpected, as divalent entry through Ba2+-
permeable channels (i.e. TRPC channels) was expected to represent a small proportion of the 
entry through Ca2+-permeable channels (i.e. a combination of TRPC and Orai channels).  
 
If Ba2+ entry represents TRPC channel activation only, and Ca2+ entry reflects the combined 
activation of TRPC and Orai channels as expected, the apparently similar size of Ba2+ and Ca2+ 
entry must be accounted for. Cytosolic Ca2+ concentration is not only affected by Ca2+ entry 
through plasma membrane channels, but also the rate of removal. Re-uptake into ER stores by 
the SERCA pump, mitochondrial sequestration and plasma membrane transporters are all 
responsible for the removal of Ca2+ from the cytoplasm; Ba2+ is not a substrate for Ca2+ 
transporters so cannot be extruded from the cytosplasm in the same way as Ca2+(Parekh & 
Putney, 2005). Fura-2 fluorescence when bound to Ba2+ is therefore an indicator of unidirectional 
Ba2+ entry, whereas that bound to Ca2+ reflects Ca2+ entry into and removal from the cytoplasm 
(Chang et al., 2007). Ca2+ entry could therefore be larger than Ba2+ entry but appear smaller due 
to its removal from the cytoplasm; as expected, Ca2+ entry could then reflect the action of a 
greater number of channels than Ba2+ entry. 
 
In HLMCs, the ratio of Ca2+- to Ba2+-bound fura-2 fluorescence was more variable than that 
calculated for LAD 2 cells; with all mechanisms of store depletion it was lower than 3.3 (see table 
3.1). As the Kd value for fura-2 bound to Ba
2+ is 3.3 fold higher than that for Ca2+, these results 
suggest that Ba2+ entry is greater than Ca2+ entry in HLMCs. However, as discussed above, Ba2+ 
fura-2 fluorescence does not reflect removal from the cytoplasm, so Ca2+ entry could in fact be 
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greater than Ba2+ entry but have lower fura-2 fluorescence due to sequestration in intracellular 
stores and removal from the cell. Whilst the ratio of Ca2+ to Ba2+-bound fura-2 did not show 
much variation in LAD 2 cells following the different mechanisms of activation, it was much lower 
in HLMCs when IgE was used to deplete stores (1.73), compared with thapsigargin and ADP 
(2.64 and 2.62, respectively). In agreement with this variability in primary cells, it has previously 
been described that primary rat peritoneal mast cells show extremely diverse calcium signals 
following FcεRI crosslinking compared with RBL-2H3 cells (Chang et al., 2007). The different 
ratios of Ca2+ to Ba2+ entry seen in this study could reflect the activation of distinct plasma 
membrane channels following the different mechanisms of store depletion. As discussed above, 
the activation of PLCγ downstream of FcεRI and PLCβ following ADP stimulation may couple to 
distinct signalling cascades in different regions of the membrane, activating separate ion 
channels. 
 
Having determined that Ba2+ ions can enter LAD 2 cells and HLMCs following store depletion, 
which suggests the involvement of the non-selective TRPC cation channels in mediating their 
entry, it was demonstrated that Ba2+and Sr2+ were able to support degranulation in LAD 2 cells. 
These data are in agreement with previous results showing that Ba2+, Sr2+ and other divalent 
ions can support degranulation in RBL-2H3 cells (Hide & Beaven, 1991; Ma et al., 2008), and 
suggest that TRPC channels may be the carriers of the divalent ions. Ma et al. (2008) reported 
that TRPC5 knock-down using shRNA impaired degranulation in RBL-2H3 cells, concluding that 
TRPC5, along with Orai1 and STIM1, is required for degranulation (Ma et al., 2008). Sanchez-
Miranda et al. (2010) showed that BMMCs from Fyn-deficient mice exhibit impaired IgE-mediated 
degranulation, and suggest that TRPC3/6/7 channels provide a Ca2+ signal for optimal mediator 
release. The preliminary results obtained in this study do not disagree with these interpretations, 
and suggest that non-selective TRPC channels may also contribute to human mast cell 
degranulation; this idea was explored further and is discussed in chapters 5 and 6. 
 
As the preliminary results obtained in this chapter suggest that TRPC channels may be involved 
in Ca2+ entry in human mast cells following different methods of stimulation, and could have a 
role in degranulation, it was then assessed which TRPC family members were expressed in 
human mast cells. RT-PCR showed that mRNA transcripts for TRPC1, 3, 5, 6 and 7 were 
expressed in LAD 2 cells; expression in HLMCs was donor-dependent for TRPC5 and TRPC7; 
mRNA for TRPC1 and TRPC6 were present in all three donors tested. These data contradict 
previous results, where GeneChip microarrays did not reveal TRPC channel mRNA in HLMCs; only 
TRPC1 was found to be present in human skin mast cells (Bradding et al., 2003). The differences 
seen between this study and that by Bradding et al. (2003) could be explained by donor 
variability; an example of donor variability is shown by the variable expression of TRPC5 in this 
study. It is possible that HLMCs from the donors tested in the GeneChip study did not express 
mRNA for any of the TRPC channels. However, given the non-redundant functions of TRPC 
channels in other systems as detailed in chapter 1.3.2, it is unlikely that some donors would not 
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express mRNA for any TRPC channels at all when others do express the channels. There are a 
number of problems with GeneChip arrays; importantly, the technology has sensitivity limits, and 
genes can be classed as absent when they are on the threshold of detection (Tadesse & Ibrahim, 
2004). The technique relies on hybridisation of gene-specific probes, and software is used to 
calculate whether the target sequence is present. Hybridisation assays can be unreliable, so a 
transcript may be classed as absent because the hybridisation has not worked, as opposed to the 
gene not being present (Tadesse & Ibrahim, 2004). It is therefore probable that the mRNA for 
some TRPC channels was present in the donors screened by Bradding et al. (2003), but could 
have been missed due to the GeneChip method used for detection. Inconsistencies have been 
observed between the results obtained by Bradding et al. (2003) and other studies; P2X7 mRNA 
was found to be absent from HLMCs using the GeneChip array (Bradding et al., 2003), but 
Wareham et al. (2009) reported strong P2X7 receptor mRNA expression in three donors of HLMCs 
detected using RT-PCR. This highlights that caution is required when interpreting GeneChip array 
results, and supports the theory that TRPC channel mRNA could have been present but not 
detected in the GeneChip array (Bradding et al., 2003). 
 
In conclusion, the initial studies into human mast cell activation carried out in this chapter show 
that mast cell activation by IgE receptor signalling and by GPCR stimulation can be measured 
using Ca2+ imaging and secretion assays. The entry of Ba2+ ions into LAD 2 cells and HLMCs 
following intracellular store depletion suggests the involvement of non-selective TRPC cation 
channels; mRNA for TRPC channels was found to be expressed in both cell types. These 
preliminary data indicate the possible involvement of TRPC channels in human mast cell Ca2+ 
signalling; this was then investigated in the remainder of the study. 
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Chapter 4: Characterisation of TRPC channels 
in HEK cell lines 
The preliminary results obtained in chapter 3 suggest that non-selective TRPC cation channels, 
the mRNA for which is expressed in human mast cells, may have a role in mediating Ca2+ entry 
following FcεRI- or P2Y- mediated activation, and downstream of intracellular store depletion. In 
order to investigate the functional expression of TRPC channels in human mast cells further, it 
was necessary to develop the protocols and tools required to study their biophysical properties. A 
HEK-293 cell line stably expressing TRPC6 (HEK-TRPC6) (Boulay et al., 1997) was used as a 
model to study the second messenger-regulated TRPC3/6/7 subgroup. Similarly, a HEK-293 cell 
line with inducible TRPC5 expression (HEK-TRPC5) (Zeng et al., 2004) was used to test activation 
mechanisms for TRPC5 channels. 
 
4.1 Characterisation of TRPC6 channels in HEK cells 
The second messenger-regulated TRPC3/6/7 channels are activated by the lipid DAG (Hofmann 
et al., 1999). Its membrane-permeable analogue, OAG, is commonly used to activate TRPC6 
channels experimentally, and has been shown to activate TRPC6-mediated Ca2+ entry and 
currents in HEK-TRPC6 cells (Estacion et al., 2006) as well as in native cells including A7r5 
smooth muscle cells (Jung et al., 2002) and primary mouse cortical neurons (Tu et al., 2009b). 
To verify that OAG could be used to activate TRPC6 channels in our laboratory, fura-2 Ca2+ 
imaging was employed to investigate OAG-induced Ca2+ fluxes in HEK-TRPC6 cells. Results are 
shown in figure 4.1; OAG elicited concentration-dependent Ca2+ entry in HEK-TRPC6 cells with an 
EC50 of 0.38µM. As shown in figure 4.1c, 100µM OAG caused maximal activation of TRPC6; this 
concentration was used for all future experiments.  
 
Whole-cell patch clamp recordings were then carried out in HEK-TRPC6 cells as detailed in 
chapter 2.6.9 to investigate the biophysical properties of the OAG-induced TRPC6 currents. It has 
previously been shown that TRPC6 channels expressed in HEK cells give rise to a typical 
outwardly-rectifying current with a reversal potential near 0mV when stimulated with OAG 
(Estacion et al., 2006). Cells were clamped at -60mV and 1 second voltage ramps from -100mV 
to +100mV were applied every 2 seconds. Results are shown in figure 4.2; a (i) and (ii) show 
two example current-time plots of OAG-induced whole-cell currents in HEK-TRPC6 cells. Currents 
were measured at +100mV (i.e. outward cation current) and -100mV (i.e. inward cation current).  
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Figure 4.1. OAG-induced Ca2+ entry in HEK-TRPC6 cells. 
a: Ca2+ fluxes, indicated by F340/380, when HEK-TRPC6 cells were perfused in standard external 
solution and 0.01µM OAG was applied as indicated by the horizontal bar. (i) shows individual cell 
traces; (ii) shows mean ± SEM (n=14).b: Experiments as in (a), where 300µM OAG was applied to 
cells. c: Concentration-response curve for OAG-activated changes in fluorescence (ΔF340/380). 
Estimated EC50= 0.38µM. n numbers are as follows: 5 for 0.01µM, 12 for 0.03µM, 19 for 0.1µM, 81 
for 1µM, 102 for 10µM, 37 for 100µM, 14 for 300µM.  ***: mean OAG-induced ΔF340/380 was 
significantly different from that induced by DMSO at 1/333 dilution (vehicle for OAG at its minimal 
dilution, n=56, N=2), p<0.0001, one-way ANOVA with Tukey post-test.  
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Figure 4.2. OAG-induced whole-cell currents in HEK cells stably expressing TRPC6. 
a (i) and (ii): Diary plot of inward and outward currents measured at -100mV (grey trace) and +100mV 
(black trace) before and after focal application of 100µM OAG. Time of drug application indicated by 
solid bar above the trace. (i) shows an example of a transient current activated by OAG, as observed in 
50% (4/8) cells. (ii) shows an example of OAG-induced current that remained after washout; this was 
seen in 50% (4/8) cells.  
b (i): Example current-time trace when OAG was focally applied to a HEK cell not expressing TRPC6; 
similar results were obtained in 3 other cells. (ii) shows an example current-time trace when DMSO at 
1/1000 dilution (vehicle for OAG) was focally applied to a HEK-TRPC6 cell; similar results were obtained 
in 2 other cells.  
c (i): Current-voltage (I/V) relationship from a single cell before OAG stimulation (black, ―leak‖) and at 
the peak current in the presence of OAG (red, ―OAG‖). The ―leak‖ I/V relationship was subtracted from 
the peak (―OAG‖) I/V relationship to give a subtracted I/V (blue, ―subtracted‖). (ii) shows the mean ± 
SEM subtracted I/V relationship (n=8) OAG-induced current had a mean reversal potential of 0.06 ± 
0.31mV (n=8). 
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Two kinetically distinct current responses were observed; 50% (4/8) of HEK-TRPC6 cells showed 
a transient current in response to OAG activation, whereas 50% exhibited a sustained current 
that remained after washout. Currents were classed as ―sustained‖ when more than 50% of 
current remained at 2 minutes after the end of drug application. Unless otherwise stated, these 
criteria will be used to classify responses for the remainder of this report.The mean peak current 
amplitude in cells with a transient response to OAG was 69.37pA/pF ± 18.40 (n=4) at +100mV, 
and 17.51pA/pF ± 4.88 (n=4) at -100mV. That in cells with a sustained response to OAG was 
measured at 108.70pA/pF ± 56.78 (n=4) at +100mV, and 19.95pA/pF ± 10.48 (n=4) at -
100mV. There was no significant difference between peak currents (either inward or outward) in 
cells showing a transient response compared with those showing a sustained response (unpaired 
Student‘s T-test), suggesting that current amplitude is not related to time-course. Application of 
OAG to HEK cells not expressing TRPC6 did not result in a current (figure 4.2b (i)), and 
application of DMSO, the vehicle for OAG, did not elicit currents in HEK-TRPC6 cells; see figure 
4.2b (ii).  
 
To calculate the current-voltage (I/V) relationship for each cell, the ―leak‖ I/V relationship, taken 
before OAG application, was subtracted from the I/V relationship taken when the current was 
maximal in the presence of OAG. Leak and maximal I/V relationships are shown in figure 4.2c (i) 
in black and red, respectively. The blue trace shows the leak-subtracted I/V curve (i.e. only 
current induced by OAG); for all future experiments, subtracted I/V curves are shown. The 
subtracted I/V relationship was calculated for each individual cell, and the mean was calculated; 
the mean ± SEM (n=8) I/V relationship for OAG-induced currents is shown in figure 4.2c (ii). As 
expected, OAG stimulation of TRPC6 channels resulted in an outwardly-rectifying current with a 
reversal potential close to 0mV; this was measured at 0.06 ± 0.31mV (n=8). The ―rectification 
index‖ was calculated for each cell using the formula:  
rectification index = current at +100mV/current at -100mV. 
The rectification index therefore shows how outwardly-rectifying the current is; a greater 
rectification index value means that there is a larger contribution from the outward current. The 
mean rectification index in cells with a transient response to OAG was 4.78 ± 1.21 (n=4) (i.e. the 
outward current was approximately 5-fold larger than the inward current); that in cells with a 
sustained response to OAG was 6.86 ± 1.23 (n=4). There was no significant difference between 
the rectification index for cells with a transient response and that for cells with a sustained 
response, suggesting that the kinetics and rectification of OAG-induced currents are not linked. 
The mean rectification index for all cells combined was 5.82 ± 0.89 (n=8). 
  
To summarise, in whole-cell patch clamp recordings, OAG activated outwardly-rectifying currents 
with the expected biophysical properties of TRPC6 channels. These experiments show that in our 
hands, OAG can be used to activate TRPC6-containing channels and can therefore be used as a 
tool to investigate functional expression of DAG-regulated TRPC3/6/7 channels in native cells. 
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It was then investigated why OAG-induced currents observed in some HEK-TRPC6 cells were 
transient and those in others were more sustained. The possibility that PKC could be switching 
off the channels was considered; 100µM OAG is known to switch on PKC (Venkatachalam et al., 
2003), which has been shown to negatively regulate TRPC6 channels. Bousquet et al. (2010)  
showed, using the same HEK-TRPC6 cell line used in this study, that OAG- and carbachol- 
induced Ca2+ entry was potentiated and more sustained in the presence of a PKC inhibitor. To 
investigate whether such a mechanism regulated the kinetics of OAG-evoked currents in HEK-
TRPC6 cells used in this study, the effects of the selective PKC inhibitor, Ro-31-8425 (Wilkinson 
et al., 1993), were assessed. To verify that the PKC inhibitor was functional and determine the 
appropriate concentration to use when investigating OAG-induced currents, a β-hexosaminidase 
secretion assay in LAD 2 cells was used, as it has previously been shown that PKC is required for 
mast cell secretion (Mazurek et al., 1987). A combination of 100nM PMA + 1µM ionomycin was 
used to induce maximal secretion of LAD 2 cells; this stimulus was used following a 5 minute 
incubation with various concentrations of Ro-31-8425, and β-hexosaminidase release from LAD 2 
cells was quantified as described in chapter 2.8. It was found that Ro-31-8425 caused 
concentration-dependent inhibition of PMA + ionomycin-induced secretion with an IC50 of 0.87µM 
(figure 4.3a). DMSO (vehicle for Ro-31-8425) at the minimal dilution did not cause inhibition of 
secretion (figure 4.3b). These results show that Ro-31-8425 can be used to effectively inhibit 
PKC, and could therefore be used to evaluate whether PKC is switching off OAG-induced TRPC6 
currents. A concentration of 3µM Ro-31-8425 was used in subsequent experiments. 
 
Whole-cell patch clamp experiments in HEK-TRPC6 cells like those shown in figure 4.2 were then 
repeated in the presence of 3µM Ro-31-8425. Control experiments were carried out on the same 
experimental days as those in the presence of Ro-31-8425, so data was culture-matched. Results 
are shown in figure 4.4; the percentage of cells displaying a sustained current was compared in 
the presence and absence of Ro-31-8425.  It was found that when PKC was inhibited, a greater 
percentage of cells showed a sustained current (78% (7/9) compared with 50% (4/8) in the 
absence of inhibitor).  
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The peak current was increased in the presence of Ro-31-8425 from 89.03pA/pF ± 28.61 (n=8) 
to 177.12pA/pF ± 47.80 (n=9) at +100mV, and from 18.73pA/pF ± 5.37 (n=8) to 43.29pA/pF ± 
12.99 (n=9) at -100mV (figure 4.4b (i)). The difference in peak current amplitude was not 
significantly different (unpaired Student‘s T-test). The mean rectification index for OAG-induced 
currents in the presence of Ro-31-8425 was 4.19 ± 0.28 (n=9); this was not significantly 
different from that calculated in the absence of Ro-31-8425 (5.82 ± 0.89, n=8, unpaired 
Student‘s T-test). The rectification and amplitude of OAG-induced currents were therefore not 
significantly affected by the presence of Ro-31-8425. When the percentage of the maximal 
current remaining at two minutes after the end of drug application was calculated, only a small 
increase from 54.93% ± 19.31 (n=8) to 73.19% ± 8.5 (n=9) at +100mV and from 56.01% ± 
14.44 (n=8) to 61.52% ± 9.79 at -100mV was seen when Ro-31-8425 was present. This 
increase did not reach statistical significance. Taken together, these results suggest that PKC-
does regulate TRPC6 function, but that other mechanisms may also be at work to regulate 
inactivation of the channels, which are discussed further in section 4.3. 
 
Figure 4.3. PMA and ionomcycin-induced β-hexosaminidase release in LAD 2 cells is 
concentration-dependently inhibited by Ro-31-8425. 
a: Cells were stimulated with 100nM PMA + 1µM ionomycin following a 5 minute pre-incubation with 
the concentrations of Ro-31-8425 shown. β-hexosaminidase release was measured as a percentage of 
total, determined following lysis with 0.5% Triton X-100. Ro-31-8425 inhibited PMA + ionomycin-
induced secretion in a concentration-dependent manner with an IC50 of 870nM.  Points show mean ± 
SEM; N=4. ***: means were significantly different from control (no Ro-31-8425), p<0.0001, one-way 
ANOVA with Tukey post-test.  
b: Bar chart showing % β-hexosaminidase release induced by PMA + ionomycin in the presence (N=4) 
and absence (N=4) of DMSO at 1/100 dilution (vehicle for Ro-31-8425 at minimum dilution). Means 
were not significantly different (unpaired Student‘s T-test).  
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The results so far show that OAG can be used as a pharmacological tool to activate TRPC6 
channels expressed in HEK cells with the expected biophysical properties. Receptor-mediated 
activation of the channel was then considered; in vivo DAG is produced downstream of signalling 
cascades initiated by ligands binding to receptors coupled to PLC. GPCRs including P2Y receptors 
and receptors for sphingosine, C3a and adenosine, as well as FcεRI, are present on the surface 
of mast cells, and regulate their activation in a physiological setting (Gilfillan & Tkaczyk, 2006). 
The possibility that second messenger-regulated TRPC channels could be activated downstream 
of receptor signalling in human mast cells was therefore explored. The HEK-TRPC6 cell line was 
used as a model to determine whether receptor-mediated TRPC6 activation could be measured 
Figure 4.4. OAG-induced currents in HEK-TRPC6 cells in the presence of Ro-31-8425. 
Experiments described in figure 4.2 were repeated in the presence of 3µM Ro-31-8425. 
a: (i) shows a current-time plot of an example whole-cell recording; solutions containing drugs were 
focally applied as indicated by the horizontal bars. (ii): Bar graph showing percentage of cells with a 
―sustained‖ or ―transient‖ response in the presence versus absence of Ro-31-8425 (―+Ro‖ and ―-Ro‖, 
respectively). A response was classed as ―sustained‖ when more than 50% of current remained at 2 
minutes after the end of drug application. 
b: (i) compares peak current at +100mV  and -100mV in the presence (red) and absence (blue) of 
Ro-31-8425. *: means were significantly different, p<0.05, unpaired Student‘s T-test. (ii): Current 
remaining at 2 minutes after drug application was calculated as a percentage of peak current in the 
presence of OAG. Means were not significantly different. n numbers are as follows; n=9 in the 
presence of Ro-31-8425, n=8 in the absence of Ro-31-8425.  
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using electrophysiological and Ca2+ imaging approaches. 
 
Firstly, it was investigated whether the stimulation of three different GPCRs led to Ca2+ entry in 
HEK-TRPC6 cells, in order to identify an appropriate method for receptor-mediated activation of 
TRPC6 channels. Carbachol was used to stimulate muscarinic acetylcholine receptors (mAChRs), 
as has been described previously using this cell line (Cayouette et al., 2004). ADP was also used, 
which binds to Gq-coupled P2Y1 as well as Gi-coupled P2Y12 and P2Y13 receptors (Burnstock et 
al., 2010). UTP, which activates Gq-coupled P2Y4 receptors (Burnstock et al., 2010), was also 
applied in this study. Ca2+ imaging of fura-2-loaded HEK-TRPC6 cells showed that application of 
all three agonists resulted in an increase in fluorescence corresponding to Ca2+ entry (figure 4.5).  
 
ADP was selected to investigate receptor-mediated stimulation of TRPC6 channels because it is 
likely to represent a physiological stimulus for human mast cells in vivo. Data from chapter 3 in 
this study showed that ADP induces Ca2+ entry in human lung mast cells (see figure 3.3); 
electrophysiological approaches were used to investigate whether this occurs through second 
messenger-regulated TRPC3/6/7 channels. For comparison, HEK-TRPC6 cells were also used to 
investigate whether ADP-induced TRPC6 currents could be measured under the recording 
conditions described in chapter 2.6.9  
 
HEK-TRPC6 cells were voltage-clamped at -60mV and 1 second ramps from -100mV to +100mV 
were applied every 2 seconds. Focal application of ADP resulted in an outwardly-rectifying 
current being switched on, which had a reversal potential of 1.44 ± 0.38mV (n=5; figure 4.6) 
and a rectification index of 4.39 ± 1.28 (n=5). This ADP-induced current was absent from HEK 
cells not expressing TRPC6. The mean current amplitude at +100mV was measured at 
105.48pA/pF ± 45.10 (n=5); that at -100mV was 24.75pA/pF ± 12.68 (n=5). 40% (2/5) of HEK-
TRPC6 cells had a transient current in response to ADP activation; 60% (3/5) displayed a 
sustained current. Therefore, agonists at P2Y receptors can activate TRPC6 channels under the 
whole-cell patch clamp conditions used in these experiments. Table 4.1 summarises the 
properties of OAG- and ADP- activated currents in HEK-TRPC6 cells and in HEK cells not 
expressing TRPC6. 
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Figure 4.5. Ca2+ entry following GPCR stimulation in HEK-TRPC6 cells 
a: Cells were perfused with standard external solution and 100µM carbachol (Cch) was bath-applied as shown. 
(i) shows F340/380 in individual representative cells; (ii) shows mean ± SEM (n=30 cells, N=2 experiments) 
b: Experiments as in (a), but 100µM ADP was applied (n= 24, N=2). 
c: Experiments as in (a) and (b), where 100µM UTP was applied (n= 58, N=2).  
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In summary, the results obtained with HEK-TRPC6 cells showed that live cell Ca2+ imaging and 
whole-cell patch clamp electrophysiology can be used to study the activation of TRPC6 channels 
either directly by OAG or following agonist stimulation of GqPCRs including P2Y receptors. These 
techniques and activation mechanisms were then applied to native human mast cells to study the 
functional expression of second messenger-regulated TRPC channels. 
 
 
 
Figure 4.6. ADP-induced currents in HEK cells stably expressing TRPC6. 
a: Current-time traces of whole-cell currents induced by 100µM ADP in (i) HEK-TRPC6 cells and (ii) 
HEK cells not overexpressing TRPC6. ADP was focally applied as indicated by horizontal bars. Current 
was sampled at -100mV (grey trace) and +100mV (black trace); individual representative cell traces 
are shown. Similar results were obtained in 4 other HEK-TRPC6 cells and 2 other HEK cells not 
expressing TRPC6. 
b: Subtracted current-voltage relationship of ADP-induced currents in HEK-TRPC6 cells; mean ± SEM, 
n=5 cells. Currents had a mean reversal potential of 1.44 ± 0.38mV.  
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Table 4.1. Properties of OAG- and ADP-evoked currents in HEK-TRPC6 cells and in HEK 
cells not expressing TRPC6 
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4.2 Activation of TRPC5 channels in HEK cells 
As discussed in chapter 1.3.2, there are a number of mechanisms by which TRPC5 channels can 
be activated, including Gd3+ ions, which uniquely activate TRPC5 channels whilst inhibiting other 
ion channels (Zeng et al., 2004), and S1P (Xu et al., 2006b). In order to study the functional 
expression of TRPC5 in HLMCs, it was firstly verified that the TRPC5 activators Gd3+ and S1P 
could be used to activate TRPC5 channels in our laboratory. HEK-TRPC5 cells with tetracycline-
inducible expression (Zeng et al., 2004) were used to test carbachol, S1P and Gd3+ as 
mechanisms for TRPC5 activation. Carbachol was firstly used, in an attempt to replicate the 
results obtained by Zeng et al. (2004) when the cell line was initially characterised. As shown in 
figure 4.7, carbachol stimulated an increase in F340/380, corresponding to a rise in intracellular 
Ca2+, in Tet+ cells (figure 4.7a). A small rise in Ca2+ was also seen in response to carbachol 
stimulation in Tet- cells, but this was abolished when the cells were pre-treated with 1µM 
thapsigargin for 30 minutes to deplete intracellular stores before stimulation (figure 4.7c).  
 
It was then investigated whether whole-cell patch clamp electrophysiology could be used to 
record TRPC5-mediated currents activated by carbachol, as reported previously (Zeng et al., 
2004). Cells were voltage-clamped at -60mV and carbachol-induced currents were recorded in 
the whole-cell configuration. 1 second ramps from -100mV to +100mV were applied every 2 
seconds. As shown in figure 4.8, carbachol application gave rise to currents in Tet+ HEK-TRPC5 
cells, but not in non-induced cells. The mean current amplitude at +100mV (95.95pA/pF ± 
19.76; n=3) and -100mV (14.71pA/pF ± 5.30; n=3) in Tet+ cells was significantly higher 
(p<0.05, unpaired Student‘s T-test) than that in Tet- cells (8.83pA/pF ± 1.64, n=3 at +100mV; 
1.68pA/pF ± 0.57, n=3 at -100mV). The I/V relationship of the carbachol-induced current (figure 
4.8b) is typical of a TRPC5 current; it is s-shaped, outwardly-rectifying and has a reversal 
potential near 0mV (mean reversal potential was measured at 0.76 ± 0.24mV; n=3). The 
rectification index of Cch-induced currents in HEK-TRPC5 cells was measured at 7.96 ± 2.16 
(n=3). Although inward and outward currents were enhanced by carbachol application, it is 
evident that currents were already active at the start of recordings in tetracycline-induced cells 
(see figure 4.8a (i)). For this reason, the I/V relationship shown in figure 4.8b has not been leak-
subtracted. The reasons for this current being switched on at the start of the experiment are 
discussed in section 4.3.  
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Figure 4.7. Carbachol-induced Ca2+ entry in HEK-TRPC5 cells. 
Cells were perfused in standard external solution and 100µM carbachol (Cch) was bath-applied as 
indicated by the horizontal bars. 
a: Ca2+ fluxes (F340/380) induced by Cch in tetracycline-induced HEK-TRPC5 cells. (i) shows individual 
representative cells; (ii) shows mean ± SEM (n=32 cells, N=2 experiments) 
b: Experiments as in (a) were carried out on non-induced (Tet-) cells (n=22, N=3) 
c: Cells were pre-treated with 1µM thapsigargin to empty intracellular stores for 30 minutes, then were 
perfused with standard external solution and stimulated with Cch as shown. Black trace shows mean ± 
SEM for Tet+ cells (n=79, N=3); blue trace shows data for Tet- cells (n=41, N=3) 
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S1P activation of TRPC5 channels was then tested in HEK-TRPC5 cells using fura-2 Ca2+ imaging. 
As shown in figure 4.9, 10µM S1P caused Ca2+ influx in HEK-TRPC5 cells induced overnight by 
tetracycline, but not in non-induced cells. The mean ΔF340/380 was significantly larger (p<0.001, 
unpaired Student‘s T-test) in Tet+ cells (1.28 ± 0.11; n=34, n=3) than in Tet- cells  (0.03 ± 0.01; 
n=85, n=3). These data confirm that S1P can be used to activate TRPC5 channels and can be 
used as a pharmacological tool to identify them in human mast cells. Gd3+ was also tested as an 
activator of TRPC5 in this cell line using fura-2 Ca2+ imaging. Since 100µM Gd3+ is reported to 
activate TRPC5 or TRPC4 channels only (Beech, 2007), whilst inhibiting other TRPC channels  
(Zitt et al., 1996; Okada et al., 1999; Inoue et al., 2001; Eder et al., 2007) and ICRAC (Liao et al., 
2008), it is a useful tool to examine TRPC5 channels in native cells whilst avoiding contamination 
from other channels. Application of 100µM Gd3+ to fura-2-loaded HEK-TRPC5 cells gave rise to 
Figure 4.8. Carbachol-induced whole cell currents in HEK-TRPC5 cells. 
a (i) and (ii): Current-time plots when cells were superfused with standard external solution and 100µM 
carbachol (Cch) was focally applied where indicated by the horizontal bars. Current was sampled at -
100mV (grey trace) and +100mV (black trace). (i) shows Cch-induced current in a HEK-TRPC5 cell 
induced with tetracycline (tet+); similar results were obtained in 2 other cells. (ii): example current-time 
plot when Cch was applied to a HEK-TRPC5 cell not induced by tetracycline (tet-). Similar results were 
observed in 2 other cells.  
b: Current-voltage relationship of the Cch-induced current in Tet+ cells (n=3). The current had a mean 
reversal potential of 0.76 ± 0.24mV. 
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Ca2+ influx in cells induced with tetracycline but not in non-induced cells; see figure 4.10. 
ΔF340/380 induced by Gd
3+ was significantly higher (p<0.001, unpaired Student‘s T-test) in Tet+ 
cells than Tet- cells (0.14 ± 0.04; n=37, N=3 and 0.02 ± 0.01; n=87, N=3, respectively). These 
results show that S1P and Gd3+ can be used effectively to activate TRPC5 channels, rendering 
these agents useful pharmacological tools to study their functional expression in human mast 
cells. Gd3+ in particular was able to be used to produce insightful results showing whether TRPC4 
or 5 were present without activating other channels. It is clear that S1P gives rise to larger Ca2+ 
fluxes in induced HEK-TRPC5 cells than Gd3+; this could be due to their different mechanisms of 
action, which will be discussed in section 4.3. 
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Figure 4.9. Sphingosine-1-phosphate stimulates Ca2+ entry in HEK-TRPC5 cells 
a: TRPC5-expressing HEK cells induced overnight with tetracycline were perfused in standard external 
solution and 10µM S1P was bath-applied as shown. (i) shows individual cell traces; (ii) shows mean ± 
SEM (n=34, N=3). 
b: Experiments as in (a), where cells were not induced overnight with tetracycline. n= 85, N=3. 
c: Bar graph comparing size of S1P- induced Ca2+ entry in tetracycline-induced (Tet+, clear bar) and non-
induced (Tet-) cells. ***: means were significantly different, p<0.0001, unpaired Student‘s T-test. 
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In summary, results obtained using the HEK-TRPC5 cell line have demonstrated that receptor-
mediated activation of TRPC5 using carbachol gives rise to Ca2+ entry and the activation of 
currents with characteristic biophysical properties. The more selective activators for TRPC5, S1P 
and Gd3+, were also able to stimulate Ca2+ entry in these cells, and may also be used to 
investigate the functional expression of TRPC5 in human mast cells. 
  
Figure 4.10. 100µM Gd3+ stimulates Ca2+ entry in HEK-TRPC5 cells 
a: TRPC5-expressing HEK cells induced overnight with tetracycline were perfused in standard external 
solution and 100µM Gd3+ was bath-applied as shown. (i) shows individual cell traces; (ii) shows mean ± 
SEM (n=37, N=3). 
b: Experiments as in (a), where cells were not induced overnight with tetracycline. n= 87, N=3. 
c: Bar graph comparing size of Gd3+- induced Ca2+ entry in tetracycline-induced (Tet+) and non-induced 
(Tet-) cells. ***: means were significantly different, p<0.0001, unpaired Student‘s T-test.  
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4.3 Discussion 
4.3.1 Characterisation of TRPC6 channels in HEK cells  
This part of the study aimed firstly to characterise TRPC6 channels expressed in HEK cells and 
establish activation mechanisms to record TRPC6-mediated Ca2+ entry and currents. Fura-2 Ca2+ 
imaging experiments showed that OAG caused concentration-dependent activation of TRPC6 with 
an EC50 of 0.38µM. Maximal activation was produced by 100µM OAG, which is in agreement with 
results obtained by Estacion et al. (2004) showing that increasing OAG concentration from 
100µM to 300µM produced no further increase in TRPC6 activity. A concentration of 100µM OAG 
was selected to use in all further experiments. Whole-cell patch clamp experiments revealed the 
activation of an outwardly-rectifying current by 100µM OAG with a reversal potential close to 
0mV (recorded at 0.06 ± 0.31mV); these biophysical properties are typical of TRPC6 channels 
expressed in HEK cells (Estacion et al., 2004; Shi et al., 2004; Estacion et al., 2006). 
 
Interestingly, OAG-induced currents were more sustained in some HEK-TRPC6 cells than in 
others. There are a number of reasons why there could have been these two types of response; 
DAG and OAG are known to activate PKC (Bell et al., 1986; Venkatachalam et al., 2003), and a 
number of studies have shown that PKC negatively regulates TRPC6. It was hypothesised that 
the OAG-induced TRPC6 currents in this study could be more transient in some cells due to the 
activation of PKC by OAG, leading to subsequent inactivation of the channel. This hypothesis was 
tested using a potent and selective PKC inhibitor, Ro-31-8425; if PKC was switching off the 
channels, currents in HEK-TRPC6 cells should have become more sustained in the presence of 
Ro-31-8425. This PKC inhibitor was derived from staurosporine, which is a potent but non-
selective PKC inhibitor, and bisindolylmaleimides, which are less potent but more selective 
inhibitors. The resulting Ro-31-8425 was able to inhibit all PKC isoforms with IC50 values ranging 
from 8–39nM (Wilkinson et al., 1993). It has been used successfully in human neutrophils to 
inhibit PMA-induced superoxide release (Merritt et al., 1997). 
 
To verify that Ro-31-8425 was functional in our laboratory, and to determine an appropriate 
concentration to be used to inhibit PKC, its effects on PMA + ionomycin- induced secretion were 
assayed in LAD 2 cells using a β-hexosaminidase secretion assay. PKC is required for mast cell 
exocytosis (Mazurek et al., 1987); therefore, maximal secretion was induced in LAD 2 cells using 
a combination of PMA and ionomycin to switch on PKC and cytosolic Ca2+ influx, respectively, in 
the presence of different concentrations of Ro-31-8425.  PMA and ionomycin maximally 
stimulated secretion from LAD 2 cells, causing 100% β-hexosaminidase release from intracellular 
granules. This was inhibited by Ro-31-8425 with an IC50 of 870nM. The IC50 for PKC inhibition 
observed in this assay was higher than that found in other studies; this could be because LAD 2 
cells contain higher levels of PKC than other cells, or that different isoforms of PKC are present. 
Inhibition of β-hexosaminidase release by Ro-31-8425 verified that it is an appropriate inhibitor 
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of PKC to use in electrophysiological studies; a sub-maximal concentration of 3µM Ro-31-8425 
was selected to be used in all future experiments. 
 
Ro-31-8425 was then used in whole-cell patch clamp studies to determine whether PKC inhibition 
resulted in more sustained OAG-induced currents in HEK-TRPC6 cells. It was found that 82% of 
cells showed a sustained current in the presence of Ro-31-8425, compared to 29% in the 
absence of inhibitor. The peak current measured at -100mV and +100mV was significantly 
increased when Ro-31-8425 was present; these results suggest that PKC, which is activated by 
DAG/OAG (Venkatachalam et al., 2003), is switching off TRPC6 channels following OAG-mediated 
activation. The results found in this study are in agreement with Bousquet et al. (2010), who 
showed that PKC inhibition potentiated agonist-induced Ca2+ entry in HEK-TRPC6 cells, and 
activation of PKC with PMA reduced this Ca2+ entry. They concluded that PKC exerts an inhibitory 
effect on TRPC6 channels, and showed using mutagenesis studies that this occurs by 
phosphorylation of serine residue 448 on PKC(Bousquet et al., 2010). Shi et al. (2004) found that 
carbachol-induced currents in HEK-TRPC6 cells were larger and had a significantly reduced time 
course of inactivation when PKC was inhibited. When the percentage of peak current remaining 
at two minutes after drug application in this study was calculated, there was a greater 
percentage of inward and outward current remaining when Ro-31-8425 was present, but this did 
not reach statistical significance. This is likely due to there being a large variation in the 
percentage of current remaining when PKC was not inhibited; the box and whisker plot in figure 
4.11 illustrates this variation. As shown, there was much greater variation in the percentage of 
current remaining when PKC was not inhibited. This could be caused by differering levels of PKC 
between cells, for example due to cell cycle-dependent variation or dialysis up the patch pipette. 
The variation in percentage current remaining was greatly reduced in the presence of PKC 
inhibitor. This lends support to the theory that the variation seen when PKC was not inhibited 
was due to differing levels of PKC. The model in figure 4.12 depicts how PKC may be regulating 
TRPC6 channels in this study. 
 
  
 Chapter 4: Characterisation of TRPC channels in HEK cell lines 
130 
 
 
 
 
 
 
 
 
 
Further experiments with a PKC inhibitor thus support the notion that PKC may be regulating the 
time course of the currents activated by OAG in HLMCs. It is unlikely to account for the 
deactivation of currents alone, however, as the percentage of current remaining at 2 minutes 
after drug application still varied from 30 to 101% in the presence of Ro-31-8425. As 
electrophysiological recordings of OAG-activated currents were all done in whole-cell mode, other 
Figure 4.12. Model of TRPC6 channel regulation by PKC 
OAG switches on TRPC6 channels in the plasma membrane, giving rise to currents. OAG also activates PKC, 
which inhibits TRPC6 channels, resulting in transient currents seen in whole-cell patch clamp recordings. 
Inhibition of PKC with Ro-31-8425 alleviates inhibition of TRPC6, resulting in more sustained currents 
Figure 4.11. Variation in TRPC6 current remaining in the presence or absence of PKC 
inhibition 
Box and whisker plot depicting variation in the percentage of peak current remaining at 2 minutes 
after drug application (data from figure 4.4b (ii)) in the presence (red box) or absence (blue box) of 
Ro-31-8425. 
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important signalling molecules may have been undergoing dialysis up the patch pipette. It could 
be tested whether or not dialysis in the whole-cell recording mode contributes to inactivation of 
the currents by carrying out the recordings in the perforated patch configuration; dialysis would 
not be able to occur through the small pores created by gramicidin (Rhee et al., 1994) or 
amphotericin (Rae et al., 1991). If currents became more sustained in the perforated patch 
configuration, it would show that dialysis contributes to channel inactivation. 
 
Another possibility is that the negative regulation of TRPC6 channels by Ca2+, discussed in 
chapter 1.3.2, could cause some currents to be more transient. Because the Ca2+ regulation is 
complex, involving positive and negative regulation, both dependently and independently of 
Ca2+-bound calmodulin kinase II (CaM-kinase II) (Shi et al., 2004), it is possible that different 
cells contained varying levels of important molecules required for regulation, leading to the 
variation seen in the inactivation of OAG-induced currents in HEK-TRPC6 cells. Ca2+ regulation of 
the channels could be tested using extracellular solutions containing different concentrations of 
Ca2+ and using a calmodulin antagonist such as calmidazolum (Shi et al., 2004). If this was 
carried in perforated patch and whole-cell recording configurations, Ca2+ regulation as well as the 
dialysis of signalling molecules could be investigated. In conclusion, whilst the regulatory 
mechanisms for TRPC6 inactivation remain somewhat elusive in this study, it is likely that PKC is 
playing a part as currents were found to be larger and more sustained when PKC was inhibited. 
In HEK-TRPC6 cells, OAG was shown to activate Ca2+-permeable currents with the expected 
biophysical properties of TRPC6 channels; inward and outward current with outward rectification, 
and a reversal potential close to 0mV. Therefore, OAG was able to be used as a pharmacological 
tool to investigate the functional expression of second messenger-regulated TRPC3/6/7 channels 
in native cells. 
 
It was also vital to consider receptor-mediated activation of TRPC6 channels; whilst DAG has 
been shown to directly activate TRPC3/6/7 channels (Hofmann et al., 1999), in vivo it is 
produced downstream of signalling cascades switched on when ligands bind to receptors on the 
cell membrane. This is particularly important in mast cell biology because ligands such as ATP, 
ADP, C3a and adenosine are found at sites of allergic inflammation, such as the asthmatic lung. 
Mast cells express many GPCRs on the cell surface including and P2Y receptors (Gilfillan & 
Tkaczyk, 2006), therefore it was considered whether TRPC6 channels could be stimulated 
downstream of GPCR activation to give rise to measurable currents and Ca2+ entry. HEK-TRPC6 
cells were used as a model for the activation of TRPC6 by GPCRs; it was shown that carbachol 
stimulation gave rise to Ca2+ entry, as reported previously for HEK-TRPC6 cells (Cayouette et al., 
2004; Estacion et al., 2004; Estacion et al., 2006). ADP, which stimulates P2Y1, P2Y12 and P2Y13 
receptors, and UTP, which activates P2Y4, both induced Ca
2+ entry in HEK-TRPC6 cells. These 
preliminary results indicated that the three agonists tested are appropriate to use for studies of 
GPCR-mediated TRPC6 activation in HEK cells.  
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ADP was selected to investigate GPCR-mediated stimulation of TRPC6 channels because in vivo, 
ATP and its breakdown products, ADP and AMP, are found at high concentrations at sites of 
allergic inflammation. ADP may represent an important mast cell stimulus in the allergic 
response; in mouse mast cells it was found to stimulate histamine release (Saito et al., 1991). It 
has previously been reported that human lung mast cells express P2Y1 receptors (Schulman et 
al., 1999), and data in chapter 3 of this study demonstrates that ADP induces Ca2+ entry in these 
cells (figure 3.3). P2Y1 receptors are coupled to PLCβ (Gilfillan & Tkaczyk, 2006); therefore, the 
downstream generation of DAG may activate TRPC3/6/7 channels. The biophysical properties of 
ADP-activated channels were investigated in human lung mast cells; HEK-TRPC6 cells were firstly 
used as a model to evaluate whether TRPC6 currents could be switched on downstream of ADP 
activation, and whether they could be recorded using the whole-cell patch clamp technique.  
 
Focal application of ADP to HEK-TRPC6 cells resulted in typical outwardly-rectifying currents with 
a mean reversal potential of 1.44 ± 0.38mV. As observed for OAG-induced currents in HEK-
TRPC6 cells, the majority of the currents stimulated by ADP were transient (83%); the reasons 
for this have already been discussed in the context of OAG-induced currents in this cell line and 
will not be explored further. The ADP-induced current was absent from HEK cells not expressing 
TRPC6 so is likely to be mediated by TRPC6 channels. These results show that ADP activation of 
P2Y receptors can be coupled to the activation of TRPC6 channels with typical biophysical 
properties.  
 
In summary, the results obtained with HEK-TRPC6 cells show that fura-2 Ca2+ imaging and 
whole-cell patch clamp electrophysiology can be used to study the direct activation of TRPC6 
channels by OAG, and by the more physiological method of P2Y receptor stimulation by ADP. 
 
4.3.2 Activation of TRPC5 channels in HEK cells 
HEK-TRPC5 cells with tetracycline-inducible expression (Zeng et al., 2004) were used to verify 
that known activation mechanisms for TRPC5 could be used to activate the channels in our 
laboratory. Carbachol was firstly used; this has been extensively employed to study TRPC5 
channels expressed in HEK cells (Zeng et al., 2004; Xu et al., 2005a; DeHaven et al., 2009), as 
well as endogenously expressed TRPC5 channels (Ma et al., 2008). Ca2+ imaging experiments 
showed that carbachol stimulated Ca2+ influx in tetracycline-induced (Tet+) cells; a small rise in 
Ca2+ induced by carbachol was also observed in Tet- cells, which was abolished when the cells 
were pre-treated with 1µM thapsigargin for 30 minutes to deplete internal Ca2+ stores. This 
indicates that the small rise in Ca2+ seen in Tet- cells was due to release from intracellular stores, 
in agreement with results obtained previously using this cell line (Zeng et al., 2004).  
 
It is also clear that Ca2+ entry in Tet+ cells was reduced in amplitude when the cells had been 
pre-treated with thapsigargin. There are a number of possible explanations for this; it has been 
shown previously that intracellular Ca2+ can stimulate mouse (m) TRPC5 channels in a 
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concentration-dependent manner (Gross et al., 2009) and that 200nM can stimulate human (h) 
TRPC5 channels (Zeng et al., 2004). The mechanism for receptor activation of TRPC5 channels is 
poorly defined; it has been shown using mouse TRPC5 that U73122 inhibits the response, 
indicating PLC involvement (Kanki et al., 2001; Plant & Schaefer, 2003), and it is known that a G-
protein is involved (Kanki et al., 2001). It is possible that Ca2+ activation of the channel is partly 
responsible for its activation downstream of receptor stimulation. Thapsigargin pre-treatment led 
to elimination of the Ca2+ store release in these cells (figure 4.7c); this could lead to incomplete 
activation of TRPC5 as the elevated intracellular Ca2+ following store depletion was not 
contributing. This would result in decreased TRPC5-mediated Ca2+ entry, as seen in figure 4.7c. 
Because previous depletion of the stores did not prevent the response to carbachol, it is unlikely 
that intracellular Ca2+-mediated activation is a major contributor to receptor stimulation of 
TRPC5. The results are in agreement with Zeng et al. (2004), who showed that pre-treatment 
with thapsigargin reduced but did not abolish carbachol-induced Ca2+ entry in Tet+ cells (Zeng et 
al., 2004). 
 
To investigate whether TRPC5 currents with the expected biophysical properties could be 
recorded in our laboratory, whole-cell patch clamp recordings of carbachol-activated currents in 
HEK-TRPC5 cells were carried out. Focal application of carbachol gave rise to currents in Tet+ 
cells, but not in non-induced cells, showing that the current recorded was mediated by TRPC5. 
The I/V relationship was s-shaped, outwardly-rectifying and had a reversal potential of 0.76± 
0.24mV; this is typical of TRPC5 currents (Jung et al., 2003; Zeng et al., 2004). The 
characteristic s-shaped I/V curve occurs because the channel does not switch off completely at 
voltages between -100mV and +100mV (Beech, 2007). Whilst the inward and outward currents 
were enhanced by carbachol application, currents were already switched on at the beginning of 
the recording after the whole-cell recording configuration was established. The I/V relationship 
before carbachol application had all the features of a TRPC5-mediated current, and currents were 
not present in Tet- cells; it can therefore be concluded that TRPC5 channels were already active 
in these recordings. Constitutive activity has been reported for mTRPC5 (Yamada et al., 2000), 
but not hTRPC5 (Zeng et al., 2004), therefore is not likely to account for pre-stimulus channel 
activity in this study. As discussed above, 200nM intracellular Ca2+ has been shown to activate 
hTRPC5 (Zeng et al., 2004) in the absence of receptor stimulation. The estimated free Ca2+ 
concentration of the intracellular solution used in this study was 70nM; it is possible that at this 
concentration some activation of TRPC5 may have occurred. Whilst it is known that extracellular 
Ca2+ activates TRPC5, previous studies have shown that a concentration of 5mM is required 
(Zeng et al., 2004); the concentration in this study was 2mM, therefore it is unlikely to have 
been activated by extracellular Ca2+. To investigate the contribution of Ca2+ to the activation of 
TRPC5 channels prior to agonist application, it would be necessary to repeat the experiment with 
different intracellular Ca2+ concentrations. It is clear that a multiplicity of signals contributes to 
the activation of hTRPC5; the possibility that another, yet undiscovered, factor caused activation 
of the channel prior to agonist application should not be excluded. To summarise, whole-cell 
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patch clamp electrophysiology and Ca2+ imaging approaches can be successfully used to record 
TRPC5 channel activity, as reported previously for this cell line (Zeng et al., 2004). 
 
The activation of HEK-TRPC5 cells with the more selective activators of TRPC5, S1P and Gd3+, 
was then tested using fura-2 Ca2+ imaging. Both agents gave rise to Ca2+ influx in Tet+ cells but 
not Tet-, showing that Ca2+ entry is due to expression of TRPC5.  Whilst lanthanides inhibit most 
TRP channels at micromolar concentrations (Beech, 2007), Gd3+ and La3+ potentiate mTRPC4 
and 5 channels at these concentrations and cause inhibition at millimolar concentrations.   
 
It is clear that the size of S1P-induced Ca2+ entry in HEK-TRPC5 cells was much larger than that 
induced by Gd3+ (compare figure 4.9a with figure 4.10a); this could be due the inhibition of 
endogenous ion channels by Gd3+, whereas S1P would be expected only to activate channels. 
However, this cannot account for the difference alone, because carbachol-induced Ca2+ entry in 
these cells (figure 4.7) was also smaller in size than S1P-evoked responses, albeit larger than 
that induced by Gd3+. This is likely to be due to the complex functions and interactions of S1P, 
both intracellularly and extracellularly. There are five membrane receptors for S1P (S1PR1-5), with 
cell-specific expression, that couple to different G-proteins (Strub et al., 2010). Whilst it has been 
shown in HEK-TRPC5 cells that S1P-induced Ca2+ entry is pertussis toxin (PTX) sensitive (Xu et 
al., 2006b), suggesting the involvement of Gi-coupled receptors, the contribution of the other 
S1P receptors to TRPC5 activation has not been assessed. HEK-293 cells express S1P1, S1P2 and 
S1P3 receptors (Meyer zu Heringdorf et al., 2001); it is therefore possible that, in addition to the 
PTX-sensitive mechanism described by Xu et al, other G protein-coupled S1P receptors may have 
been activated, which could have led to a large Ca2+ entry when combined with direct activation 
of TRPC5. S1P can also act as an intracellular messenger; in addition to its effects on TRPC5 (Xu 
et al., 2006b), caged S1P has been shown to cause Ca2+ rises in neuroepithelioma and 
hepatocellular carcinoma cell lines that do not respond to extracellular S1P. Sphingosine kinase 2 
knockout mice have defective Ca2+ mobilisation following FcεRI crosslinking, which cannot be 
restored with extracellular S1P (Olivera et al., 2007); this also suggests an intracellular target. 
These data, along with the large Ca2+ influx induced by S1P in this study compared to other 
activation mechanisms of TRPC5, highlight the complex functions of S1P. Because S1P-induced 
Ca2+ entry was absent in Tet- cells, it is reasonable to conclude that its actions observed in this 
study were due to activation of the channel. However, when S1P was used to probe for TRPC5 
activation in mast cells, it was important to consider that it is associated with complex signalling 
pathways and may as a result have off-target effects. 
 
In summary, data obtained using HEK-TRPC5 cells show that receptor activation with carbachol, 
stimulation with S1P and external ionic activation with Gd3+ can be used to activate TRPC5 
channels as reported previously. Gd3+ in particular was a useful tool to investigate TRPC5 
activation in human mast cells; it only activates TRPC4 and 5 channels whilst inhibiting the 
others, and RT-PCR results revealed that mRNA for TRPC4 was not present in human mast cells 
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(figure 3.9). It could therefore be used to selectively probe for functional TRPC5 expression. As 
described in chapter 1.3.2, TRPC5 and TRPC6 channel activity can be distinguished by their I/V 
relationships. Whilst TRPC5 channels have a characteristic s-shaped I/V curve, that of TRPC6 
channels is more linear with outward rectification (compare figures 4.2 and 4.8).  The 
pharmacological profile of the channels can also be used to distinguish them in native cell types; 
whilst 100µM Gd3+ activates TRPC5 channels, as shown in figure 4.10, it inhibits TRPC6 and 
other channels at this concentration. OAG activates TRPC6 but not TRPC5, and S1P has only 
been shown to activate TRPC5. These tools were able to be used to study the functional 
expression of TRPC channels in human mast cells. 
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Chapter 5: Store-operated TRPC channels in 
human mast cells 
 
As discussed in chapter 1.3.2.11, a large body of evidence exists to support the role of TRPC 
channels, particularly from the TRPC1/4/5 subgroup, in SOCE. A model has been proposed, 
based on studies in HSG cells, whereby TRPC1 channels are present in recycling vesicles, and 
following store depletion they are retained at the plasma membrane by STIM1. TRPC1 and Orai1, 
whilst not forming a heteromeric assembly, are thought to be maintained in close proximity by 
plasma membrane lipid raft microdomains. Ca2+ entry through Orai1 channels following store 
depletion is thought to enhance TRPC1 channel insertion in the plasma membrane, suggesting 
functional interactions of the three proteins. The model, recapitulated from that shown in figure 
1.17, is depicted in figure 5.1. 
  
The entry of Ba2+ ions following intracellular store depletion in LAD 2 cells and HLMCs (chapter 
3.3) suggests that TRPC channels are involved in SOCE in human mast cells. This chapter aimed 
to investigate the involvement of TRPC channels in SOCE further, and the putative contribution 
of TRPC5 was investigated using the activators described in chapter 4.2. In the second half of 
this chapter, the activation of TRPC channels downstream of FcεRI cross-linking in HLMCs was 
investigated electrophysiologically, and the potential role of TRPC channels in IgE-mediated 
HLMC degranulation was assessed. 
 
5.1 Characterisation of Synta 66 as a selective ICRAC inhibitor 
To assess the contribution of TRPC channels to store-operated Ca2+ entry, the selective ICRAC 
inhibitor Synta 66 (3-fluoropyridine-4-carboxylic acid 
(2‘,5‘-dimethoxybiphenyl-4-yl)amide) was used to inhibit the Orai1-mediated component of 
SOCE. Synta 66 is a recently characterised Orai1 inhibitor, blocking ICRAC currents in RBL cells 
with reported IC50 values of 3µM (Ng et al., 2008) and 1.4µM (Di Sabatino et al., 2009), with no 
significant effect on other receptors, ion channels and enzymes (Di Sabatino et al., 2009). Synta 
66 was verified in our laboratory as an effective blocker of ICRAC using HEK cells over-expressing 
Orai1 and STIM1 (HEK-Orai/STIM cells), and in HLMCs. Using the whole-cell patch clamp 
technique, 2µM InsP3 and 10mM BAPTA were internally applied via the patch pipette to activate 
ICRAC currents; divalent-free (DVF) solution was externally applied as shown in figure 5.2a to 
potentiate the current and facilitate recording. 
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Figure 5.1. Model for TRPC1 activation by store depletion 
STIM1 is located in the ER membrane, and Orai1 in the plasma membrane. TRPC1 is hypothesised 
to be localised in vesicles. Following store depletion, STIM1 aggregates and translocates to the 
plasma membrane, activating Orai1 channels. Orai1-mediated Ca2+ entry enhances TRPC1 insertion 
into the plasma membrane where it is gated by STIM1 to cause further SOCE. 
N.B. Model is the same as that shown in figure 1.15 
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Figure 5.2. Synta 66 inhibits ICRAC currents in HLMCs and HEK-Orai-STIM cells  
a: Time-course of ICRAC recordings in isolated primary human lung mast cells activated by internal 
application of 2µM IP3 and 10mM BAPTA and perfusion of divalent free solution (DVF) to cause rapid sodium 
influx. (i) shows an example control recording; in (ii) 10µM synta 66 was present as indicated. 
b (i): Bar graph showing mean current density recorded at -80mV in HLMCs in the presence and absence of 
synta 66. *: means were significantly different, p<0.05, unpaired Student‘s T-test. n=6 cells, N=1 donor. 
(ii): Current-voltage relationships in DVF solution in the presence (red) and absence (black) of synta 66. 
Ramps from -150mV to +150mV were applied every 2 seconds. Traces show mean ± SEM; n=6, N=1 
donor. 
c: HEK-Orai-STIM cells were held at 0mV and 2µM IP3 and 10mM BAPTA were internally applied to activate 
ICRAC currents. DVF solution was applied in the presence of synta 66 at the concentrations shown; graph 
shows the percentage of DVF current remaining in the presence of synta 66. IC50 = 0.07µM. *: means were 
significantly different, p<0.05, **: p<0.01, one-way ANOVA of log-transformed data with Tukey post-test. 
Experiments were carried out by Jasmine Farrington  
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As shown in figure 5.2b (ii), InsP3- and BAPTA-evoked currents in HLMCs recorded in the 
presence of DVF external solution had the characteristic properties of ICRAC currents including 
inward rectification and a positive reversal potential. Using the same protocol in HEK-Orai/STIM 
cells, the inward current was measured in the presence of various concentrations of synta 66, 
applied externally. As shown in figure 5.2c, synta 66 gave rise to concentration-dependent 
inhibition of ICRAC currents in HEK-Orai/STIM cells with an IC50 of 0.07µM. Maximal inhibition was 
achieved by 10µM synta 66. In HLMCs, ICRAC currents were also significantly inhibited by 10µM 
synta 66 (figure 5.2a and b); together these data show that synta 66 is an effective inhibitor of 
ICRAC currents in HEK-Orai/STIM cells and HLMCs. 10µM synta 66 was used for all other 
experiments as it caused maximal inhibition of ICRAC. 
 
Previous studies have reported that 10µM synta 66 selectively inhibits Orai1-mediated ICRAC 
currents without affecting other targets including GABA, muscarinic receptors, P2X receptors, K+ 
channels, Cl- channels, Na+ channels and TRPC channels (Di Sabatino et al., 2009; Li et al., 
2011). To verify that synta 66 does not inhibit TRPC channels in our laboratory, its effects on 
Ca2+ entry in HEK-TRPC5 and HEK-TRPC6 cells were investigated. As shown in figure 5.3, there 
was no reduction in OAG-evoked Ca2+ entry in HEK-TRPC6 cells when synta 66 was present 
throughout the experiment; OAG-induced ΔF340/380 was measured at 0.44 ± 0.03 (n=31, N=3) in 
control cells and 0.59 ± 0.02 (n=65, N=3) in the presence of 10µM synta 66. These data show 
that, at a concentration causing maximal inhibition of ICRAC, synta 66 does not inhibit TRPC6 
channels. In Tet+ HEK-TRPC5 cells, there was no difference in the amplitude of S1P-stimulated 
Ca2+ entry in the presence and absence of synta 66 (figure 5.4); ΔF340/380 in the absence of synta 
66 was 1.27 ± 0.11 (n=35, N=3), and that in the presence of synta 66 was 1.24 ± 0.07 (n=108, 
N=3). Taken together with published data showing that synta 66 does not inhibit TRPC1/5 
heteromeric assemblies (Li et al., 2011), these results suggest that synta 66 can be used to 
inhibit Orai1 channels whilst TRPC channels remain unaffected. 
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Figure 5.3. OAG-induced calcium entry in HEK-TRPC6 cells is not inhibited by Synta-66 
a: Cells were perfused in standard external solution and 100µM OAG was bath-applied as shown. (i) 
shows individual representative cell traces; (iii) shows mean ± SEM (n=32, N=3) 
b: Experiments as in (a), with 10µM Synta-66 present throughout the experiment (n= 65, N=3). 
c: Bar chart showing the size of OAG-induced calcium entry (ΔF340/380) in control cells (―c‖) and in the 
presence of 10µM Synta-66 (―syn‖).  
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Figure 5.4. Synta-66 does not inhibit S1P-induced calcium entry in HEK-TRPC5 cells 
a: TRPC5-expressing HEK cells induced overnight with tetracycline were perfused in standard external 
solution and 10µM S1P was bath-applied as shown. (i) shows individual cell traces; (ii) shows mean ± 
SEM. b: Experiments as in (a), with 10µM synta-66 present throughout the experiment. 
c: Bar graph showing size of S1P-induced calcium entry in tetracycline-induced (Tet+) and non-
induced (Tet-) cells, and in the presence of 10µM synta-66 or 1/1000 DMSO (solvent control for synta-
66) ***: mean was significantly different from control, p<0.001, one-way ANOVA with Tukey post-
test. Mean calcium entry in the presence of synta-66 was not significantly different from that in the 
absence of synta-66. n numbers are as follows: n=35 N=3 for Tet+, n=85 N=3 for Tet-, n=108 N=3 
for synta, n=22 N=2 for DMSO. 
N.B. Contol data in part (a) is the same data as shown in figure 4.8. 
 Chapter 5: Store-operated TRPC channels in human mast cells 
142 
 
5.2 Store-operated Ca2+ entry in human mast cells 
Having established that synta 66 can be used in our laboratory to inhibit ICRAC currents without 
affecting TRPC5- or TRPC6-mediated Ca2+ entry, experiments assessing Ba2+ and Ca2+ entry 
following store depletion in LAD 2 cells and HLMCs (described in chapter 3.3) were repeated in 
the presence of synta 66. In LAD 2 cells (figure 5.5), the presence of 10µM synta 66 significantly 
reduced ΔF340/380 corresponding to Ba
2+ entry following thapsigargin stimulation by 0.16 (from 
0.19 to 0.03); Ca2+ entry was significantly reduced by 0.6 (from 0.66 to 0.06). Following FcεRI 
cross-linking, Ba2+ entry was non-significantly reduced by 0.05 (from 0.14 to 0.09) in the 
presence of synta 66, and Ca2+ entry was significantly reduced by 0.35 (from 0.53 to 0.18). 
When P2Y receptors were activated with ADP, Ba2+ entry was significantly reduced by 0.06 (from 
0.15 to 0.09) in the presence of synta 66; Ca2+ entry was significantly reduced by 0.39 (from 
0.51 to 0.12). DMSO at 1/1000 dilution (vehicle for synta 66) did not cause a significant 
reduction in Ba2+ or Ca2+ entry following store depletion. Synta 66-insensitive Ba2+ and Ca2+ 
entry occurred to a greater extent following FcεRI cross-linking and ADP activation of P2Y 
receptors than following thapsigargin stimulation. The size of Ca2+ release from intracellular 
stores was highly variable, as illustrated in figure 5.6, and was not significantly different in 
experiments where synta 66 was subsequently applied, compared with control experiments. In 
the context of the model shown in figure 5.1, the small inhibition of Ba2+ entry by synta 66 
following FcεRI cross-linking and ADP stimulation of P2Y receptors could be due to the inhibition 
of Orai1 channels. As the activity of TRPC1 channels is thought to be enhanced by Orai1, 
inhibition of Orai1 with synta 66 could give rise to reduced Ca2+ entry through TRPC1 channels. 
It is evident that the synta 66-insensitive divalent ion entry is smaller when thapsigargin was 
used to deplete stores, compared with P2Y stimulation or FcεRI cross-linking (compare figure 
5.5d (i) with 5.5d (ii) and (iii)); the possible reasons for this will be explored in section 5.6. 
However, synta 66-insensitive divalent ion entry occurred following Ca2+ store release 
downstream of stimulation by all three methods in LAD 2 cells, providing evidence for the 
involvement of TRPC channels in SOCE in these cells.  
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Figure 5.5. Ba2+ and Ca2+ entry into LAD 2 cells following store depletion in the presence of 
10µM Synta-66. 
Fura 2-loaded LAD 2 cells were superfused with Ca2+-free external solution and stimulated with (a) 2µM 
thapsigargin (TG), (b)1/300 anti-IgE, following overnight incubation with 300ng/ml IgE, or (c) 100µM ADP. 
Solutions containing 2mM Ba2+ or Ca2+ were bath-applied as indicated by the horizontal bars. For (a), (b) and 
(c), (i) shows example individual cell traces in the absence of synta 66; (ii) shows individual cell traces in the 
presence of synta 66. (iii) shows mean ± SEM in the absence (black traces) and presence (red traces) of synta 
66. n numbers for control data are as follows; (a): n=36 cells, N=4 experiments. (b): n=40, N=4. (c): n=57 
N=4. n numbers for synta data are (a): n=48, N=3. (b): n=60, N=3. (c): n=59, N=3. 
d: Bar graphs comparing size of Ba2+ and Ca2+ entry (ΔF340/380) following thapsigargin (i), anti-IgE (ii) or ADP 
(iii)-evoked Ca2+ store release in the presence (red) and absence (white) of synta 66, or in the presence of 
1/1000 DMSO (blue, vehicle for synta-66). Bars show mean ± SEM; n numbers in the presence of DMSO are 
(i): n=25 N=3, (ii): n=40 N=3, (iii): n=24 N=3. ***: means were significantly different, p<0.001; **: p<0.01, 
one-way ANOVA with Tukey post-test. 
N.B. Traces in the absence of synta 66 are the same as those shown in figure 3.6. 
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The Gd3+ sensitivity of Ba2+ and Ca2+ entry following store depletion with thapsigargin in LAD 2 
cells was assessed; previous studies (Broad et al., 1999; DeHaven et al., 2009) have suggested 
that sensitivity to low µM concentrations of Gd3+ can be used as a further tool to distinguish ICRAC 
from TRPC channel activity. Experiments like those shown in figure 5.5 were repeated in the 
presence of various concentrations of Gd3+; Ba2+ and Ca2+ entry were both inhibited by Gd3+ at 
concentrations of 10µM and 30µM (figure 5.7c). No inhibition of Ba2+ entry occurred when Gd3+ 
was present at 1µM. Ca2+ entry was partially, but significantly, inhibited by 1µM Gd3+, with 
complete inhibition occurring at 10µM. The sensitivity of Ba2+ and Ca2+ entry to 10µM Gd3+ 
provides further support for the hypothesis that TRPC channels are involved in SOCE in LAD 2 
cells. The observed reduction in Ca2+ entry, but not Ba2+ entry, caused by 1µM Gd3+ is indicative 
of ICRAC-mediated SOCE. It is likely that Ba
2+ entry was not inhibited by 1µM Gd3+ because ICRAC 
does not permeate Ba2+ (Lis et al., 2007), and Gd3+ at this concentration inhibits ICRAC, but not 
TRPC channels (Broad et al., 1999; DeHaven et al., 2009). The inhibition of Ba2+ entry by 10µM 
Gd3+, but not by 1µM, provides further evidence for the involvement of TRPC channels in Ba2+ 
entry downstream of store depletion. 
Figure 5.6. Ca2+ store release following LAD 2 cell stimulation 
The size of Ca2+ released from stores in LAD 2 cells following stimulation with thapsigargin 
(―TG‖), FcεRI cross-linking (―IgE‖) or ADP was compared in experiments where synta 66 was 
subsequently applied (―synta‖, red bars) and when synta 66 was not applied (―C‖, white bars). 
Error bars indicate standard deviation, to illustrate variation in results. ns: means were not 
significantly different, one-way ANOVA with Tukey post-test.  
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Figure 5.7. Ba2+ and Ca2+ entry into LAD 2 cells following store depletion is inhibited 
by Gd3+. 
a: Traces showing Ba2+ and Ca2+ entry in LAD 2 cells following TG-mediated store depletion in control 
cells; solutions were bath-applied as indicated by the horizontal bars. (i) shows individual cell traces; (ii) 
shows mean ± SEM (n=36 cells, N=4 experiments). b: Experiments as in (a), in the presence of 10µM 
Gd3+. c: Bar chart showing size of Ba2+ (i) and Ca2+ (ii) entry (ΔF340/380) in the presence of Gd
3+ at the 
concentrations shown. Bars show mean ± SEM; n numbers are as follows: 19 for 1µM, 36 for 10µM, 55 
for 30µM. N= at least 2 experiments for each condition. ***: means were significantly different from 
control (no Gd3+); p<0.001, one way ANOVA with Tukey post test. 
 
N.B. Control data is the same as that shown in Figure 3.4. 
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In HLMCs, Ba2+ entry following passive store depletion with thapsigargin was unaffected by the 
presence of 10µM synta 66 (figure 5.8a). This result is not in accordance with that in LAD 2 cells, 
where Ba2+ entry was significantly reduced by synta 66 following thapsigargin application, 
suggesting that Ca2+ influx via Orai1 channels is not required for the stabilisation of TRPC 
channels at the membrane in HLMCs to the same degree as in LAD 2 cells. In HLMCs Ca2+ entry 
following thapsigargin stimulation was significantly reduced by 0.39 (from 0.50 to 0.11) in the 
presence of synta 66. When FcεRI cross-linking was the stimulus (figure 5.8b), a small but 
significant reduction in Ba2+ entry was observed (reduced by 0.11 from 0.23 to 0.12); Ca2+ entry 
was significantly attenuated by 0.22 (from 0.40 to 0.18). Following ADP stimulation (figure 5.8c), 
synta 66 reduced Ba2+ entry by 0.13 (from 0.21 to 0.08); this reduction was not statistically 
significant. Ca2+ entry was significantly reduced by 0.37 (from 0.55 to 0.18). As with LAD 2 cells, 
the size of Ca2+ release from stores was highly variable in HLMCs and was not significantly 
different in experiments where synta 66 was subsequently applied and those where synta was 
not applied (figure 5.9). It is evident that Ca2+ store release was larger when ADP and anti-IgE 
were used as the stimulus, compared with thapsigargin, and the time courses were different. 
This is expected due to the distinct mechanisms of action of the three agonists, which were 
explored in detail in chapter 3.5 so will not be discussed here. 
 
In line with the model proposed for the store-operated behaviour of TRPC1 in human mast cells 
(figure 5.1), the partial inhibition of Ba2+ entry following FcεRI cross-linking and ADP stimulation 
of P2Y receptors is likely to be due to the blocking action of synta 66 on Orai1 causing a 
reduction in the gating of TRPC1 by STIM1, as discussed above for LAD 2 cells. Whilst these data 
are in accordance with results obtained in LAD 2 cells, data showing that Ba2+ entry is unaffected 
by synta 66 in HLMCs are not. Inhibition of thapsigargin-mediated Ba2+ entry by synta 66 could 
have occurred to a greater degree in LAD 2 cells than in HLMCs due to the differential expression 
of TRPC channels between the two cell types, or differences in compartmentalised signalling; 
these ideas will be discussed in section 5.6. The existence of synta 66-insensitive Ba2+ and Ca2+ 
entry provides evidence for the involvement of TRPC channels in SOCE in HLMCs; as Ca2+ entry 
is likely to represent TRPC and ICRAC activation, it is probable that synta 66-insensitive Ca
2+ entry 
is carried by TRPC channels. 
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Figure 5.8. Ba2+ and Ca2+ entry into HLMCs following store depletion in the presence of 10µM 
Synta-66. 
Fura 2-loaded HLMCs were stimulated with (a) 2µM thapsigargin (TG), (b)1/300 anti-IgE, following overnight 
incubation with 300ng/ml IgE or (c) 100µM ADP in the absence of extracellular calcium. Solutions containing 2mM 
Ba2+ or Ca2+ were bath-applied as indicated by the horizontal bars. For (a), (b) and (c), (i) shows example individual 
cell traces in the absence of synta 66; (ii) shows individual cell traces in the presence of synta 66. (iii) shows mean ± 
SEM in the absence (black traces) and presence (red traces) of synta 66. n numbers for control data are as follows; 
(a): n=33 cells, N=4 experiments, 2 donors. (b): n=30, N=4, 2 donors. (c): n=9, N=3, 2 donors. n numbers for synta 
data are (a): n=11, N=3, 1 donor. (b): n=23, N=3, 1 donor. (c): n=6, N=2, 1 donor.  
d: Bar graphs comparing size of Ba2+ and Ca2+ entry (ΔF340/380) following thapsigargin (i), anti-IgE (ii) or ADP (iii)-
evoked Ca2+ store release in the presence (red) and absence (white) of synta 66, or in the presence of 1/1000 DMSO 
(blue, vehicle for synta-66). Bars show mean ± SEM; n numbers for divalent entry in the presence of DMSO are (i): 
n=8, N=2, 1 donor. (ii): n=12, N=2, 1 donor. (iii): n=4, N=2, 1 donor. *: means were significantly different, p<0.05; 
**: p<0.01; ***: p<0.001, one-way ANOVA with Tukey post- test.  
N.B. Control data is the same as that shown in Figure 3.7. 
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Ba2+ and Ca2+ entry following passive store depletion with thapsigargin were then assessed in 
HLMCs in the presence of the non-selective TRPC channel inhibitor SKF-96365 (figure 5.10). 
ΔF340/380 corresponding to Ba
2+ entry was significantly reduced by 0.12 (from 0.19 to 0.07) in the 
presence of SKF-96365. Taken together with data showing that store-operated Ba2+ and Ca2+ 
entry have synta 66-insensitive components, the sensitivity of Ba2+ and Ca2+ entry to SKF-96365 
provides evidence for the involvement of TRPC channels in SOCE in HLMCs. 
 
Figure 5.9. Ca2+ store release following HLMC stimulation 
The size of Ca2+ release from stores in HLMCs following stimulation with thapsigargin (―TG‖), 
FcεRI cross-linking (―IgE‖) or ADP was compared in experiments where synta 66 was 
subsequently applied (―synta‖, red bars) and when synta 66 was not applied (―C‖, white bars). 
Error bars indicate standard deviation, to illustrate variation in results. ns: means were not 
significantly different, one-way ANOVA with Tukey post-test.  
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Figure 5.10. Ba2+ and Ca2+ entry following store depletion in HLMCs is sensitive to 
SKF-96365. 
Fura 2-loaded HLMCs were stimulated with 2µM thapsigargin (TG) in the absence of extracellular 
calcium and solutions containing 2mM Ba2+ or Ca2+ were bath-applied as indicated by the 
horizontal bars in (a) and (b).  
a: Divalent ion entry in the absence of SKF-96365 (―SKF‖); (i) shows individual representative cell 
traces and (ii) shows mean ± SEM (n=33 cells, N=4 experiments, representative of 2 donors). 
b: Experiments as in (a), with 10µM SKF present throughout the experiment (n=50, N=3, 1 donor). 
c: Bar graph comparing size of Ba2+ and Ca2+ entry (ΔF340/380) in the presence (red) and absence 
(white) of SKF-96365. ***: means are significantly different, p<0.001, unpaired Student‘s T-test. 
 
 
N.B. Control data is the same as that shown in Figure 3.5 and 6.6. 
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5.3 TRPC5 activation in LAD 2 cells and HLMCs 
To determine whether TRPC5 channels are involved in Ba2+ and Ca2+ entry following store 
depletion in human mast cells, S1P and Gd3+ were used to probe for the functional expression of 
TRPC5 channels in both cell types. 100µM Gd3+ activates TRPC4 and TRPC5 channels (Jung et 
al., 2003; Zeng et al., 2004) whilst inhibiting other TRP channels (Beech, 2007). S1P activates 
TRPC5 homomeric channels, and TRPC5-TRPC1 heteromeric assemblies (Xu et al., 2006b); data 
in chapter 4.2 show that these agents can be used to activate TRPC5 channels expressed in HEK-
293 cells in our laboratory. As shown in figure 5.11, 10µM S1P and Gd3+ did not elicit Ca2+ entry 
in LAD 2 cells; the peak F340/380 in the presence of S1P or Gd
3+ was not significantly different from 
the mean baseline F340/380 (unpaired Student‘s T-test). The mean ΔF340/380 in response to S1P 
application was 0.09 ± 0.03 (n=18, N=2) in LAD 2 cells, compared with 1.28 ± 0.11 (n=34, 
N=3) in Tet+ HEK-TRPC5 cells. For Gd3+ experiments, the ΔF340/380 was 0.09 ± 0.03 (n=49, N=3) 
in LAD 2 cells and 0.14 ± 0.04 (n=37, N=3) in Tet+ HEK-TRPC5 cells. 1µM ionomycin was 
applied to LAD 2 cells following S1P application to verify that Ca2+ signalling was functional. 
Taken together these data suggest that functional TRPC5 homomeric channels, or TRPC5-TRPC1 
heteromeric assemblies, are not present in LAD 2 cells. It is therefore possible that synta 66-
insensitive store-operated Ba2+ and Ca2+ entry in LAD 2 cells is carried by homomeric TRPC1 
channels. 
 
In HLMCs from 1 of 5 donors tested (donor 387), 10µM S1P and 100µM Gd3+ application gave 
rise to Ca2+ entry (figure 5.12). The maximum F340/380 in the presence of S1P (0.53 ± 0.03; 
n=12) was significantly higher (p<0.01, unpaired Student‘s T-test) than the mean baseline 
F340/380 (0.67 ± 0.03; n=12), and 100% of cells responded to S1P application, where 
―responders‖ were classed as cells where F340/380 in the presence of S1P increased by more than 
10 standard deviations above the mean baseline fluorescence. It is evident that two responses to 
S1P occurred in some cells; this is likely to be due to the two mechanisms by which S1P can 
activate TRPC5 channels, which will be discussed in section 5.6. Similarly, the peak F340/380 in the 
presence of 100µM Gd3+ (0.46 ± 0.01; n=22) was significantly higher (p<0.01, unpaired 
Student‘s T-test) than the baseline fluorescence (0.39 ± 0.01; n=22), and 100% of cells 
responded to Gd3+ application. Taken together with RT-PCR data (chapter 3.4) showing that 
HLMCs from donor 387 express mRNA for TRPC1 and TRPC5, these results suggest that 
functional TRPC5 homomeric channels, or TRPC1-TRPC5 heteromers, are present in HLMCs from 
this donor. Analysis of the I/V relationships of S1P- and Gd3+- evoked currents in these cells 
would show whether homomeric or heteromeric channels are responsible for Ca2+ entry; 
homomeric TRPC5 channels have a characteristic s-shaped I/V relationship, whereas the I/V of 
TRPC1-TRPC5 has greater linearity (Beech, 2007). Unfortunately, technical difficulties prevented 
patch clamp experiments from being carried out on HLMCs from donor 387 before the cells 
expired. 
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Figure 5.11. S1P and Gd3+ do not induce calcium entry in LAD 2 cells 
a: LAD 2 cells were perfused with standard external solution and 10µM sphingosine-1-phosphate (S1P) 
was bath-applied as indicated. 1µM ionomycin was applied as a positive control at the end of the 
experiment. (i) shows individual cell traces; (ii) shows mean ± SEM of n=18 cells, N=2 experiments. 
b: 100µM Gd3+ was applied to cells as indicated; (ii) shows mean ± SEM for n=49, N=3. 
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HLMCs from the remaining 4/5 donors tested (360, 370, 410 and 411) did not respond to S1P 
and Gd3+ application (figure 5.13); in fura-2 Ca2+ imaging experiments there was no significant 
difference (unpaired Student‘s T-test) between the baseline F340/380  and the peak F340/380 in the 
presence of S1P or Gd3+. In whole-cell patch clamp experiments on cells from donor 360, ΔpA/pF 
at +100mV following application of 10µM S1P was 0.13 ± 0.80 (n=5); that elicited by 100µM 
Gd3+ was -0.00 ± 0.37 (n=4). Peak currents measured at +100mV and -100mV in the presence 
of either Gd3+ or S1P were not significantly different from mean baseline currents (one-way 
ANOVA with Tukey post-test). These data indicate that TRPC5 channels are not functionally 
expressed in HLMCs from donors 360, 370, 410 and 411. As experiments assessing Ba2+ and 
Ca2+ entry following store depletion were also carried out on donors 410 and 411 (figures 5.8–
5.10), the lack of TRPC5 functional expression in these cells indicates that TRPC1 alone is likely 
to be contributing to SOCE in these cells.  
 
Figure 5.12. S1P and Gd3+ induce calcium entry in 1/5 HLMC donors 
a: HLMCs (donor A387) were perfused with standard external solution and 10µM sphingosine-
1-phosphate (S1P) was bath-applied as indicated. (i) shows individual cell traces; (ii) shows 
mean ± SEM of n=12 cells, N=2 independent experiments. 
b: 100µM Gd3+ was applied to cells as indicated; (ii) shows mean ± SEM for n=22 cells, N=3. 
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To summarise, the presence of synta 66-insensitive Ba2+ and Ca2+ entry following store depletion 
in LAD 2 cells and concentration-dependent attenuation by Gd3+ suggests that TRPC channels 
are involved in divalent ion entry. The lack of responsiveness to the TRPC5 activators S1P and 
100µM Gd3+ indicates that TRPC5 channels are not functionally expressed in LAD 2 cells. Of the 
TRPC channels that are thought to be activated by store depletion (TRPC1, 4 and 5), it is likely 
that TRPC1 is responsible for the observed Ba2+ and Ca2+ entry; TRPC4 mRNA was not found to 
be expressed in these cells. In HLMCs from donors 410 and 411, synta-insensitive Ba2+ and Ca2+ 
entry following store depletion is also likely to be mediated by TRPC1; functional TRPC5 channels 
were not present in these donors, and TRPC4 mRNA was not detected. Although beyond the 
scope of this project, selective molecular knock-down of TRPC1 in both cell types is required in 
future studies to verify its involvement in SOCE in human mast cells.   
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Figure 5.13. S1P and Gd3+ do not activate HLMCs from 4/5 donors 
a: HLMCs were perfused with standard external solution and 10µM sphingosine-1-phosphate 
(S1P) was bath-applied as indicated. (i) shows individual cell traces; (ii) shows mean ± SEM 
of n=35 cells, N=8 independent experiments, representative of 4 donors. 
b: 100µM Gd3+ was applied to cells as indicated; (ii) shows mean ± SEM for n=49 cells, 
N=8, 4 donors. 
c: Representative whole-cell currents in HLMCs at -100mV (grey) and +100mV (black). In (i) 
cells were superfused with standard external solution and 10µM S1P was focally applied as 
indicated; similar results were obtained in 4 other cells. In (ii) 100µM Gd3+ was focally 
applied; similar results were obtained in 3 other cells. 
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5.4 The involvement of TRPC channels in the IgE response 
Data in this chapter indicate that TRPC channels may be activated downstream of Ca2+ store 
release following FcεRI cross-linking in HLMCs. This, along with the observation that Ba2+ and 
Ca2+ can support degranulation in human mast cells (chapter 3.3), suggests that TRPC channels 
may be involved in IgE-dependent Ca2+ signalling. To investigate this possibility, whole-cell patch 
clamp experiments were carried out in HLMCs to investigate the biophysical properties of anti-
IgE-induced currents. Cells were voltage-clamped at -60mV and 1 second ramps from -100mV to 
+100mV were applied every 2 seconds; results are shown in figure 5.14. Application of 3µg/ml 
anti-IgE to HLMCs incubated overnight with 300ng/ml IgE induced currents in 4/7 cells; in 3/7 
cells the peak current in the presence of anti-IgE did not increase significantly above baseline 
(unpaired Student‘s T-test). Of the responding cells, 3/4 displayed an outwardly-rectifying 
current in response to anti-IgE application, with a rectification index of 4.46 ± 0.08 (n=3) and a 
mean reversal potential of 0.58 ± 0.16 (n=3); these current properties suggest TRPC channel 
activation. In 1/4 responding cells, an inwardly-rectifying current was activated, with a 
rectification index of 0.42. The I/V relationship of this current is characteristic of Ca2+-selective 
ICRAC currents, with large currents occurring at negative membrane potentials (Hoth & Penner, 
1992; Feske et al., 2006; Prakriya et al., 2006; Scrimgeour et al., 2009). Figure 5.14c (ii) 
summarises the current amplitude at +100mV and -100mV in cells with TRPC-like currents, ICRAC-
like currents, and when 0.135M NaCl (vehicle for anti-IgE) was applied. As ICRAC-like currents 
were only observed in 1 of 7 cells tested, more experiments are required to confirm their 
activation downstream of FcεRI cross-linking. The conditions in this study were not optimised for 
the recording of ICRAC-like currents; it is therefore possible that the currents were present but not 
detected.  
 
To further investigate the contribution of TRPC channels to IgE-dependent Ca2+ signalling, the 
sensitivity of IgE-evoked Ca2+ entry in HLMCs to synta 66 was assessed. It was also examined 
whether synta 66-insensitive Ca2+ entry could be further inhibited by the non-selective TRPC 
channel blockers Gd3+ (10µM) and SKF-96365. In the presence of synta 66, ΔF340/380 induced by 
FcεRI cross-linking was significantly reduced by 0.35 (from 1.01 to 0.66); see figure 5.15. In the 
presence of 10µM synta 66 + 10µM Gd3+, ΔF340/380 was reduced by 0.54 (from 1.01 to 0.47), and 
by 0.55 (from 1.01 to 0.46) in the presence of 10µM synta 66 + 10µM SKF-96365; this was a 
significant reduction from both anti-IgE alone and anti-IgE + 10µM synta 66. DMSO at 1/1000 
dilution (vehicle for synta 66 its maximal concentration) did not significantly change anti-IgE-
induced Ca2+ entry. Results are summarised in figure 5.16.
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Figure 5.14. Anti-IgE-induced currents in HLMCs. 
Cells incubated overnight with 300ng/ml human IgE were superfused with standard external solution and 
1/300 anti- human IgE was focally applied as indicated by the horizontal bars. Anti-IgE induced a current 
in 4/7 cells; of these 3/4 displayed an outwardly-rectifying current with a reversal potential of 0.58 ±0.16 
mV for the peak current. 1/4 responding cells displayed an inwardly-rectifying current with a reversal 
potential of -0.2mV for the peak current. 
a: Example cell showing an outwardly-rectifying current. (i) shows a current-time graph where current was 
sampled at -100mV (grey trace) and +100mV (black trace). (ii) shows example I/V curves taken at points 
1-6 shown in (i); see legend for trace colours. 
b: Current-time graph (i) and I/V relationships taken from points 1-6 (ii) from cell displaying inwardly-
rectifying current in response to anti-IgE application. 
C (i): Application of 1/300 0.135M NaCl (vehicle for anti-IgE) did not give rise to a current in HLMCs. 
Traces show current-time plot for a single representative cell; similar results were obtained in 1 other cell. 
(ii): bar graph summarising the current amplitude at -100mV and +100mV for TRP-like (white) and ICRAC-
like (blue) currents induced by anti-IgE, when 0.135M NaCl (vehicle for anti-IgE) was applied to cells.  
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Figure 5.15. Anti-IgE- induced calcium fluxes in HLMCs are sensitive to synta-66, 
GdCl3 and SKF-96365. 
Fura 2-loaded HLMCs incubated overnight with 300ng/ml IgE were perfused in standard external 
solution and 1/300 anti-IgE was bath-applied where indicated by the horizontal bars. (a) shows 
calcium entry, indicated by F340/380, induced by anti- IgE in control cells (no inhibitor); in all sections 
(i) shows traces from example cells and (ii) shows the mean ± SEM. In (a), n=30 cells, N=4 separate 
experiments, representative of 2 donors. (b): experiment as in (a), but 10µM synta-66 was present 
throughout the experiment. (ii) shows the mean response; n=68 cells, N=4 representative of 2 
donors. In (c) 10µM Gd3+, as well as 10µM synta-66, was present throughout the experiment (n=68 
cells, N=4, representative of 2 donors) and in (d) 10µM SKF-96365 was present as well as 10µM 
synta-66 (n=46 cells, N=4, representative of 2 donors). 
N.B. Control data in part (a) is the same as that shown in figure 7.1. The amplitude of calcium entry 
in these experiments is summarised in figure 7.4.  
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The significant reduction of anti-IgE-induced Ca2+ entry by 10µM synta 66 indicates that ICRAC is 
activated downstream of FcεRI cross-linking; the presence of synta 66-insensitive Ca2+ entry 
suggests that TRPC channels may also be involved. The significant attenuation of synta 66-
insensitive Ca2+ entry by the non-selective TRPC channel inhibitors Gd3+ and SKF-96365 provides 
further evidence for the involvement of TRPC channels in Ca2+ entry downstream of FcεRI cross-
linking. As cytosolic Ca2+ influx is essential for mast cell degranulation, the possibility that TRPC 
channels are involved in the release of the granule markers histamine and β-hexosaminidase in 
human mast cells was then investigated. The release of these markers in response to FcεRI 
cross-linking was assessed in the presence of synta 66 and TRPC channel inhibitors. In LAD 2 
cells, β-hexosaminidase release was inhibited by Gd3+ with an estimated IC50 of 0.95µM, and by 
synta 66 with an estimated IC50 of 2.69µM (figure 5.17). 
Figure 5.16. Inhibition of IgE-induced calcium entry in HLMCs 
Bar graph comparing the size of IgE-induced calcium entry, calculated by subtracting  the baseline 
F340/380 from the maximum F340/380 in the presence of anti-IgE to give ΔF340/380. 
***: Means were significantly different, p<0.001, one-way ANOVA. **: Means were significantly 
different, p<0.01. *: Means were significantly different, p<0.05.  
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At 1µM Gd3+, a concentration that inhibits ICRAC but not TRPC channels, β-hexosaminidase release 
was reduced by 64% in LAD 2 cells; 30µM Gd3+, which inhibits both ICRAC and TRPC channels, 
inhibited β-hexosaminidase release by 98%. 10µM synta 66, a concentration that has been 
shown to completely inhibit ICRAC currents (figure 5.1 and (Ng et al., 2008; Di Sabatino et al., 
2009; Li et al., 2011)), inhibited β-hexosaminidase release in LAD 2 cells by 60%. Concentrations 
of synta 66 greater that 10µM were not able to be tested as the compound is insoluble at 
concentrations greater than 10µM (J. Farrington, unpublished observation). This partial inhibition 
by 10µM synta 66, along with the Gd3+ sensitivity profile, is indicative of the involvement of both 
Orai1 and TRPC channels in IgE-stimulated mediator release in LAD 2 cells. 
Figure 5.17. IgE-induced β-hexosaminidase release in LAD 2 cells is inhibited by 
Gd3+ and synta 66. 
a: Cells were sensitised overnight with 300ng/ml IgE and stimulated with 3µg/ml anti-IgE  in the 
presence of various concentrations of Gd3+.  Data are plotted as % inhibition, calculated by 100-(% 
of control β-hexosaminidase release remaining). N numbers are as follows: 5 for 0.03µM, 5 for 
0.1µM, 5 for 0.3µM, 7 for 1µM, 7 for 3µM, 7 for 10µM, 2 for 30µM, 2 for 100µM. 
b: Experiments were carried out as in (a), in the presence of various concentrations of synta 66. 
N=6 for all concentrations of synta 66. *: significant inhibition compared with solvent only (DMSO 
for synta 66, H2O for Gd3+), p<0.05. ***: p<0.001, one-way ANOVA of log-transformed data with 
Tukey post-test.  
Experiments were carried out by Oliver Houston. 
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Degranulation assays were also carried out on impure HLMC suspensions to investigate the 
involvement of TRPC channels in FcεRI-stimulated histamine and β-hexosaminidase release. As 
shown in figure 5.18, 10µM synta 66 significantly attenuated anti-IgE-evoked histamine release 
in HLMCs by 83% (from 39.36% to 6.72%); DMSO did not significantly reduce histamine release. 
This significant inhibition by synta 66 suggests that Ca2+ entry via ICRAC channels is essential for 
HLMC histamine release. There was a great deal of variability in the inhibition of histamine 
release by synta 66 (illustrated in figure 5.18a (ii)); the percentage inhibition varied from 21.54% 
to 98.69%. Donors were separated into those where synta 66 inhibited IgE-dependent histamine 
release by >90% (complete inhibition) and those where release was inhibited by <90% (partial 
inhibition); 3/6 donors were in each category. Release in the donors where partial inhibition 
occurred was compared in the presence of synta 66, and when the non-selective TRPC channel 
inhibitors Gd3+ and SKF-96365 were applied together with synta 66. Inhibition was significantly 
greater when both synta 66 + Gd3+ or synta 66 + SKF-96365 were present, compared with synta 
66 alone; see figure 5.18b (ii).  
 
The same samples from 5 of the 6 donors used to test histamine secretion were assayed for β-
hexosaminidase release; results are shown in figure 5.19. A similar pattern of results was 
observed as that described above; partial inhibition of β-hexosaminidase release was observed in 
the same 3 donors as partial inhibition of histamine release. Synta 66-insensitive β-
hexosaminidase release was further inhibited by 10µM Gd3+ or SKF-96365, but this did not reach 
statistical significance. Taken together, although a greater pool of donors is required to verify 
these data, results are indicative of the role of both Orai1 and TRPC channels in IgE-dependent 
secretion in some donors. In donors where synta 66 inhibition was close to 100%, it is likely that 
Orai1 channels dominate in causing Ca2+ entry necessary for FcεRI-stimulated degranulation. 
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Figure 5.18. Inhibition of IgE-induced histamine release in HLMCs 
Freshly isolated impure HLMCs were stimulated with anti-IgE and histamine release was measured as a % total 
release, determined by lysis with 0.5% perchloric acid. 
a (i): Histamine release when cells were stimulated with 3µg/ml anti-IgE alone (white; N=11, 6 donors) anti-
IgE in the presence of 1/1000 DMSO (blue; vehicle for synta 66) (N=6, 3 donors) or 10µM synta 66 (red; 
N=12, 6 donors), and with 10µM synta 66 alone (green; N=8, 4 donors). (ii): Box plot highlighting the 
variability in the sensitivity of anti-IgE-induced histamine release to synta 66. 
b (i): Donors were separated into those where histamine release was partially inhibited by 10µM synta 66 
(<90% inhibition, 3/6 donors), and those where histamine release was fully inhibited (>90% inhibition, 3/6 
donors). (ii): Bar chart comparing IgE-mediated histamine release in donors with partial inhibition by synta 66 
with histamine release in the presence of 10µM synta 66 + 10µM Gd3+ (N=4, 2 donors), or 10µM synta 66 + 
10µM SKF-96365 (N=4, 2 donors). 
*: means were significantly different, p<0.05, **: p<0.01, ***: p<0.001, one-way ANOVA with Tukey post-
test. 
Experiments in 1 donor (N=2) were carried out by Jasmine Farrington  
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Figure 5.19. Inhibition of IgE-induced β-hexosaminidase release in HLMCs 
Freshly isolated impure HLMCs from the same samples used in figure 7.7 were stimulated with anti-IgE and β-
hexosaminidase release was measured as a % total release, determined by lysis with 0.5% Triton X-100. 
a (i): β-hexosaminidase release when cells were stimulated with 3µg/ml anti-IgE alone (white; N=10, 5 
donors) anti-IgE in the presence of 1/1000 DMSO (blue; vehicle for synta 66 and SKF-96365. N=6, 3 donors) 
or 10µM synta 66 (red; N=10, 5 donors), and with 10µM synta 66 alone (green; N=6, 3 donors). (ii): Box plot 
highlighting the variability in the sensitivity of anti-IgE-induced β-hexosaminidase release to synta 66. 
b (i): Donors were separated into those where β-hexosaminidase release was partially inhibited by 10µM synta 
66 (<90% inhibition, 3/5 donors), and those where histamine release was fully inhibited (>90% inhibition, 2/5 
donors). (ii): Bar chart comparing IgE-mediated β-hexosaminidase release in donors with partial inhibition by 
synta 66 with histamine release in the presence of 10µM synta 66 + 10µM Gd3+ (N=4, 2 donors), or 10µM 
synta 66 + 10µM SKF-96365 (N=4, 2 donors). 
*: means were significantly different, p<0.05, **: p<0.01,  ***: p<0.001, one-way ANOVA with Tukey post-
test.  
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The results obtained in mediator release assays where synta 66 caused partial inhibition of 
secretion are in accordance with Ca2+ imaging data showing that synta 66 partially inhibits Ca2+ 
entry, and synta 66-insensitive Ca2+ entry is inhibited further by Gd3+ and SKF-96365. 
Unfortunately, Ca2+ imaging and secretion assay experiments were unable to be carried out on 
HLMCs from the same donors, as sufficient numbers of pure HLMCs were not able to be obtained 
in our laboratory for secretion assays due to limited availability of lung tissue. Although only two 
donors were used to investigate the synta 66 sensitivity of FcεRI-stimulated Ca2+ entry, inhibition 
was partial in both donors, whereas partial inhibition of histamine secretion occurred in 50% of 
donors (3/6). As Ca2+ imaging experiments throughout this study were carried out at room 
temperature and mediator release assays at 37oC, the possibility was considered that synta 66 
sensitivity is affected by temperature. Ca2+ imaging experiments like shown in figure 5.15 were 
repeated at 35oC, in the same donors (410 and 411). As shown in figure 5.20, synta 66 gave rise 
to partial inhibition of IgE-dependent Ca2+ entry in donors 410 and 411 at 35oC. There was no 
significant difference in ΔF340/380 corresponding to IgE-evoked Ca
2+ entry in the presence or 
absence of synta 66 at the two different temperatures. Synta 66 therefore gave rise to partial 
inhibition of IgE-dependent Ca2+ entry in both donors tested. Although time and tissue 
availability did not permit more experiments, further investigations into the inhibition of IgE-
induced Ca2+ entry by synta 66 using HLMCs from more donors would reveal whether similar 
donor-dependency exists in the contribution of TRPC channels to IgE-evoked Ca2+ entry as that 
observed in mediator release assays. 
 
To summarise, donor variability exists in the sensitivity of IgE-evoked histamine and β-
hexosaminidase to synta 66. These data indicate that Orai1 is the principal channel governing 
Ca2+ entry required for mediator release in HLMCs from some donors. In other donors however, 
the Gd3+ and SKF-96365 sensitivity of synta 66-insensitive mediator release suggests that TPRC 
channels, as well as Orai1 channels, may be important for degranulation in HLMCs. 
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Figure 5.20. Synta-66 partially inhibits anti-IgE-induced calcium entry at 35oC 
Fura 2-loaded HLMCs were perfused in standard external solution, which was heated to 35oC, and 
1/300 anti-IgE was bath-applied where indicated by the horizontal bars. (a) shows anti-IgE-induced 
calcium entry, indicated by F340/380, in control cells (no inhibitor); (i) shows traces from example cells 
and (ii) shows the mean ± SEM (n=14 cells, N=4 experiments, representative of 2 donors). (b): 
experiment as in (a), but 10µM synta-66 was present throughout the experiment. (ii) shows the mean 
response; n=17 cells, N=4 representative of 2 donors.  
c: Bar chart comparing the size of IgE-induced calcium entry at room temperature (―RT‖, clear bars) 
and 35oC (blue bars) in the presence and absence of synta-66. There was no significant difference 
between room temperature and 35oC in control cells or in the presence of synta-66 (unpaired Student‘s 
T-test).  
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5.5 Assessment of TRPC5 channels’ contribution to HLMC 
degranulation 
As shown earlier in this chapter (figures 5.12 and 5.13), the TRPC5 activators S1P and 100µM 
Gd3+ gave rise to Ca2+ entry in HLMCs from 1/5 donors, indicating that these channels may be 
functionally expressed in some donors. To assess whether TRPC5 channel activation causes 
degranulation, histamine and β-hexosaminidase release in response to these agonists were 
assessed. Results are shown in figure 5.21; 100µM Gd3+ gave rise to histamine release of 3.43% 
± 0.49 (N=6, 3 donors), and β-hexosaminidase release of 5.25% ± 4.75 (N=4, 2 donors). S1P 
induced histamine release of 0.33% ± 1.08 (n=4, 2 donors) and β-hexosaminidase release of 
4.75% ± 2.07 (N=4, 2 donors). For comparison, anti-IgE application gave rise to histamine 
release of 38.13% ± 2.56 (N=8, 4 donors) and β-hexosaminidase release of 24.90% ± 4.54 
(N=6, 3 donors). Both histamine and β-hexosaminidase release evoked by S1P were not 
significantly different from that induced by methanol (vehicle for S1P; unpaired Student‘s T-test). 
Therefore, application of agonists shown in this study to activate TRPC5 channels does not 
stimulate release of the granule-associated mediators histamine and β-hexosaminidase. Given 
that TRPC5 stimulation does not evoke degranulation in HLMCs, and Ca2+ entry in response to 
Gd3+ and S1P only occurred in 1/5 donors, it is unlikely that TRPC5 channels are responsible for 
the synta 66-insensitive FcεRI-evoked degranulation seen in figure 5.18. From the TRPC1/4/5 
subgroup, TRPC1 is the most likely candidate to be involved in Ca2+ entry and degranulation 
downstream of FcεRI in HLMCs; as shown by RT-PCR, TRPC4 was not expressed in HLMCs from 
3/3 donors tested. TRPC1 was present in all donors tested; synta 66-insensitive Ba2+ entry 
occurred following store depletion with thapsigargin, as well as receptor stimulation, in HLMCs, 
suggesting that this channel is activated by store depletion in these cells. Synta 66-insensitive 
Ca2+ entry was further reduced by 10µM Gd3+ and SKF-96365; further inhibition of degranulation 
was also seen in donors where synta 66 did not inhibit release by 100%. The I/V relationship of 
currents activated downstream of FcεRI cross-linking provides further evidence for the 
involvement of TRPC1 channels; TRPC1 currents are almost linear with a reversal potential close 
to 0mV (Rychkov & Barritt, 2007). Taken together with the likely involvement of TRPC1 in 
thapsigargin-evoked Ba2+ entry, these data suggest that TRPC1 could be involved in IgE-
dependent degranulation. Further experiments employing selective molecular knock-down of 
TRPC1 channels would verify the involvement of these channels in FcεRI-dependent Ca2+ 
signalling and mediator release. 
 
Of the DAG-activated TRPC3/6/7 subgroup, TRPC6 mRNA was expressed in HLMCs from 3/3 
donors, TRPC7 in 1/3 donors and TRPC3 in 0/3 donors. As DAG is produced by PLCγ downstream 
of FcεRI cross-linking, it is possible that TRPC6 or perhaps TRPC7 channels could contribute to 
FcεRI-evoked Ca2+ signalling and mediator release. The functional expression of this subgroup of 
TRPC channels in HLMCs is characterised in chapter 6, and their contribution to FcεRI-dependent 
signalling is assessed. 
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Figure 5.21. Activators of TRPC5 channels do not stimulate degranulation in HLMCs 
a: Freshly isolated impure HLMCs were stimulated with the agonists shown and histamine release was 
measured as % total release, determined by lysis with 0.5% perchloric acid. Anti-IgE-induced 
histamine release in the donors tested for responsiveness to other agonists is shown for comparison. 
N=8, 4 donors for IgE (3µg/ml); N=6, 3 donors for Gd3+ (100µM); N=4, 2 donors for S1P (10µM). 
***: release was significantly lower than that induced by anti-IgE, one-way ANOVA with Tukey post 
test. There was no significant difference between histamine release induced by DMSO and methanol 
(vehicles for OAG and S1P, respectively), and that induced by agonists. Histamine release experiments 
in 1 donor (N=2) were carried out by Jasmine Farrington. 
b: Freshly isolated impure HLMCs were stimulated with the agonists shown and β-hexosaminidase 
release was measured as % total release, determined by lysis with 0.5% Triton X-100. Anti-IgE-
induced β-hexosaminidase release in the donors tested for responsiveness to other agonists is shown 
for comparison. N=6, 4 donors for IgE (3µg/ml); N=4, 2 donors for Gd3+ (100µM); N=4, 2 donors for 
S1P (10µM). ***: release was significantly lower than that induced by anti-IgE, one-way ANOVA with 
Tukey post test.   
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5.6 Discussion 
As detailed in chapter 1.3.2, Orai1 channels are not thought to be the sole mediators of SOCE in 
mast cells; divalent ions such as Ba2+, Sr2+ and Mn2+ have been shown to support mast cell 
degranulation in the absence of Ca2+ (see chapter 3.3 and (Hide & Beaven, 1991; Ma et al., 
2008)). It has been proposed that TRPC channels, which lack the Ca2+ selectivity of ICRAC, 
conducting other divalent ions including Ba2+ and Sr2+ (Ma et al., 2008), form another type of 
SOCE channel, distinct from ICRAC and sometimes referred to as ISOC (Parekh & Putney, 2005; 
Cheng et al., 2011). In the recently-proposed model for the role of TRPC channels in SOCE 
(depicted in figure 5.1 and based on studies in HSG cells), TRPC1 channels are present in 
recycling vesicles, and following store depletion they are retained at the plasma membrane by 
STIM1. TRPC1 and Orai1, whilst not forming the same channel, are maintained in discrete 
plasma membrane microdomains by cholesterol- and sphingomyelin- rich lipid raft regions 
(Brazer et al., 2003; Lingwood & Simons, 2010; Calloway et al., 2011). Ca2+ entry through Orai1 
channels following store depletion is thought to enhance TRPC1 channel insertion in the plasma 
membrane and gating by STIM1, suggesting functional interactions of the three proteins. 
 
As discussed in chapter 1.3.2, there is a lack of conclusive evidence implicating TRPC3, 6 and 7 
channels in SOCE, whereas a number of studies suggest that TRPC1 channels, along with TRPC4 
and TRPC5, are involved in SOCE. This discussion will therefore focus mainly on TRPC1 and 
TRPC5 channels, which were detected in both LAD 2 cells and HLMCs by RT-PCR. 
 
The entry of Ba2+ ions in human mast cells following Ca2+ store depletion indicates that Orai1 
channels are unlikely to be the sole mediators of SOCE, and suggests the involvement of TRPC 
channels, as discussed in chapter 3.5. The selective ICRAC inhibitor, synta 66, was used in this 
chapter to further investigate the contribution of TRPC channels to SOCE. Synta 66 has been 
shown to inhibit ICRAC currents in RBL cells with estimated IC50 values of 3µM (Ng et al., 2008) 
and 1.4µM (Di Sabatino et al., 2009), and in vascular SMCs with an estimated IC50 of 26nM (Li et 
al., 2011). In our laboratory, synta 66 blocked ICRAC currents in HEK-Orai/STIM cells with an IC50 
of 70nM; of the published IC50 values for synta 66 inhibition of ICRAC, this is closest to that 
reported in vascular SMCs (26nM). Li et al. (2011) suggest that the greater potency of synta 66 
in SMCs could indicate a fundamental difference in the mechanisms of ICRAC in vascular and 
immune cells, highlighting the importance of using an appropriate concentration of synta 66 to 
inhibit ICRAC in a given cell type. In accordance with published results in both RBL cells (Ng et al., 
2008; Di Sabatino et al., 2009) and vascular SMCs (Li et al., 2011), 10µM synta 66 gave rise to 
complete inhibition of ICRAC currents in HLMCs; this concentration was used for the remaining 
experiments in this chapter where synta 66 was used to inhibit Orai1 channels. In agreement 
with previous studies (detailed in chapter 1.3) showing that synta 66 is selective for ICRAC 
inhibition (Di Sabatino et al., 2009; Li et al., 2011), 10µM synta 66 did not affect OAG-induced 
Ca2+ entry in HEK-TRPC6 cells, or S1P-induced Ca2+ entry in HEK-TRPC5 cells in this study, 
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confirming that it does not affect these channels. As both Orai1 and some TRPC channels can be 
activated by store depletion, synta 66 may be an important tool to study TRPC-mediated SOCE in 
isolation from Orai1 channel activity. 
 
In LAD 2 cells, the presence of 10µM synta 66 caused significant reduction of Ca2+ entry 
following direct store depletion by thapsigargin, and via receptor-operated mechanisms, 
indicating the involvement of Orai1 channels in SOCE in these cells. Ba2+ entry was inhibited by 
85% when thapsigargin was used to deplete Ca2+ stores, by 35% following FcεRI cross-linking, 
and by 41% when ADP was the stimulus. This result was unexpected, as Orai1 channels are not 
thought to permeate Ba2+ ions, and as discussed above, synta 66 is not expected to inhibit TRPC 
channels. As shown in figure 5.1, it is possible that Orai1 and TRPC1 are present in the same 
plasma membrane domains in LAD 2 cells, as previously demonstrated in HEK cells (Kim et al., 
2009b), platelets (Jardin et al., 2008), HSG cells (Cheng et al., 2011) and RBL cells (Ma & 
Beaven, 2011). If, as shown in figure 5.1, Orai1 enhances TRPC1 surface expression and gating 
by STIM1, inhibition of Orai1 by synta 66 could reduce TRPC1 activity due to the conformation 
coupling of the two channels, thus reducing Ba2+ entry through TRPC1. This hypothesis is 
depicted in figure 5.22. Orai1 inhibition would not be expected to completely inhibit TRPC1-
mediated Ba2+ entry, as the surface expression of TRPC1 is not entirely dependent on Orai1. 
Cheng et al. (2011) showed that TRPC1 plasma membrane expression was reduced, but not 
prevented, by expression of the dominant negative Orai1 mutant E106Q, concluding that Orai1 
increases the expression of TRPC1 at the membrane. It can therefore be hypothesised that when 
synta 66 is present, TRPC1-dependent divalent ion entry is reduced due to the inhibition of Orai1 
channels. It is evident that the amplitude of synta 66-insensitive Ba2+ entry was smaller following 
store depletion with thapsigargin than downstream of P2Y receptor stimulation or FcεRI cross-
linking. This could be because compartmentalised signalling occurs to a lesser degree when 
thapsigargin is the stimulus for store depletion, compared with receptor simulation. Whilst PLCβ 
and PLCγ are activated downstream of P2Y receptors and FcεRI, respectively, thapsigargin has 
been shown to cause minimal activation of PLC in RBL-2H3 cells (Cissel et al., 1998). 
PtdIns(4,5)P2, the target of PLC, is known to be maintained in discrete membrane lipid raft 
regions, giving rise to compartmentalised signalling and the activation of SOCE channels in 
discrete plasma membrane domains. It can be hypothesised that when TRPC1 and Orai1 
channels are brought together in lipid rafts following PLC activation downstream of receptor 
stimulation, TRPC1 channels are more likely to be in the correct position for gating by STIM1. 
When thapsigargin is the stimulus, however, the channels are less likely to be brought together 
in specific membrane domains due to the lack of PLC involvement; when Orai1 is inhibited by 
synta 66, fewer TRPC1 channels could be in the correct location for gating by STIM1, giving rise 
to greater inhibition of Ba2+ entry.  
 
 Chapter 5: Store-operated TRPC channels in human mast cells 
169 
 
 
 
 
 
 
 
 
Figure 5.22. Model of Orai1 inhibition by synta 66 and the effects on TRPC1 channels. 
As shown in figure 6.1, Orai1 activation by STIM1 enhances TRPC1 expression at the plasma membrane 
and gating by STIM1. When both channels are active downstream of store depletion, Ca2+ ions enter 
the cell through Orai1 channels; Ba2+ and Ca2+ ions enter through TRPC1 channels (top). In the 
presence of synta 66 (black circle, bottom), Orai1 is inhibited, which could affect TRPC1 channel 
surface expression and gating by STIM1, thus reducing Ba2+ ion entry through TRPC1 channels.  
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Gd3+ sensitivity has been suggested as another means to isolate TRPC from ICRAC channel 
activity; low (~1) µM concentrations of Gd3+ are thought to inhibit ICRAC currents, whereas 
concentrations of 10µM and above inhibit TRPC1, 3, 6 and 7 channels (Broad et al., 1999; 
DeHaven et al., 2009). Ca2+ entry following thapsigargin-mediated store depletion was inhibited 
by Gd3+ in LAD 2 cells; the small but significant inhibition by 1µM Gd3+ is likely to represent 
reduction in ICRAC only. This is confirmed by the lack of inhibition of Ba
2+ entry by Gd3+ at this 
concentration. Concentrations of 10 and 30µM Gd3+ gave rise to much greater inhibition of Ba2+ 
and Ca2+ entry; this was expected, as TRPC and ICRAC channels are both inhibited by Gd
3+ at 
these concentrations. The partial inhibition of Ca2+ entry by 1µM Gd3+ is in accordance with 
partial inhibition by synta 66, as both antagonists inhibit Orai1 channels. However, 1µM Gd3+ did 
not inhibit Ba2+ entry, whereas synta 66 caused partial inhibition. This is likely to be due to the 
different mechanism of action of the two antagonists; Gd3+ blocks ion channels by pore 
occlusion, but the mechanism of action of synta 66 is unknown. As depicted above (figure 5.22), 
the presence of synta 66 could interfere with the functional interaction between TRPC1 and Orai1 
in the membrane, reducing TRPC1 membrane expression and gating by STIM1. Gd3+, however, 
may not have this effect due to its differential binding site, affecting Orai1 channels only at low 
concentrations, resulting in functional gating of TRPC1 channels by STIM1, and inhibiting both 
channel types at higher concentrations. Taken together, the presence of synta 66-insensitive and 
Gd3+ sensitive Ba2+ and Ca2+ entry in LAD 2 cells suggests that TRPC1 channels are involved in 
SOCE in these cell types. A contribution from TRPC5 channels, whose mRNA was expressed in 
LAD 2 cells, can be excluded as LAD 2 cells did not respond to the selective TRPC5 activators, 
S1P and 100µM Gd3+.  
 
In HLMCs, Ca2+ entry following store depletion with all methods was significantly inhibited by 
10µM synta 66, indicating the involvement of Orai1 channels in SOCE in these cells. These data 
are in accordance with other results obtained in our laboratory, showing that currents with the 
expected biophysical properties of ICRAC are activated in HLMCs following InsP3- mediated store 
depletion (J. Farrington, unpublished data). Synta 66- insensitive Ba2+ and Ca2+ entry occurred in 
HLMCs following all methods of stimulation, indicating the involvement of TRPC channels in 
divalent ion entry. As with LAD 2 cells, the partial inhibition of Ba2+ entry following FcεRI cross-
linking or P2Y receptor stimulation could be due to synta 66 interfering with the functional 
interaction of TRPC1 and Orai1 channels, giving rise to impaired gating of TRPC1 by STIM1, as 
illustrated in figure 5.22. However, unlike LAD 2 cells, Ba2+ entry was not inhibited by 10µM 
synta 66 following thapsigargin-mediated store depletion in HLMCs. This is indicative of the 
involvement of TRPC channels in Ba2+ entry, but was unexpected due to previous reports of 
interactions between TRPC1 and Orai1 (Ong et al., 2007; Jardin et al., 2008; Kim et al., 2009b), 
and enhancement of TRPC1 cell surface expression by Orai1 (Cheng et al., 2011). It is possible 
that the variation in synta 66-dependent inhibition of Ba2+ entry observed when different 
methods were used to deplete Ca2+ stores in HLMCs is due to differential spatial regulation of the 
TRPC channels. As discussed in detail in chapter 3.5, it is likely that PLCγ and PLCβ, which are 
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activated downstream of FcεRI and P2Y1 receptors, respectively (Park et al., 1991; Gilfillan & 
Tkaczyk, 2006), are targeted to distinct plasma membrane signalling microdomains. Differential 
expression of Orai1 in these signalling domains could lead to varied effects on TRPC1 channels 
when Orai1 is inhibited by synta 66. As discussed above, passive store depletion by thapsigargin 
is unlikely to give rise to spatial regulation of TRPC1 channels to the same degree as when ADP 
or anti-IgE were used as a stimulus. The lack of dependency of TRPC1 on Orai1 channels in this 
situation could account for the absence of inhibition of Ba2+ entry by synta 66 when thapsigargin 
was used to deplete stores.  
 
Inhibition of thapsigargin-mediated Ba2+ entry by synta 66 could have occurred to a greater 
degree in LAD 2 cells than in HLMCs due to differential expression of TRPC1 channels in the two 
cell types. Maturation-dependent expression of proteins has previously been demonstrated in 
mast cells; terminally-differentiated skin mast cells were found to have higher levels of tryptase 
and chymase than less mature LAD 2 cells (Guhl et al., 2010). Additionally, B cells have been 
reported to exhibit maturation stage-dependent differences in Ca2+ signalling (Benschop et al., 
2001). It is possible that TRPC1 channels are expressed at higher levels in HLMCs than in LAD 2 
cells, and are thus present at high levels in the plasma membrane. As compartmentalised 
signalling is likely to occur to a lesser degree following thapsigargin stimulation than receptor 
stimulation, the requirement of Orai1 to enhance TRPC1 surface expression could be reduced as 
TRPC1 is already present at high levels in the plasma membrane at the correct location for gating 
by STIM1. In LAD 2 cells, however, lower expression levels of TRPC1 could mean that it is not 
expressed at the cell surface to the same degree as in HLMCs, and channels could be present in 
recycling vesicles, as suggested previously in HSG cells (Cheng et al., 2011). As the channels are 
unlikely to be assembled in lipid rafts following thapsigargin-evoked store depletion to the same 
extent as following receptor stimulation, the lower expression levels could mean that fewer 
channels are correctly positioned for gating by STIM1 in LAD2 cells, giving rise to reduced Ba2+ 
entry through TRPC1 channels when Orai1 channels are inhibited by synta 66 and are thus 
unable to enhance the surface expression of TRPC1. 
 
Whilst differences between the two cell types occur, which are likely to be accounted for by 
maturation-dependent variation, the existence of synta 66-senstitive and -insensitive Ba2+ and 
Ca2+ entry in LAD 2 cells and HLMCs provides evidence for the involvement of both Orai1 and 
TRPC channels in SOCE in both cell types. In HLMCs from the two donors (410 and 411) where 
synta 66-insensitive Ba2+ and Ca2+ entry was observed, 100µM Gd3+ and 10µM S1P did not give 
rise to Ca2+ influx, suggesting the lack of functional TRPC5 expression in these donors. These 
data were confirmed by RT-PCR (chapter 3.4) results, showing that mRNA transcripts for TRPC5 
were not expressed in HLMCs from donors 410 and 411. TRPC1 mRNA was detected in all donors 
tested; it is therefore a likely candidate to mediate synta 66-insensitive SOCE in HLMCs. As 
depicted above (figure 5.22), interference with the functional interaction between Orai1 and 
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TRPC1 channels in discrete lipid raft microdomains could account for the partial reduction of Ba2+ 
entry following Ca2+ store release downstream of receptor activation.  
 
The non-selective TRPC channel blocker SKF-96365 has been confirmed as an inhibitor of TRPC1 
channels in mouse pulmonary artery smooth muscle cells. SOCE was abolished in these cells by a 
TRPC1 inhibitory antibody, an effect that was mimicked by SKF-96365 (Ng et al., 2009). A similar 
study in bovine aortic endothelial cells showed that molecular knock-down of TRPC1 and SKF-
96365 attenuated SOCE downstream of P2Y receptor activation to a similar degree (Bishara & 
Ding, 2010). In this study, SKF-96365 significantly inhibited Ba2+ and Ca2+ entry downstream of 
thapsigargin-mediated store depletion, providing further evidence for the contribution of TRPC1 
channels to SOCE in HLMCs. As evidenced in figure 5.10, Ca2+ store release was potentiated in 
the presence of SKF-96365; this could be due to the off-target effects of SKF-96365. For 
example, Leung et al. (1996) showed that 30µM SKF-96365 promoted Ca2+ entry in HL-60 cells, 
and it was reported to stimulate phosphoinositide hydrolysis in human astrocytoma cells (Arias-
Montano et al., 1998). Such non-specific effects in HLMCs could lead to an increase in cytosolic 
Ca2+ and potentiation of Ca2+ store release. However, taken together with synta 66-insensitive 
Ba2+ and Ca2+ entry, the significant inhibition of divalent ion entry following thapsigargin 
stimulation by SKF-96365 provides further evidence for the involvement of TRPC1 channels in 
SOCE in HLMCs. 
Further studies employing selective molecular knock-down techniques, although beyond the 
scope of this project, would confirm the activation of TRPC1 downstream of Ca2+ store release in 
HLMCs. Such studies would provide valuable information on the differential contribution of TRPC 
and Orai channels to SOCE downstream of different mechanisms of activation.  
 
S1P was identified as an activator of TRPC5 in search for novel activators of the channel using 
tetracycline-inducible HEK-TRPC5 cells (the cell line used in this study). S1P was reported to give 
rise to Ca2+ entry in tetracycline-induced, but not non-induced, cells in a concentration-
dependent manner. S1P was also shown to activate TRPC1-TRPC5 heteromeric assemblies 
expressed in HEK cells, but not TRPC1 channels alone (Xu et al., 2006b). The authors described 
that S1P-evoked Ca2+ entry in human saphenous vein vascular SMCs has two phases, which are 
both sensitive to the inhibitory TRPC5 antibody T5E3. Treatment of HEK-TRPC5 cells with 
pertussis toxin or the PLC inhibitor U73122 inhibited S1P-evoked Ca2+ entry, indicating the 
respective involvement of Gi/o-coupled receptors and PLC in the activation of TRPC5 by S1P. A 
recent study suggested that group 6 phospholipase A2 (PLA2) enzymes, which release the fatty 
acids lysophosphatidylcholine (LPC) and arachidonic acid (AA) from glycerol, are involved in the 
activation of TRPC5 by extracellular S1P (Al-Shawaf et al., 2011). An intracellular mechanism of 
action of S1P has also been suggested; it was reported to elicit single-channel events in inside-
out patch clamp experiments of HEK-TRPC5 cells (Xu et al., 2006b). As S1P can be transported 
across the membrane or accumulate intracellularly following activation of S1P receptors (Saba & 
Hla, 2004), it was concluded that TRPC5 can be activated by S1P by two different mechanisms; it 
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can act as an ionotropic receptor for intracellular S1P, or become activated downstream of PLC 
production following S1P receptor stimulation (Xu et al., 2006b). Consistent with these reports, 
S1P gave rise to two phases of Ca2+ entry in HLMCs in this study. This is likely to be due to S1P 
acting in both an intracellular and extracellular manner to activate the channels. Unfortunately, 
technical difficulties prevented patch clamp experiments from being carried out on HLMCs from 
donor 387; future experiments investigating the I/V relationship of S1P-evoked currents in 
HLMCs will reveal whether homomeric TRPC5 channels are activated, or whether they form 
heteromeric assemblies with TRPC1. Inside-out patch clamp experiments, or whole-cell patch 
clamp experiments with S1P in the pipette solution would also reveal whether S1P acts 
intracellularly to activate TRPC5-containing channels in HLMCs. 
 
The donor-dependent nature of TRPC5 expression in HLMCs could have important physiological 
consequences. Although relatively little is known about its biological roles, TRPC5 has been 
reported to mediate the Ca2+ entry in hippocampal neurones that hinders growth cone extension 
(Greka et al., 2003). Ca2+ entry in arteriolar smooth muscle cells occurs through TRPC5 (Xu et 
al., 2005b), and TRPC5-mediated Ca2+ entry has been implicated in vascular smooth muscle cell 
motility stimulated by S1P (Xu et al., 2006b). Ca2+ permeability is thus central to all the known 
roles of TRPC5 channels in different systems. The possibility that Ca2+ entry through TRPC5 in 
HLMCs from 1/5 donors in this study could be important in the control of downstream mediators 
involved in lung disease was considered. From the medical records of HLMC donors, donor 387 
(HLMCs expressing TRPC5) did not suffer from asthma, allergies or chronic obstructive 
pulmonary disease. Donors 410 and 411 (not expressing TRPC5) suffered from iodine allergies 
and COPD, respectively; TRPC5 expression does therefore not appear to correlate with lung 
disease incidence. Donor 387 smoked cigarettes until 3 months before the tissue was obtained; 
of the 4/5 donors not expressing TRPC5, 410 and 411 were non-smokers, and smoking data was 
not available for donors 360 and 370. Tobacco smoke is a complex mixture of over 4700 
different chemicals including carbon oxides, esters, phenols, hydrocarbons and free radicals, 
which have multifaceted effects in the body (Borgerding & Klus, 2005). The expression of a 
number of genes is known to be up-regulated in response to cigarette smoke in rat pulmonary 
arteries (Wright et al., 2002) and human airway epithelial cells (Beane et al., 2007); this up-
regulation can be transient, rapidly-reversible or irreversible (Beane et al., 2007). It is possible 
that TRPC5 channels are expressed in donor 387 due to cigarette smoking. Interestingly, one 
study has suggested that TRPC6 channel expression is up-regulated in non-small cell lung 
cancer, which is most commonly caused by smoking (Zhang et al., 2010a). Collecting more data 
on the functional expression of TRPC5 channels in HLMCs from smokers and non-smokers is 
necessary to draw reliable conclusions on whether chemicals in cigarette smoke up-regulate 
TRPC5 expression; data obtained in this study suggest that it is a possibility, and represents an 
interesting avenue for further investigation.  
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The possibility that the donors‘ drug history could affect TRPC5 expression was also considered. 
Known patient information is summarised in table 5.1; of interest is that whilst donor 387 was 
not taking aspirin or other oral anti-inflammatory medication, donors 410 and 411 were taking 
aspirin. Donor 370 was taking etodolac, another non-steroidal anti-inflammatory drug. These 
compounds work by inhibiting cyclo-oxygenase enzymes, which are responsible for the 
production of prostaglandins (Vane & Botting, 2003), second messengers that regulate 
inflammation. It is possible that the anti-inflammatory effects due to long-term use of aspirin and 
etodolac could include the down-regulation of ion channel expression in mast cells, which could 
account for the lack of TRPC5 expression in some donors. Donor 360 was taking amlodipine and 
donor 370 felodipine; these Ca2+ channel inhibitors block L-type voltage-gated Ca2+ channels, but 
could affect other channels. A study investigating the selectivity of amlodipine in Xenopus 
oocytes showed that it also significantly inhibits N-type Ca2+ channels (Furukawa et al., 1999); 
complex cellular effects of this and other drugs could be responsible for the variation seen in 
TRPC5 expression between donors. Future analysis of TRPC5 activity in HLMCs from a greater 
pool of donors will provide insightful information on whether donors‘ drug history affects channel 
expression. 
 
In conclusion, the data presented in the first part of this chapter suggest that TRPC1 and Orai1 
channels are involved in SOCE in HLMCs, with a possible contribution from TRPC5 in some 
donors. The potential involvement of different channels in SOCE between donors could be 
important for mast cell functions in conditions such as asthma. Following Ca2+ influx, exocytic 
release of pre-formed pro-inflammatory mediators within secretory granules occurs as the mast 
Table 5.1. HLMC Donor information 
Table summarising HLMC donor information and TRPC5 expression. Blank box=no data.  
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cell degranulates. Granule-associated mediators include biogenic amines such as histamine, 
which causes increased capillary permeability and bronchoconstriction (Lundequist & Pejler, 
2011). Serotonin, which was previously thought to be restricted to rodent mast cells (Lundequist 
& Pejler, 2011), has recently been shown to be present in human peripheral blood-derived mast 
cells (Kushnir-Sukhov et al., 2007), and gives rise to vasoconstriction and pain (Theoharides et 
al., 2007). Lysosomal enzymes are also released in mast cell degranulation, including β-
hexosaminidase, which is present in mast cells from all species and is thought to be involved in 
carbohydrate processing (Theoharides et al., 2007; Lundequist & Pejler, 2011). Proteoglycans, 
proteases and pre-formed cytokines are also stored in mast cell granules and released upon 
degranulation (Lundequist & Pejler, 2011). Mast cells thus store an extensive array of pre-formed 
mediators in their cytoplasmic granules, which have a profound effect on surrounding tissues 
when released in response to mast cell activation. 
 
Whilst TRPC channels have been reported to be involved in FcεRI-mediated Ca2+ entry and 
degranulation in RBL-2H3 cells (Ma et al., 2008), the involvement of TRPC channels in human 
mast cell mediator release has not been investigated. In accordance with the results obtained by 
Ma et al. (2008), data obtained in this chapter suggest that both ICRAC and TRPC channels are 
involved in Ca2+ entry downstream of FcεRI cross-linking in HLMCs; IgE-dependent Ca2+ entry 
was partially inhibited by synta 66, and synta 66-insensitive Ca2+ entry was further reduced by 
the non-selective TRPC channel inhibitors Gd3+ and SKF-96365. These data are in accordance 
with Ca2+ imaging data discussed above showing that TRPC1 channels are likely to be involved in 
Ba2+ and Ca2+ entry following FcεRI-dependent Ca2+ store depletion.  
 
Electrophysiological experiments revealed TRPC-like currents activated downstream of FcεRI 
cross-linking in 3/7 cells, and ICRAC-like currents in 1/7 cells. These data appear to contradict Ca
2+ 
imaging data showing that IgE-dependent Ca2+ entry was partially inhibited by synta 66 in all 
cells. However, the electrophysiological recording conditions were not optimised to record ICRAC-
like currents. As Orai1 channels have very low conductance (Hogan et al., 2010), they are very 
difficult to detect under standard recording conditions. Ca2+ ions are frequently replaced with Na+ 
ions when recording ICRAC currents to increase the conductance and facilitate identification 
(Lepple-Wienhues & Cahalan, 1996; Mercer et al., 2006; Prakriya et al., 2006; Scrimgeour et al., 
2009). As the extracellular solution contained 2mM Ca2+ in this study and divalent ions were not 
replaced with Na+, it is possible that ICRAC currents were too small to detect in the presence of 
the larger non-selective TRPC currents. Electrophysiological data in this chapter therefore provide 
evidence for the activation of TRPC channels downstream of FcεRI cross-linking, but the 
contribution of ICRAC cannot be ascertained under the experimental conditions used.. 
 
In accordance with the Ca2+ imaging data, synta 66 gave rise to partial inhibition of FcεRI-
dependent histamine and β-hexosaminidase release in 50% of HLMCs. Synta 66-insensitive 
release was sensitive to the non-selective TRPC channel blockers Gd3+ and SKF-96365, providing 
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evidence for the involvement of both Orai1 and TRPC1 channels in HLMC degranulation. In the 
other 50% of donors, however, synta 66 completely inhibited histamine and β-hexosaminidase 
release. Repeating Ca2+ imaging experiments at 35oC showed that the temperature did not affect 
the sensitivity of FcεRI responses to synta 66. These data suggest that in some donors, ICRAC 
alone is responsible for mediating the Ca2+ influx required for degranulation, whereas in other 
donors TRPC1 and ICRAC channels are both involved. Two questions arise from these 
observations; why are two different Ca2+ channels involved in FcεRI-dependent Ca2+ entry and 
degranulation in HLMCs, and why does donor dependency exist? 
 
To address the first question, it is possible that TRPC1 and Orai1 channels function together to 
bring about FcεRI-dependent Ca2+ entry, as discussed above and depicted in figure 5.1. It has 
been suggested, based on experiments in HSG cells, that TRPC1 and Orai1 channels have distinct 
downstream effects and are both required for HSG cell function. Orai1 mediated Ca2+ entry was 
reported to be sufficient for the activation of nuclear factor of activated T-cells (NFAT) 
transcription factor, but a higher concentration of intracellular Ca2+, provided by TRPC1 
activation, was shown to be required for the full activation of the transcription factor nuclear 
factor-κB (NFκB) and KCa channels (Cheng et al., 2011). The existence of the two types of store-
operated Ca2+ channel allows fine control of cellular functions regulated by store depletion. Both 
NFAT and NFκB are activated downstream of FcεRI cross-linking and regulate cytokine 
transcription in mast cells (Hutchinson & McCloskey, 1995; Marquardt & Walker, 2000). NFAT is 
important for the production of TNFα, a pro-inflammatory cytokine that activates the airway 
epithelium, antigen-presenting cells and macrophages in the asthmatic airway (Chung & Barnes, 
1999). The production of IL-2 is also regulated by NFAT (Marquardt & Walker, 2000); this pro-
inflammatory cytokine causes T cell differentiation and eosinophilia. NFκB enhances the 
transcription of many genes for proteins involved in inflammation including cytokines, adhesion 
molecules and growth factors (Marquardt & Walker, 2000). It has been shown in mouse mast 
cells that NFκB activated downstream of FcεRI is vital for the production of IL-6 (Marquardt & 
Walker, 2000), which acts as a growth factor for T and B cells in allergic inflammation (Chung & 
Barnes, 1999). Fine control of these transcription factors by differential Ca2+ entry through Orai1 
and TRPC1 channels would allow the mast cell to tightly regulate downstream cytokine 
production, and thus activate different cells important in airway inflammation. Whilst the 
transcription of some cytokines is tightly controlled by Ca2+ and likely to be regulated by the 
different channels, it is possible that both TRPC1 and Orai1 channels contribute to the Ca2+ influx 
required for degranulation, which can be produced by Ca2+ ionophores in the absence of FcεRI 
cross-linking (Cochrane & Douglas, 1974). It can be speculated that the two channel types can 
bring about degranulation in HLMCs as a ‗fail-safe‘ mechanism to ensure that mediator release 
still occurs when inactivating single nucleotide polymorphisms arise in the genes encoding one of 
the channels. Such a mechanism has been proposed to account for the evolution of 
complementary signalling cascades for mast cell activation (Gilfillan & Tkaczyk, 2006). 
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To address the second question of why donor dependency exists in the contribution of TRPC1 
and Orai1 channels to HLMC degranulation, it is important to consider that compartmentalised 
signalling is likely to occur. As described previously, the plasma membrane localisation and 
association of ion channel subunits is tightly controlled by lipids, proteins and other signalling 
molecules; donor-dependent variations in these molecules could give rise to varied membrane 
expression of TRPC1 and Orai1 channels. For example, a higher level of ordered PtdIns(4,5)P2 in 
some donors could give rise to a greater association of STIM1 and Orai1 (Calloway et al., 2011) 
than in other donors, resulting in a greater contribution of ICRAC to FcεRI-dependent Ca
2+ entry 
and degranulation. 
 
It is also possible that the expression of TRPC1 and Orai1 channels varies between donors, as 
discussed above for TRPC5. Unfortunately it was not possible to electrophysiologically investigate 
the contribution of the different ion channels in the same donors that were used for histamine 
and β-hexosaminidase secretion assays, as sufficient numbers of pure HLMCs were not able to 
be obtained in our laboratory to carry out functional assays. If TRPC1 and Orai1 were both 
expressed to a high level in one donor, they could both contribute to FcεRI-dependent Ca2+ 
signalling and degranulation as depicted in figure 5.1. If TRPC1 expression levels were low in 
another donor insufficient membrane trafficking could occur, and TRPC1 membrane expression 
may not be sufficient for gating by STIM1. Orai1 alone could mediate Ca2+ entry required for 
degranulation downstream of FcεRI cross-linking in these donors.  
 
Differential contribution of Orai1 and TRPC1 to FcεRI-evoked Ca2+ entry between donors could 
have important functional consequences. Whilst degranulation occurred to a similar extent in all 
donors in this study regardless of the involvement of the different ion channels, it is likely that 
cytokine expression would be affected. As discussed above, the greater Ca2+ conductance 
effected by TRPC1 is required for the complete activation of NFκB (Cheng et al., 2011). Cytokines 
play an integral role in asthmatic airway inflammation as they induce many of the characteristic 
symptoms of the disease including airway smooth muscle cell hyperplasia and the infiltration of 
other immune cells (Chung & Barnes, 1999). Donor-dependent TRPC1 and Orai1 channel 
contribution to Ca2+ entry could therefore have important consequences for the development of 
inflammation in the asthmatic airway. Although beyond the scope of this project, determining the 
cytokine expression profile of HLMCs from different donors in combination with molecular knock-
down of TRPC1 and Orai1 would be an interesting avenue of investigation and would reveal 
whether TRPC1 and Orai1- mediated Ca2+ entry regulates the transcription of different cytokines. 
 
To summarise the findings in this chapter, TRPC1 channels are likely to be involved in SOCE in 
human mast cells, possibly interacting functionally with Orai1. Results provide evidence for the 
involvement of TRPC channels in FcεRI-dependent Ca2+ signalling and mediator release in some 
donors.  
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Chapter 6: Diacylglycerol-sensitive 
TRPC3/6/7 channels in human mast cells 
 
The results described in chapter 3 demonstrated that TRPC channels, which are expressed in 
both LAD 2 cells and HLMCs, may be involved in Ca2+ entry following receptor stimulation. 
Chapter 4 discussed the development of pharmacological methods to investigate second 
messenger-regulated TRPC3/6/7 channels using HEK-TRPC6 cells. Having established that LAD 2 
cells express mRNA for all three TRPC channels in this subgroup, and HLMCs expressed TRPC6 in 
3/3 donors and TRPC7 in 1/3 donors, these tools were then applied to study the functional 
expression and biophysical properties of TRPC3/6/7 channels in human mast cells. 
 
6.1 OAG activation of TRPC3/6/7 channels in HLMCs 
OAG was applied to fura-2-loaded HLMCs to test for functional expression of TRPC3/6/7 
channels. As shown in figure 6.1, application of 100µM OAG to HLMCs in the presence of 
extracellular Ca2+ gave rise to Ca2+ entry in 97% of cells tested, where ―responders‖ were 
classed as cells where the fluorescence increased by more than 10 standard deviations above the 
baseline fluorescence following OAG application. As similar results were obtained in four separate 
donors, figure 6.1a (ii) shows the mean response from all donors tested. OAG-induced Ca2+ entry 
was significantly reduced in the absence of extracellular Ca2+; the change in fura-2 fluorescence 
ratio in response to OAG application was 0.68 ± 0.03 (n=95, N=7) in the presence of Ca2+, 
compared with 0.05 ± 0.01 (n=7, N=3) in the absence of extracellular Ca2+. DMSO at 1/1000 
dilution (vehicle for OAG) did not result in Ca2+ entry when applied to cells. 
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Figure 6.1. OAG-induced Ca2+ entry in HLMCs 
Fura 2-loaded HLMCs were perfused in standard external solution, and OAG was bath-applied as 
indicated by the horizontal bars.  
a: Ca2+ fluxes in HLMCs stimulated with OAG in the presence of extracellular Ca2+. (i) shows individual 
example cells; (ii) shows the mean response (n=95 cells, N=7 experiments, representative of 4 donors). 
97% of cells responded to OAG application. 
b: Experiments as in (a), in the absence of extracellular Ca2+; n=6, N=3, 1 donor.  
c: Bar chart showing size of Ca2+ influx (ΔF340/380) in the presence (white) and absence (green) of 
extracellular Ca2+ and when applying 1/1000 DMSO (blue), the vehicle for OAG (n=48, N=4, 
representative of 2 donors). ***: means are significantly different, p<0.0001, one-way ANOVA with 
Tukey post-test. 
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The effect of the non-selective TRPC channel inhibitors Gd3+ and SKF-96365 on OAG-induced 
Ca2+ entry in HLMCs was then assessed. Gd3+ has previously been shown to block heterologously 
expressed TRPC3 and TRPC6 channels with IC50 values of 2.5µM and 2.3µM, respectively (Inoue 
et al., 2001; Dietrich et al., 2005b). SKF-96365 inhibits heterologously expressed TRPC6 channels 
with an IC50 of 4.2µM (Inoue et al., 2001), and receptor-mediated Ca
2+ entry in platelets  with an 
IC50 of 8.5µM (Merritt et al., 1990). Experiments like those shown in figure 6.1 were repeated in 
the presence of Gd3+ and SKF-96365; as shown in figure 6.2, both inhibitors caused 
concentration-dependent inhibition of OAG-induced Ca2+ entry in HLMCs. When analysing the 
single-cell traces shown in figure 6.2a, it is apparent that the both inhibitors caused a reduction 
in the amplitude of the Ca2+ signal in each cell; they did not cause fewer cells to respond. Figure 
6.2c shows concentration-response curves for  inhibition by Gd3+; in donor A410 (5.2c (i)), the 
estimated IC50 for Gd
3+ inhibition was 2.77µM, and complete inhibition was achieved by 10µM. 
Whilst the Gd3+ sensitivity varied between donors (estimated IC50 in donor 411= 18.4µM), the 
average estimated IC50 for N=2 donors (figure 6.2c (ii)) was 6.5µM. A sub-maximal concentration 
of 10µM Gd3+ was chosen for use in further experiments.  
 
SKF-96365 also had concentration-dependent effects on OAG-induced Ca2+ entry; as shown in 
figure 6.2d (i), concentrations below 1µM appeared to potentiate Ca2+ entry. For example, 
ΔF340/380 was increased by 0.27 (from 0.68 to 0.95) in the presence of 0.001µM SKF-96365. 
Inhibition of OAG-induced Ca2+ entry occurred at concentrations greater than 1µM. Analysis of 
concentrations of 1µM SKF-96365 and above revealed an IC50 of 10.25µM, which is in range of 
previously reported values for the inhibition of heterologously expressed TRPC6 channels (Inoue 
et al., 2001; Dietrich et al., 2005b). Due to the potentiating effect of lower concentrations of 
SKF-956365, a ―% inhibition‖ graph was not plotted as was done for Gd3+ inhibition. H2O at 
1/100 dilution (vehicle for maximal concentrations of Gd3+ and SKF-96365) did not have an effect 
on OAG-induced Ca2+ entry; see figure 6.2d (ii). 
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Figure 6.2. OAG-induced Ca2+ entry in HLMCs is inhibited by Gd3+ and SKF-96365. 
a: Individual representative cell traces showing Ca2+ fluxes in HLMCs. (i) shows control responses to 100µM OAG; 
in (ii) and (iii) OAG was applied in the presence of 100µM Gd3+ and 30µM SKF-96365, respectively.  
b: Mean traces ± SEM for experiments shown in (a); (i) shows control OAG response, (ii) shows OAG response in 
the presence of 100µM Gd3+ and (iii) shows OAG response in the presence of 30µM SKF-96365. 
c (i): Concentration-response curve showing change in fluorescence (ΔF340/380) against Gd
3+ concentration 
present in donor A410. IC50=2.77µM. (ii) shows % inhibition of OAG-induced Ca
2+ entry by different 
concentrations of Gd3+ compared to control data. Points show mean ± SEM for N=2 donors. IC50=6.5µM. n 
numbers are as follows:  Donor A410: 10 for 0.1µM, 8 for 1 µM, 10 for 3µM, 5 for 10µM, 8 for 100µM. 
Donor A411: 13 for 0.1µM, 9 for 1 µM, 7 for 3µM, 9 for 10µM, 7 for 30µM 3 for 100µM.  
d (i): Concentration-response curve showing  OAG-induced change in fluorescence against concentration of SKF-
96365. n numbers are as follows: 7 for 0.001µM, 3 for 0.1µM, 7 for 1µM, 14 for 10µM, 8 for 30µM, 8 for 100µM. 
(ii) shows OAG-induced change in fluorescence in the presence and absence of 1/100 H2O (vehicle for Gd
3+ and 
SKF-96365 at minimal dilution); means were not significantly different (unpaired Student‘s T-test). 
**: means were significantly different, p<0.01. ***: p<0.0001, one-way ANOVA with Tukey post-test. 
N.B. Control OAG data is the same as that shown in figure 6.1.  
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Whole-cell patch clamp recordings were then carried out as detailed in chapter 2.6.9 in order to 
investigate the biophysical properties of OAG-induced currents in HLMCs. Cells were voltage-
clamped at -60mV, and 1 second voltage ramps from -100mV to +100mV were applied. Results 
are shown in figure 6.3; focal application of OAG gave rise to an outwardly-rectifying current in 
88% of cells. Currents had the expected biophysical properties of the DAG-activated TRPC 
channels, showing outward rectification and a reversal potential close to 0mV. In 37.5% of 
responding cells (3/8), the OAG-induced current was sustained; the mean inward current 
amplitude measured at -100mV was 11.1pA/pF±10.3, and the outward current measured at 
+100mV was 51.6pA/pF±41.5. 62.5% of responding cells (5/9) displayed a transient response; 
in these cells the mean inward current amplitude was 75.3pA/pF ± 36.35, and the mean outward 
current amplitude was 147.2pA/pF±52.34. For comparison, 50% of HEK-TRPC6 cells had a 
sustained response to OAG. Examples of cells showing sustained and transient responses are 
shown in figure 6.3a (i) and (ii), respectively. As with OAG-induced currents in HEK-TRPC6 cells, 
currents were classed as ―sustained‖ when more than 50% of current remained at 2 minutes 
after the end of drug application. 2/3 cells displaying a sustained response to OAG application 
were from the same donor (370). The other cell displaying a sustained current was from donor 
410; 2/3 cells from donor 410 had a transient current. Currents were transient in all cells tested 
from donor 360 (n=3). The kinetics of current onset were not found to be related to whether 
currents were transient or sustained; in cells with a transient OAG-induced current, the peak 
current occurred at 124.67 seconds ± 30.64 (n=5) after the beginning of OAG application. In 
cells displaying a sustained current, the peak occurred at 118.40 seconds ± 23.47 (n=3) after 
OAG application; there was no significant difference in the time taken for the current to peak 
between the cells displaying the two types of response (unpaired Student‘s T-test). 
 
Example I/V relationships from time points 1–6 in figure 6.3a (i) and (ii) are shown in figure 6.3b 
(i) and (ii). In order to examine the relative size of the inward and outward currents in OAG-
responding cells, a ―rectification index‖ was calculated using the formula: rectification index = 
peak current at +100mV/ peak current at -100mV. 
 
In the bar graph in figure 6.3b (iii), the rectification index in cells showing a sustained response 
to OAG is compared with that in cells showing a transient response. The rectification index was 
significantly higher in cells with a sustained response, showing that the current was more 
outwardly-rectifying in these cells. For comparison, in HEK-TRPC6 cells the rectification index of 
OAG-evoked currents was 6.86 ± 1.23 (n=4) for sustained currents and 4.78 ± 1.12 (n=4) for 
transient currents; these values were not significantly different.  
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As shown in figure 6.3c, focal application of DMSO at 1/1000 dilution did not induced currents in 
HLMCs, and OAG-induced currents were significantly inhibited by 10µM Gd3+ (ΔpA/pF at +100mV 
= 122.5 ± 41.3 in the absence of Gd3+ and 2.2 ± 1.1 when Gd3+ was present. At -100mV ΔpA/pF 
= 53.0±24.8 in the absence of Gd3+ and 1.8 ± 1.7 in the presence of Gd3+). 
 
Experiments in HEK-TRPC6 cells (chapter 4.1) indicated that PKC may have a role in the negative 
regulation of TRPC6 channels as reported previously (Estacion et al., 2004; Shi et al., 2004; 
Bousquet et al., 2010), giving rise to the transient currents seen in response to OAG application 
in some cells. To investigate whether such a mechanism regulates the kinetics of OAG-evoked 
currents in HLMCs, the effects of the selective PKC inhibitor, Ro-31-8425, were examined. Whole-
cell patch clamp experiments like those shown in figure 6.3 were then repeated in the presence 
of 3µM Ro-31-8425. Unfortunately, due to experimental timings and the short-lived nature of 
HLMCs from some donors in culture, experiments in the presence of Ro-31-8425 were only able 
Figure 6.3. OAG induces an outwardly-rectifying current in HLMCs that is sensitive to 
10µM Gd3+ 
a (i) and (ii): Current-time plots of whole-cell current induced by 100µM OAG in HLMCs.OAG was 
focally applied where indicated by the horizontal bars. Current was sampled at -100mV (grey trace) 
and +100mV (black trace). (i): example trace showing OAG-induced current that remained after 
washout, as observed in 25% of cells (3/9). (ii) shows example traces of a current that reached a 
peak in the presence of OAG, which then declined, as observed in 62.5% of cells (5/9). The 
remaining 12.5% of cells (1/9) did not respond to OAG application.  
b (i): Current-voltage relationships taken from time points 1-6 in part a (i) from cell displaying a 
sustained current in response to OAG application. (ii): Current-voltage relationships taken from time 
points 1-6 in part a (ii) from cell showing a transient response. (iii): Bar chart comparing the 
rectification index (peak current at +100mV/peak current at -100mV) of OAG-induced current in cells 
displaying sustained versus transient responses. *: means are statistically significant, p<0.05, 
unpaired Student‘s T-test. 
c (i): Current-time plot of whole-cell currents from an example cell when 1/1000 DMSO (vehicle for 
OAG) was focally applied. Similar results were obtained in 2 other cells. (ii): Current-time plot of OAG-
induced current in the presence of 10µM Gd3+, which was focally applied as indicated by red 
horizontal bar. Traces are shown for a single representative cell; similar currents were observed in 5 
other cells. 
d (i): Current-voltage relationship of OAG-induced current in the presence of 10µM Gd3+ showing 
mean current ±SEM; n=6 cells, N=2 donors. Currents had a mean reversal potential of -6.26mV 
±1.84. (ii): Bar graph comparing size of currents induced by OAG (white), DMSO (blue) and OAG + 
Gd3+ (red). Current before agonist application was subtracted from the maximum current in the 
presence of agonist, to give ―ΔpA/pF‖. *: Results are statistically significant, p<0.05, one-way ANOVA 
with Tukey post-test. 
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to be carried out on one of the donors (410) shown in figure 6.3. Data obtained were culture-
matched; control experiments using donor 410 were carried out on the same days as 
experiments in the presence of Ro-31-8425.  
 
Data are shown in figure 6.4; the percentage of cells displaying a sustained current induced by 
OAG was increased from 33% (3/9) to 83% (5/6) when Ro-31-8425 was present. For 
comparison, the percentage of HEK-TRPC6 with a sustained current increased from 50% to 78% 
in the presence of Ro-31-8425. As shown in figure 6.4b (i), the peak current was reduced by 
67pA/pF (from 128.4 to 60.93) at +100mV, and by 38.3pA/pF (from 55.0 to 16.7) at -100mV in 
the presence of Ro-31-8425. The peak currents were variable, indicated by the large error bars 
in figure 6.4b (i), and this reduction in peak current was not statistically significant. These data 
suggest that PKC is unlikely to have a role in determining the amplitude of the initial current 
evoked by OAG. The rectification index of the OAG-induced current was measured at 3.93 ± 0.31 
(n=6) in the presence of Ro-31-8425, showing that the outward current amplitude was 
approximately 4 fold larger than the inward current. When comparing this value to the calculated 
rectification index values for currents obtained in the absence of Ro-31-8425 (6.17 ± 1.76 (n=3) 
and 2.69 ± 0.39 (n=5) for sustained and transient currents, respectively), it is apparent that it is 
more similar to that obtained for transient currents when Ro-31-8425 was not present. As few 
cells (3/9) displayed a sustained current in response to OAG application when Ro-31-8425 was 
absent, more n numbers would be required to draw conclusions about the direction of cation 
flow through TRPC3/6/7 channels under the different conditions from the rectification index 
values. Given the low availability of human lung tissue and limited time-frame in which HLMCs 
can be used for patch-clamp experiments, more n numbers were not able to be obtained in this 
study. 
 
The percentage of the maximum current remaining at two minutes after the end of OAG 
application was significantly greater when Ro-31-8425 was present (figure 6.4b (ii)). The 
percentage of current remaining increased by 66.2% (from 36.8 to 103.0) at + 100mV, and by 
54.3% (from 24.3 to 78.6) at -100mV. These data suggest that PKC does negatively regulate 
TRPC3/6/7 function in HLMCs following activation of the channels with OAG. 
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Figure 6.4. OAG-induced currents in HLMCs in the presence of Ro-31-8425. 
Experiments like those described in figure 6.3 were repeated in the presence of 3µM Ro-31-8425. a (i): 
Diary plot of an example whole-cell recording; solutions containing drugs shown were focally applied as 
indicated by the horizontal bars. Grey trace shows current sampled at -100mV; black trace shows current 
at +100mV. (ii): Bar graph showing percentage of cells with a ―sustained‖ or ―transient‖ response in the 
presence vs absence of Ro-31-8425. A response was classed as ―sustained‖ when more than 50% of 
current remained at 2 minutes after the end of drug application. In control cells, 33% (3/9) of cells had a 
sustained response; in the presence of Ro-31-8425, 83% of cells (5/6) had a sustained response. 
b: (i) Comparison of peak current at +100mV and -100mV in the presence (red; 60.9pA/pF ±29.4 at 
+100mV, 16.7pA/pF ±8.2 at -100mV) and absence (white; 128.4pA/pF ±40.8 at +100mV, 55.0pA/pF ± 
24.8 at -100mV) of Ro-31-8425. (ii): Current remaining at 2 minutes after drug application was calculated 
as a percentage of peak current in the presence of OAG. At +100mV, 36.8% ± 14.2 remained in the 
absence of Ro-31-8425; 103% ± 21.5 remained. At -100mV, 24.3% ± 10.0 remained in the absence of 
Ro-31-8425; 78.6% ± 12.1 remained. Means were significantly different; p<0.05 (*) or p<0.01 (**), 
unpaired Student‘s T-test of log-transformed data. 
n numbers are as follows: n=6 cells, N=1 donor in the presence of Ro-31-8425, n=8 cells, N=3 donors in 
the absence of Ro-31-8425. 
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The results shown so far suggest that HLMCs express functional OAG-activated TRPC3/6/7 
channels; it was then investigated whether LAD 2 cells are an appropriate model to study this 
subgroup of TRPC channels using fura-2 Ca2+ imaging and electrophysiology. As shown in figure 
6.5a, very weak Ca2+ entry was observed in 25% (15/59) of cells tested, where ―responding 
cells‖ were classed as those where the fluorescence in the presence of OAG rose by more than 
10 standard deviations above the mean baseline fluorescence. The mean amplitude of OAG-
induced Ca2+ entry in responding LAD 2 cells was 0.37 ± 0.09 (n=15, N=3); this was significantly 
lower than that observed in HLMCs (0.68 ± 0.03; n=95, N=7. p<0.0001, unpaired Student‘s T-
test). Whole-cell patch clamp recordings revealed the activation of currents in response to focal 
application of OAG in 20% of LAD 2 cells (figure 6.5b); the currents were outwardly-rectifying 
with a reversal potential of -0.09 ± 0.09mV, typical properties of TRPC3/6/7 channel activity. The 
rectification index of OAG-induced currents in responding LAD 2 cells was calculated to be 4.4 ± 
2.3 (n=3). OAG-induced currents were very small; the mean change in current in response to 
OAG application measured at +100mV in responding LAD 2 cells was 1.8pA/pF ± 0.4 (n=3), 
compared with 128.4pA/pF ± 40.8 (n=8) in HLMCs and 32.57pA/pF ± 8.00 (n=7) in HEK-TRPC6 
cells. Taken together, these results suggest that LAD 2 cells are a poor model to study second 
messenger-regulated TRPC channel expression in human mast cells; the reasons for this will be 
discussed in section 6.5. 
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Figure 6.5. OAG-induced Ca2+ entry and currents in LAD 2 cells 
a: Ca2+ fluxes in fura 2-loaded LAD 2 cells stimulated with100µM OAG as indicated by the horizontal bar.  (i) 
shows Ca2+ fluxes, represented by fluorescence at 340/380nm, in individual responding and non-responding 
example cells.  25% of cells (15/59) responded to OAG application; ―responders‖ were classified as cells 
where the fluorescence in the presence of OAG rose by more than 10 standard deviations above the mean 
baseline fluorescence. (ii): Mean ± SEM F340/380 from n=59 cells, N=3 independent experiments. 
b: whole-cell currents induced by 100µM OAG in LAD 2 cells, as observed in 20% (3/15) cells. (i): current-
time plot of  a representative responding cell. Cells were superfused with standard external solution and 
OAG was focally applied where indicated.  Current was sampled at -100mV (grey trace) and +100mV (black 
trace). (ii) shows the current-voltage relationship of the OAG-induced current in a representative responding 
cell; similar I/V curves were obtained in the 2 other responding cells. Currents had a mean reversal potential 
of -0.09 ± 0.09mV (n=3).  
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6.2 Receptor activation of TRPC3/6/7 channels in HLMCs 
The results obtained so far in this chapter show that OAG can activate Ca2+-permeable channels 
in HLMCs with the expected biophysical and pharmacological properties of the TRPC3/6/7 
channel subfamily. Receptor-mediated activation of the channels was then investigated, which is 
representative of the situation in vivo. DAG is produced downstream of PLCβ generation, which 
occurs following the stimulation of cell surface receptors, such as G protein-coupled P2Y1 
receptors (Gilfillan & Tkaczyk, 2006). ADP, an endogenous ligand for P2Y receptors, is found at 
sites of inflammation such as the asthmatic lung, and was shown in chapter 3 to stimulate Ca2+ 
influx in HLMCs. It may therefore represent an important mechanism for inflammatory activation 
of HLMCs; studies in this chapter aimed to elucidate whether channels from the TRPC3/6/7 
subfamily are activated downstream of P2Y receptor activation by ADP. 
 
It was firstly investigated which P2Y receptor subtype was being switched on by ADP in HLMCs; 
whilst P2Y1, P2Y12 and P2Y13 are all activated by ADP (Bulanova & Bulfone-Paus, 2010), only 
P2Y1 mRNA has been detected in HLMCs (Schulman et al., 1999). N
6-methyl-2‘-deoxyadenosine-
3‘,5‘-bisphosphate (MRS2179) is a potent and selective P2Y1 receptor antagonist (Camaioni et al., 
1998; Kaiser & Buxton, 2002); the IC50 for P2Y1 receptor inhibition in turkey erythrocytes is 
0.3µM, and maximal inhibition achieved with 10µM (Camaioni et al., 1998). ADP-induced Ca2+ 
entry was assessed in the presence of 10µM MRS2179 in order to investigate the involvement of 
P2Y1 receptors in ADP-induced Ca
2+ entry in HLMCs. As shown in figure 6.6b, ADP-induced Ca2+ 
entry was significantly reduced in the presence of MRS2179; ΔF340/380 was reduced by 0.18 (from 
0.26 to 0.08). As similar results were obtained in two separate donors, the mean trace in figure 
6.6b (ii) is representative of data from both donors. This sensitivity to MRS2179 is indicative of 
Gq-coupled P2Y1 receptor involvement, as 10-100µM MRS2179 has previously been shown to 
have no effect on the other P2Y receptor subtypes (von Kugelgen, 2006).  
 
To assess the contribution of the TRPC3/6/7 subfamily of channels to ADP-induced, P2Y1-
mediated Ca2+ entry in HLMCs, Ca2+ entry was assessed in the presence of 10µM Gd3+ (figure 
6.6c) and 10µM SKF-96365 (figure 6.6d). Both antagonists significantly reduced ADP-induced 
Ca2+ entry; ΔF340/380 was reduced by 0.19 (from 0.26 to 0.07) in the presence of 10µM Gd
3+, and 
to by 0.19 (from 0.26 to 0.07) in the presence of 10µM SKF-96365. The change in fluorescence 
elicited by ADP in the presence of all three antagonists is summarised in figure 6.7. 
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Figure 6.6. ADP-induced Ca2+ entry is sensitive to MRS 2179, Gd3+ and SKF-96365. 
Fura 2-loaded HLMCs were perfused in standard external solution and 100µM ADP was bath-applied where 
indicated by the horizontal bars. (a) shows Ca2+ entry, indicated by F340/380, in control cells (no inhibitor); in 
all sections (i) shows traces from example cells and (ii) shows the mean ± SEM.  (a) (ii): n=53 cells, N=8 
experiments, representative of 4 donors. (b): experiment as in (a), but 10µM MRS 2179 was present 
throughout the experiment; n=30, N=4, 2 donors. In (c) 10µM Gd3+ was present throughout the experiment 
(n=26, N=3, 2 donors) and in (d) 10µM SKF-96365 was present (n=25, N=3, 1 donor).  
N.B. Control data is the same as that shown in figure 3.3. 
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As shown above, MRS2179 and the TRPC channel inhibitors Gd3+ and SKF-96365 significantly 
inhibited ADP-induced Ca2+ entry in HLMCs, suggesting the involvement of P2Y1 receptors and 
TRPC channels, respectively. Whole-cell patch clamp recordings were then carried out to 
investigate the biophysical properties of ADP-induced currents and to further evaluate the 
contribution of the DAG-activated TRPC channels. As shown in figure 6.8a, focal application of 
100µM ADP to HLMCs gave rise to outwardly-rectifying currents in 100% of cells tested; 78% of 
cells (7/9) exhibited a sustained current, and 22% of cells (2/9) displayed a transient current. 
One cell from each donor tested displayed a transient current in response to ADP. The amplitude 
of the ADP-induced current was 51.21pA/pF ± 36.0 (n=9, N=2 donors) at +100mV and 
10.5pA/pF ± 7.9 (n=9, N=2) at -100mV. The I/V relationship of the ADP-induced current (figure 
6.8a (iii)) was similar to that induced by OAG in HLMCs (figure 6.3a (iii)), showing inward and 
outward current with outward rectification, and a reversal potential of -4.38mV± 2.0 (n=9, N=2). 
The rectification index of ADP-induced currents in HLMCs was calculated at 4.83 ± 1.61 (n=9, 
N=2). As with OAG-induced currents, the presence of 10µM Gd3+ throughout the experiment 
inhibited the activation of currents by ADP (figure 6.8b); current amplitudes at +100mV were 
reduced by 49.53pA/pF (from 51.21 to 1.68), and those at -100mV were reduced by 9.52pA/pF 
(from 10.50 to 0.98). This inhibition did not reach statistical significance due to the large 
variation in peak current when 10µM Gd3+ was not present. 
  
Figure 6.7. Inhibition of ADP-induced Ca2+ entry by MRS 2179, Gd3+ and SKF-
96365. 
Bar graph comparing the size of ADP-induced Ca2+ entry (ΔF340/380) in control experiments (―c‖, 
white) and in the presence of 10µM MRS2179 (blue), 10µM Gd3+ and 10µM SKF-96365. ***: 
means were significantly different compared to control, p<0.0001, one-way ANOVA with Tukey 
post-test.  
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Figure 6.8. ADP induces an outwardly-rectifying current in HLMCs that is sensitive to 
10µM Gd3+ 
a: Whole-cell current induced by 100µM ADP in HLMCs. (i) and (ii): Cells were superfused with standard 
external solution; ADP was focally applied where indicated by the horizontal bars. (i): example traces 
showing ADP-induced current at -100mV (grey) and +100mV (black)  that remained after washout, as 
observed in 62.5% of cells (5/8). (ii) shows an example of a transient current activated by ADP, as seen in 
37.5% of cells (3/8). The current-voltage relationship of the ADP-induced current is shown in (iii); mean ± 
SEM, n=8 cells, representative of 2 donors. The mean reversal potential of the ADP-induced current was  -
4.38mV± 2. 
b (i): ADP was focally applied in the presence of 10µM Gd3+ as indicated by the horizontal bars. Current at 
+100mV is shown in black; -100mV is in grey. Traces are for an example cell; similar currents were 
observed in 5 other cells. (ii): I/V relationship in the presence of 100µM ADP and 10µM Gd3+; current 
reversed at -5.75mV ± 2.23 (n=6 cells, representative of 2 donors). (iii): Bar graph comparing ADP-
induced current at +100mV and -100mV in the presence and absence of 10µM Gd3+. Current before drug 
application was subtracted from the maximum current in the presence of ADP, to give ―Δ pA/pF‖. White 
bars indicate ADP-induced current in the absence of Gd3+; red bars show current in the presence of Gd3+. 
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In conclusion, ADP activates Ca2+-permeable channels in HLMCs via P2Y1 receptor stimulation 
that are sensitive to the TRPC channel blockers Gd3+ and SKF-96365. ADP-induced currents in 
HLMCs have the expected biophysical properties of TRPC channels, displaying outward 
rectification, a reversal potential close to 0mV and sensitivity to 10µM Gd3+. Table 6.1 
summarises the properties of OAG- and ADP-evoked currents in HEK-TRPC6 cells, LAD 2 cells 
and HLMCs. As shown, ADP-induced currents in HLMCs have similar properties to those activated 
by OAG and to ADP-evoked currents in HEK-TRPC6 cells, indicating that the same channels could 
be involved. 
 
 
Table 6.1. Summary of OAG- and ADP-induced currents in HEK-TRPC6 cells, LAD 2 
cells and HLMCs. 
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6.3 Flufenamic acid-induced activation of human mast cells 
Flufenamic acid (FFA) is a nonselective cation channel blocker (Popp et al., 1993), but it has 
been shown to potentiate mouse TRPC6 channel activity at 100-500µM in HEK-TRPC6 cells 
(Inoue et al., 2001), A7r5 smooth muscle cells (Jung et al., 2002), primary megakaryocytes 
(Carter et al., 2006) and cortical neurons (Tu et al., 2009b), whilst inhibiting the other TRPC 
channels (Inoue et al., 2001). It has recently been shown in human podocytes that 200µM FFA 
stimulates 2-APB and SKF-96365- sensitive Ca2+ entry, which is abolished by dominant negative 
TRPC6 expression; the authors concluded that FFA is a tool to selectively activate TRPC6 
channels and study them in native cells (Foster et al., 2009). FFA activation of LAD 2 cells and 
HLMCs was therefore investigated in this study.  
 
As shown in figure 6.9a, FFA application gave rise to concentration-dependent Ca2+ entry in LAD 
2 cells, with an estimated EC50 of 99.5µM. Whole-cell patch clamp recordings showed that focal 
application of 100µM FFA to voltage-clamped LAD 2 cells switched on an outwardly-rectifying 
current in 100% of cells tested (figure 6.9c), with a mean reversal potential of 0.25mV±0.09 
(n=6). The mean FFA-induced current amplitude was 17.46pA/pF ± 4.71 (n=6) at +100mV and 
9.35pA/pF ± 1.60 (n=6) at -100mV. The rectification index of the FFA-induced current was 
measured at 1.79 ± 0.21 (n=6). Ethanol at a 1/666.7 dilution (vehicle for FFA at the minimal 
dilution) did not give rise to Ca2+ entry or currents in LAD 2 cells; see figure 6.9 parts b (iii) and c 
(ii). Whilst these data are in agreement with results obtained previously (Carter et al., 2006; 
Foster et al., 2009; Tu et al., 2009b) and suggest the activation of TRPC6 channels, 100µM FFA 
also elicited a large increase in cytosolic Ca2+ in 100% of cells tested when the experiment was 
carried out in the absence of extracellular Ca2+ (figure 6.9b). The change in fura-2 fluorescence 
evoked by 100µM FFA was measured at 0.17 ± 0.01 (n=47, N=3) in the presence of 
extracellular Ca2+, and 0.27 ± 0.02 (n=41, N=3) in the absence of extracellular Ca2+; this is 
illustrated in figure 6.9b (iii). This Ca2+ influx elicited by FFA in the absence of extracellular Ca2+ 
suggests that FFA causes Ca2+ release from intracellular stores, and contests the theory that it is 
a selective activator of TRPC6; this will be discussed in section 6.5. 
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Figure 6.9. Flufenamic acid-induced Ca2+ entry and currents in LAD 2 cells 
a: Fura 2-loaded LAD 2 cells were perfused in standard Ca2+-containing extracellular solution and 100µM 
flufenamic acid (FFA) was bath-applied as indicated by the horizontal bar. (i) shows individual 
representative cells; (ii) shows mean ± SEM (n=47 cells, N=3 experiments). (iii): Concentration-response 
curve showing size of FFA-induced Ca2+ entry (ΔF340/380) at different concentrations. n numbers are as 
follows:  29 for 3µM, 62 for 30µM, 47 for 100µM, 31 for 200µM, 30 for 300µM. N≥2 experiments for each 
concentration. 
b (i) and (ii): 100µM FFA was applied to cells in the absence of extracellular Ca2+ (n=41, N=3). (iii): Bar 
graph comparing Ca2+ entry induced by 100µM FFA in the presence and absence of extracellular Ca2+, and 
that induced by ethanol at 1/666.7 dilution (solvent control for maximum concentration of FFA; n=26, 
N=2). ***: means are significantly different, p<0.0001, one-way ANOVA. 
c: FFA-induced currents in LAD 2 cells. (i): Diary plot from an example cell showing whole-cell currents 
measured at +100mV (black trace) and -100mV (grey trace); FFA was focally applied as indicated by the 
horizontal bar. Similar results were obtained in 5 other cells. (ii): Example traces where ethanol at 1/666.7 
dilution was focally applied as indicated. Similar results were obtained in 2 other cells. (iii): Current-
voltage relationship of FFA-induced currents, calculated by subtracting current before FFA application from 
peak current in the presence of FFA. Trace shows mean ± SEM, n=6 cells. Currents had a mean reversal 
potential of 0.25mV±0.09.  
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FFA-induced activation of HLMCs was then assessed; as shown in figure 6.10, 100µM FFA gave 
rise to Ca2+ entry in the presence and absence of extracellular Ca2+ in 100% of cells tested. 
When comparing the Ca2+ traces in LAD 2 cells in the presence and absence of extracellular Ca2+ 
(figure 6.9a and b), the time-course is very similar. In HLMCs, however, the time-course was 
altered when extracellular Ca2+ was removed. Figure 6.10c compares the peak change in 
fluorescence in HLMCs induced by FFA in the presence (0.26 ± 0.03; n=20, N=3, 1 donor) and 
absence (0.21 ± 0.01; n=13, N=3, 1 donor) of extracellular Ca2+; there was no significant 
difference. When the change in fluorescence 4 minutes after FFA application was compared, 
however, it was significantly greater in the presence of extracellular Ca2+ (0.15 ± 0.03; n=20, 
N=3) than when Ca2+ was not present (0.05 ± 0.01; n=13, N=3). Therefore, FFA-induced Ca2+ 
was more sustained in the HLMCs when extracellular Ca2+ was present, suggesting that a more 
transient Ca2+ release seen in the absence of extracellular Ca2+ could be mediated by release 
from stores, with Ca2+ entry from outside the cell following. This difference was not seen in LAD 
2 cells, implying that similar Ca2+ entry from outside the cell does not occur in LAD 2 cells. 
 
To summarise, whilst FFA is reported to be a selective activator of TRPC6 and has been shown in 
this study to activate currents with the expected biophysical properties of TRPC6 channels, Ca2+ 
imaging data show that FFA stimulates cytosolic Ca2+ rises in the absence of extracellular Ca2+. 
Therefore FFA has other effects on human mast cells in addition to TRPC6 activation, so cannot 
be considered a selective activator. 
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Figure 6.10. Flufenamic acid-induced Ca2+ entry and currents in HLMCs 
a: Fura 2-loaded HLMCs were perfused in standard Ca2+-containing extracellular solution and 
100µM flufenamic acid (FFA) was bath-applied as indicated by the horizontal bar. (i) shows 
individual representative cells; (ii) shows mean ± SEM (n=20 cells, N=3 experiments, 
representative of 1 donor). 
b (i) and (ii): Experiments as in (a), but in the absence of extracellular Ca2+ (n=13, N=3, 1 
donor).  
c (i): Bar graph comparing peak change in fluorescence (ΔF340/380) induced by 100µM FFA in 
the presence (white) and absence  (blue) of extracellular Ca2+. Means were not significantly 
different. (ii) compares the change in fluorescence at 4 minutes after FFA application in the 
presence and absence of extracellular Ca2+; means were significantly different, p<0.05, 
unpaired Student‘s T-test. 
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6.4 Functional roles of the DAG-sensitive TRPC channels and 
involvement in the IgE response 
As discussed in chapter 5.6, it is likely that store-operated TRPC1 channels are involved in FcεRI-
dependent Ca2+ signalling and degranulation in HLMCs. As DAG is produced by PLCγ downstream 
of FcεRI cross-linking, it is possible that TRPC6 or perhaps TRPC7 channels could also contribute 
to FcεRI-evoked Ca2+ signalling and mediator release. Synta 66-insensitive Ca2+ entry induced by 
anti-IgE was further inhibited by 10µM Gd3+ and SKF-96365 (figure 5.15), and currents activated 
by anti-IgE (figure 5.14) had similar properties to OAG-activated currents in HLMCs (figure 6.3). 
Both currents had a similar rectification index, measured at 4.46 ± 0.08 (n=3) for IgE-induced 
currents and 3.99 ± 0.89 (n=9) for OAG-activated currents. The mean reversal potential of 
TRPC-like currents activated by anti-IgE (0.58 ± 0.16, n=3) was not significantly different 
(unpaired Student‘s T-test) to that for OAG-induced currents (0.75 ± 0.74, n=9). These similar 
properties suggest that the same channel (i.e. TRPC6) could be activated by FcεRI cross-linking 
and OAG. To address this possibility, Ca2+ imaging experiments were carried out to assess 
whether applying OAG to cells following FcεRI cross-linking stimulated further Ca2+ entry. If 
TRPC6 was already activated, OAG should not have caused further rises in Ca2+. Data are shown 
in figure 6.11. 
 
As shown in figure 6.11a, no further increases in F340/380 occurred when OAG was applied to cells 
already stimulated with anti-IgE; this suggests that TRPC6 channels are activated downstream of 
FcεRI cross-linking so could not be switched on by subsequent application of OAG. However, 
when the experiment was repeated in the presence of 3µM Ro-31-8425 to inhibit PKC, OAG 
caused further increases in F340/380 in 67% of cells (8/12). The amplitude of OAG-activated Ca
2+ 
entry in responding cells following FcεRI cross-linking in the presence of Ro-31-8425 was not 
significantly different to that in the absence of FcεRI cross-linking (unpaired Student‘s T-test). 
These data suggest that TRPC6 channels are not activated by FcεRI cross-linking, but that PKC 
activation by DAG produced downstream of FcεRI prevented the activation of TRPC6 channels by 
OAG. It is therefore likely that TRPC6 channels are not the main contributors to the TRPC-like 
currents seen in response to FcεRI cross-linking.  
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Figure 6.11. OAG responses in HLMCs following IgE receptor crosslinking. 
HLMCs were perfused in standard external solution and agonists were applied as indicated by the horizontal 
bars. 
a:  100µM OAG was applied following anti-IgE stimulation of cells; no further calcium entry occurred when 
OAG was applied to cells. Part (i) shows individual representative cell traces; part (ii) shows mean ± SEM 
(n=29 cells, N=4, representative of 2 donors). 
b: 100µM OAG was applied following anti-IgE stimulation in the presence of the 3µM Ro-31-8425. In 67% of 
cells (8/12), OAG caused a further calcium rise when applied after IgE receptor stimulation. Individual 
representative cells where this occurred are shown in part (i). In 33% of cells (4/12), OAG stimulation did not 
lead to further calcium entry in the presence of Ro-31-8425; representative cell traces are shown in part (ii). 
c: Bar graph comparing size of OAG response in responding cells following anti-IgE stimulation in the 
presence of Ro-31-8425 (―after IgE‖, blue, n=8) with a time-matched control where OAG was applied in the 
presence of DMSO (vehicle for Ro-31-8425, n=7) and without pre-application of anti-IgE (―no IgE‖, white). 
There was no significant difference in ΔF340/380 in response to OAG between control cells and those that had 
previously been stimulated with anti-IgE. 
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It was then investigated whether the activation of TRPC6-containing channels using OAG and 
ADP stimulates histamine and β-hexosaminidase release in impure suspensions of HLMCs. 
Results are shown in figure 6.12; 100µM OAG and 100µM ADP did not induce histamine release, 
giving rise to 0.03% ± 0.52 (N=8, 4 donors) and 0.12% ± 0.82 (N=8, 4 donors) release, 
respectively. For comparison, anti-IgE application gave rise to 38.13% ± 2.56 (N=8, 4 donors) 
histamine release; this was significantly higher than that induced by the TRPC6 channel agonists. 
Similar results were obtained for β-hexosaminidase release; OAG application gave rise to 2.44% 
± 1.91 (N=6, 3 donors) release and ADP -1.73% ± 0.89 (N=6, 3 donors), compared with 
24.90% ± 4.54 (N=6, 3 donors) release induced by anti-IgE. Therefore, application of agonists 
shown in this chapter to activate TRPC6-like channels does not stimulate release of the granule-
associated mediators histamine and β-hexosaminidase. It is possible that DAG-regulated TRPC6 
channels have other important functional roles in HLMCs, such as the regulation of cytokine 
transcription or prostaglandin and leukotriene release. Although beyond the scope of this study, 
a thorough assessment of the role of TRPC channels in these processes is required to determine 
their function in HLMCs. 
 
In addition to mediator and cytokine release, the migration of mast cells is also an important 
determinant of the asthmatic phenotype. The micro-localisation of mast cells in airway smooth 
muscle bundles contributes to the symptoms of asthma; it has been shown that smooth muscle-
derived chemokines stimulate HLMC migration and accumulation with airway smooth muscle cells 
through CXCR3 activation (Brightling et al., 2005). Transforming growth factor-β (TGF-β) 
isoforms have also been shown to mediate migration of HMC-1 and human cord blood-derived 
mast cells. The ion channels activated downstream of chemokine receptors involved in mast cell 
migration, however, have not been investigated. It has been shown in neutrophils that TRPC6 
channels are required for migration stimulated by OAG or macrophage inflammatory protein-2 
(MIP-2) (Damann et al., 2009); TRPC channels have also been suggested to have a role in 
monocyte migration induced by lysophosphatidylcholine (LPC). Pilot experiments were carried out 
in LAD 2 cells to assess whether DAG-activated TRPC channels are involved in mast cell motility; 
very little effect was observed, and investigations were not taken further as sufficient numbers of 
HLMCs were not available. 
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Figure 6.12. Activators of TRPC3/6/7 channels do not stimulate degranulation in 
HLMCs 
a: Freshly isolated impure HLMCs were stimulated with the agonists shown and histamine release was 
measured as % total release, determined by lysis with 0.5% perchloric acid. Anti-IgE-induced 
histamine release in the donors tested for responsiveness to other agonists is shown for comparison. 
N=8, 4 donors for IgE (3µg/ml); N=8, 4 donors for OAG (100µM) and ADP (100µM). Histamine 
release experiments in 1 donor (N=2) were carried out by Jasmine Farrington. 
b: Freshly isolated impure HLMCs were stimulated with the agonists shown and β-hexosaminidase 
release was measured as % total release, determined by lysis with 0.5% Triton X-100. Anti-IgE-
induced β-hexosaminidase release in the donors tested for responsiveness to other agonists is shown 
for comparison. N=6, 4 donors for IgE (3µg/ml); N=6, 3 donors for OAG (100µM) and ADP (100µM). 
***: release was significantly lower than that induced by anti-IgE, one-way ANOVA with Tukey post 
test.   
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6.5 Discussion 
6.5.1 OAG activation of TRPC3/6/7 channels 
TRPC3/6/7 channels are activated directly by DAG in a PKC-independent, store depletion-
independent manner (Hofmann et al., 1999). OAG, the membrane-permeable DAG analogue, is 
used extensively to study TRPC channels from this subfamily in heterologous expression systems 
(Venkatachalam et al., 2003; Estacion et al., 2004; Shi et al., 2004; Estacion et al., 2006) and in 
native cells (El Boustany et al., 2008; Guilbert et al., 2008; Tu et al., 2009b). In this study, OAG 
stimulated Ca2+ entry in 97% of HLMCs tested (figure 6.1a), suggesting that functional 
TRPC3/6/7 channels could be present. RT-PCR (chapter 3.4) was carried out on two of the four 
donors exhibiting Ca2+ entry in response to OAG; TRPC6 was present in both donors, TRPC7 in 
one donor, and TRPC3 was not found to be present in HLMCs in this study. RT-PCR in one 
further donor not tested for OAG responsiveness was found to express mRNA for TRPC6 only 
from this subgroup. It is therefore likely that TRPC6 could mediate the Ca2+ entry shown in figure 
6.1a, with a possible contribution from TRPC7 in one donor. Although the contribution of TRPC3 
cannot be definitively excluded because mRNA expression was not assessed in all donors, 
transcripts were not detected in 3/3 donors tested, and have not been detected in previous 
studies (Bradding et al., 2003). TRPC3 is predominantly expressed in the brain and embryonic 
tissues (Eder et al., 2007), and TRPC3-deficient mice exhibit defects in walking behaviour, 
indicating a key role of the channel in motor co-ordination (Hartmann et al., 2008). These mice 
have not been reported to show any immune phenotypes. Based on these roles of TRPC3 and 
lack of expression in HLMCs from 2/3 donors, it is unlikely to be required for HLMC function. The 
remainder of this discussion will therefore focus mainly on TRPC6 channels. 
 
The results obtained in figure 6.1 are in accordance with those obtained in HEK-TRPC6 cells in 
this study (chapter 4.1) and previous reports showing that OAG stimulates Ca2+ influx in TRPC6-
expressing cells (Boulay et al., 1997; Hofmann et al., 1999). A study by Venkatachalam et al. 
(2003) showed that OAG inhibits channels from the TRPC1/4/5 subgroup via the activation of 
PKC, in contrast to the direct stimulatory action on channels from the TRPC3/6/7 subgroup, 
which is known to be PKC- independent (Hofmann et al., 1999; Inoue et al., 2001; 
Venkatachalam et al., 2003; Estacion et al., 2004). The observed OAG-induced Ca2+ entry in 
HLMCs therefore suggests the direct activation of TRPC3/6/7 channels, without contribution from 
the TRPC1/4/5 subfamily. The lack of Ca2+ entry in the absence of extracellular Ca2+ (figure 6.1b) 
indicates that an increase in fura-2 fluorescence did not occur as a result of Ca2+ release from 
internal stores, but from the outside of the cell as expected.  
 
Whilst studies such as that by Boulay et al. (1997) illustrate that OAG stimulation is associated 
with an increase in cytosolic Ca2+, it has been reported that increasing extracellular Ca2+ 
concentration in Na+-containing solutions during patch clamp recordings of TRPC6 and TRPC7 
channels causes a reduction in channel activity (Inoue et al., 2001; Shi et al., 2004), suggesting 
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that Ca2+ blocks TRPC6 and TRPC7 channels. Estacion et al. (2006) showed, using simultaneous 
recordings of current and fura-2 fluorescence in HEK-TRPC6 cells, that at a membrane potential 
of 0mV, the Ca2+ conductance of TRPC6 channels is low relevant to Na+; very little OAG-induced 
Ca2+ entry was observed. At a holding potential of -50mV, however, Ca2+ permeability was 
increased and OAG was shown to increase intracellular Ca2+ to 100nM. The authors propose that 
the Ca2+ permeability of TRPC6 is dependent upon the holding potential of the cell; in cells with  
a less negative membrane potential, TRPC6 channel activation primarily causes Na+ influx and 
depolarisation, which attenuates Ca2+ entry. In cells with a negative membrane potential, 
however, the depolarising effect of Na+ influx through TRPC6 is reduced, thus enhancing the 
driving force for Ca2+ entry (Estacion et al., 2006).  
 
When comparing OAG-induced Ca2+ entry in HLMCs (figure 6.1) and HEK-TRPC6 cells (figure 
4.1), it is apparent that the time-course differs between the two cell types. Ca2+ entry in HLMCs 
was more sustained, whereas fura-2 fluorescence peaked and returned to baseline in the 
presence of OAG in HEK-TRPC6 cells. This could be due to differential ion channel expression in 
the two cell types affecting the membrane potential following OAG-mediated stimulation. HEK-
293 cells express a number of voltage-activated ion channels (Varghese et al., 2006); it is 
possible that initial Ca2+ and Na+ influx in HEK-TRPC6 cells caused depolarisation, thus inhibiting 
Ca2+ entry and causing a drop in fura-2 fluorescence. Another possibility is that PKC-mediated 
regulation occurs to a different degree in the two cell types. As discussed in chapter 4, a number 
of studies have demonstrated that PKC, which is activated by OAG (Bell et al., 1986), negatively 
regulates TRPC6 channels. Results obtained in HEK-TRPC6 cells (figure 4.4) and HLMCs (figure 
6.4) in this study also suggest that PKC negatively regulates TRPC6 channels; different levels of 
PKC in the two cell types may result in channel deactivation to a greater degree in HEK-TRPC6 
cells, giving rise to the more transient Ca2+ response. Patch clamp data in this study suggests 
that PKC-mediated inactivation of TRPC6 channels occurs to a similar degree in the two cell 
types, but dialysis of PKC in the whole-cell configuration could have resulted in apparently similar 
regulation when the enzyme was in fact present at higher levels in HEK-TRPC6 cells.  
 
As discussed in chapter 1.3.2, lanthanides can be used as diagnostic tools for the involvement of 
TRPC3/6/7 channels in Ca2+ signalling. Gd3+ inhibited OAG-induced Ca2+ entry with an average 
estimated IC50 of 6.5µM (N=2 donors). This is in the range of the estimated IC50 value obtained 
for the inhibition of heterologously expressed TRPC6 channels, 2.3µM (Inoue et al., 2001). This 
was donor-dependent; in donor 410 the estimated IC50 was 2.77µM, with complete inhibition 
occurring at 10µM. In donor 411, however, Gd3+ inhibited OAG-induced Ca2+ entry with an 
estimated IC50 of 18.4µM. This could be due to donor-dependent expression of the DAG-
activated TRPC channels; donor 410 expressed mRNA for TRPC6 and TRPC7, whereas donor 411 
expressed TRPC6 mRNA only. Differential assembly of the TRPC channel pore into homomeric or 
heteromeric channels depending on their expression in different donors could result in distinct 
sensitivity to blockade. If the inhibition of TRPC channels by Gd3+ is mediated from the cytosolic 
 Chapter 6: TRPC3/6/7 channels in human mast cells 
204 
 
side of the membrane in HLMCs, as has been described for the regulation of TRPC3 in CHO cells 
(Halaszovich et al., 2000)), donor-dependent variability in the rate at which intracellular and 
extracellular Gd3+ concentrations reach equilibrium could account for the differences seen in the 
inhibition of OAG-induced Ca2+ entry. Cell membranes were previously thought to be 
impermeable for lanthanides (Evans et al., 1990), but it has been shown using fluorescent 
imaging techniques that lanthanides enter red blood cells (Cheng et al., 1999) and ventricular 
cells (Peeters et al., 1989), as well as CHO cells (Halaszovich et al., 2000). Quicker uptake or 
slower extrusion of Gd3+ ions in HLMCs from donor 410 could therefore be responsible for the 
lower IC50 value observed for Gd
3+ inhibition of OAG-induced Ca2+ entry. As only two donors 
were able to be tested in this study, significant conclusions about the donor-dependency of Gd3+ 
inhibition of TRPC3/6/7 channels cannot be drawn; investigating this in HLMCs from a larger pool 
of donors could reveal donor-dependent differences, and represents an interesting avenue of 
investigation for future projects. 
 
The non-selective cation channel blocker SKF-96365 has also been used extensively to 
characterise TRPC channels (Eder et al., 2007), inhibiting mTRPC6 channels expressed in HEK 
cells with an IC50 of 4.2µM, and receptor- activated TRPC6 currents in rabbit portal vein smooth 
muscle with an IC50 of 5.1µM (Inoue et al., 2001). More recently, 10µM SKF-96365 has been 
reported to abolish OAG-induced TRPC6 currents in human epithelial breast cancer cells (Guilbert 
et al., 2008). In this study, SKF-96365 inhibited OAG-induced Ca2+ entry in a concentration-
dependent manner at concentrations greater than 1µM, but potentiation of OAG-induced Ca2+ 
entry occurred at concentrations less than 1µM. This potentiation is likely to be due to the non-
specific effects of SKF-96365 that have been reported in some systems. As well as inhibiting 
TRPC channels, 10µM SKF-96365 has been shown to inhibit the voltage-gated Ca2+ channels 
Cav1, Cav2 and Cav3 expressed in HEK-293 cells (Singh et al., 2010). In human leukaemic HL-60 
cells, SKF-96365 has been reported to have dual effects, causing partial inhibition of Ca2+ entry 
at 1-3µM, but promoting Ca2+ entry at 30-100µM (Leung et al., 1996).  This SKF-96365- induced 
Ca2+ entry was not observed in human astrocytoma cells (Arias-Montano et al., 1998), but it was 
reported to stimulate phosphoinositide hydrolysis in these cells. It has been suggested that SKF-
96365 inhibits intracellular Ca2+ store refilling (Leung et al., 1996; Arias-Montano et al., 1998), 
which could lead to Ca2+ re-entry in some cells. The non-specific effects of SKF-96365 at 
concentrations less than 1µM have not been investigated, but it is evident from previous reports 
that the compound has other cellular effects in addition to the inhibition of TRPC channels. It is 
possible that in this study, SKF-96365 inhibited the re-uptake of Ca2+ into intracellular stores, as 
has been demonstrated in human astrocytoma cells (Arias-Montano et al., 1998). This could have 
caused passive store depletion and the concomitant activation of store-operated Ca2+ channels 
such as Orai1 channels (Feske et al., 2006; Prakriya et al., 2006; Vig et al., 2006b), and possibly 
store-operated TRPC channels (Ong et al., 2007; Liao et al., 2008; Ma et al., 2008). SKF-96365 
has been reported to inhibit ICRAC currents, which have since been shown to be mediated by 
Orai1 channels, with an IC50 of 4µM in rat peritoneal mast cell (Franzius et al., 1994). TRPC1, 
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which is expressed in HLMCs from all donors in this study and has been suggested to be 
activated by store depletion (Zagranichnaya et al., 2005; Ong et al., 2007; Yuan et al., 2007; 
Cheng et al., 2011), can be inhibited by 10µM SKF-96365 (Zagranichnaya et al., 2005). 
Therefore, at concentrations greater than 1µM, SKF-96365 would be expected to inhibit channels 
activated by passive store depletion, as well as OAG-activated TRPC3/6/7 channels. This would 
result in a reduced overall Ca2+ signal, as seen with concentrations of SKF-96365 above 1µM. At 
lower concentrations of SKF-96365, however, inhibition of TRPC3/6/7 channels does not occur, 
and store-operated Ca2+ channels would not be inhibited. If passive store depletion by inhibition 
of re-uptake into intracellular stores occurs at 0.001-1µM SKF-96365, store-operated Ca2+ 
channels could be activated, but SKF-96365 at these concentrations would not cause inhibition of 
these channels. This, along with the activation of TRPC6/7 channels by OAG that are not 
inhibited by 0.001-1µM SKF-96365, could lead to an overall increase in cytosolic Ca2+ and 
apparent potentiation of OAG-induced Ca2+ entry. 
 
When a concentration-response curve was fitted using concentrations of 1µM and above only, 
the estimated IC50 for the inhibition of OAG-induced Ca
2+ entry by SKF-96365 was 10.25µM; this 
value is close to that obtained by Inoue et al. (2001) for the inhibition of TRPC6 channels in 
rabbit portal vein smooth muscle cells (5.1µM). It is evident from previous studies showing that 
SKF-96365 has off-target effects that caution must be applied when using SKF-96365 as the sole 
pharmacological agent to identify the contribution of TRPC channels to Ca2+ entry. However, 
taken together with the RT-PCR data and the concentration-dependent inhibition by Gd3+, the 
reduction of OAG-induced Ca2+ entry by SKF-96365 with an IC50 of 10.25µM suggests that TRPC6 
channels, with a possible contribution from TRPC7, are activated by OAG and mediate Ca2+ entry 
in HLMCs.  
 
The biophysical properties of OAG-induced currents in HLMCs were then investigated using 
whole-cell patch clamp electrophysiology. Data in this study and published data have shown that 
OAG activation of TRPC6 channels in HEK-293 cells gives rise to outwardly-rectifying currents 
with a reversal potential close to 0mV (Inoue et al., 2001; Estacion et al., 2004; Shi et al., 2004; 
Estacion et al., 2006). These properties have been used to identify native TRPC6 currents in 
rabbit portal vein smooth muscle cells (Inoue et al., 2001), mouse cortical neurons (Tu et al., 
2009b) and mouse megakaryocytes (Carter et al., 2006). In accordance with previous reports, 
data obtained in this study show that OAG activates outwardly-rectifying currents in HLMCs with 
a reversal potential of -5.31mV ± 2.59 (n=8). As observed with HEK-TRPC6 in chapter 4, some 
cells (55%) showed a transient response to OAG and others (33%) exhibited a sustained 
response. The rectification index (peak current at +100mV/ peak current at -100mV) was 
significantly higher in cells with a sustained response compared to those with a transient 
response, indicating that the current was more outwardly-rectifying in cells with a sustained 
response. This could be due to the negative regulation of TRPC6 channels by Ca2+; as described 
in chapter 1.3.2, both intracellular and extracellular Ca2+ can cause channel deactivation (Shi et 
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al., 2004). A more inwardly-rectifying current is likely to have a greater inward Ca2+ current, 
which could give rise to Ca2+-dependent deactivation and a more transient current. The patch 
clamp solutions and protocols in this study were not designed to assess the presence of other ion 
channels, but differences in expression of other ion channels between donors could give rise to 
variations in rectification. The mean inward current measured at -100mV at the start of 
experiments was 14.9pA ± 3.22 (n=8); the mean outward current measured at +100mV was 
77.14pA ± 19.95 (n=8), indicating that channels could be active. A detailed characterisation of 
the ion channels expressed in HLMCs would be a valuable avenue of investigation in future 
studies. Current-clamp experiments in HLMCs following OAG stimulation would reveal changes in 
the membrane potential and provide insightful information on the driving force for cation entry 
when the membrane potential is not clamped. 
 
It is also possible that the composition of the OAG-activated TRPC channels varied in different 
HLMCs, giving rise to responses with different kinetics and rectification. The kinetics of the 
response showed some donor-dependency; 2/3 cells displaying a sustained response were from 
the same donor (370), and all cells tested from donor 360 had a transient response (n=3). 2/3 
cells from donor 410 had a transient current. Unfortunately, due to the time taken to optimise 
RNA extraction from small cell numbers, RT-PCR was only carried out on one of the donors used 
to study OAG-induced currents in HLMCs (donor 410, which expressed TRPC6 and TRPC7); 
differential expression of TRPC6 and TRPC7 channels could give rise to different channel 
assemblies with different pore properties. The contribution of TRPC3 in the donors where RT-PCR 
was not carried out cannot be excluded, although this channel was not present in 3/3 donors 
where RT-PCR was carried out, and has not been detected in HLMCs in previous studies 
(Bradding et al., 2003). 
 
The time taken for the OAG-induced current to reach a peak was variable in this study. Estacion 
et al. (2004) reported that currents activated by OAG in HEK-hTRPC6 cells were slow to activate; 
the authors suggest that this could reflect a time-dependent insertion of TRPC6 channels into the 
membrane. Cayouette et al. (2004) showed that OAG stimulates the externalisation of mTRPC6 
channels via an exocytic mechanism prior to Ca2+ entry. TRPC6 channels are thought to be 
located in vesicles, which fuse with the plasma membrane upon cell stimulation, increasing the 
level of TRPC6 channels at the plasma membrane (Cayouette et al., 2004). It is possible that the 
variation in the time taken to reach a peak current in this study was due to the availability of 
vesicles close to the plasma membrane; in some cells TRPC6 channels may have already been 
present in the membrane, giving rise to a current with a quicker rate of onset. 
 
In accordance with the Ca2+ imaging data obtained in this study (figure 6.2), and previous 
reports showing that Gd3+ inhibits TRPC3/6/7 channels (Zhu et al., 1998; Broad et al., 1999; 
Halaszovich et al., 2000; Inoue et al., 2001; Jung et al., 2002), the presence of 10µM Gd3+ 
inhibited the activation of OAG-induced currents in this study. This sensitivity of OAG-induced 
 Chapter 6: TRPC3/6/7 channels in human mast cells 
207 
 
currents in HLMCs to Gd3+, along with the currents having the expected biophysical properties of 
TRPC3/6/7, Ca2+ permeability and sensitivity to SKF-96365, provides strong evidence for the 
functional expression of DAG-activated TRPC channels in HLMCs. Taken together with the RT-
PCR data (chapter 3.4), these data suggest that TRPC6 channels mediate OAG-induced currents 
in HLMCs. Further studies employing specific molecular knockdown of TRPC6, along with TRPC3 
and TRPC7, are necessary to confirm the results obtained using Gd3+ and SKF-96365, and to 
verify which DAG-activated TRPC channel(s) is/are responsible for mediating OAG-induced 
currents in HLMCs. siRNA or dominant negative pore mutants could be used for selective channel 
knock-down. Dominant negative TRPC6 has successfully been used in human microvascular 
endothelial cells using an adenoviral delivery method to show that TRPC6 is involved in receptor-
evoked Ca2+ entry, proliferation and migration in these cells (Hamdollah Zadeh et al., 2008). As 
RT-PCR data revealed donor-dependent expression of TRPC7 channels, assessing the relative 
contribution of this channel and that of TRPC6 to OAG-induced Ca2+ entry in different donors 
would be an interesting avenue of investigation. 
 
The role of PKC in the negative regulation of TRPC3/6/7 channels was discussed extensively in 
chapter 4.3 so will not be described in detail here. Briefly, previous studies have shown that PKC 
is involved in the negative regulation of hTRPC6 expressed in HEK-293 cells (Estacion et al., 
2004), and hTRPC3 expressed in the DT40 chicken B-cell line (Venkatachalam et al., 2003). The 
results obtained in HLMCs are in accordance with published observations (figure 6.4); the 
presence of the PKC inhibitor Ro-31-8425 did not have a significant effect on the current 
amplitude, but did increase the number of cells displaying a sustained current in response to 
OAG application from 33% (3/9) to 83% (5/6), and the percentage of the peak current 
remaining at 2 minutes after OAG application was significantly increased in the presence of Ro-
31-8425. These data suggest that PKC does have a role in the inactivation of TRPC6 channels, in 
agreement with the results obtained in HEK-TRPC6 cells in this study, and with previous 
published work.  
 
PKC levels may vary between recordings as discussed in chapter 4.3.1, as a result of dialysis into 
the patch pipette in the whole-cell recording configuration or cell cycle-dependent variation. It 
was previously thought that terminally differentiated mast cells did not proliferate, and that their 
increased numbers at tissue sites such as the asthmatic lung were due to the diversion of a 
larger proportion of haematopoietic progenitor cells into a mast cell fate, or increased survival of 
mast cells (Kambe et al., 2001). However, it has since been shown that primary human skin mast 
cells (Kambe et al., 2001) and HLMCs (Duffy et al., 2003; Cruse et al., 2006) do proliferate; 
HLMC numbers were reported to increase by 5 fold over 4 weeks when cultured in the presence 
of SCF, IL-6 and IL-10 (Duffy et al., 2003), meaning their doubling time is approximately 1.6 
weeks. HEK-293 cells have a doubling time of approximately 22 hours (Hopper-Borge et al., 
2004), therefore the cell cycle in HEK-293 cells would be expected to progress a great deal more 
quickly than that in HLMCs. This difference in the two cell types could account for the greater 
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variation in the percentage of OAG-induced current remaining at 2 minutes after OAG application 
seen in HEK cells (51.72 ± 26.11, n=7) compared with HLMCs (36.8 ± 14.2, n=8) when Ro-31-
8425 was not present.  
 
Whilst PKC is likely to have a role in TRPC6 regulation in HLMCs, 17% of cells still had a transient 
current when PKC was inhibited. It is therefore likely that other mechanisms also contribute to 
the inactivation of the channels. As discussed in chapter 4.3, dialysis of OAG or other important 
signalling molecules into the patch pipette could account for the deactivation of TRPC6 channels. 
Interacting molecules such as the InsP3 receptor and PtdIns(4,5)P2 have been suggested to be 
important for TRPC6-mediated cation entry; TRPC6 and the InsP3 receptor have been shown to 
interact (Boulay et al., 1999; Cayouette et al., 2004), although the functional significance is not 
yet known as TRPC6 channels are believed to be activated independently of store depletion 
(Dietrich & Gudermann, 2007). PtdIns(4,5)P2 binding has also been proposed to be important for 
the regulation of TRPC6; OAG and receptor stimulation have been shown to synergistically 
activate hTRPC6 (Estacion et al., 2004), and the authors suggest that PtdIns(4,5)P2 hydrolysis 
per se could be an important event in channel activation. A number of other ion channels 
including TRPV1 (Chuang et al., 2001) and TRPM7 (Runnels et al., 2002) are thought to be 
regulated by PtdIns(4,5)P2. It is known that membrane PtdIns(4,5)P2 levels gradually deplete in 
the absence of PLC hydrolysis; lipid kinases including phosphatidyl inositol 4 kinases (PI4K) are 
required in the presence of ATP to resynthesise PtdIns(4,5)P2. It has been shown in HEK-293 
cells that inhibition of PI4K leads to rundown of PtdIns(4,5)P2 levels (Suh & Hille, 2002). The 
dialysis of important molecules such as PI4K and ATP in the whole-cell recording configuration 
used in this study could have a role in the depletion of PtdIns(4,5)P2 levels in the membrane and 
the deactivation of TRPC6 channels.  OAG-induced Ca2+ entry measured in intact HLMCs did not 
decline in the presence of OAG (see figure 6.1), suggesting that dialysis of signalling molecules 
may be a key factor in the inactivation of TRPC6 channels seen in whole-cell patch clamp 
recordings.  
 
As described in chapter 4.3, it is also known that TRPC6 and TRPC7 channels undergo complex 
regulation by Ca2+ from both sides of the membrane, dependently and independently of 
calmodulin (Shi et al., 2004). Cell-dependent differences in the levels of molecules involved in 
Ca2+- dependent channel regulation, perhaps due to differing degrees of dialysis in the whole-cell 
recording configuration, could also contribute to the inactivation of OAG-induced currents in 
HLMCs. Experiments carried out in the presence of different concentrations of intracellular and 
extracellular Ca2+, and in the presence of a calmodulin antagonist such as calmidazolum (Shi et 
al., 2004), would reveal whether Ca2+ regulation contributes to the inactivation of OAG-mediated 
currents. Recording OAG-induced currents in HLMCs using the perforated patch clamp technique 
would reveal whether the dialysis of PKC, OAG or other signalling molecules contributes to the 
deactivation of the channels.  
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To summarise, whilst a number of different factors may be responsible for the kinetics of the 
response, the TRPC3/6/7 channel activator OAG gave rise to Gd3+-sensitive, outwardly-rectifying 
currents in HLMCs with a reversal potential close to 0mV; these properties are typical of 
TRPC3/6/7 channels. Taken together with the Ca2+ imaging results showing that OAG mediates 
Gd3+- and SKF-96365- sensitive Ca2+ entry in HLMCs, and PCR data showing that TRPC6 mRNA 
present in 3/3 donors tested and TRPC7 mRNA in 1/3 donors, results suggest that functional 
TRPC6 channels are expressed in HLMCs.  
 
LAD 2 cells were the only human mast cell line reported to degranulate in response to FcεRI 
cross-linking (Kirshenbaum et al., 2003) at the time this work was done, and have previously 
been shown in our laboratory to be a good model to ion channels in human mast cells (Wykes et 
al., 2007; Wareham et al., 2009). Therefore, LAD 2 cells represented a potentially good model to 
study the functional expression of DAG-activated TRPC3/6/7 channels in human mast cells. 
mRNA transcripts for all channels from this subgroup were present, but Ca2+ entry only occurred 
in 25% of LAD 2 cells in response to OAG application, compared with 97% of HLMCs. Similarly, 
20% of LAD 2 cells exhibited outwardly-rectifying currents following OAG stimulation, compared 
with 89% of HLMCs; LAD 2 cells are therefore a poor model to study second messenger-
regulated TRPC channels in human mast cells. Maturation stage-dependent expression of 
proteins has previously been reported in mast cells; terminally differentiated skin mast cells were 
found to contain higher levels of tryptase and chymase than the less  mature LAD 2 cells (Guhl et 
al., 2010). It has also been reported that B cells exhibit maturation stage-dependent expression 
of signalling molecules activated downstream of B cell antigen receptor, including PLCγ, B cell 
linker protein and Bruton‘s tyrosine kinase (Benschop et al., 2001). It is therefore possible that 
the DAG-activated TRPC channels, the mRNA for which is expressed in LAD 2 cells, are not 
expressed at the protein level in immature LAD 2 cells. Immature mast cell progenitors migrate 
to tissues such as the lung, where they terminally differentiate under the influence of the tissue 
environment (Kitamura, 1989). It is possible that the DAG-activated TRPC channels are not fully 
expressed in human mast cells until terminal differentiation has occurred, which would give rise 
to only a small percentage of LAD 2 cells responding to OAG. TRPC6 channels are known be 
present at the plasma membrane at rest in HEK-293 cells, and the number of channels at the 
membrane increases upon activation by OAG or GPCRs (Cayouette et al., 2004); it is also 
possible that TRPC6 protein is present in LAD 2 cells but it is ineffectively trafficked to the 
membrane. Unsuccessful attempts were made to characterise the surface expression of TRPC6 
channels in LAD 2 cells with flow cytometry and immunocytochemistry using a rabbit anti-
hTRPC6 antibody, which was a gift from a collaborator, Thierry Capiod. This antibody has 
previously been used to detect TRPC6 surface expression in human hepatoma cell lines by 
immunocytochemistry (El Boustany et al., 2008). . Whilst 99% of cells were found to be positive 
for c-kit expression, demonstrated with flow cytometry using a PE-tagged anti-c-kit antibody, all 
cells appeared negative for TRPC6 expression. Similar results were obtained with 
immunocytochemistry. When the antibody was tested in HEK-TRPC6 cells it also failed to reveal 
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TRPC6 expression, suggesting that the antibody was unsuitable for this kind of experiment. 
Analysis of surface expression with a more suitable antibody would reveal whether TRPC6 protein 
is expressed at the surface; Western Blotting could also be used to determine whether the 
protein is produced in LAD 2 cells. 
 
 
6.5.2 Receptor activation of TRPC3/6/7 channels in HLMCs 
As discussed in chapter 1.3.2, stimulation of PLC-linked receptors represents a physiological 
mode of activation for TRPC6 channels. As shown in chapter 3.2 and in accordance with previous 
studies showing that P2Y1 is expressed in HLMCs and causes mediator release (Saito et al., 1991; 
Schulman et al., 1999), application of ADP to HLMCs stimulates Ca2+ entry. It is known that P2Y1, 
P2Y12 and P2Y13 receptors are all ADP-sensitive; whilst P2Y1 couples to Gq proteins and PLCβ, 
P2Y12 and P2Y13 are coupled to Gi proteins (Communi et al., 2001; Nicholas, 2001), causing 
downstream inhibition of cyclic adenosine monophosphate (cAMP) production. ADP-induced Ca2+ 
entry in the presence of the selective P2Y1 antagonist, MRS2179 (Camaioni et al., 1998; Kaiser & 
Buxton, 2002), was significantly inhibited in this study (see figures 6.6 and 6.7), showing that 
Ca2+ entry occurs downstream of Gq-coupled P2Y1 receptors in HLMCs stimulated with ADP. The 
possibility that TRPC3/6/7 channels are activated downstream of P2Y1 receptors in HLMCs was 
therefore considered. As previously discussed, Gd3+ is a commonly-used inhibitor of TRPC 
channels (Zhu et al., 1998; Broad et al., 1999; Halaszovich et al., 2000; Inoue et al., 2001; Jung 
et al., 2002), and inhibited OAG-induced Ca2+ entry in this study with an estimated IC50 of 6.5µM. 
SKF-96365 has also been used extensively for the characterisation of TRPC channels in various 
systems (Merritt et al., 1990; Halaszovich et al., 2000; Inoue et al., 2001; Eder et al., 2007; 
Guilbert et al., 2008; Finney-Hayward et al., 2010), and caused concentration-dependent 
inhibition of OAG-induced Ca2+ entry in HLMCs in this study. 10µM Gd3+ or SKF-96365 caused 
significant inhibition of ADP-induced Ca2+ entry in HLMCs (see figures 5.6 and 5.7), suggesting 
that TRPC channels are involved in mediating Ca2+ entry downstream of P2Y1 receptor activation 
in HLMCs. This is the first demonstration of a P2Y1-mediated TRPC current in HLMCs, indicating 
that TRPC-mediated Ca2+ entry occurring downstream of P2Y receptor activation in HLMCs could 
be important in HLMC activation. 
 
It is evident that the amplitude of the OAG-induced Ca2+ signal in HLMCs is much larger than 
that occurring in response to ADP. The same four donors were used for experiments using both 
agonists, so this difference is not donor-dependent. It is likely to be due to the different 
mechanisms of action of the two agonists. Evidence from platelets suggests that PLCβ2 is the 
predominant isoform activated downstream of P2Y1 receptors (Kahner et al., 2006); platelets 
from PLCβ2/β3 knockout mice have defects in Ca
2+ mobilisation and secretion in response to P2Y1 
stimulation (Lian et al., 2005). Impaired InsP3 production and Ca
2+ signalling have been reported 
in platelets from patients with reduced PLCβ2 expression (Mao et al., 2002), again demonstrating 
that PLCβ2 is a key effector molecule involved in P2Y1 receptor signalling. PLCβ2 catalyses the 
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production of InsP3 and DAG at the membrane from PtdIns(4,5)P2; InsP3 triggers Ca
2+ release 
from intracellular stores, and DAG is thought to activate PKCδ (Kahner et al., 2006), as well as 
TRPC3/6/7 channels (Hofmann et al., 1999). The complex signalling cascade activated 
downstream of P2Y1 receptors is therefore likely to have multiple effects on the cell, in addition 
to the activation of TRPC channels. Ca2+ release from stores and the activation of store-operated 
Ca2+ channels such as Orai1, and possibly TRPC channels including TRPC1, occurs following InsP3 
production. An increase in intracellular Ca2+ has been shown to cause inactivation of TRPC6 and 
7 channels, which is associated with decreased single channel conductance. The activation of 
Ca2+ store depletion by P2Y1-mediated stimulation, but not by OAG, could therefore down-
regulate DAG-activated TRPC channels switched on downstream of P2Y1.  
 
It is also possible that TRPC6 channels are activated to a greater extent when directly stimulated 
with OAG, in comparison with activation downstream of the P2Y1-mediated signalling cascade. 
Estacion et al. (2004), as well as data shown in chapter 4.1 in this study, showed that 100µM 
OAG caused maximal activation of TRPC6 channels; increasing the concentration to 300µM did 
not stimulate further channel activity. It is possible that whilst OAG activated TRPC6 channels 
maximally in this study, DAG activated downstream of P2Y1 was not present at a sufficient 
concentration to maximally activate the channel. As a large number of signalling molecules are 
involved in the production of DAG downstream of P2Y1 receptor stimulation, one of them could 
be a limiting factor in channel activation. As discussed in chapter 3, phosphoinositides such as 
PtdIns(4,5)P2 are maintained in distinct membrane compartments (Mao & Yin, 2007), giving rise 
to specific microdomains of Ca2+ signalling at regions where ion channels are located. TRPC 
channels, Orai1 channels and voltage-gated Ca2+ channels have been shown to localise in distinct 
plasma membrane regions (Brazer et al., 2003; Pani & Singh, 2009). Activation of Ca2+ entry 
downstream of P2Y1 receptor stimulation would therefore be expected to occur only at 
membrane regions where PtdIns(4,5)P2 and Ca
2+ channels are clustered together. Unlike DAG, 
OAG is membrane-permeable and was applied directly to cells, so the activation of TRPC3/6/7 
channels would not be expected to occur only at distinct regions where other signalling 
molecules are present. This could result in a much larger, non-physiological, Ca2+ signal in cells 
stimulated with OAG compared to those stimulated with ADP. 
 
Although the amplitude of the Ca2+ signals was different following OAG and ADP stimulation of 
HLMCs, the sensitivity to Gd3+ was very similar. These observations suggest that, although the 
two stimuli may have activated the channels to a different extent, it is likely that the TRPC6 (and 
possibly TRPC7) channels activated by OAG were also activated downstream of P2Y1 receptor 
stimulation. 
 
The currents induced by OAG and P2Y1 receptor stimulation were similar, as shown in table 6.1. 
The current properties are also similar to those in the study by Carter et al. (2006) showing that 
ADP stimulates outwardly-rectifying currents mediated by TRPC6 in mouse megakaryocytes. The 
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reversal potential for ADP-induced currents in HLMCs was measured at 4.38mV ± 2.00 (n=9, 
N=2 donors), and that for ADP-induced TRPC6 currents in mouse megakaryocytes was around 
0mV (Carter et al., 2006). Receptor operated TRPC6 currents measured in HEK cells in this study 
had a reversal potential of 1.44mV ± 0.38 (n=5), and those in previous studies have a reversal 
potential of around 0mV (Hofmann et al., 1999; Estacion et al., 2004; Shi et al., 2004; Estacion 
et al., 2006). When examining the example current-voltage relationship for ADP-induced currents 
in mouse megakaryocytes, the outward current appears to be approximately 4 fold larger than 
the inward current (Carter et al., 2006), which would give rise to a rectification index of around 
4, suggesting that similar channels are activated in both systems. The rectification of ADP-
induced currents measured in HLMCs in this study also appears similar to that of receptor-
operated TRPC6 channels expressed in HEK cells; carbachol-induced currents recorded in HEK-
TRPC6 cells by Shi et al. (2004) appear to have an outward current that is around 3 fold larger 
than the inward current. ADP-induced currents in HEK-TRPC6 cells in this study (chapter 4.1) had 
a rectification index of 4.39 ± 1.28 (n=5); OAG-induced currents in HLMCs had a mean 
rectification index of 3.99 ± 0.89 (n=8, N=3 donors). The similar rectification properties of ADP-
induced currents to those induced by OAG in HLMCs, and receptor-operated TRPC6 channels in 
heterologous expression systems, suggest that TRPC6-like channels are activated downstream of 
P2Y1 receptor stimulation by ADP in HLMCs. The sensitivity of ADP-induced currents to 10µM 
Gd3+ also provides evidence for the activation of TRPC channels downstream of P2Y1 receptor 
activation. The exact mechanism for receptor- mediated activation of TRPC6 channels remains 
elusive; whilst Hofmann et al. (1999) showed that DAG directly activates the channels, Estacion 
et al. (2004) reported that TRPC6-mediated currents in the presence of carbachol plus OAG were 
larger than the sum of the currents induced by either agent alone. The authors concluded that 
DAG production alone may not cause complete activation of TRPC6, and it may act synergistically 
with other events downstream of receptor stimulation to maximally activate TRPC6 (Estacion et 
al., 2004). It is known that PLC is necessary for receptor activation of TRPC6 channels, because 
pre-incubation with the PLC inhibitor U73122 inhibited histamine-induced Mn2+ influx in CHO cells 
expressing hTRPC6 (Hofmann et al., 1999). Estacion et al. (2004) suggested that PtdIns(4,5)P2 
hydrolysis per se may have a role in receptor-mediated TRPC6 channel activation in synergy with 
DAG. To verify the involvement of DAG in the activation of TRPC6-like currents activated 
downstream of P2Y1 receptor activation, experiments could be carried out in the presence of 
DAG kinase, which breaks down DAG; a reduction in the current would indicate that DAG is 
required for channel activation. Co-immunoprecipitation studies using antibodies to TRPC6 and 
other signalling proteins could be used to reveal whether other second messengers activated 
downstream of P2Y1 receptor stimulation, such as PtdIns(4,5)P2, are associated with TRPC6 
following ADP stimulation. 
 
Given that InsP3 is produced downstream of P2Y1 stimulation (Kahner et al., 2006), and InsP3-
mediated store release is sensed by STIM1, which has been shown to translocate to distinct 
puncta in the plasma membrane (Stathopulos et al., 2006) and activate ICRAC currents mediated 
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by Orai1 in mast cells (Feske et al., 2006; Prakriya et al., 2006; Vig et al., 2006b), it might be 
expected that ICRAC activation downstream of P2Y1 receptor stimulation could occur. . ICRAC-like 
currents (properties described in chapter 1.3.1) were not observed following ADP stimulation of 
HLMCs; as conditions in this study were not optimised to measure ICRAC activation, it is possible 
that the current was active following P2Y1 stimulation but was not visible in the recording 
conditions used. Stimulating cells with ADP in recording conditions designed to detect ICRAC 
currents, such as the application of divalent-free solution during recordings, would reveal 
whether such currents are activated. Another possibility is that ICRAC currents are not activated 
downstream of P2Y1 receptor activation; distinct pools of PtsIns(4,5)P2 in the membrane may 
interact with different isoforms of PLC, targeting them to different regions. It has been suggested 
that Orai1 and TRPC channels are localised in distinct membrane regions; experiments using 
MβCD, which sequesters cholesterol, have shown that TRPC3 channel function is suppressed by 
cholesterol sequestration, whereas Orai1 function is unaffected (DeHaven et al., 2009). The 
authors concluded that the two types of channels exist in distinct plasma domains; it is possible 
in this study that following P2Y1 activation by ADP, PLCβ is targeted to distinct plasma membrane 
regions containing discrete pools of PtdIns(4,5)P2 to activate TRPC channels but not Orai1 
channels. Distinct receptor signalling pathways, such as FcεRI-mediated signalling, may result in 
the recruitment of PLCγ to regions of the plasma membrane containing Orai1 and the activation 
of ICRAC. This hypothesis is in accordance with results in chapter 3.3 showing that IgE and ADP 
activate Ca2+ store release and entry with different amplitudes, which can be explained by PLCβ 
and PLCγ activating different ion channels depending on their spatial orientation in the 
membrane. Therefore, it is possible that ICRAC currents were not observed following P2Y1 receptor 
stimulation in this study because the two ion channel types (TRPC and Orai1) are subject to tight 
spatial regulation and differentially activated depending on the stimulus and concomitant 
signalling cascade.  
 
Attempts were made to verify the involvement of TRPC6 in OAG- and ADP- activated currents 
using FFA. As discussed in chapter 1.3.2, FFA has been used as a diagnostic tool for TRPC6 
channel activation in a number of studies, as it activates TRPC6 whilst suppressing other TRPC 
channels. In this study, application of FFA to LAD 2 cells and HLMCs gave rise to Ca2+ entry and 
currents with the typical biophysical properties of TRPC6 channels. However, a number of 
observations challenge the view that FFA is a selective activator of TRPC6. Firstly, FFA application 
gave rise to Ca2+ entry in 100% of LAD 2 cells tested; as shown in figure 6.5, Ca2+ entry 
following OAG application only occurred in 25% of LAD 2 cells. As discussed above, it is likely 
that LAD 2 cells are not an appropriate model to study TRPC6 channels in human mast cells 
because they are not fully differentiated. Secondly, a large increase in cytosolic Ca2+ occurred 
when FFA was applied to LAD 2 cells in the absence of extracellular Ca2+, showing that Ca2+ was 
being released from inside the cell not entering across the plasma membrane. A similar 
observation was made by Tu et al. (2009a), who reported that FFA caused a rise in cytosolic 
calcium in cultured cortical neurons even in cells kept in calcium-free extracellular solution or 
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when intracellular stores were depleted with thapsigargin. The FFA-induced calcium rise was 
shown to be strongly diminished by bongkrekic acid, which is a ligand of the mitochondrial 
ADP/ATP carrier, and the authors suggested that FFA exerts its effects on plasma membrane 
channels by affecting the mitochondria (Tu et al., 2009a). Mitochondria exert complex effects on 
calcium signalling in the cell, therefore interfering with their function could have many 
downstream effects. 
 
To summarise, data in this chapter shows that OAG stimulates Gd3+ and SKF-96365- sensitive 
Ca2+ entry in HLMCs; OAG-evoked currents have the expected biophysical properties of 
TRPC3/6/7 channels. Taken together with the RT-PCR data shown in figure 3.9, these data 
suggest that TRPC6 channels, possibly along with TRPC7, are functionally expressed in HLMCs. 
ADP stimulation of P2Y1 receptors in HLMCs activates Gd
3+ and SKF-96365- sensitive Ca2+ entry 
and currents with similar properties to those activated by OAG, suggesting that TRPC6 channels 
may be switched on downstream of P2Y1 receptor activation in HLMCs. This is the first 
demonstration of TRPC6-like current activation in HLMCs.  
 
6.5.3 Functional roles of DAG-activated TRPC channels 
The lack of histamine and β-hexosaminidase release in response to OAG suggests that 
TRPC3/6/7 channels are not required for HLMC degranulation. This observation is in accordance 
with Ca2+ imaging results showing that OAG stimulates Ca2+influx following FcεRI cross-linking, 
suggesting that TRPC3/6/7 channels are not required for FcεRI-dependent Ca2+ entry. ADP has 
previously been shown to stimulate histamine release in mouse BMMCs (Saito et al., 1991) and 
RBL-2H3 cells (Gao et al., 2010), but HLMCs did not release histamine and β-hexosaminidase in 
response to ADP in this study. It is known that species-dependent differences exist between 
human and rodent mast cells (Bischoff, 2007); this discrepancy highlights the need to use 
primary human mast cells to study their activation mechanisms.  
 
The observation that HLMCs degranulate in response to FcεRI cross-linking but not P2Y1 receptor 
stimulation supports the theory that PLCγ and PLCβ are subject to spatial regulation in the cell 
and differentially couple to downstream signalling molecules. As discussed in chapter 1.3, 
signalling molecules and ion channels are brought together in lipid raft complexes in the plasma 
membrane (Lingwood & Simons, 2010; Calloway et al., 2011); the coupling of PLCγ and PLCβ to 
different signalling molecules and ion channels would give rise to differential downstream effects. 
It is known that the secretion of granule-associated mediators in mast cells is controlled by 
SNARE proteins. Specific SNARE proteins on intracellular vesicles (v-SNAREs) bind to their 
cognate SNAREs on the target plasma membrane (t-SNAREs) to mediate fusion and the release 
of granule contents (Puri & Roche, 2008). It has recently been shown that mast cells possess 
distinct subsets of mediators contained in different secretory granules, and different SNARE 
isoforms are required for their release. VAMP-8, for example, mediates the secretion of serotonin 
but not histamine from mouse mast cells (Puri & Roche, 2008). It is possible that PLCγ- and 
 Chapter 6: TRPC3/6/7 channels in human mast cells 
215 
 
PLCβ-dependent signalling cascades couple to differential SNARE proteins to effect the secretion 
of distinct mediators. The study by Puri & Roche (2008) highlights that the release of histamine 
and β-hexosaminidase may not accurately reflect the behaviour of all granule-associated 
mediators in HLMCs; it is possible that other mediators such as proteoglycans, proteases or pre-
formed cytokines stored in distinct granules are released downstream of PLCβ signalling. Further 
studies investigating the release of other granule-associated mediators are required to elucidate 
whether P2Y1 receptor stimulation is involved in HLMC degranulation. 
 
In addition to the plethora of granule-associated mediators released by the mast cell, newly-
synthesised mediators are produced upon mast cell activation. It is known that mast cells are 
capable of differential mediator release without degranulation as they are involved in the 
pathogenesis of inflammatory diseases without causing anaphylactic shock (Theoharides et al., 
2007). Eicosanoids including prostaglandin D2 and leukotriene C4 are released by the mast cell 
and contribute to inflammation, and the transcription of a range of cytokines occurs following 
Ca2+ entry (Gilfillan & Tkaczyk, 2006). As degranulation is a rapid process taking place over 
minutes, whereas transcriptional regulation of cytokine production occurs over hours, a more 
sustained Ca2+ signal is required for de novo synthesis of mediators (Gilfillan & Tkaczyk, 2006). 
As discussed in the previous chapter, it is likely that store-operated TRPC1 channels, along with 
Orai1 channels, are activated downstream of FcεRI cross-linking. It is possible that P2Y1 receptor 
activation and PLCβ are coupled to TRPC6 channels in HLMCs whereas FcεRI and PLCγ are 
coupled to TRPC1. Whilst TRPC6-mediated Ca2+ entry may not be coupled to the release of 
granule-associated mediators, it could provide a more sustained Ca2+ signal required for cytokine 
transcription. A comprehensive investigation of HLMC mediator release following ADP stimulation 
in future studies would reveal whether signalling downstream of P2Y1 receptors contributes to 
allergic inflammation in the asthmatic airway. 
 
To summarise, data in this chapter show for the first time that TRPC6-like channels are 
functionally expressed in HLMCs, and they can be activated directly by OAG, or via ADP 
stimulation of P2Y1 receptors. These channels were not found to have a role in HLMC 
degranulation or motility, but it is possible that Ca2+ entry through TRPC6 channels has another 
role, such as the de novo synthesis of cytokines, which could be important in the development of 
asthma. 
` Chapter 7: Discussion 
216 
 
Chapter 7: Discussion and future directions 
7.1 Discussion 
This study demonstrated for the first time that TRPC channels are functionally expressed in 
human lung mast cells. Of the DAG-sensitive TRPC family, it is likely that TRPC6 is present in 
HLMCs; TRPC6-like currents were activated by the DAG analogue OAG and downstream of P2Y1 
receptor activation by ADP. TRPC6 channel activation by these methods was not found to 
stimulate release of the granule-associated mediators histamine and β-hexosaminidase, 
suggesting that the channels are unlikely to have a role in HLMC degranulation. As further Ca2+ 
rises could be stimulated by OAG following FcεRI cross-linking, it is unlikely that TRPC6 channels 
contribute to IgE-dependent mast cell activation.  
 
As discussed in chapter 1.2, the IgE-dependent pathway is not the only important mechanism of 
mast cell activation; they express receptors for many other physiological ligands, which may 
induce degranulation, promote survival, growth or chemotaxis of mast cells, prime cells for 
activation by FcεRI cross-linking, or provide co-stimulatory signals (Gilfillan & Tkaczyk, 2006). 
Nucleotides such as ATP and ADP are thought to be among the first released and most abundant 
molecules released from cells in response to tissue injury, infection and hypoxia (Feng et al., 
2004; Bulanova & Bulfone-Paus, 2010). The sources of extracellular nucleotides are summarised 
in figure 7.1. The demonstration in this study that ADP can activate TRPC6-like currents 
downstream of P2Y1 receptor activation indicates that TRPC6-mediated Ca
2+ entry could be an 
important mechanism of HLMC activation in the inflammatory response. Whilst β-hexosaminidase 
and histamine release are not likely to be dependent on Ca2+ entry through TRPC6 channels, a 
rise in cytosolic Ca2+ is also essential for the de novo synthesis and release of other pro-
inflammatory mediators, including prostaglandins, leukotrienes and cytokines (Chung et al., 
1986; Metcalfe et al., 1997; Theoharides et al., 2007). TRPC6-dependent Ca2+ entry could be 
coupled to eicosanoid or cytokine production in HLMCs, thus coupling nucleotide release in 
inflammation to HLMC activation. It has recently been shown in T cells that the product of 
ORMDL3, a genetic risk factor for asthma (Moffatt et al., 2007), inhibits the SERCA pump 
(Cantero-Recasens et al., 2010). This gives rise to reduced Ca2+ concentration in the ER, which 
triggers the unfolded-protein response (UPR), increasing the expression of genes involved in the 
onset of inflammation (Cantero-Recasens et al., 2010). A genome-wide association study found 
that genetic variants in the IL-6 receptor (IL-6R) gene were associated with atopic asthma, and it 
has been suggested that tocilizumab, an IL-6R antagonist approved to treat rheumatoid arthritis, 
could also be used in the treatment of asthma (Ferreira et al., 2011). These studies indicate that 
genetic dysregulation of cytokine signalling in immune cells is important in the development of 
asthma (Ferreira et al., 2011); elucidating the role of TRPC channels in mast cell cytokine 
production may unveil new therapeutic targets for aberrant cytokine signalling. 
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The migration of mast cells is also an important determinant of the asthmatic phenotype; their 
micro-localisation in airway smooth muscle bundles contributes to the symptoms of asthma, and 
they migrate to these sites through CXCR3 activation (Brightling et al., 2005). It has been shown 
in neutrophils that TRPC6 channels are required for migration stimulated by OAG or macrophage 
inflammatory protein-2 (MIP-2) (Damann et al., 2009); TRPC channels have also been suggested 
to have a role in monocyte migration induced by lysophosphatidylcholine (LPC) (Schilling & Eder, 
2009). The ion channels involved in HLMC migration have not been investigated; given the 
importance of TRPC6 channels for neutrophil migration, it can be hypothesised that they have a 
similar importance in HLMCs. The involvement of TRPC channels in HLMC migration was unable 
to be assessed in this study due to insufficient cell availability, but would represent an interesting 
avenue for future investigation. 
 
This study is the first known demonstration of a TRPC-like current in response to P2Y1 receptor 
activation in HLMCs; the existence of this current indicates that TRPC channels could be 
important in regulating mast cell activation in the inflammatory response, suggesting that they 
could be involved in the development of allergic asthma. Nucleotides are known to have 
important effects on other cells involved in the asthmatic phenotype, giving rise to neutrophil and 
eosinophil chemotaxis (Myrtek & Idzko, 2007), along with the release of the pro-inflammatory 
cytokines IL-1β and TNF-α from macrophages (Ferrari et al., 1997; Myrtek & Idzko, 2007). Given 
the importance of P2 receptor-mediated activation in these other cell types, it is reasonable to 
hypothesise that P2Y1 receptors, which are sensitive to both ADP and ATP, are important for 
mast cell activation. 
 
Elevated concentrations of ATP (Idzko et al., 2007) and its breakdown product adenosine (Driver 
et al., 1993) have been detected in BALF from patients with asthma compared with non-
asthmatics, highlighting the importance of purinergic signalling in the development of asthma. 
The demonstration that TRPC-like currents are activated downstream of P2Y1 receptor activation 
provides a mechanism by which P2Y1 stimulation leads to elevated Ca
2+ entry and mast cell 
Figure 7.1. Sources of extracellular nucleotides and mast cell responses 
Reproduced with permission from (Bulanova & Bulfone-Paus, 2010) 
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activation, and highlights TRPC channels in HLMCs as potential therapeutic targets for asthma. 
Selective molecular knock-down of TRPC6 channels in HLMCs is required in future studies to 
verify their activation downstream of P2Y1 receptors. This could be carried out using a dominant 
negative TRPC6 pore mutant; this approach has successfully been used to inhibit TRPC6 
channels in human microvascular endothelial cells and human podocytes (Hamdollah Zadeh et 
al., 2008; Foster et al., 2009). As techniques to transfect human mast cells are currently being 
optimised in our laboratory, it should be possible to use dominant negative mutants to verify the 
contribution of TRPC6 channels to Ca2+ entry downstream of P2Y1 receptor activation in the near 
future. Molecular knock-down studies used in combination with mediator release screens could 
be used to reveal whether TRPC6 channels activated following P2Y1 receptor stimulation are 
important for the synthesis and release of eicosanoids and cytokines that could contribute to the 
asthmatic phenotype. 
 
It has previously been shown that ATP can enhance IgE-dependent histamine release in HLMCs 
(Schulman et al., 1999). This enhancement was unaffected by a P2X purinoceptor antagonist, 
pyridoxalphosphate-6-azophenyl-2‘,4‘-disulphonic acid (PPADS) , suggesting a P2Y-dependent 
mechanism (Schulman et al., 1999). It is therefore possible that P2Y1 receptor activation by ADP 
in HLMCs could have a role in modifying FcεRI-dependent mediator release. Ca2+ entry through 
TRPC channels downstream of PLCβ-dependent DAG generation could provide a co-stimulatory 
signal for IgE-dependent mediator release, or the phosphorylation of key adaptor molecules 
following Gq protein stimulation could enhance FcεRI signalling. This hypothesis could be tested 
in future studies by comparing mediator release and Ca2+ entry in HLMCs stimulated with anti-
IgE alone, or anti-IgE together with ADP. If TRPC channels activated downstream of P2Y1 
receptors provide a co-stimulatory signal for FcεRI-dependent mediator release, they could be a 
potential therapeutic target for the attenuation of the allergic response. 
 
Whilst HLMCs are most well-known for their involvement in allergic asthma, making them an 
attractive therapeutic target in allergic individuals, it must also be considered that mast cells 
have an important role in protective immunity. As described in chapter 1.1.4, studies in mice 
have shown that mast cell-derived mediators are important for the recruitment of other 
inflammatory cells to sites of infection, and that mast cells are essential for survival in bacterial 
infections (Echtenacher et al., 1996; Malaviya et al., 1996; Metz & Maurer, 2007). They are 
thought to have a role in both innate and acquired immunity. Nucleotides including ATP and ADP 
are considered ―danger signals‖ in the immune system; their role is to alert the body to potential 
danger and activate the immune response to destroy invading pathogens (Di Virgilio, 2005). P2Y1 
receptor activation and subsequent Ca2+ entry by TRPC channels could thus have a protective 
role in the lung; mediators released by HLMCs in response to invading pathogens could activate 
other components of the immune system to efficiently destroy the pathogen. As asthmatic 
patients have increased numbers of mast cells in the lung (Broide et al., 1991; Brightling et al., 
2002; Bradding et al., 2006), it is possible that TRPC channels activated downstream of P2Y1 
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receptors could contribute to mast cells‘ protective role in non-asthmatics, but play a role in the 
development of the asthmatic phenotype in hypersensitive individuals. Comparison of TRPC 
channel expression between asthmatic and non-asthmatic individuals would reveal whether the 
channels are likely to have an immunoprotective role or whether they specifically contribute to 
mast cell activation in hypersensitive individuals. mRNA expression could be compared by 
quantitative PCR and protein expression by flow cytometry or immunohistochemistry. HLMC ADP 
responsiveness and the comparison of mediator release between asthmatic and non-asthmatic 
individuals would also reveal whether TRPC channels activated downstream of P2Y1 receptors are 
important in the allergic response, protective immunity, or both. The demonstration that DAG-
activated TRPC channels are likely to cause Ca2+ entry in HLMCs following P2Y1 receptor 
activation is a significant development in the field of mast cell biology, and will lead to further 
investigations like those discussed above to elucidate their role in mast cell function. 
 
This study also revealed for the first time that TRPC1 channels are expressed in HLMCs, and that 
they are likely to be involved in SOCE. As described in chapter 1.3, SOCE is an important 
mechanism for Ca2+ entry in mast cells; following allergic activation via FcεRI cross-linking, PLCγ 
generates InsP3 from PtdIns(4,5)P2, which causes Ca
2+ release from stores in the ER and 
subsequent activation of SOC channels in the plasma membrane (Gilfillan & Tkaczyk, 2006). The 
resulting Ca2+ influx is essential for mast cell degranulation, as well as cytokine transcription and 
eicosanoid production (Cochrane & Douglas, 1974; Gilfillan & Tkaczyk, 2006; Melicoff et al., 
2009). The demonstration that TRPC1 channels are likely to be involved in SOCE in human mast 
cells adds to a growing body of evidence, described in chapter 1.3.2, that these channels are 
important components of SOCE in a number of different cell types (Liu et al., 2007; Yuan et al., 
2007; Liao et al., 2008; Ma et al., 2008; Ng et al., 2009; Zhang et al., 2010a; Cheng et al., 2011; 
Hong et al., 2011). Results indicate that both non-selective TRPC1 and highly Ca2+-selective 
Orai1 channels are likely to be involved in SOCE in human mast cells; as described in chapter 
1.3.2, it is likely that the channels function together to bring about FcεRI-dependent Ca2+ entry, 
but give rise to distinct downstream effects. In HSG cells, Orai1 mediated Ca2+ entry activates 
the transcription factor NFAT, but a higher concentration of intracellular Ca2+ provided by TRPC1 
activation is required for the full activation of NFκB (Cheng et al., 2011). In mast cells, NFAT is 
required for TNFα and IL-2 production; TNFα is a pro-inflammatory cytokine that is centrally 
involved in asthma, activating the airway epithelium, antigen-presenting cells and macrophages 
in the airway (Chung & Barnes, 1999). The transcription factor NFκB enhances the transcription 
of genes for cytokines, adhesion molecules and growth factors (Marquardt & Walker, 2000). Fine 
control of these transcription factors by differential Ca2+ entry through Orai1 and TRPC1 channels 
could allow the mast cell to tightly regulate downstream cytokine production, and thus activate 
different cells important in airway inflammation. Given the importance of the cytokines produced 
following NFAT and NFκB activation in mast cells, it can be hypothesised that if a similar 
dependence on TRPC1- and Orai1- mediated Ca2+ entry exists in HLMCs as that for described for 
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HSG cells, both channels would be important in the pathophysiology of asthma. These channels 
could thus be important therapeutic targets for future asthma treatments. 
 
Also shown for the first time in this study is that TRPC1 channels, along with Orai1 channels, are 
likely to be involved in FcεRI-dependent Ca2+ entry and degranulation. As a number of mast cell 
mediators are released upon degranulation that contribute to asthmatic airway inflammation, 
these findings are of significance for the development of future mast cell-stabilising drugs. 
Inhibition of the essential Ca2+ influx required for degranulation following FcεRI cross-linking 
would inhibit the release of mediators such as histamine, chymase and tryptase, all of which 
contribute to airway inflammation (Metcalfe et al., 1997). The clinical potential of inhibiting the 
IgE-dependent pathway of mast cell activation has recently been demonstrated by the success of 
the humanised monoclonal antibody omalizumab in clinical trials. This antibody treatment works 
by binding to circulating IgE, thus preventing it from binding to FcεRI (Thomson et al., 2011). It 
has been shown to improve symptoms in patients with allergic asthma and reduce airway 
inflammation (Walker et al., 2006; Rodrigo et al., 2011), highlighting the importance of this 
pathway in mast cells as a therapeutic target. Whilst the safety and efficacy of omalizumab is 
generally good, preliminary data has indicated a possible increase in cardiovascular problems 
(Thomson et al., 2011). As existing drugs for asthma lack potency or are ineffective in some 
patients (Church & Hiroi, 1987; Giannini et al., 1996; Rodrigo et al., 2011), there is a need for 
the development of new therapies. This study identifies TRPC1 channels as a target for new 
asthma therapies; inhibiting TRPC1- mediated Ca2+ influx in HLMCs could attenuate the release 
of mediators and consequently reduce asthmatic airway inflammation. 
 
 
7.2 Future directions 
This study reveals TRPC1 as a potentially important therapeutic target for HLMC stabilisation to 
improve the symptoms of asthma; as mast cells are involved in the pathophysiology of many 
other allergic diseases including allergic rhinitis, coeliac disease, inflammatory bowel disease and 
rheumatoid arthritis (Sellge & Bischoff, 2006; Nigrovic & Lee, 2007; Owen, 2007; Beaven, 2009), 
TRPC1 channels may also contribute to mast cell activation in these diseases. Analysis of mRNA 
expression in mast cells from different sites including the human intestine, skin and synovial fluid 
in the joints would indicate whether TRPC channels are likely to have a role in the activation of 
mast cells from different sites. Results from an oligonucleotide probe array screen to identify ion 
channel genes in mast cells indicate that TRPC1 mRNA is present in human skin mast cells 
(Bradding et al., 2003), suggesting that the channel may also have an important role in Ca2+ 
entry in mast cells from other sources. As mast cells display heterogeneity between species and 
between sites within the same organism (Bischoff, 2007), it is important to study primary human 
mast cells from the site of interest where possible to gain insight into their mechanisms of 
activation. 
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The functional expression of TRPC5 was found to be highly variable between donors; 
investigation of its expression in a larger pool of donors is necessary to elucidate whether 
environmental factors such as cigarette smoking or medication affect the expression of this 
channel. Quantitative PCR could be used to compare mRNA levels between donors; comparisons 
between asthmatic and non-asthmatic patients could show whether the channel has a role in the 
development of asthma. 
 
An interesting avenue for future investigation for TRPC channels from both subfamilies would be 
assessing their role in the secretion of different mediators. This study addressed the secretion of 
the granule-associated mediators β-hexosaminidase and histamine; further investigation is 
required to elucidate whether TRPC channels have a role in FcεRI- and P2Y1- evoked release of 
other mediators. Again the specific role of TRPC1 and TRPC6 in regulating the functions of 
primary human mast cells will require gene knockdown studies (siRNA) and targeted loss of 
function studies by expression of dominant-negative pore mutants. As FcεRI is coupled to PLCγ 
and P2Y1 to PLCβ (Gilfillan & Tkaczyk, 2006), it is likely that the two signalling pathways are 
coupled to different ion channels in distinct membrane lipid raft domains (Lingwood & Simons, 
2010). PLCβ-coupled Ca2+ entry could thus give rise to differential mediator secretion compared 
with PLCγ-coupled Ca2+ entry. It has been shown in mouse BMMCs that different SNARE proteins 
regulate the exocytosis of distinct mediators; serotonin secretion was inhibited, but histamine 
secretion was unaffected, in BMMCs from mice lacking the SNARE protein vesicle-associated 
membrane protein 8 (VAMP-8) (Puri & Roche, 2008). Analysis of the mediators secreted 
downstream of the different PLC isoforms would reveal whether similar differential mediator 
release occurs in human mast cells. siRNA could be used to inhibit the different isoforms of PLC, 
as has been described for PLCβ in rat fibroblasts (Kelley et al., 2006), in order to determine their 
involvement in mediator release.  
 
Results in this study indicate that TRPC1 and Orai1 may functionally interact to mediate SOCE in 
HLMCs. To confirm this conclusion, which is based on data using the selective pharmacological 
Orai1 inhibitor synta 66, specific molecular knock-down of Orai1 channels could be used to 
assess the effect on TRPC1 current. Combined patch clamp and Ca2+ imaging experiments could 
be used to compare store-activated TRPC1 currents in the presence and absence of Orai1 
inhibition. Such experiments would verify the functional dependence of the channels, and would 
provide insight into whether pharmacological inhibition of one or both channels would be 
beneficial for the modulation of mast cell secretion. The ICRAC inhibitor synta 66 has been shown 
to inhibit Orai1 channels with potency and selectivity (Ng et al., 2008; Di Sabatino et al., 2009; Li 
et al., 2011), thus has the potential to be developed into a mast cell-modulating drug. If TRPC1 
channel activation is indeed modulated by Orai1 channel inhibition, agents targeting Orai1 such 
as synta 66 could sufficiently reduce the activity of both channels to attenuate mast cell mediator 
secretion. 
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Although more donors were assayed for IgE-dependent mediator release than Ca2+ entry in this 
study, donor variability in the contribution of TRPC channels was apparent in mediator release 
assays but Ca2+ imaging experiments revealed a contribution from TRPC channels in 100% of 
donors tested. Whilst mediator release assays were carried out on freshly isolated HLMCs, 
cultured HLMCs were used for Ca2+ imaging experiments. It would be interesting to assess 
whether culture conditions affect the surface expression of TRPC channels; it is known that the 
mast cell microenvironment determines its phenotype (Metcalfe et al., 1997; Metz & Maurer, 
2007), and it is possible that TRPC channel expression is up-regulated in cultured HLMCs 
compared with freshly isolated cells. mRNA expression could be compared in freshly isolated cells 
and in those kept in culture using quantitative PCR, and flow cytometry using anti-TRPC 
antibodies could be employed to quantify the surface expression. 
 
In order to determine the in vivo role of TRPC channels in mast cells, knockout mouse models 
could be used. Such models have been extremely useful in determining some in vivo functions of 
TRPC channels. For example, TRPC1-deficient mice were used to show that TRPC1 channels are 
essential for salivary gland function and SOCE in salivary gland cells (Liu et al., 2007). Knockout 
mice are available for all TRPC channels, with the exception of TRPC7 (Wu et al., 2010). Such 
models could be used to assess the localisation of mast cells to identify whether TRPC channels 
have an important role in microlocalisation in the lung, for example. Mast cells from different 
sites in the knockout mouse could be compared with those in wild-type mice to assess effects on 
Ca2+ signalling and mediator release. TRPC-deficient mouse models could would also be useful to 
assess whether the absence of a particular TRPC channel has adverse effects on the whole 
organism; this would provide valuable information on whether pharmacologically inhibiting TRPC 
channels as a target for asthma therapy would have systemic effects. Whilst experiments using 
mouse mast cells have disadvantages due to the species-dependent differences that occur 
(Bischoff, 2007), meaning that all results would need to be verified in human mast cells, 
experiments using knockout mice would be extremely valuable to assess the in vivo roles of 
TRPC channels in mast cells. 
 
In summary, there are many avenues of work that can be pursued following the results of this 
study. It has shown for the first time that TRPC channels are functionally expressed in human 
lung mast cells, and are likely to represent an important route for Ca2+ entry. These channels are 
thus an exciting potential therapeutic target for the modulation of allergic diseases such as 
asthma. 
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